

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 17:32:40 ; Search time 183.78 Seconds
(without alignments)
134.791 Million cell updates/sec

Title: US-09-540-843-5
Perfect score: 11
Sequence: 1 gtaggattag 11

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 2185239 seqs, 112599159 residues
Total number of hits satisfying chosen parameters: 2063506

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: N.Geneseq_101002.*
2: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
3: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
4: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
5: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
6: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
7: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
8: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
9: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
10: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
11: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
12: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
13: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
14: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
15: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
16: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
17: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
18: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
19: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
20: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
21: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
22: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
23: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
24: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
25: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result.	No.	Score	Query	Match	Length	DB	ID	Description
	1	11	100.0	11	18	AAV07769		N3 to P5 oligonucleotide
	2	11	100.0	11	18	AAT89250		DNA oligonucleotide
	3	11	100.0	11	18	AAT89237		Peptide nucleic ac
	4	11	100.0	11	18	AAT90060		Telomerase primer.
	5	11	100.0	11	21	AAA37556		PNA sequence #13 u
	6	11	100.0	11	21	AAA37561		PNA sequence #18 u
	7	11	100.0	11	21	AAA37562		PNA sequence #19 u
	8	11	100.0	11	21	AAA37573		PNA sequence #31 u
	9	11	100.0	11	21	AAA37586		Antisense sequence

10	11	100.0	11	22	AAT81185		
11	11	100.0	11	22	AAT26728		
12	11	100.0	11	22	AAT26732		
13	11	100.0	11	23	AAI14909		
14	11	100.0	11	23	AAI14913		
15	11	100.0	11	23	AAI15434		
16	11	100.0	11	23	AAI15450		
17	11	100.0	11	23	AAI15457		
18	11	100.0	11	24	AAK98619		
19	11	100.0	11	24	ABA97513		
20	11	100.0	12	18	AAT99232		
21	11	100.0	12	21	AAI37551		
22	11	100.0	12	23	AAI15429		
23	11	100.0	12	23	ABIO5288		
24	11	100.0	12	23	AB134202		
25	11	100.0	13	18	AAT89225		
26	11	100.0	13	18	AAT89236		
27	11	100.0	13	21	AAI37544		
28	11	100.0	13	21	AAI37555		
29	11	100.0	13	22	AAF81195		
30	11	100.0	13	23	AAI15423		
31	11	100.0	13	23	AAI15433		
32	11	100.0	13	23	ABC19880		
33	11	100.0	13	23	ABC19881		
34	11	100.0	13	23	ABF02802		
35	11	100.0	13	23	ABF02803		
36	11	100.0	15	18	AAT89226		
37	11	100.0	15	18	AAT89229		
38	11	100.0	15	18	AAT90068		
39	11	100.0	15	21	AAI37545		
40	11	100.0	15	21	AAI37548		
41	11	100.0	15	21	AAI37587		
42	11	100.0	15	23	AAI15424		
43	11	100.0	15	23	AAI15427		
44	11	100.0	15	23	AAI15458		
45	11	100.0	16	16	AAT01177		

ALIGNMENTS

RESULT 1	
AAV07769	
ID AAV07769 standard; DNA; 11 BP.	
XX AAV07769;	
DT 07-DEC-1998 (first entry)	
XX N3 to P5 oligonucleotide phosphoramidate useful as telomerase inhibitor.	
DE telomerase inhibitor; phosphoramidate; telomerase-binding region; TBR;	
KW cell proliferation; tumour; leukaemia; duplex; ss.	
XX Synthetic.	
OS	
XX	
FH Key	Location/Qualifiers
FT msc_feature	1..11
FT	/*tag= a
FT	/note= "each linkage is a phosphoramidate linkage"
XX	
PN W09737691-A1.	
PD 16-OCT-1997.	
XX	
PF 08-APR-1997; 97MO-US05773.	
XX	
PR 10-APR-1996; 96US-0630242.	
XX	
PA (LYNX-) LYNX THERAPEUTICS INC.	
XX	
PI Lloyd DH;	
XX	

oligonucleotide th
phosphoramidate-11
phosphoramidate-11
Melanogenesis asso
PNA 7/TV inhibitin
oligonucleotide #6
phosphorothioate (1
peptide nucleic ac
peptide nucleic ac
PNA sequence #1 us
PNA sequence #12 u
Thiophosphoramidat
PNA 8/VI inhibitin
PNA 6/X inhibitin
oligonucleotide SE
oligonucleotide SE
oligonucleotide SE
oligonucleotide pr
peptide nucleic ac
peptide nucleic ac
Telomerase primer
PNA sequence #2 us
PNA sequence #5 us
Antisense sequence
PNA VII inhibitin
PNA XIII inhibitin
phosphorothioate (1
Telomeric repeat-b

DR WPI; 1997-512422/47.
 XX Treating elevated telomerase levels with N3 to p5 oligonucleotide
 PT phosphoramidates - that bind to the RNA component of telomerase,
 PT specifically for preventing growth of cancer cells, fungi and
 PT protozoa
 XX
 PS Claim 5; Page 25; 38pp; English.
 XX
 CC The invention relates to treatment of conditions associated with high
 CC levels of telomerase activity in a cell. The treatment comprises
 CC administering an oligonucleotide N3' -> p5' phosphoramidate having a
 CC sequence complementary to part of the telomere-binding region (TBR) of
 CC the RNA component of telomerase, so as to inhibit its activity. The
 CC N3' -> p5' oligonucleotide phosphoramidates are used therapeutically to
 CC inhibit cell proliferation, e.g. against a wide range of solid tumours
 CC or leukemia, and also against fungal and protozoal pathogens. They are
 CC soluble and resistant to nuclease, and they bind strongly to RNA forming
 CC short but stable duplexes under physiological conditions. Thus they are
 CC very effective and selective inhibitors of telomerase. The present
 CC sequence represents a specific example of an oligonucleotide N3' -> p5'
 CC phosphoramidate disclosed in the specification.
 XX
 SQ Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;
 Query Match 100.0%; Score 11; DB 18; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.7e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GTTAGGGTTAG 11
 DB 1 GTTAGGGTTAG 11
 RESULT 2
 AAT89250/c
 ID AAT89250 standard; DNA; 11 BP.
 XX
 AC AAT89250;
 XX
 DT 12-MAY-1998 (first entry)
 XX
 DE DNA oligonucleotide 6, used in the measurement of Tm values.
 XX
 KW Peptide nucleic acid; PNA; cancer; telomerase; probe; hybridisation;
 KW inhibitor; human telomerase RNA; hTR; PCR; oligonucleotide; ss.
 XX
 OS Synthetic.
 XX
 PN WO9738013-A1.
 XX
 PD 16-OCT-1997.
 XX
 PF 09-APR-1997; 97WO-US05931.
 XX
 PR 09-APR-1996; 96US-0630019.
 XX
 PA (GERO-) GERON CORP.
 XX
 PI Corey D, Norton JC, Piatyszek MA, Shay JW, Wright WE;
 XX
 DR WPI; 1997-512647/47.
 XX
 PT New peptide nucleic acids hybridising to mammalian telomerase RNA -
 PT used to inhibit telomerase, for treating tumours and other
 PT proliferative diseases, also for diagnosis
 XX
 PS Example 2; Page 49; 76pp; English.
 XX
 CC This is an oligonucleotide used in the measurement of Tm values and
 CC their complementary peptide nucleic acids (PNAs), (e.g.
 CC AAT89231-789240). PNAs hybridise specifically to an RNA component of
 CC mammalian telomerase, and include the sequence GGG for specific

CC hybridisation to the template region of this component. PNAs can be used
 CC as probes to detect the RNA component of mammalian telomerase and as
 CC inhibitors of telomerase activity, especially in the treatment of
 CC cancer.
 XX
 SQ Sequence 11 BP; 4 A; 5 C; 0 G; 2 T; 0 other;
 Query Match 100.0%; Score 11; DB 18; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.7e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GTTAGGGTTAG 11
 DB 11 GTTAGGGTTAG 1
 RESULT 3
 AAT89237
 ID AAT89237 standard; DNA; 11 BP.
 XX
 AC AAT89237;
 XX
 DT 12-MAY-1998 (first entry)
 XX
 DE Peptide nucleic acid 12, targeted to mammalian telomerase.
 XX
 KW Peptide nucleic acid; PNA; cancer; telomerase; probe; hybridisation;
 KW inhibitor; ss.
 XX
 OS Synthetic.
 XX
 PH Key Location/Qualifiers
 FT modified_base 1..13
 FT /*tag- a
 FT /note- "Sugar-phosphate backbone has been replaced by
 FT modified_base 13
 FT /*tag- b
 FT /note- "Optionally conjugated to peptide AAW31919"
 FT /*tag- c
 FT /note- "Optionally conjugated to peptide AAW31919"
 XX
 PN WO9738013-A1.
 XX
 PD 16-OCT-1997.
 XX
 PF 09-APR-1997; 97WO-US05931.
 XX
 PR 09-APR-1996; 96US-0630019.
 XX
 PA (GERO-) GERON CORP.
 XX
 PI Corey D, Norton JC, Piatyszek MA, Shay JW, Wright WE;
 XX
 DR WPI; 1997-512647/47.
 XX
 PT New peptide nucleic acids hybridising to mammalian telomerase RNA -
 PT used to inhibit telomerase, for treating tumours and other
 PT proliferative diseases, also for diagnosis
 XX
 PS Claim 9; Page 59; 76pp; English.
 XX
 CC This sequence is a novel peptide nucleic acid (PNA), which acts as
 CC an inhibitor of mammalian, preferably human, telomerase. The PNAs
 CC hybridise specifically to an RNA component of mammalian telomerase,
 CC and include the sequence GGG for specific hybridisation to the template
 CC region of this component. PNAs can be used as probes to detect the
 CC RNA component of mammalian telomerase and as inhibitors of telomerase
 CC activity, especially in the treatment of cancer.
 XX
 SQ Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

Query Match 100.0%; Score 11; DB 18; Length 11;
 Best Local Similarity 100.0%; Pred. NO. 1.7e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GTTAGGCTTAG 11
 11
 1 GTTAGGCTTAG 11
 DB 1 GTTAGGCTTAG 11

RESULT 4

AAT90060
 ID AAT90060 standard; DNA; 11 BP.

AC AAT90060;

DT 24-NOV-1997 (first entry)

DE Telomerase primer.

XX Detection; telomerase; amplification; polymerase chain reaction;
 KM PCR; primer; cancer; carcinoma; sarcoma; leukemia; leukemia;
 KM myeloma; lymphoma; neuroblastoma; astrocytoma; glioma;
 KM glioblastoma; retinoblastoma; melanoma; screen; drug;
 KM determination; telomere length; ss.

OS Synthetic.

PN WO9711198-A1.

PD 27-MAR-1997.

PF 20-SEP-1996; 96WO-US15162.

PR 20-SEP-1995; 95US-0531743.

PA (CTRC-) CTCRC RES FOUNDED.

PI Chen S, Fletcher TM, Maine I, Qiu M, Wandle BE;

DR WPI; 1997-202904/18.

PT Detecting telomerase activity by ligation sequential reaction -
 PI useful for diagnosis of cancer or to screen for telomerase
 PI inhibitors

PS Claim 40; Page 27; 71pp; English.

XX A novel method of detecting telomerase activity in a sample,
 CC comprises amplifying a sample with a telomerase primer, e.g. the
 CC present sequence, and contacting the product with 1st and 2nd
 CC oligonucleotides, which hybridise to the product so that no single
 CC stranded region intervenes between them. The hybridised product and
 CC oligonucleotides are then contacted with ligase and the ligated
 CC form of the oligonucleotides detected.
 CC The method can be used to detect cancer, e.g. carcinomas of the
 CC breast, colon, oesophagus, kidney, liver, lung, ovaries, prostate,
 CC stomach, uterus, pancreas and head and neck, sarcomas of bone and
 CC muscle, leukaemias, myelomas, lymphomas, neuroblastomas,
 CC astrocytomas, gliomas, glioblastomas, retinoblastomas and
 CC melanomas. The method can also be used to screen for
 CC anti-telomerase activity in candidate drugs and to determine
 CC telomere length.

SO Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

Query Match 100.0%; Score 11; DB 18; Length 11;
 Best Local Similarity 100.0%; Pred. NO. 1.7e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGCTTAG 11
 11
 1 GTTAGGCTTAG 11
 DB 1 GTTAGGCTTAG 11

RESULT 5
 AAA37556
 ID AAA37556 standard; DNA; 11 BP.

AC AAA37556;

DT 15-AUG-2000 (first entry)

DE PNA sequence #13 used to inhibit telomerase activity.

XX Peptide nucleic acid; PNA; telomerase; ribonucleoprotein enzyme; cancer;
 KM inhibitor; neoplasia; neurodegenerative disease; aging; hyperplasia;
 KM AIDS; HIV; fungal infection; forensic identification; detect; tumour;
 KW paternity testing; ss.

OS Synthetic.

XX Key Location/Qualifiers
 FH 1.11
 FT misc_feature /tag-
 FT /note-
 FT "Peptide nucleic acid molecule, where
 FT N-(2-aminoethyl)glycine units are linked to
 FT nucleotide bases via glycine amino N through a
 FT methylene-carbonyl linker"

PN US6046307-A.

PD 04-APR-2000.

PF 09-APR-1997; 97US-0838545.

PR 09-APR-1996; 96US-0630019.

PA (TEXA) UNIV TEXAS SYSTEM.

PI Wright WE, Piatyszek MA, Shay JW, Norton JC, Corey DR;

DR WPI; 2000-292432/25.

PT New peptide nucleic acid (PNA) compounds that inhibit telomerase
 PT activity in mammalian cells. Is useful as probes to detect the RNA
 PT component of a mammalian telomerase

PS Claim 6; Column 71; 45pp; English.

XX The present sequence represents a peptide nucleic acid molecule which
 CC hybridises to the mRNA component of mammalian telomerase, and inhibits
 CC telomerase activity. Telomerase is a ribonucleoprotein enzyme that
 CC synthesizes one strand of the telomeric DNA, using as a template an 11
 CC nucleotide sequence contained within the RNA component of the enzyme. The
 CC invention relates to PNA molecules having a sequence of no more than 25
 CC bases, which include the sequence GTTAGG. The uncharged nature of the PNA
 CC backbone increases the melting temperature of associating strands,
 CC increases the rate of association with targeted nucleic acids, and
 CC affords greater resistance of degradation by proteases or nucleases. The
 CC therapeutic PNAs may be used for treating disease conditions such as
 CC cancers, neoplasia, hyperplasia, neurodegenerative diseases, aging, human
 CC immunodeficiency virus (HIV) infection/AIDS (acquired immunodeficiency
 CC syndrome) and associated pathologies, fungal infections, and other
 CC diseases characterized by abnormal telomere metabolism or telomerase
 CC activity. In combination with antineoplastic and other cytotoxic or
 CC cytostatic agents, antifungal agents, and other nucleotides. PNAs may be
 CC used for molecular diagnostics, labelled PNAs are used as hybridization
 CC probes to detect or quantitate polynucleotides having a human telomerase
 CC RNA (hTR) sequence. PNA probes are also used for forensic identification
 CC of individuals, e.g. paternity testing, based on hTR gene restriction
 CC fragment length polymorphism (RFLP) pattern. PNAs are also useful as
 CC inhibitors of telomerase activity. The method of the present invention
 CC allows cancerous conditions to be detected with increased confidence and
 CC possibly at an earlier stage, before cells are detected as cancerous
 CC based on pathological characteristics. The diagnostic and prognostic

XX WPI: 2000-292432/25.

DR New peptide nucleic acid (PNA) compounds that inhibit telomerase

XX PT activity in mammalian cells is useful as probes to detect the RNA

XX PT component of a mammalian telomerase

PS Claim 9; Column 71-72; 45pp; English.

XX The present sequence represents a peptide nucleic acid molecule which

CC hybridizes to the mRNA component of mammalian telomerase, and inhibits

CC telomerase activity. Telomerase is a ribonucleoprotein enzyme that

CC synthesizes one strand of the telomeric DNA, using as a template an 11

CC nucleotide sequence contained within the RNA component of the enzyme. The

CC invention relates to PNA molecules having a sequence of no more than 25

CC bases, which include the sequence GTTAGG. The uncharged nature of the PNA

CC backbone increases the melting temperature of associating strands,

CC increases the rate of association with targeted nucleic acids, and

CC affords greater resistance of degradation by proteases or nucleases. The

CC therapeutic PNAs may be used for treating disease conditions such as

CC cancers, neoplasia, hyperplasia, neurodegenerative diseases, aging, human

CC immunodeficiency virus (HIV) infection/AIDS (acquired immunodeficiency

CC syndrome) and associated pathologies, fungal infections, and other

CC diseases characterized by abnormal telomere metabolism or telomerase

CC activity, in combination with antineoplastic and other cytotoxic or

CC cytostatic agents, antifungal agents, and other nucleotides. PNAs may be

CC used for molecular diagnostics, labelled PNAs are used as hybridization

CC probes to detect or quantitate polynucleotides having a human telomerase

CC RNA (htr) sequence. PNA probes are also used for forensic identification

CC of individuals, e.g. paternity testing, based on htr gene restriction

CC fragment length polymorphism (RFLP) pattern. PNAs are also useful as

CC inhibitors of telomerase activity. The method of the present invention

CC allows cancerous conditions to be detected with increased confidence and

CC possibly at an earlier stage, before cells are detected as cancerous

CC based on pathological characteristics. The diagnostic and prognostic

CC methods of the present invention can be used to detect an immortal or

CC neoplastic cell or tumour tissue or cancer of any origin, provided the

CC cell expresses telomerase activity and its RNA component.

XX SQ Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

XX Query Match 100.0%; Score 11; DB 21; Length 11;

XX Best Local Similarity 100.0%; Pred. No. 1.7e+03;

XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11

Db 1 GTTAGGGTTAG 11

RESULT 8

AAA37573/c

AAA37573 standard; DNA; 11 BP.

XX AAA37573;

XX 15-AUG-2000 (first entry)

XX PNA sequence #31 used to inhibit telomerase activity.

XX Peptide nucleic acid; PNA; telomerase; ribonucleoprotein enzyme; cancer;

XX inhibitor; neoplasia; neurodegenerative disease; aging; hyperplasia;

KW AIDS; HIV; fungal infection; forensic identification; detect; tumour;

KW paternity testing; ss.

XX Synthetic.

XX OS

XX Key Location/Qualifiers

FT misc_feature 1..11

FT /tag= a

FT /note= "Peptide nucleic acid molecule, where

FT N-(2-aminoethyl)glycine units are linked to

FT nucleotide bases via glycine amino N through a

FT methylenecarbonyl linker"

XX US6046307-A.

XX 04-APR-2000.

XX 09-APR-1997; 97US-0838545.

XX 09-APR-1996; 96US-0630019.

XX (TEXA) UNIV TEXAS SYSTEM.

XX Wright WE, Piatyzek MA, Shay JW, Norton JC, Corey DR;

XX WPI: 2000-292432/25.

XX New peptide nucleic acid (PNA) compounds that inhibit telomerase

XX PT activity in mammalian cells is useful as probes to detect the RNA

XX PT component of a mammalian telomerase

XX Example 2; Column 33; 45pp; English.

XX The present sequence represents a peptide nucleic acid molecule which

CC hybridizes to the mRNA component of mammalian telomerase, and inhibits

CC telomerase activity. Telomerase is a ribonucleoprotein enzyme that

CC synthesizes one strand of the telomeric DNA, using as a template an 11

CC nucleotide sequence contained within the RNA component of the enzyme. The

CC invention relates to PNA molecules having a sequence of no more than 25

CC bases, which include the sequence GTTAGG. The uncharged nature of the PNA

CC backbone increases the melting temperature of associating strands,

CC increases the rate of association with targeted nucleic acids, and

CC affords greater resistance of degradation by proteases or nucleases. The

CC therapeutic PNAs may be used for treating disease conditions such as

CC cancers, neoplasia, hyperplasia, neurodegenerative diseases, aging, human

CC immunodeficiency virus (HIV) infection/AIDS (acquired immunodeficiency

CC syndrome) and associated pathologies, fungal infections, and other

CC diseases characterized by abnormal telomere metabolism or telomerase

CC activity, in combination with antineoplastic and other cytotoxic or

CC cytostatic agents, antifungal agents, and other nucleotides. PNAs may be

CC used for molecular diagnostics, labelled PNAs are used as hybridization

CC probes to detect or quantitate polynucleotides having a human telomerase

CC RNA (htr) sequence. PNA probes are also used for forensic identification

CC of individuals, e.g. paternity testing, based on htr gene restriction

CC fragment length polymorphism (RFLP) pattern. PNAs are also useful as

CC probes to detect the RNA component of a mammalian telomerase and as

CC inhibitors of telomerase activity. The method of the present invention

CC allows cancerous conditions to be detected with increased confidence and

CC possibly at an earlier stage, before cells are detected as cancerous

CC based on pathological characteristics. The diagnostic and prognostic

CC methods of the present invention can be used to detect an immortal or

CC neoplastic cell or tumour tissue or cancer of any origin, provided the

CC cell expresses telomerase activity and its RNA component.

XX SQ Sequence 11 BP; 4 A; 5 C; 0 G; 2 T; 0 other;

XX Query Match 100.0%; Score 11; DB 21; Length 11;

XX Best Local Similarity 100.0%; Pred. No. 1.7e+03;

XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11

Db 11 GTTAGGGTTAG 1

RESULT 9

AAA37586

AAA37586 standard; DNA; 11 BP.

XX AAA37586;

XX 15-AUG-2000 (first entry)

Antisense sequence #44 used to inhibit telomerase activity.

Peptide nucleic acid; PNA; telomerase; ribonucleoprotein enzyme; cancer inhibitor; neoplasia; neurodegenerative disease; aging; hyperlasia; AIDS; HIV; fungal infection; forensic identification; detect; tumour; paternity testing; ss.

Synthetic.

Key	Location/Qualifiers
misc_feature	1..11

```

/note= "Phosphorothioate internucleotide linkages"

```

US6046307-A.

04-APR-2000.

09-APR-1997; 97US-0838545.

09-APR-1996; 96US-0630019.

(TEXA) UNIV TEXAS SYSTEM.

Wright WE, Platyszek MA, Shay JW, Norton JC, Corey DR;

WPI; 2000-292432/25.

New peptide nucleic acid (PNA) compounds that inhibit telomerase activity in mammalian cells is useful as probes to detect the RNA component of a mammalian telomerase -

Example 1; Column 27-28; 45pp; English.

The present sequence represents an antisense oligonucleotide used as a control sequence alongside a peptide nucleic acid molecule which hybridises to the RNA component of mammalian telomerase, and inhibits telomerase activity. Telomerase is a ribonucleoprotein enzyme that synthesises one strand of the telomeric DNA, using as a template an 11 nucleotide sequence contained within the RNA component of the enzyme. The invention relates to PNA molecules having a sequence of no more than 25 bases, which include the sequence GTTAGC. The uncharged nature of the PNA backbone increases the melting temperature of associating strands, increases the rate of association with targeted nucleic acids, and affords greater resistance of degradation by proteases or nucleases. The therapeutic PNAs may be used for treating disease conditions such as cancers, neoplasia, hyperplasia, neurodegenerative diseases, aging, human immunodeficiency virus (HIV) infection/AIDS (acquired immunodeficiency syndrome) and associated pathologies, fungal infections, and other diseases characterized by abnormal telomere metabolism or telomerase activity. In combination with antineoplastic and other cytotoxic or cytostatic agents, antifungal agents, and other nucleosides, PNAs may be used for molecular diagnostics. Labelled PNAs are used as hybridization probes to detect or quantitate polynucleotides having a human telomerase RNA (HTR) sequence. PNA probes are also used for forensic identification of individuals, e.g. paternity testing, based on HTR gene restriction fragment length polymorphism (RFLP) pattern. PNAs are also useful as probes to detect the RNA component of a mammalian telomerase and as inhibitors of telomerase activity. The method of the present invention allows cancerous conditions to be detected with increased confidence and possibly at an earlier stage, before cells are detected as cancerous based on pathological characteristics. The diagnostic and prognostic methods of the present invention can be used to detect an immortal or neoplastic cell or tumour tissue or cancer of any origin, provided the cell expresses telomerase activity and its RNA component.

50 Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

Query Match	100.0%;	Score 11;	DB 21;	Length 11;
Best Local Similarity	100.0%;	Pred. No. 1.7e+03;		
Matches	11;	Conservative	0;	Mismatches 0;
			Indels	0;
			Gaps	0;

QY 1 GTTAGGGTTAG 11

Db 1 GTTAGCGTTAG 11

RESULT 10

ID AAF81185 standard; DNA; 11 BP.

AC AAF81185;

DT 30-MAY-2001 (first entry)

DE Oligonucleotide thiophosphoramidate, SEQ ID NO: 1.

KM Thioposphoramidate oligonucleotide; viruicide; cytostatic;
KM Immunosuppressive; contraceptive; RNA inhibitor; telomerase inhibitor;
KM antitense pressure; viral infection; cancer; hyperproliferative disorder;
KM autoimmune disorder; ss.

OS Synthetic.

PN W0200118015-A1.

PD 15-MAR-2001

PF 08-SEP-2000; 2000WO-US24688.

PR 10-SEP-1999; 99US-0153201.

XX

XX XX

100

[illegible]

XX cell, and for treating cancer and viral infection -
PT DNA having a given target sequence, for inhibiting RNA function in a
PT Novel thiophosphoramidate polynucleotide useful for detection of RNA or
PT Novel thiophosphoramidate polynucleotide useful for detection of RNA or
PS Example 3; Page 39; 68pp; English.

Example 3; Page 39; 68pp; English.

The present sequence was synthesised in an example illustrating an invention relating to polynucleotides comprising a non-homopolymeric sequence of nucleoside subunits joined by at least one inter-subunit linkage that is a N3'-p5' thiophosphoramidate. The thiophosphoramidate oligonucleotides retain a high RNA binding affinity and exhibit a much higher acid stability. They are useful for detecting a specific sequence in a sample, by forming a hybridisation complex with the sequence. They are useful for inhibiting function of an RNA in a cell (for inhibiting translation of a mRNA or for inhibiting telomerase enzyme in a cell). They are also useful in the preparation of a medicament for treatment of viral infection or cancer. The oligonucleotides are useful for anti-sense and anti-gene diagnostic or therapeutic applications and may be used for treating telomerase-mediated conditions or diseases, such as hyperproliferative and autoimmune disorders, and for contraceptive purposes.

Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

Query Match	100.0%	Score 11;	DB 22;	Length 11;
Best Local Similarity	100.0%;	Pred. No. 1.7e+03;		
Matches 11;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0

```
QY      1 GTTAGGGTTAG 11
          |||||
Db      1 GTTAGGGTTAG 11
```

Db 1 GTTAGGGCTTAG 11

RESULT 11	
AAH26728	
ID	AAH26728 standard; DNA; 11 BP.

```

AC AAH26728;
XX
DT 26-NOV-2001 (first entry)
XX
DE Phosphoramidate-linked 2'-arabino-fluorooligonucleotide.
XX
KW 2'-arabino-fluorooligonucleotide; phosphoramidate; telomerase;
XX inhibitor; infection; cancer; diagnosis; therapy; cytostatic;
XX virucide; antisense; antigen; ss.
XX
OS Synthetic.
XX
FH Key
FT modified_base 2..11 Location/Qualifiers
FT /tag= a
FT /mod_base= "OTHER"
FT /note= "2'-arabino-fluoronucleosides"
FT modified_base 2..11
FT /tag= b
FT /mod_base= "OTHER"
FT /note= "phosphoramidate linkage"
XX
PN WO200153307-A1.
XX
PD 26-JUL-2001.
XX
PF 19-JAN-2001; 2001WO-US01918.
XX
PR 21-JAN-2000; 2000US-178248P.
XX
PA (GERO-) GERON CORP.
XX
PI Gryaznov S, Schultz RG;
XX
DR WPI: 2001-569652/66.
XX
PT Polynucleotides, used to detect and isolate nucleic acids, inhibit
PT function of RNA and telomerase enzymes and to treat e.g. viral
PT infections, contain 2'-arabino-fluoronucleoside(s) linked to
PT nucleoside(s) -
XX
PS Example 6; Page 46; 61pp; English.
XX
CC The present sequence is that of a N3'-P5' 2'-arabino-fluoro
CC phosphoramidate oligonucleotide that is complementary to
CC telomerase RNA. The oligonucleotide was used to assess the
CC relative efficacy of novel 2'-arabino-fluoro phosphoramidate
CC oligonucleotides and their 2'-ribo fluorooligonucleotide
CC counterparts (see AAH26728-35) for the inhibition of telomerase
CC activity. Novel phosphoramidate 2'-arabino-fluorooligonucleotides
CC are generally more acid stable, more resistant to cellular
CC proteases, and also show greater telomerase inhibition activity
CC than 2'-ribose-fluoro phosphoramidates. They are therefore useful
CC for treating cancer (claimed) and other diseases in which telomerase
CC activity is present at abnormal levels, such as hyperproliferative
CC or autoimmune diseases e.g. psoriasis, rheumatoid arthritis,
CC immune system disorders requiring immunosuppression, and in the
CC treatment of viral infection (claimed).
XX
SQ Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;
XX
Query Match 100.0%; Score 11; DB 22; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GTTAGGGTTAG 11
DB 1 GTTAGGGTTAG 11

```

```

XX
AC AAH26732;
XX
DT 26-NOV-2001 (first entry)
XX
DE Phosphoramidate-linked 2'-ribose-fluorooligonucleotide.
XX
KW 2'-ribose-fluorooligonucleotide; phosphoramidate; telomerase;
XX inhibitor; infection; cancer; diagnosis; therapy; cytostatic;
XX virucide; antisense; antigen; ss.
XX
OS Synthetic.
XX
FH Key
FT modified_base 2..11 Location/Qualifiers
FT /tag= a
FT /mod_base= "OTHER"
FT /note= "2'-ribose-fluoronucleosides"
FT modified_base 2..11
FT /tag= b
FT /mod_base= "OTHER"
FT /note= "phosphoramidate linkage"
XX
PN WO200153307-A1.
XX
PD 26-JUL-2001.
XX
PF 19-JAN-2001; 2001WO-US01918.
XX
PR 21-JAN-2000; 2000US-178248P.
XX
PA (GERO-) GERON CORP.
XX
PI Gryaznov S, Schultz RG;
XX
DR WPI: 2001-569652/66.
XX
PT Polynucleotides, used to detect and isolate nucleic acids, inhibit
PT function of RNA and telomerase enzymes and to treat e.g. viral
PT infections, contain 2'-arabino-fluoronucleoside(s) linked to
PT nucleoside(s) -
XX
PS Example 6; Page 46; 61pp; English.
XX
CC The present sequence is that of a 2'-ribose-fluoro
CC phosphoramidate oligonucleotide that is complementary to
CC telomerase RNA. The oligonucleotide was used to assess the
CC relative efficacy of novel 2'-arabino-fluoro phosphoramidate
CC oligonucleotides and their 2'-ribose fluorooligonucleotide
CC counterparts (see AAH26728-35) for the inhibition of telomerase
CC activity. Novel phosphoramidate 2'-arabino-fluorooligonucleotides
CC are generally more acid stable, more resistant to cellular
CC proteases, and also show greater telomerase inhibition activity
CC than 2'-ribose-fluoro phosphoramidates. They are therefore useful
CC for treating cancer (claimed) and other diseases in which telomerase
CC activity is present at abnormal levels, such as hyperproliferative
CC or autoimmune diseases e.g. psoriasis, rheumatoid arthritis,
CC immune system disorders requiring immunosuppression, and in the
CC treatment of viral infection (claimed).
XX
SQ Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;
XX
Query Match 100.0%; Score 11; DB 22; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GTTAGGGTTAG 11
DB 1 GTTAGGGTTAG 11

```

RESULT 12
 AAH26732
 ID AAH26732 standard; DNA; 11 BP.

RESULT 13
 AAS14909

1D	AA514905	standard; DNA; 11 BP.
XX	AC	
XX	AA514909;	
DY	14-FEB-2002	(first entry)
XX		
DE	Melanogenesis associated oligonucleotide #5.	
XX		
KW	Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;	
KW	anti-inflammatory; dermatological; ophthalmological; anti-allergic;	
KW	immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;	
KW	tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;	
KW	carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;	
KW	conjunctivitis; allergic rhinitis; vitiligo; ss.	
XX		
OS	Synthetic.	
XX		
XX		
FT	key	Location/Qualifiers
FT	modified_base	1
FT		/*tag= a
FT		/mod_base= g
FT		/note= "Optionally phosphorylated"
FT	modified_base	1..11
FT		/*tag= b
FT		/mod_base= OTHER
FT		/note= "OTHER= optionally phosphorochiolate linkages"
XX		
PN	WO200174342-A2.	
XX		
PD	11-OCT-2001.	
XX		
PF	30-MAR-2001; 2001WO-US10162.	
XX		
PR	31-MAR-2000; 2000US-0540843.	
XX		
PA	(UYBO-) UNIV BOSTON.	
XX		
PI	Gilchrist BA, Yaar M, Eller M;	
XX		
DR	WPI; 2001-626338/72.	
XX		
PT	Inhibiting proliferation of epithelial cells, useful e.g. for treating	
PT	carcinoma, using specific oligonucleotides that mimic the effects of	
PT	ultra-violet light	
XX		
PS	Claim 1; Page 37; 74pp: English.	
XX		
CC	The invention describes inhibition of mammalian epithelial cell	
CC	proliferation by treating cells with at least one oligonucleotide, or	
CC	its fragment. The compounds, which have cytostatic, anti-allergic,	
CC	anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and	
CC	immunosuppressive activities, function as 'ultra-violet mimics' to induce	
CC	DNA repair processes (or a protective response to later exposure to	
CC	radiation or chemicals), as a proliferation inhibitor, apoptosis inducer	
CC	or a tumour necrosis factor inhibitor. Probably they mimic products of	
CC	DNA damage, or processed DNA-damage intermediates, by inducing the p53	
CC	pathway, resulting in transient arrest of cell growth, allowing more time	
CC	for DNA repair to occur before cell division takes place. The method is	
CC	especially used to treat carcinoma but may also be used to: treat other	
CC	hyperproliferative states (e.g. psoriasis or precancerous conditions);	
CC	reduce photoaging, oxidative stress or damage; prevent skin cancer; treat	
CC	allergically mediated inflammation (atopic or contact dermatitis,	
CC	allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in	
CC	cells caused by radiation or chemicals; increase melanin production	
CC	(pigmentation) in epithelial cells (e.g. for treating vitiligo), and to	
CC	promote apoptosis in epithelial cells that contain damaged DNA. Also	
CC	oligonucleotides that contain non-hydrolyzable backbones are used to	
CC	inhibit apoptosis, in response to DNA damage, in epithelial cell. This	
CC	sequence is melanogenesis associated oligonucleotide #5, representative	
CC	of the telomere overhang sequence and one of the oligonucleotides used	
CC	to inhibit mammalian epithelial cell proliferation, described in the	
XX	method of the invention.	
XX		

SQ	Sequence	11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;
	Query Match	100.0%; Score 11; DB 23; Length 11;
	Best Local Similarity	100.0%; Pred. No. 1.7e+03;
	Matches	11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1 GTTAGGGTTAG 11 1 GTTAGGTTAG 11	
DB		
	RESULT 14	
	AAS14913/C	
ID	AAS14913 standard; DNA; 11 BP.	
XX	AAS14913;	
AC		
XX	14-FEB-2002 (first entry)	
DT		
XX	Melanogenesis associated oligonucleotide #9.	
DE		
XX	Melanin: melanogenic; oligomer; cytosolic; anti-allergic; p53;	
KW	anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;	
KW	immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;	
KW	tumour necrosis factor inhibitor; photocaging; hyperproliferative disease;	
KW	carcinoma; oxidative stress; skin cancer; allergic mediated inflammation;	
KW	conjunctivitis; allergic rhinitis; villigo; ss.	
XX		
OS	Synthetic.	
FH		
FT	Key	Location/Qualifiers
FT	modified_base	1 /'tag= a
FT		/mod_base='c
FT		/note="Phosphorylated"
PX	WO200174342-A2.	
PN		
XX	11-OCT-2001.	
PD		
XX	30-MAR-2001; 2001MO-US10162.	
PF		
XX	31-MAR-2000; 2000US-0540843.	
PR	(UYBO-) UNIV BOSTON.	
PA	Gilchrest BA, Yaar M, Eller M;	
XX		
PI		
DR	WPI; 2001-626338/72.	
XX		
PT	Inhibiting proliferation of epithelial cells, useful e.g. for treating	
PT	carcinoma, using specific oligonucleotides that mimic the effects of	
PT	ultra-violet light -	
XX		
PS	Example 12; page 37; 74pp; English.	
XX		
CC	The invention describes inhibition of mammalian epithelial cell	
CC	proliferation by treating cells with at least one oligonucleotide, or	
CC	its fragment. The compounds, which have cytostatic, anti-allergic,	
CC	anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and	
CC	immunosuppressive activities, function as 'ultra-violet mimics' to induce	
CC	DNA repair processes (or a protective response to later exposure to	
CC	radiation or chemicals), as a proliferation inhibitor, apoptosis inducer	
CC	or a tumour necrosis factor inhibitor. Probably they mimic products of	
CC	DNA damage, or processed DNA-damage intermediates, by inducing the p53	
CC	pathway, resulting in transient arrest of cell growth, allowing more time	
CC	for DNA repair to occur before carcinoma but may also be used to: treat other	
CC	especially used to treat carcinoma (e.g. psoriasis or precancerous conditions);	
CC	hyperproliferative states (e.g. psoriasis or precancerous conditions);	
CC	reduce photocaging, oxidative stress or damage; prevent skin cancer; treat	
CC	allergically mediated inflammation (atopic or contact dermatitis,	
CC	allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in	
CC	cells caused by radiation or chemicals; increase melanin production	

CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #9, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell proliferation,
 CC described in the method of the invention.
 CC
 SQ Sequence 11 BP; 4 A; 5 C; 0 G; 2 T; 0 other;
 Query Match 100.0%; Score 11; DB 23; Length 11;
 Best Local Similarity 100.0%; Pred. NO. 1.7e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTAGGGTTAG 11
 Db 11 GTTAGGGTTAG 1

RESULT 15
 AAS15434 standard; DNA; 11 BP.
 XX
 AC AAS15434;
 XX
 DT 14-FEB-2002 (first entry)
 XX
 DE PNA 7/IV inhibiting human and mammalian telomerase activity.
 XX
 KM Mammalian; peptide nucleic acid; probe; forensic; paternity testing;
 KM human telomerase RNA component; htr gene RFLP pattern; cancer;
 KM inflammation; lymphoproliferative disease; autoimmune disease;
 KM neurodegenerative disease; neoplasia; hyperplasia; HIV; AIDS;
 KM human immunodeficiency virus; acquired immunodeficiency syndrome;
 KM telomere metabolism; mutant; cytostatic; anti-inflammatory;
 KM immunosuppressive; polyamide backbone; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1.11
 FT /*tag- a
 FT /note- "This sequence is a peptide nucleic acid, i.e. it
 FT contains a polyamide backbone instead of a
 FT deoxyribose backbone"
 XX
 PN US6294650-B1.
 XX
 PD 25-SEP-2001.
 XX
 PF 08-JUL-1999; 99US-0349532.
 XX
 PR 09-APR-1997; 97US-0838545.
 PR 09-APR-1996; 96US-0630019.
 XX
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 PI Shay JW, Wright WE, Piatyszek MA, Corey DR, Norton JC;
 XX WPI; 2001-638024/73.
 DR
 XX
 PT New peptide nucleic acids that hybridizes to the RNA component of
 PT mammalian telomerase, useful for treating or preventing cancer,
 PT inflammation, lymphoproliferative diseases, autoimmune disease, or
 PT neurodegenerative diseases -
 XX
 BS Claim 7; Column 73; 46pp; English.
 CC
 CC The present invention relates to peptide nucleic acids (PNAs), comprising
 CC a sequence of 6-25 nucleobases, that inhibit telomerase activity in
 CC mammalian cells by hybridising to the RNA component of mammalian
 CC telomerase. The PNAs are useful as probes to detect the RNA component

CC of mammalian telomerase and as inhibitors of telomerase activity, or to
 CC detect and/or quantitate polynucleotide having the human telomerase
 CC RNA component (hTR) sequence, as well as in forensic identification of
 CC individuals, such as paternity testing or identification of criminal
 CC suspects or unknown descendants based on the htr gene RFLP pattern. The
 CC PNA can be further used for treating or preventing cancer, inflammation,
 CC lymphoproliferative diseases, autoimmune disease, or neurodegenerative
 CC diseases. The PNAs in combination with other pharmaceuticals (such as
 CC antineoplastic or cytostatic agents) can be used for treating neoplasia,
 CC hyperplasia, human immunodeficiency virus (HIV) infections, acquired
 CC immunodeficiency syndrome (AIDS) and associated pathologies, and other
 CC diseases characterised by abnormal telomere metabolism or telomerase
 CC activity. The present sequence represents one of the PNA sequences
 CC of the invention.
 CC
 SQ Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;
 Query Match 100.0%; Score 11; DB 23; Length 11;
 Best Local Similarity 100.0%; Pred. NO. 1.7e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTAGGGTTAG 11
 Db 1 GTTAGGGTTAG 11

Search completed: June 2, 2003, 18:45:12
 Job time : 183.98 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:29:55 ; Search time 1380.37 Seconds
(without alignments)
129.060 Million cell updates/sec

Title: US-09-540-843-5

Perfect score: 11

Sequence: 1 gtagagtag 11

Scoring table:

Gapop 10.0, Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 60474

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

EST:
1: em_estb:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hlc:*
9: gb_est1:*
10: gb_est2:*
11: gb_hlc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vit:*
22: em_gss_fun:*
23: em_gss_mam:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_rtd:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	11	100.0	19	17	AZ614760
2	11	100.0	20	17	TA158A03P
3	11	100.0	25	17	TA84A06P
4	11	100.0	27	17	AZ803795
5	11	100.0	40	17	AZ380089
6	9.4	85.5	22	17	AZ666649

	C	7	9.4	85.5	29	17	AZ514597	AZ514597	1M0361E14
	8	9.4	85.5	33	12	BG419809	BG419809	602453261	
	9	9.4	85.5	33	12	AZ334282	AZ334282	1M0063B08	
	10	9.4	85.5	34	17	AZ76073	AZ76073	2M0009M20	
	11	9.4	85.5	36	17	AZ767851	AZ767851	ArabiDops	
	12	9.4	85.5	39	9	AU008671	AU008671	ArabiDops	
	13	9.4	81.8	22	14	D18745	D18745	M05G01807	
	14	9.4	81.8	31	17	AL756692	AL756692	ArabiDops	
	15	9.4	81.8	32	9	AU255689	AU255689	ArabiDops	
	16	9.4	81.8	33	17	BH862417	BH862417	SALK_0898	
	17	9.4	81.8	34	17	AZ643251	AZ643251	1M0506F04	
	18	9.4	81.8	36	17	BH789800	BH789800	SALK_0467	
	19	9.4	81.8	40	9	AI507758	AI507758	SB12C12.Y	
	20	9.4	81.8	40	14	W12126	W12126	ma60905.r1	
	21	8.4	76.4	21	17	AZ766315	AZ766315	1M0563K14	
	22	8.4	76.4	23	17	TA319C11P	TA319C11P	ArabiDops	
	23	8.4	76.4	24	9	AU256889	AU256889	ArabiDops	
	24	8.4	76.4	25	10	AV544203	AV544203	ArabiDops	
	25	8.4	76.4	25	17	TA274G11Q	TA274G11Q	ArabiDops	
	26	8.4	76.4	27	17	AU255344	AU255344	ArabiDops	
	27	8.4	76.4	27	14	L32043	L32043	H0XXP2G6A.H	
	28	8.4	76.4	27	17	AZ789654	AZ789654	2M0037G08	
	29	8.4	76.4	30	10	BE385567	BE385567	601275826	
	30	8.4	76.4	30	17	AZ761166	AZ761166	1M0555A21	
	31	8.4	76.4	31	17	BE409249	BE409249	601301117	
	32	8.4	76.4	31	13	BM017239	BM017239	603643882	
	33	8.4	76.4	31	17	AZ782241	AZ782241	2M0022A21	
	34	8.4	76.4	32	12	BE901763	BE901763	601675392	
	35	8.4	76.4	32	17	AZ803815	AZ803815	2M0064H19	
	36	8.4	76.4	32	17	AL766020	AL766020	ArabiDops	
	37	8.4	76.4	33	17	AZ591773	AZ591773	1M0402M06	
	38	8.4	76.4	34	9	AI047833	AI047833	u64C05.x	
	39	8.4	76.4	34	9	AI132658	AI132658	u63B11.x	
	40	8.4	76.4	34	12	BE729288	BE729288	601561653	
	41	8.4	76.4	34	13	BI913027	BI913027	603176563	
	42	8.4	76.4	34	17	TA293C07Q	TA293C07Q	ArabiDops	
	43	8.4	76.4	35	9	AU263853	AU263853	ArabiDops	
	44	8.4	76.4	35	17	AZ389531	AZ389531	1M0150P07	
	45	8.4	76.4	36	14	R77023	R77023	y166d09.r1	

ALIGNMENTS

RESULT 1
LOCUS AZ614760
DEFINITION 1M0443A17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
ACCESSION AZ614760
VERSION AZ614760.1 GI:11736950
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
REFERENCE
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Rilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0443 row: A column: 17
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 19.

FEATURES

source

1. 19
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUCG1M043A17"
 /clone_1lb="Mouse 10kb plasmid UUCG1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42ny; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT

3 a 0 c 10 g 6 t

ORIGIN

Query Match 100.0%; Score 11; DB 17; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.1e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTAGGGTTAG 11
 |||||
 Db 3 GTTAGGGTTAG 13

RESULT 2

TA158A03P/c

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

1 (bases 1 to 20)

Hall, N., Bowman, S., Lennard, N.J., Doggett, J., Atkin, R.,

Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L.,

Melville, S.E., Rajandream, M.A. and Barrell, B.G.

Direct Submission

Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing

project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,

Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and

nh@sanger.ac.uk

Constructed at the Institute for Genomic Research (TIGR),

Rockville, MD. Genomic DNA isolated from a cloned population of

Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared

to give a tight size distribution (4 kb). The v + i method used for the library construction is

described in detail in Smith, H. and Venter, J.C. (Making small

insert libraries for whole genome shotgun sequencing projects. In

Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.

Barrell, Oxford University Press, 1999).
 Email: nelsayed@tigr.org
 Details of T. brucei sequencing at the Sanger Centre are available
 at http://www.sanger.ac.uk/projects/T_brucei/.

FEATURES

source

1. 20
 /organism="Trypanosoma brucei"
 /strain="TREU927"
 /db_xref="taxon:5691"
 /clone="158A03"
 /clone_1lb="Mouse 10kb plasmid UUCG1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42ny; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT

6 a 11 c 0 g 3 t

ORIGIN

Query Match 100.0%; Score 11; DB 17; Length 20;
 Best Local Similarity 100.0%; Pred. No. 7.2e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTAGGGTTAG 11
 |||||
 Db 20 GTTAGGGTTAG 10

RESULT 3

TA84A06P

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

1 (bases 1 to 25)

Hall, N., Bowman, S., Lennard, N.J., Doggett, J., Atkin, R.,

Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L.,

Melville, S.E., Rajandream, M.A. and Barrell, B.G.

Direct Submission

Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing

project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,

Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and

nh@sanger.ac.uk

Constructed at the Institute for Genomic Research (TIGR),

Rockville, MD. Genomic DNA isolated from a cloned population of

Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared

to give a tight size distribution (4 kb). The v + i method used for the library construction is

described in detail in Smith, H. and Venter, J.C. (Making small

insert libraries for whole genome shotgun sequencing projects. In

Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.

RESULT 4
AZ803795/c

LOCUS 27 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M064D22F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0064D22 F, DNA sequence.

ACCESSION AZ803795
VERSION AZ803795.1 GI:12956118
KEYWORDS GSS.

SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A., and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)

COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0064 row: D column: 22

Seq primer: CCTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 27.

FEATURES
source Location/Qualifiers

1. 27

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC2M0064D22"

/clone_1lb="Mouse 10kb plasmid UUGC1M library"

/sex="Male"

/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"

/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g114732114[gb|AF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 9 a 11 c 2 g 5 t

ORIGIN

Query Match 100.0%; Score 11; DB 17; Length 27;
Best Local Similarity 100.0%; Pred. No. 7.9e+03;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
|||||
Db 26 GTTAGGCTTAG 16

RESULT 5
AZ380089/c

LOCUS 40 bp DNA linear GSS 02-OCT-2000
DEFINITION 1M0135K14R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0135K14 R, DNA sequence.

ACCESSION AZ380089
VERSION AZ380089.1 GI:10493789
KEYWORDS GSS.

SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 40)
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A., and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)

COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0135 row: K column: 14

Seq primer: CACACGAGAAACGCTATGAC
Class: plasmid ends
High quality sequence stop: 40.

FEATURES
source Location/Qualifiers

1. 40

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC1M0135K14"

/clone_1lb="Mouse 10kb plasmid UUGC1M library"

/sex="Male"

/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"

/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The

adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g114732114[gb|AF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 14 a 15 c 1 g 10 t

ORIGIN

Query Match 100.0%; Score 11; DB 17; Length 40;
Best Local Similarity 100.0%; Pred. No. 8.9e+03;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
|||||
Db 12 GTTAGGCTTAG 2

RESULT 6
A2666649 22 bp DNA linear GSS 14-DEC-2000
LOCUS 1M0548M19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0548M19 R, DNA sequence.
ACCESSION A2666649
VERSION A2666649.1 GI:11803795
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 22)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Rellily
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
Plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert length: 10000 Std Error: 0.00
Plate: 0548 row: M column: 19
Seq primer: CACACGAGAAACAGCTATGACG
Class: plasmid ends
High quality sequence stop: 22.
Location/Qualifiers
1..22
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0548M19"
/clone_1lb="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g114732114[gb]AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance.

BASE COUNT 3 a 0 c 14 g 5 t
ORIGIN
Query Match 85.5%; Score 9.4; DB 17; Length 22;
Best Local Similarity 90.9%; Pred. No. 6.9e+04;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
| | | | | | | | | |
DB 4 GTTAGGGGTAG 14

RESULT 7
A2514597/c 29 bp DNA linear GSS 05-OCT-2000
LOCUS 1M0361E14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0361E14 F, DNA sequence.
ACCESSION A2514597
VERSION A2514597.1 GI:10695829
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 29)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Rellily
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
Plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert length: 10000 Std Error: 0.00
Plate: 0361 row: E column: 14
Seq primer: CGTTGTAAACGACGCGCACT
Class: plasmid ends
High quality sequence stop: 29.
Location/Qualifiers
1..29
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0361E14"
/clone_1lb="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g114732114[gb]AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance.

BASE COUNT 6 a 9 c 6 g 8 t
ORIGIN
Query Match 85.5%; Score 9.4; DB 17; Length 29;
Best Local Similarity 90.9%; Pred. No. 7.5e+04;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
| | | | | | | | | |
DB 12 GTTAGGGTTAG 2

RESULT 8
Bg419809 33 bp mRNA linear EST 14-MAR-2001
LOCUS 602453261F1 NIH_MGC_14 Homo sapiens cDNA clone IMAGE:4591599 5',
DEFINITION mRNA sequence.
ACCESSION Bg419809
VERSION Bg419809.1 GI:13326315
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 33)
AUTHORS NIH-MGC <http://mhc.nci.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: DCTD/DPF
cDNA Library Preparation: Ling Hong/Rubin Laboratory
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>
Plate: L1CM1328 row: j column: 16
High quality sequence stop: 33.
Location/Qualifiers
1..33
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:4591599"
/clone_lib="NIH_MGC_14"
/tissue_type="renal cell adenocarcinoma"
/lab_host="PH10B (phage-resistant)"
/note="Organ: kidney; Vector: pOT7; Site_1: XhoI; Site_2:
EcoRI; cDNA made by oligo-dT priming. Directionally
cloned into EcoRI/XhoI sites using the following 5'
adaptor: GGCACGAG(G). Size-selected >500bp for average
insert size 1.8kb. Library constructed by Ling Hong in
the laboratory of Gerald M. Rubin (University of
California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies)."
BASE COUNT 9 a 3 c 12 g 9 t
ORIGIN
Query Match 85.5%; Score 9.4; DB 12; Length 33;
Best Local Similarity 90.9%; Pred. No. 7.8e+04;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GTTAGGGTTAG 11
| | | | | | | | | | | | |
Db 7 GTTAGGGTTAG 17
| | | | | | | | | | | | |
RESULT 9
A2334282 33 bp DNA linear GSS 29-SEP-2000
LOCUS 1M0063808R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0063808 R, DNA sequence.
ACCESSION A2334282
VERSION A2334282.1 GI:10401456
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 33)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb

JOURNAL
COMMENT Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0063 row: B column: 08
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 33.
Location/Qualifiers
1..33
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0063808"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/note="Vector: pMD24nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(<http://www.jax.org/resources/documents/dnares/>). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD24 (g114732114[9b]AT29072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT 11 a 13 c 2 g 7 t
ORIGIN
Query Match 85.5%; Score 9.4; DB 17; Length 33;
Best Local Similarity 90.9%; Pred. No. 7.8e+04;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GTTAGGGTTAG 11
| | | | | | | | | | | | |
Db 22 GTTAGGGTTAG 12
| | | | | | | | | | | | |
RESULT 10
A2776073 34 bp DNA linear GSS 16-FEB-2001
LOCUS 2M0009M20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC2M0009M20 F, DNA sequence.
ACCESSION A2776073
VERSION A2776073.1 GI:12903271
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 34)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb

JOURNAL
COMMENT
Plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0009 row: M column: 20
Seq primer: CGTTGTAACGACGCGCAGT
Class: Plasmid ends
High quality sequence stop: 34.
Location/Qualifiers
1. .34
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG2M0009M20"
/clone_1lb="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42ny; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114[gb|AF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN
19 a 9 c 2 g 4 t

Query Match 85.5%; Score 9.4; DB 17; Length 34;
Best Local Similarity 90.9%; Pred. No. 7.9e+04;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
||||| |||||
Db 20 GTTAGACTTAG 10

RESULT 11
AL767851 36 bp DNA linear GSS 18-JUN-2002
LOCUS Arabidopsis thaliana T-DNA flanking sequence GK-222E01-014236,
DEFINITION genomic survey sequence.
ACCESSION AL767851
VERSION AL767851.1 GI:21520970
KEYWORDS GSS.
SOURCE
ORGANISM
Arabidopsis thaliana
thale cress.
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosidae; eurosoids II; Brassicales; Brassicaceae; Arabidopsis.
1
REFERENCE
AUTHORS
Strizhov,N., Li,Y., Rosso,M., Viehoveer,P., Dekker,K., Saedler,H.
and Weisshaar,B.
TITLE
A pipeline for automated high-throughput generation of FSTs
(flanking sequence tags) from Arabidopsis thaliana T-DNA

JOURNAL
COMMENT
transformed lines
Unpublished
REFERENCE
AUTHORS
TITLE
JOURNAL
AUTHORS
REFERENCE
TITLE
COMMENT
Rosso,M., Strizhov,N., Li,Y., Reiss,B., Dekker,K. and Weisshaar,B.
A new Arabidopsis thaliana T-DNA mutagenised population (GABI-Kat)
for flanking sequence tag based reverse genetics
Unpublished
3 (bases 1 to 36)
Rosso,M., Strizhov,N., Li,Y. and Weisshaar,B.
Direct Submission
Submitted (17-JUN-2002) Weisshaar B., Max-Planck-Institut fuer
Zuechtungsforshung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
This sequence is recovered from the left border of the T-DNA. It
indicates an insertion within the locus defined by clone F28H19.
The sequences are generated at the MPI for Plant Breeding Research
in the context of the GABI-Kat project. GABI-Kat is part of the
German Plant Genomics program designated 'GABI'. Information on
line availability can be found at:
http://www.mpiz-koeln.mpg.de/GABI-Kat/.

FEATURES
source
1. .36
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="GK-222E01-014236"
/clone_1lb="Arabidopsis thaliana T-DNA insertion lines"
/note="PCR was performed on DNA from Arabidopsis thaliana
plants (T1) which were transformed with the T-DNA from
vector PAC161. The lines contain one or more T-DNA
insertions. The DNA fragment(s) resulting from the PCR
were directly sequenced to determine the genomic sequence
flanking the insertion. Sequences displaying significant
similarity to the A. thaliana nuclear genome sequence were
processed for submission. T-DNA derived sequences were
removed"

BASE COUNT
ORIGIN
14 a 10 c 4 g 8 t

Query Match 85.5%; Score 9.4; DB 17; Length 36;
Best Local Similarity 90.9%; Pred. No. 8e+04;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
||||| |||||
Db 24 GATAGGCTTAG 14

RESULT 12
AU008671 39 bp mRNA linear EST 31-JUL-1998
LOCUS AU008671 Schizosaccharomyces pombe late log phase cDNA
DEFINITION Schizosaccharomyces pombe cDNA clone spc03845, mRNA sequence.
ACCESSION AU008671
VERSION AU008671.1 GI:3345129
KEYWORDS EST.
SOURCE
ORGANISM
fission yeast.
Schizosaccharomyces pombe
Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
Schizosaccharomycetales; Schizosaccharomycetaceae;
Schizosaccharomyces.
1 (bases 1 to 39)
REFERENCE
AUTHORS
Morimyo,M. and Mita,K.
TITLE
Identification of expressed sequence tags of Schizosaccharomyces
pombe
JOURNAL
COMMENT
Unpublished (1998)
Contact: Mitsunori Morimyo
Genome Research Group
National Institute of Radiological Sciences
9-1, Anagawa-4-chome, Inage-ku, Chiba, Chiba 263-8555, Japan
Email: morimyo@nirs.go.jp.
LOCATION/Qualifiers
1. .39
/organism="Schizosaccharomyces pombe"

SOURCE	thal cross.
ORGANISM	Arabidopsis thaliana
REFERENCE	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsids. 1
AUTHORS	Strizhov,N., Li,Y., Rosso,M., Viehoever,P., Dekker,K., Saedler,H. and Weisshaar,B.
TITLE	A pipeline for automated high-throughput generation of FSTs (flanking sequence tags) from Arabidopsis thaliana T-DNA transformed lines
JOURNAL	unpublished
REFERENCE	Rosso,M., Strizhov,N., Li,Y., Reiss,B., Dekker,K. and Weisshaar,B. A new Arabidopsis thaliana T-DNA mutagenised population (GABI-Kat) for flanking sequence tag based reverse genetics
AUTHORS	unpublished
TITLE	3 (bases 1 to 31)
JOURNAL	Strizhov,N., Rosso,M., Li,Y. and Weisshaar,B. Direct Submission Submitted (17-JUN-2002) Weisshaar B., Max-Planck-Institut fuer Zuechtungsfoerhung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany This sequence is recovered from the right border of the T-DNA. It indicates an insertion close to or within gene At1g17190. The sequences are generated at the MPI for Plant Breeding Research in the context of the GABI-Kat project. GABI-Kat is part of the German Plant Genomics program designated 'GABI'. Information on line availability can be found at: http://www.mpiz-koeln.mpg.de/GABI-Kat/ .
FEATURES	location/Qualifiers
SOURCE	1..31 /organism="Arabidopsis thaliana" /strain="Columbia 0" /db_xref="taxon:3702" /clone="GK-11H11-012331" /clone.lib="Arabidopsis thaliana T-DNA insertion lines" /note="PCR was performed on DNA from Arabidopsis thaliana plants (T1) which were transformed with the T-DNA from vector pAC161. The lines contain one or more T-DNA insertions. The DNA fragment(s) resulting from the PCR were directly sequenced to determine the genomic sequence flanking the insertion. Sequences displaying significant similarity to the A. thaliana nuclear genome sequence were processed for submission. T-DNA derived sequences were removed."
BASE COUNT	8 a 0 c 10 g 13 t
ORIGIN	
Query Match	81.8%; Score 9; DB 17; Length 31;
Best Local Similarity	100.0%; Pred. NO.1.3e+05;
Matches	9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 GTTAGGGTT 9
Dn	10 GTTAGGGTT 18
RESULT 15	
AU255689/c	32 bp mRNA linear EST 25-APR-2002
LOCUS	AU255689
DEFINITION	AU255689 3'-directed mouse CDNA library Mus musculus cDNA clone
ACCESSION	BEPD006171 3', mRNA sequence.
VERSION	AU255689
KEYWORDS	AU255689.1 GI:20318670
SOURCE	EST.
ORGANISM	house mouse. Mus musculus
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muride; Murinae; Mus. 1 (bases 1 to 32)
AUTHORS	Kato,K. and Matoba,R.
TITLE	Generation of expressed sequence tags from mouse brain
JOURNAL	Unpublished (2002)

COMMENT

Contact: Kikuya Kato
Graduate School of Biological Sciences
Nara Institute of Science and Technology
8916-5 Takayama, Ikoma, Nara 630-0101, Japan
Tel: 81-743-72-5581
Fax: 81-743-72-5589
Email: kkatodbs.aist-nara.ac.jp,
URL: <http://love2.aist-nara.ac.jp/BED/index.html>.

FEATURES

source

1. 32
/organism="Mus musculus"
/db_xref="taxon:10090"
/clone="BED0006171"
/clone_lib="3'-directed mouse cDNA library"
/tissue_type="brain"
/note="Vector: pGEM-T-easy"
Location/Qualifiers

BASE COUNT

10 a 8 c 6 g 8 t

ORIGIN

Query Match 81.8%; Score 9; DB 9; Length 32;
Best Local Similarity 100.0%; Pred. No. 1.4e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TTAGGGTTA 10
|||||

DB 31 TTAGGGTTA 23

Search completed: June 2, 2003, 20:35:47
Job time : 1384.37 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:31:20 ; Search time 45.0732 Seconds
(without alignments)
74.844 Million cell updates/sec

Title: US-09-540-843-5
Perfect score: 11
Sequence: 1 gtttaggttag 11

Scoring table:
IDENTITY_NMC
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 558892

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_MN:*
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PCOTUS.COMB.seq:*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match length	ID	Description
1	11	100.0	11 1 US-08-330-123A-2	Sequence 2, Appl1
2	11	100.0	11 1 US-08-482-115B-2	Sequence 2, Appl1
3	11	100.0	11 2 US-08-660-678A-2	Sequence 2, Appl1
4	11	100.0	11 2 US-08-531-743-11	Sequence 11, Appl1
5	11	100.0	11 2 US-08-531-743-12	Sequence 12, Appl1
6	11	100.0	11 2 US-08-485-778-36	Sequence 36, Appl1
7	11	100.0	11 2 US-08-472-802C-3	Sequence 3, Appl1
8	11	100.0	11 2 US-08-520-550A-36	Sequence 36, Appl1
9	11	100.0	11 3 US-08-630-019A-9	Sequence 9, Appl1
10	11	100.0	11 3 US-08-630-019A-30	Sequence 30, Appl1
11	11	100.0	11 3 US-08-630-019A-39	Sequence 39, Appl1
12	11	100.0	11 3 US-08-838-545-13	Sequence 13, Appl1
13	11	100.0	11 3 US-08-838-545-31	Sequence 31, Appl1
14	11	100.0	11 3 US-08-838-545-44	Sequence 44, Appl1
15	11	100.0	11 3 US-08-998-443-2	Sequence 2, Appl1
16	11	100.0	11 4 US-09-060-523-2	Sequence 2, Appl1
17	11	100.0	11 4 US-09-349-532-13	Sequence 13, Appl1
18	11	100.0	11 4 US-09-349-532-31	Sequence 31, Appl1
19	11	100.0	11 4 US-09-349-532-44	Sequence 44, Appl1
20	11	100.0	11 4 US-09-580-517-2	Sequence 2, Appl1
21	11	100.0	11 3 US-08-630-019A-10	Sequence 10, Appl1
22	11	100.0	12 3 US-08-838-545-8	Sequence 8, Appl1
23	11	100.0	12 4 US-09-349-532-8	Sequence 8, Appl1
24	11	100.0	13 4 US-08-630-019A-11	Sequence 11, Appl1
25	11	100.0	13 3 US-08-630-019A-15	Sequence 15, Appl1
26	11	100.0	13 3 US-08-838-545-1	Sequence 1, Appl1
27	11	100.0	13 3 US-08-838-545-12	Sequence 12, Appl1

28	11	100.0	13 4 US-09-349-532-1	Sequence 1, Appl1
29	11	100.0	13 4 US-09-349-532-12	Sequence 12, Appl1
30	11	100.0	15 2 US-08-531-743-4	Sequence 4, Appl1
31	11	100.0	15 3 US-08-630-019A-12	Sequence 12, Appl1
32	11	100.0	15 3 US-08-630-019A-18	Sequence 18, Appl1
33	11	100.0	15 3 US-08-630-019A-40	Sequence 40, Appl1
34	11	100.0	15 3 US-08-838-545-2	Sequence 2, Appl1
35	11	100.0	15 3 US-08-838-545-5	Sequence 5, Appl1
36	11	100.0	15 3 US-08-838-545-45	Sequence 45, Appl1
37	11	100.0	15 4 US-09-349-532-2	Sequence 2, Appl1
38	11	100.0	15 4 US-09-349-532-5	Sequence 5, Appl1
39	11	100.0	15 4 US-09-349-532-45	Sequence 45, Appl1
40	11	100.0	16 1 US-08-153-051B-11	Sequence 11, Appl1
41	11	100.0	16 2 US-08-151-477A-11	Sequence 11, Appl1
42	11	100.0	16 3 US-08-819-867-20	Sequence 20, Appl1
43	11	100.0	16 4 US-08-464-011B-60	Sequence 60, Appl1
44	11	100.0	17 2 US-08-531-743-13	Sequence 13, Appl1
45	11	100.0	17 4 US-08-857-721-12	Sequence 12, Appl1

ALIGNMENTS

RESULT 1
US-08-330-123A-2/c
; Sequence 2, Application US/08330123A
; Patent No. 5583016
GENERAL INFORMATION:
; APPLICANT: VILLEPONTIEU, Bryant
; APPLICANT: FENG, Junli
; APPLICANT: FUNK, Walter
; APPLICANT: ANDREWS, William H.
; TITLE OF INVENTION: HUMAN TELOMERASE
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Knourle and Crew
; STREET: 379 Lytton Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: US
; ZIP: 94301
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/330,123A
; FILING DATE: 27-OCT-1994
CLASSIFICATION:
; CLASSIFICATION: 435
PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/272,102
; FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M
; REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15389-000810
TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 326-2400
; TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-08-330-123A-2

Query Match 100.0%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGCTTAG 11
Db 11 GTTAGGCTTAG 1

RESULT 2

US-08-482-115B-2/c
; Sequence 2, Application US/08482115B
; Patent No. 5776679
; GENERAL INFORMATION:
; APPLICANT: Villeponteau, Bryant
; APPLICANT: Feng, Junli
; APPLICANT: Funk, Walter
; TITLE OF INVENTION: Assays for the RNA Component of Human
; TITLE OF INVENTION: Telomerase
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/482,115B
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/272,102
; FILING DATE: 07-JUL-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/330,123
; FILING DATE: 27-OCT-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Storella, John R.
; REGISTRATION NUMBER: 32,944
; REFERENCE/DOCKET NUMBER: 015389-0008300S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-08-482-115B-2

Query Match 100.0%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGCTTAG 11
Db 11 GTTAGGCTTAG 1

RESULT 3

US-08-660-678A-2/c
; Sequence 2, Application US/08660678A
; Patent No. 5837857
; GENERAL INFORMATION:
; APPLICANT: Villeponteau, Bryant
; APPLICANT: Feng, Junli
; APPLICANT: Funk, Walter
; APPLICANT: Andrews, William H.

;; TITLE OF INVENTION: Mammalian Telomerase
;; NUMBER OF SEQUENCES: 30
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Townsend and Townsend and Crew LLP
;; STREET: Two Embarcadero Center, Eighth Floor
;; CITY: San Francisco
;; STATE: California
;; COUNTRY: USA
;; ZIP: 94111-3834

;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/660,678A
;; FILING DATE: 05-JUN-1996
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/330,123
;; FILING DATE: 27-OCT-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/272,102
;; FILING DATE: 07-JUL-1994

;; ATTORNEY/AGENT INFORMATION:
;; NAME: Storella, John R.
;; REGISTRATION NUMBER: 32,944
;; REFERENCE/DOCKET NUMBER: 015389-000811US
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 576-0200
;; TELEFAX: (415) 576-0300
;; INFORMATION FOR SEQ ID NO: 2:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 11 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: RNA
US-08-660-678A-2

Query Match 100.0%; Score 11; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGCTTAG 11
Db 11 GTTAGGCTTAG 1

RESULT 4

US-08-531-743-11
; Sequence 11, Application US/08531743
; Patent No. 5856096
; GENERAL INFORMATION:
; APPLICANT: Windle, Bradford E.
; APPLICANT: Qiu, Ming
; APPLICANT: Chen, Shi-fong
; APPLICANT: Fletcher, Terrace M.
; APPLICANT: Maine, Ira
; TITLE OF INVENTION: Rapid and Sensitive Assays for Detecting and
; TITLE OF INVENTION: Distinguishing Between Processive and
; TITLE OF INVENTION: No. 5856096-Processive Telomerase Activities
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: United States of America
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/531,743
FILING DATE: 20-SEP-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Highlander, Steven L.
REGISTRATION NUMBER: 37,642
REFERENCE/DOCKET NUMBER: CTRC:026/HYL
TELECOMMUNICATION INFORMATION:
TELEPHONE: (512) 418-3000
TELEFAX: (512) 474-7577
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-531-743-11

Query Match 100.0%; Score 11; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGCTAG 11
|||||
DB 1 GTTAGGCTAG 11

RESULT 5
US-08-531-743-12/C
Sequence 12, Application US/08531743
Patent No. 5856096
GENERAL INFORMATION:
APPLICANT: Windle, Bradford E.
APPLICANT: Qiu, Ming
APPLICANT: Chen, Shi-fong
APPLICANT: Fletcher, Terrace M.
APPLICANT: Maine, Iita
TITLE OF INVENTION: Rapid and Sensitive Assays for Detecting and
TITLE OF INVENTION: Distinguishing Between Processive and
TITLE OF INVENTION: No. 5856096-Processive Telomerase Activities
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: United States of America
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/531,743
FILING DATE: 20-SEP-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Highlander, Steven L.
REGISTRATION NUMBER: 37,642
REFERENCE/DOCKET NUMBER: CTRC:026/HYL
TELECOMMUNICATION INFORMATION:
TELEPHONE: (512) 418-3000
TELEFAX: (512) 474-7577
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-531-743-12

Query Match 100.0%; Score 11; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGCTAG 11
|||||
DB 11 GTTAGGCTAG 1

RESULT 6
US-08-485-778-36/C
Sequence 36, Application US/08485778
Patent No. 5876979
GENERAL INFORMATION:
APPLICANT: Andrews, William H.
APPLICANT: Avillion, Ariel Athena
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Greider, Carol
APPLICANT: Mathuenda, Maria Antonia Blasco
APPLICANT: Villeneuve, Bryant
TITLE OF INVENTION: RNA COMPONENT OF TELOMERASE
NUMBER OF SEQUENCES: 45
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: Two Millicia Drive
CITY: Lexington
STATE: MA
COUNTRY: US
ZIP: 02173
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,778
FILING DATE: 07-JE-1995
CLASSIFICATION: 435
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/387,524
FILING DATE: 13-FEB-1995
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: CSHL94-05A4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
US-08-485-778-36

Query Match 100.0%; Score 11; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGCTAG 11
|||||
DB 11 GTTAGGCTAG 1

RESULT 7

US-08-472-802C-3/C
Sequence 3, Application US/08472802C
Patent No. 5938680
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/472,802C
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15389-000820
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-472-802C-3

Query Match 100.0%; Score 11; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||
Db 11 GTTAGGGTTAG 1

RESULT 8

US-08-520-550A-36/C
Sequence 36, Application US/08520550A
Patent No. 6013468
GENERAL INFORMATION:
APPLICANT: Andrews, William H.
APPLICANT: Avilion, Ariel A.
APPLICANT: Feng, Junli
APPLICANT: Greider, Carol
APPLICANT: Funk, Walter
APPLICANT: Marhuenda, Maria A. B.
APPLICANT: Villeponteau, Bryant
TITLE OF INVENTION: RNA Component of Telomerase
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:

ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: Two Millitia Drive
CITY: Lexington
STATE: MA
COUNTRY: US
ZIP: 02173

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/520,550A
FILING DATE: 29-AUG-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/387,524
FILING DATE: 13-FEB-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: CSHL94-05A3B
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
US-08-520-550A-36

Query Match 100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||
Db 11 GTTAGGGTTAG 1

RESULT 9

US-08-630-019A-9
Sequence 9, Application US/08630019A
Patent No. 6015710
GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Piatyszek, Mieczyslaw A.
APPLICANT: Corey, David
APPLICANT: No. 6015710ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30

;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/630,019A
;; FILING DATE: 09-JUN-1996
;; CLASSIFICATION: 536
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Storella, John R.
;; REGISTRATION NUMBER: 32,944
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 576-0200
;; TELEFAX: (415) 576-0300
;; INFORMATION FOR SEQ ID NO: 9:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 11 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: other nucleic acid
;; DESCRIPTION: /desc = "peptide nucleic acid (PNA),
;; DESCRIPTION: where (deoxy)ribose-phosphate linkages are replaced by
;; DESCRIPTION: N-(2-aminoethyl)glycine units linked to nucleotide bases via
;; DESCRIPTION: glycine amino nitrogen through a methylenecarbonyl linker"
US-08-630-019A-9

Query Match 100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
DB 1 GTTAGGCTTAG 11

RESULT 10
US-08-630-019A-30/C
; Sequence 30, Application US/08630019A
; Patent No. 6015710
; GENERAL INFORMATION:
; APPLICANT: Shay, Jerry W.
; APPLICANT: Wright, Woodring E.
; APPLICANT: Piatyszek, Mieczyslaw A.
; APPLICANT: Corey, David
; APPLICANT: No. 6015710ton, James C.
; TITLE OF INVENTION: Modulation of Mammalian Telomerase by
; TITLE OF INVENTION: Peptide Nucleic Acids
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/630,019A
; FILING DATE: 09-JUN-1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Storella, John R.
; REGISTRATION NUMBER: 32,944
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid

;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: RNA
US-08-630-019A-30

Query Match 100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
DB 1 GTTAGGCTTAG 11

RESULT 11
US-08-630-019A-39
; Sequence 39, Application US/08630019A
; Patent No. 6015710
; GENERAL INFORMATION:
; APPLICANT: Shay, Jerry W.
; APPLICANT: Wright, Woodring E.
; APPLICANT: Piatyszek, Mieczyslaw A.
; APPLICANT: Corey, David
; APPLICANT: No. 6015710ton, James C.
; TITLE OF INVENTION: Modulation of Mammalian Telomerase by
; TITLE OF INVENTION: Peptide Nucleic Acids
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/630,019A
; FILING DATE: 09-JUN-1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Storella, John R.
; REGISTRATION NUMBER: 32,944
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "phosphorothioate (PS) nucleic acid"
US-08-630-019A-39

Query Match 100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
DB 1 GTTAGGCTTAG 11

RESULT 12
US-08-838-545-13
; Sequence 13, Application US/08838545
; Patent No. 6046307

```

GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Platyszek, Mieczyslaw A.
APPLICANT: Corey, David R.
APPLICANT: No. 6046307ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/838,545
FILING DATE: 09-APR-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/630,019
FILING DATE: 09-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-00161005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "peptide nucleic acid (PNA),
DESCRIPTION: where (deoxy/ribose-phosphate linkages are replaced by
DESCRIPTION: N-(2-aminoethyl)glycine units linked to nucleotide bases via
DESCRIPTION: glycine amino N through a methylencarbonyl linker"
US-08-838-545-13

Query Match 100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGCGTTAG 11
DB 1 GTTAGCGTTAG 11

RESULT 13
US-08-838-545-31/c
Sequence 31, Application US/08838545
GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Platyszek, Mieczyslaw A.
APPLICANT: Corey, David R.
APPLICANT: No. 6046307ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 60
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/838,545
FILING DATE: 09-APR-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/630,019
FILING DATE: 09-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-00161005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "peptide nucleic acid (PNA),
DESCRIPTION: where (deoxy/ribose-phosphate linkages are replaced by
DESCRIPTION: N-(2-aminoethyl)glycine units linked to nucleotide bases via
DESCRIPTION: glycine amino N through a methylencarbonyl linker"
US-08-838-545-31

```

```

CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/838,545
FILING DATE: 09-APR-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/630,019
FILING DATE: 09-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-00161005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "peptide nucleic acid (PNA),
DESCRIPTION: where (deoxy/ribose-phosphate linkages are replaced by
DESCRIPTION: N-(2-aminoethyl)glycine units linked to nucleotide bases via
DESCRIPTION: glycine amino N through a methylencarbonyl linker"
US-08-838-545-31

Query Match 100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGCGTTAG 11
DB 1 GTTAGCGTTAG 11

RESULT 14
US-08-838-545-44
Sequence 44, Application US/08838545
GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Platyszek, Mieczyslaw A.
APPLICANT: Corey, David R.
APPLICANT: No. 6046307ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/838,545
FILING DATE: 09-APR-1997

```

```
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/630,019
FILING DATE: 09-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-001610US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 44:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "phosphorothioate (PS)
US-08-838-545-44
nucleic acid"
```

```
Query Match          100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 GTTAGGGTTAG 11
        |||
Db       1 GTTAGGGTTAG 11
```

```
RESULT 15
US-08-998-443-2/c
Sequence 2, Application US/08998443
Patent No. 6054575
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/998,443
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/660,678
FILING DATE: 05-JUN-1996
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000811US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
```

```
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-998-443-2
```

```
Query Match          100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 GTTAGGGTTAG 11
        |||
Db       11 GTTAGGGTTAG 1
```

```
Search completed: June 2, 2003, 20:38:35
Job time : 46.0732 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 19:09:45 ; Search time 78.0732 Seconds
(Without alignments)
189.976 Million cell updates/sec

Title: US-09-540-843-5

Perfect score: 11

Sequence: 1 gttagggttag 11

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 845702 seqs, 674182571 residues

Total number of hits satisfying chosen parameters: 477662

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_NA:*

1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/2/pubpna/PCR_NEM_PUB.seq:*
3: /cgn2_6/ptodata/2/pubpna/US06_NEM_PUB.seq:*
4: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
5: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
6: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
7: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/2/pubpna/US09_NEM_PUB.seq:*
10: /cgn2_6/ptodata/2/pubpna/US09_PUBCOMB.seq:*
11: /cgn2_6/ptodata/2/pubpna/US10_NEM_PUB.seq:*
12: /cgn2_6/ptodata/2/pubpna/US10_PUBCOMB.seq:*
13: /cgn2_6/ptodata/2/pubpna/US60_NEM_PUB.seq:*
14: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	11	100.0	11	9	US-09-835-370-63
2	11	100.0	11	9	US-10-122-630-5
3	11	100.0	11	9	US-10-122-630-9
4	11	100.0	11	9	US-10-122-633-5
5	11	100.0	11	9	US-10-122-633-9
6	11	100.0	11	10	US-09-057-351-2
7	11	100.0	13	9	US-09-893-252-4
8	11	100.0	13	9	US-10-038-335-1
9	11	100.0	13	9	US-10-038-335-2
10	11	100.0	18	8	US-08-463-404-5
11	11	100.0	18	8	US-08-463-404-5
12	11	100.0	18	9	US-09-893-252-1
13	11	100.0	18	9	US-10-132-002-2
14	11	100.0	18	9	US-10-132-002-4
15	11	100.0	18	9	US-10-238-732-2
16	11	100.0	18	9	US-10-044-692-295
17	11	100.0	18	9	US-10-044-692-296
18	11	100.0	18	10	US-09-057-351-26
19	11	100.0	18	10	US-09-947-659-1

20	11	100.0	18	10	US-09-947-659-2	Sequence 2, Appli
21	11	100.0	18	10	US-09-947-659-7	Sequence 7, Appli
22	11	100.0	19	10	US-09-817-387-19	Sequence 19, Appli
23	11	100.0	20	9	US-09-888-326-808	Sequence 808, App
24	11	100.0	20	9	US-10-112-653-824	Sequence 824, App
25	11	100.0	20	9	US-10-017-993-853	Sequence 853, App
26	11	100.0	20	9	US-09-776-479-853	Sequence 853, App
27	11	100.0	20	10	US-09-057-351-40	Sequence 40, Appli
28	11	100.0	20	10	US-09-816-248-36	Sequence 36, Appli
29	11	100.0	20	10	US-09-816-248-37	Sequence 37, Appli
30	11	100.0	21	9	US-10-079-5008-1	Sequence 1, Appli
31	11	100.0	21	9	US-10-040-3708-1	Sequence 1, Appli
32	11	100.0	21	10	US-09-817-387-23	Sequence 23, Appli
33	11	100.0	21	10	US-09-817-387-28	Sequence 28, Appli
34	11	100.0	21	10	US-09-801-346-2	Sequence 2, Appli
35	11	100.0	21	10	US-09-923-541-1	Sequence 1, Appli
36	11	100.0	22	9	US-09-940-1738-2	Sequence 2, Appli
37	11	100.0	22	9	US-09-940-1738-8	Sequence 8, Appli
38	11	100.0	22	10	US-09-057-351-41	Sequence 41, Appli
39	11	100.0	22	10	US-09-730-893-2	Sequence 2, Appli
40	11	100.0	22	10	US-09-730-893-8	Sequence 8, Appli
41	11	100.0	23	10	US-09-817-387-14	Sequence 14, Appli
42	11	100.0	23	10	US-09-817-387-16	Sequence 16, Appli
43	11	100.0	23	10	US-09-817-387-18	Sequence 18, Appli
44	11	100.0	24	8	US-08-463-404-6	Sequence 6, Appli
45	11	100.0	24	8	US-08-463-404-29	Sequence 29, Appli

ALIGNMENTS

RESULT 1
US-09-835-370-63
Sequence 63, Application US/09835370
Publication No. US20030022172A1
GENERAL INFORMATION:
APPLICANT: UHLMANN, EDGEN
BREIPOHL, GERHARD
APPLICANT: WILF, DAVID W
TITLE OF INVENTION: POLYMERASE NUCLEIC ACID DERIVATIVES AND AGENTS AND
TITLE OF INVENTION: POLYMERASE NUCLEIC ACID DERIVATIVES AND AGENTS AND
FILE REFERENCE: 02481.1742 SEQUENCE LISTING
CURRENT FILING DATE: 2001-04-17
NUMBER OF SEQ ID NOS: 64
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 63
LENGTH: 11
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: nucleotide
OTHER INFORMATION: base sequence of PNA derivatives that bind to
OTHER INFORMATION: viral and cellular targets
US-09-835-370-63
Query Match 100.0%; Score 11; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTAGGCTTAG 11
DB 1 GTTAGGCTTAG 11
RESULT 2
US-10-122-630-5
Sequence 5, Application US/10122630
Publication No. US20030032610A1
GENERAL INFORMATION:
APPLICANT: Gilchrist, Barbara A.
APPLICANT: Eller, Mark S.
APPLICANT: Yeat, Mina

```

; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; PCT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-5
```

```

Query Match          100.0%; Score 11; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GTTAGGGTTAG 11
        |||||||
Db       1 GTTAGGGTTAG 11
```

```

RESULT 3
US-10-122-630-9/c
; Sequence 9, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; PCT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-9
```

```

Query Match          100.0%; Score 11; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GTTAGGGTTAG 11
        |||||||
Db       1 GTTAGGGTTAG 11
```

```

Db       11 GTTAGGGTTAG 1

RESULT 4
US-10-122-633-5
; Sequence 5, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PCT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-5
```

```

Query Match          100.0%; Score 11; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GTTAGGGTTAG 11
        |||||||
Db       1 GTTAGGGTTAG 11
```

```

RESULT 5
US-10-122-633-9/c
; Sequence 9, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PCT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-9
```

```

Query Match          100.0%; Score 11; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GTTAGGGTTAG 11
        |||||||
Db       11 GTTAGGGTTAG 1
```


RESULT 6
US-09-057-351-2/c
; Sequence 2, Application US/09057351
; Patent No. US20010034439A1
; GENERAL INFORMATION:
; APPLICANT: Villeponteau, Bryant
; APPLICANT: Feng, Junli
; APPLICANT: Funk, Walter
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: Mammalian Telomerase
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/057,351
; FILING DATE: 08-APR-1994
; CLASSIFICATION: 435
; ERROR APPLICATION DATA:
; APPLICATION NUMBER: US 08/272,102
; FILING DATE: 07-JUL-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/330,123
; FILING DATE: 27-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/472,802
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Storella, John R.
; REGISTRATION NUMBER: 32,944
; REFERENCE/DOCKET NUMBER: 015389-000821US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-09-057-351-2

Query Match 100.0%; Score 11; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|:|||||:
Db 11 GTTAGGGTTAG 1

RESULT 7
US-09-893-252-4
; Sequence 4, Application US/09893252
; Publication No. US20030012755A1
; GENERAL INFORMATION:
; APPLICANT: Styczynski, Peter
; APPLICANT: Ahluwalia, Gurpreet S.
; TITLE OF INVENTION: REDUCTION OF HAIR GROWTH
; FILE REFERENCE: 00216-552001
; CURRENT APPLICATION NUMBER: US/09/893,252

; CURRENT FILING DATE: 2001-10-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-893-252-4

Query Match 100.0%; Score 11; DB 9; Length 13;
Best Local Similarity 63.6%; Pred. No. 2.2e+03;
Matches 7; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|:|||||:
Db 3 GUVAGGGUUVAG 13

RESULT 8
US-10-038-335-1
; Sequence 1, Application US/10038335
; Publication No. US20030096776A1
; GENERAL INFORMATION:
; APPLICANT: Eckert, David J.
; APPLICANT: Wyatt, Jacqueline
; APPLICANT: Bennett, C. Frank
; APPLICANT: Hanecak, Ronnie
; APPLICANT: Brown-Driver, Vickie
; APPLICANT: Vickers, Timothy
; APPLICANT: Chiang, Ming-yi
; APPLICANT: Anderson, Kevin
; TITLE OF INVENTION: Modulation of Telomere Length By Oligonucleotides Having A G-C
; FILE REFERENCE: ISIS-4976
; CURRENT APPLICATION NUMBER: US/10/038,335
; FILING DATE: 2001-01-02
; PRIOR APPLICATION NUMBER: 09/299,058
; PRIOR FILING DATE: 1999-04-23
; PRIOR APPLICATION NUMBER: 08/403,888
; PRIOR FILING DATE: 1995-06-12
; PRIOR APPLICATION NUMBER: PCT/US93/09297
; PRIOR FILING DATE: 1993-09-29
; PRIOR APPLICATION NUMBER: 07/954,185
; PRIOR FILING DATE: 1992-09-29
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 1
; LENGTH: 13
; TYPE: DNA
; ORGANISM: No. US20030096776A1el sequence
; FEATURE:
; OTHER INFORMATION: Antisense sequence
US-10-038-335-1

Query Match 100.0%; Score 11; DB 9; Length 13;
Best Local Similarity 63.6%; Pred. No. 2.2e+03;
Matches 7; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|:|||||:
Db 3 GUVAGGGUUVAG 13

RESULT 9
US-10-038-335-2
; Sequence 2, Application US/10038335
; Publication No. US20030096776A1
; GENERAL INFORMATION:
; APPLICANT: Eckert, David J.
; APPLICANT: Wyatt, Jacqueline
; APPLICANT: Bennett, C. Frank
; APPLICANT: Hanecak, Ronnie
; APPLICANT: Brown-Driver, Vickie

APPLICANT: Vickers, Timothy
APPLICANT: Chiang, Ming-Yi
APPLICANT: Anderson, Kevin
TITLE OF INVENTION: Modulation of Telomere Length By Oligonucleotides Having A G-Core
TITLE OF INVENTION: Sequence
FILE REFERENCE: ISIS-4976
CURRENT APPLICATION NUMBER: US/10/038,335
CURRENT FILING DATE: 2001-01-02
PRIOR APPLICATION NUMBER: 09/299,058
PRIOR FILING DATE: 1999-04-23
PRIOR APPLICATION NUMBER: 08/403,888
PRIOR FILING DATE: 1995-06-12
PRIOR APPLICATION NUMBER: PCT/US93/09297
PRIOR FILING DATE: 1993-09-29
PRIOR APPLICATION NUMBER: 07/954,185
PRIOR FILING DATE: 1992-09-29
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2
LENGTH: 13
TYPE: DNA
ORGANISM: No. US20030096776A1el sequence
FEATURE:
OTHER INFORMATION: Antisense sequence
US-10-038-335-2

Query Match 100.0%; Score 11; DB 9; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
DB 3 GTTAGGTTAG 13

RESULT 10
US-08-463-404-4/C
Sequence 4, Application US/08463404
Patent No. US20020127634A1
GENERAL INFORMATION:
APPLICANT: Michael D. West
APPLICANT: Jerry W. Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth Blackburn
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF CONDITIONS
RELATED TO TELOMERE LENGTH AND/OR
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,404
FILING DATE: 05-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,952
FILING DATE: May 13, 1993
APPLICATION NUMBER: 07/882,438
FILING DATE: May 13, 1992
APPLICATION NUMBER: 08/038,766
FILING DATE: March 24, 1993

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 202/045
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-463-404-4

Query Match 100.0%; Score 11; DB 8; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
DB 13 GTTAGGTTAG 3

RESULT 11
US-08-463-404-5
Sequence 5, Application US/08463404
Patent No. US20020127634A1
GENERAL INFORMATION:
APPLICANT: Michael D. West
APPLICANT: Jerry W. Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth Blackburn
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF CONDITIONS
RELATED TO TELOMERE LENGTH AND/OR
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,404
FILING DATE: 05-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,952
FILING DATE: May 13, 1993
APPLICATION NUMBER: 07/882,438
FILING DATE: May 13, 1992
APPLICATION NUMBER: 08/038,766
FILING DATE: March 24, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 202/045
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:

LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-463-404-5

Query Match 100.0%; Score 11; DB 8; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11
Db 6 GTTAGGGTTAG 16

RESULT 12
US-09-893-252-1
Sequence 1, Application US/09893252
Publication No. US20030012755A1
GENERAL INFORMATION:
APPLICANT: Styczynski, Peter
APPLICANT: Ahluwalia, Gurpreet S.
TITLE OF INVENTION: REDUCTION OF HAIR GROWTH
FILE REFERENCE: 00216-552001
CURRENT APPLICATION NUMBER: US/09/893,252
CURRENT FILING DATE: 2001-10-12
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 1
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-09-893-252-1

Query Match 100.0%; Score 11; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11
Db 6 GTTAGGGTTAG 16

RESULT 13
US-10-132-002-2/c
Sequence 2, Application US/10132002
Publication No. US20030022204A1
GENERAL INFORMATION:
APPLICANT: Lansdorp, Peter
TITLE OF INVENTION: Method for Detecting Multiple Copies of
a Repeat Sequence in a Nucleic Acid Molecule
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESSES:
ADDRESSEE: HOWSON & HOWSON
STREET: 321 NO. US20030022204A1ristown Road
CITY: Spring House
STATE: PA
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/132,002
FILING DATE: 25-Apr-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/730,635
FILING DATE: 11-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.

REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-132-002-2

Query Match 100.0%; Score 11; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11
Db 13 GTTAGGGTTAG 3

RESULT 14
US-10-132-002-4
Sequence 4, Application US/10132002
Publication No. US20030022204A1
GENERAL INFORMATION:
APPLICANT: Lansdorp, Peter
TITLE OF INVENTION: Method for Detecting Multiple Copies of
a Repeat Sequence in a Nucleic Acid Molecule
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESSES:
ADDRESSEE: HOWSON & HOWSON
STREET: 321 NO. US20030022204A1ristown Road
CITY: Spring House
STATE: PA
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/132,002
FILING DATE: 25-Apr-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/730,635
FILING DATE: 11-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-10-132-002-4

Query Match 100.0%; Score 11; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;

Matches 11: Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
|||||
Db 6 GTTAGGTTAG 16

RESULT 15

US-10-238-732-2/C
; Sequence 2, Application US/10238732
; Publication No. US20030077635A1
; GENERAL INFORMATION:
; APPLICANT: DAKO A/S
; TITLE OF INVENTION: DENDRIMERS AND METHODS FOR THEIR PREPARATION AND USE
; FILE REFERENCE: P65587US1
; CURRENT APPLICATION NUMBER: US/10/238,732
; CURRENT FILING DATE: 2002-09-11
; PRIOR APPLICATION NUMBER: 09/606,315
; PRIOR FILING DATE: 2000-06-29
; PRIOR APPLICATION NUMBER: PA 1999 00934
; PRIOR FILING DATE: 1999-06-29
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Linker sequence.
US-10-238-732-2

Query Match 100.0%; Score 11; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
|||||
Db 16 GTTAGGTTAG 6

Search completed: June 2, 2003, 23:43:14
Job time : 79.0732 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:06:10 ; Search time 247.39 Seconds
(without alignments)
823.475 Million cell updates/sec

Title: US-09-540-843-3

Perfect score: 7
Sequence: 1 agtata 7

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 774614

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : GenBank:
1: gb_da:*
2: gb_htg:*
3: gb_in:*
4: gb_lm:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vt:*
15: em_da:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vt:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htg_mus:*
34: em_htg_pln:*
35: em_htg_rtd:*
36: em_htg_mam:*
37: em_htg_vrt:*
38: em_sy:*
39: em_htgo_hum:*
40: em_htgo_mus:*
41: em_htgo_other:*

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	DB ID	Description
1	7	100.0	7	AX268755	AX268755 Sequence
2	7	100.0	7	AX268759	AX268759 Sequence
3	7	100.0	9	AX268753	AX268753 Sequence
4	7	100.0	10	AX377258	AX377258 Sequence
5	7	100.0	10	BD007857	BD007857 LPS activ
6	7	100.0	11	AX470905	AX470905 Sequence
7	7	100.0	12	AX1497	AX1497 Sequence 24
8	7	100.0	13	AX018746	AX018746 Sequence
9	7	100.0	14	A33152	A33152 Synthetic H
10	7	100.0	14	AR082813	AR082813 Sequence
11	7	100.0	14	AR088823	AR088823 Sequence
12	7	100.0	14	AX018748	AX018748 Sequence
13	7	100.0	14	AX345036	AX345036 Sequence
14	7	100.0	15	A33153	A33153 Synthetic H
15	7	100.0	15	AR041154	AR041154 Sequence
16	7	100.0	15	AR082814	AR082814 Sequence
17	7	100.0	15	AR130719	AR130719 Sequence
18	7	100.0	15	AR130720	AR130720 Sequence
19	7	100.0	15	AR131705	AR131705 Sequence
20	7	100.0	15	AR132890	AR132890 Sequence
21	7	100.0	15	AX018750	AX018750 Sequence
22	7	100.0	15	AX377250	AX377250 Sequence
23	7	100.0	15	I77317	I77317 Sequence 24
24	7	100.0	15	I77620	I77620 Sequence 32
25	7	100.0	16	AR002583	AR002583 Sequence
26	7	100.0	16	AR072256	AR072256 Sequence
27	7	100.0	16	AR105728	AR105728 Sequence
28	7	100.0	16	I26367	I26367 Sequence 59
29	7	100.0	17	A26687	A26687 Sonde L1p8
30	7	100.0	17	AR032060	AR032060 Sequence
31	7	100.0	17	AR039517	AR039517 Sequence
32	7	100.0	17	AR039519	AR039519 Sequence
33	7	100.0	17	AR039521	AR039521 Sequence
34	7	100.0	17	AR039523	AR039523 Sequence
35	7	100.0	17	AR039965	AR039965 Sequence
36	7	100.0	17	AR039967	AR039967 Sequence
37	7	100.0	17	AR060343	AR060343 Sequence
38	7	100.0	17	AR082789	AR082789 Sequence
39	7	100.0	17	AX263248	AX263248 Sequence
40	7	100.0	17	AX263249	AX263249 Sequence
41	7	100.0	17	AX324985	AX324985 Sequence
42	7	100.0	17	AX324986	AX324986 Sequence
43	7	100.0	17	AX457048	AX457048 Sequence
44	7	100.0	17	AX457049	AX457049 Sequence
45	7	100.0	17	I37448	I37448 Sequence 46

ALIGNMENTS

RESULT 1
AX268755
LOCUS
DEFINITION
AX268755
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL

Pred. No. is the number of results predicted by chance to have a

FEATURES
source
1. .7
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
3 a 0 c 2 g
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 7; DB 6; Length 7;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
1 AGTATGA 7
|||||
1 AGTATGA 7

Db
1 AGTATGA 7

RESULT 2
AX268759 7 bp DNA linear PAT 29-OCT-2001
LOCUS
DEFINITION
Sequence 7 from Patent WO0174342.
AX268759
ACCESSION
AX268759.1 GI:16541831
VERSION
KEYWORDS
SOURCE
synthetic construct.
ORGANISM
artificial sequences.

REFERENCE
1
AUTHORS
Gilchrest, B.A., Yaar, M. and Eller, M.
TITLE
Use of locally applied dna fragments
JOURNAL
Patent: WO 0174342-A 7 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
FEATURES
source
1. .7
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
3 a 0 c 2 g
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 7; DB 6; Length 7;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
1 AGTATGA 7
|||||
1 AGTATGA 7

Db
1 AGTATGA 7

RESULT 3
AX268753 9 bp DNA linear PAT 29-OCT-2001
LOCUS
DEFINITION
Sequence 1 from Patent WO0174342.
AX268753
ACCESSION
AX268753.1 GI:16541825
VERSION
KEYWORDS
SOURCE
synthetic construct.
ORGANISM
artificial sequences.

REFERENCE
1
AUTHORS
Gilchrest, B.A., Yaar, M. and Eller, M.
TITLE
Use of locally applied dna fragments
JOURNAL
Patent: WO 0174342-A 1 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
FEATURES
source
1. .9
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
3 a 0 c 4 g
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 7; DB 6; Length 9;

Best Local Similarity 100.0%; Pred. No. 3.2e+09;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
1 AGTATGA 7
|||||
2 AGTATGA 8

Db
2 AGTATGA 8

RESULT 4
AX377258/c 10 bp DNA linear PAT 18-MAR-2002
LOCUS
DEFINITION
Sequence 20 from Patent WO0212562.
AX377258
ACCESSION
AX377258
VERSION
AX377258.1 GI:19573546
KEYWORDS
SOURCE
human.

ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1
AUTHORS
Kazeml, A., Kilem, S.E. and Koshy, B.
TITLE
Haplotypes of the plazgib gene
JOURNAL
Patent: WO 0212562-A 20 14-FEB-2002;
Genaisance Pharmaceuticals, Inc. (US)
FEATURES
source
1. .10
/organism="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT
3 a 3 c 0 g 4 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 7; DB 6; Length 10;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
1 AGTATGA 7
|||||
9 AGTATGA 3

Db
9 AGTATGA 3

RESULT 5
BD007857 10 bp DNA linear PAT 31-JAN-2002
LOCUS
DEFINITION
LPS activated human monocyte expressing genes.
BD007857
ACCESSION
BD007857.1 GI:18636230
VERSION
JP 2001069993-A/133.
KEYWORDS
SOURCE
Homo sapiens.
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1 (bases 1 to 10)
AUTHORS
Matsushima, K., Hashimoto, S. and Suzuki, T.
TITLE
LPS activated human monocyte expressing genes
JOURNAL
Patent: JP 2001069993-A 133 21-MAR-2001;
JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT
OS Homo sapiens (human)
PN JP 2001069993-A/133
PD 21-MAR-2001
PF 28-APR-2000 JP 2000131079

PR KOJI MATSUSHIMA, SHINICHI HASHIMOTO, TAKUJI SUZUKI PC
C12N15/09, C07K14/47, C07K16/18, G01N33/50, G01N33/53//A61K45/00, PC
A61P29/00,
PC A61P31/00, C12P21/08, C12N15/00

CC
FH
FT
Key
source
Location/Qualifiers
1. .10
/organism="Homo sapiens"
/db_xref="taxon:9606"

BASE COUNT 4 a 0 c 4 g 2 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||
1 AGTATGA 7

Db

RESULT 6
LOCUS AX470905 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 482 from Patent WO2053773.
ACCESSION AX470905
VERSION AX470905.1 GI:22206030
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 482 11-JUL-2002;
HENKEL KGAA (DE)

FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/db_xref="taxon:9606"

BASE COUNT 4 a 2 c 2 g 3 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||
1 AGTATGA 7

Db

RESULT 7
LOCUS A91497 12 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 24 from Patent WO9824928.
ACCESSION A91497
VERSION A91497.1 GI:6740452
KEYWORDS
SOURCE unidentified.
ORGANISM unidentified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Pallisgaard,N. and Hokland,P.
TITLE DETECTION OF CHROMOSOMAL ABNORMALITIES
JOURNAL Patent: WO 9824928-A 24 11-JUN-1998;
PALLISGAARD NIELS (DK); HOKLAND PETER (DK)

FEATURES
source Location/Qualifiers
1..12
/organism="unidentified"
/db_xref="taxon:32644"

BASE COUNT 2 a 4 c 2 g 4 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.9e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||
11 AGTATGA 5

Db

RESULT 8
LOCUS AX018746/c 13 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 4 from Patent WO943848.
ACCESSION AX018746
VERSION AX018746.1 GI:10042869
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 13)
AUTHORS Ong,C.J. and Jirik,F.R.
TITLE Protein interaction and transcription factor trap
JOURNAL Patent: WO 943848-A 4 02-SEP-1999;
ONG CHRISTOPHER J (CA); JIRIK FRANK R (CA)

FEATURES
source Location/Qualifiers
1..13
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligomer for adjusting a reading frame for ligation"

BASE COUNT 3 a 4 c 1 g 5 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 13;
Best Local Similarity 100.0%; Pred. No. 6.8e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||
7 AGTATGA 1

Db

RESULT 9
LOCUS A33152 14 bp DNA linear PAT 07-MAY-1996
DEFINITION Synthetic HLA DR typing probe.
ACCESSION A33152
VERSION A33152.1 GI:1567736
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
FEATURES
source Location/Qualifiers
1..14
/organism="synthetic construct"
/db_xref="taxon:32630"

BASE COUNT 6 a 1 c 4 g 3 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||
8 AGTATGA 14

Db

RESULT 10
LOCUS AR082813 14 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 27 from patent US 5976789.
ACCESSION AR082813
VERSION AR082813.1 GI:10009603
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)

AUTHORS Allibert,P.Andre., Cros,P., Mach,B.Francois., Mandrand,B.Fabien.
and Tiercy,J.-M.
TITLE System of probes enabling HLA-DR typing to be performed, and typing
method using said probes
JOURNAL Patent: US 5976789-A 27 02-NOV-1999;
FEATURES Location/Qualifiers
source 1..14
BASE COUNT 6 a 1 c 4 g 3 t

Query Match 100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 8 AGTATGA 14

RESULT 11
AR088823/c
LOCUS AR088823 14 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 4 from patent US 5990294.
ACCESSION AR088823
VERSION AR088823.1 GI:10015586
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 14)
AUTHORS Murphy,G.P., Boynton,A.L. and Sehgal,A.
TITLE Nucleotide and amino acid sequences of C4-2, a tumor suppressor
gene, and methods of use thereof
JOURNAL Patent: US 5990294-A 4 23-NOV-1999;
FEATURES Location/Qualifiers
source 1..14
BASE COUNT 2 a 4 c 2 g 5 t 1 others

Query Match 100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 14 AGTATGA 8

RESULT 12
AX018748/c
LOCUS AX018748 14 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 6 from Patent WO943848.
ACCESSION AX018748
VERSION AX018748.1 GI:10042871
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 14)
AUTHORS Ong,C.J. and Jirik,F.R.
TITLE Protein interaction and transcription factor trap
JOURNAL Patent: WO 943848-A 6 02-SEP-1999;
ONG CHRISTOPHER J (CA); UNIV BRITISH COLUMBIA (CA); JIRIK FRANK R
(CA)
FEATURES Location/Qualifiers
source 1..14
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligomer for adjusting a reading frame for
ligation"

BASE COUNT 3 a 4 c 2 g 5 t

ORIGIN
Query Match 100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 7 AGTATGA 1

RESULT 13
AX343036/c
LOCUS AX343036 14 bp DNA linear PAT 12-JAN-2002
DEFINITION Sequence 22 from Patent WO0198350.
ACCESSION AX343036
VERSION AX343036.1 GI:18152236
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1
AUTHORS Reinhard,C., Jefferson,A.B., Winter,J.A. and Randazzo,F.
TITLE Compositions and methods for treating neoplastic disease using net
-4 modulators
JOURNAL Patent: WO 0198350-A 22 27-DEC-2001;
CHIRON CORPORATION (US)
FEATURES Location/Qualifiers
source 1..14
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligonucleotide NET-4 oligo 868 used for in-situ
hybridization"

BASE COUNT 3 a 4 c 2 g 5 t

ORIGIN
Query Match 100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 13 AGTATGA 7

RESULT 14
A33153
LOCUS A33153 15 bp DNA linear PAT 07-MAY-1996
DEFINITION Synthetic HLA DR typing probe.
ACCESSION A33153
VERSION A33153.1 GI:1567737
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 15)
AUTHORS
TITLE
JOURNAL
LOCATION/Qualifiers
source 1..15
/organism="synthetic construct"
/db_xref="taxon:32630"

BASE COUNT 6 a 1 c 5 g 3 t

ORIGIN
Query Match 100.0%; Score 7; DB 6; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 9 AGTATGA 15

RESULT 15
AR041154/c

LOCUS AR041154 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2 from patent US 5811270.
ACCESSION AR041154
VERSION AR041154.1 GI:5961650
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 15)
TITLE Grandgenett, D.P.
JOURNAL In vitro method for concerted integration of donor DNA molecules
using retroviral integrase proteins
Patent: US 5811270-A 2 22-SEP-1998;
FEATURES
source 1..15
location/Qualifiers
BASE COUNT 2 a /organism="unknown" 4 c 4 g 5 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 15;
Best Local Similarity 100.0%; Pred. No. 6,7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||
Db 9 AGTATGA 3

Search completed: June 2, 2003, 19:09:36
Job time : 249.39 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:06:10 ; Search time 318.073 Seconds

(without alignments)
823.475 Million cell updates/sec

Title: US-09-540-843-1

Perfect score: 9

Sequence: 1 gagatgag 9

Scoring table: IDENTITY_NDC

Gapop 10.0 , Gapext 1.0

Searched: 2054640 segs, 14551402878 residues

774614

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 40

Database :

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Genembl:*

- 1: gb_ba:*
- 2: gb_hcg:*
- 3: gb_in:*
- 4: gb_om:*
- 5: gb_ov:*
- 6: gb_pat:*
- 7: gb_ph:*
- 8: gb_pl:*
- 9: gb_pr:*
- 10: gb_ro:*
- 11: gb_sy:*
- 12: gb_un:*
- 13: gb_vl:*
- 14: gb_vl:*
- 15: em_ba:*
- 16: em_fun:*
- 17: em_hum:*
- 18: em_in:*
- 19: em_mu:*
- 20: em_om:*
- 21: em_or:*
- 22: em_ov:*
- 23: em_pat:*
- 24: em_ph:*
- 25: em_pl:*
- 26: em_ro:*
- 27: em_sy:*
- 28: em_un:*
- 29: em_vl:*
- 30: em_hcg_hum:*
- 31: em_hcg_inv:*
- 32: em_hcg_other:*
- 33: em_hcg_mus:*
- 34: em_hcg_pln:*
- 35: em_hcg_rtd:*
- 36: em_hcg_mam:*
- 37: em_hcg_vrt:*
- 38: em_sy:*
- 39: em_hcg_hum:*
- 40: em_hcg_mus:*
- 41: em_hcg_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	9	100.0	9	AX268753	AX268753 Sequence
2	9	100.0	15	AR130719	AR130719 Sequence
3	9	100.0	15	AR130720	AR130720 Sequence
4	9	100.0	17	AR039517	AR039517 Sequence
5	9	100.0	17	AR039519	AR039519 Sequence
6	9	100.0	17	AR039521	AR039521 Sequence
7	9	100.0	17	AR039523	AR039523 Sequence
8	9	100.0	18	AR039525	AR039525 Sequence
9	9	100.0	20	AR116520	AR116520 Sequence
10	9	100.0	20	AR116521	AR116521 Sequence
11	9	100.0	22	AX338664	AX338664 Sequence
12	9	100.0	23	AX404121	AX404121 Sequence
13	9	100.0	25	AX454970	AX454970 Sequence
14	9	100.0	25	E13462	E13462 PCR primer
15	9	100.0	26	AX112180	AX112180 Sequence
16	9	100.0	26	AX327686	AX327686 Sequence
17	9	100.0	27	AX115612	AX115612 Sequence
18	9	100.0	30	I08713	I08713 Sequence 1
19	9	100.0	31	AR07084	AR07084 Sequence 12
20	9	100.0	31	AX87152	AX87152 Sequence 12
21	9	100.0	31	AX229078	AX229078 Sequence
22	9	100.0	31	AX249534	AX249534 Sequence
23	9	100.0	32	AX339727	AX339727 Sequence
24	9	100.0	33	AX281025	AX281025 Sequence
25	9	100.0	33	AX281060	AX281060 Sequence
26	9	100.0	33	AX463705	AX463705 Sequence
27	9	100.0	34	AR080618	AR080618 Sequence
28	9	100.0	34	AX416939	AX416939 Sequence
29	9	100.0	36	AR07098	AR07098 Sequence 8
30	9	100.0	36	AR07126	AR07126 Sequence 36
31	9	100.0	36	AR206352	AR206352 Sequence
32	9	100.0	36	AR206380	AR206380 Sequence
33	9	100.0	36	AX300708	AX300708 Sequence
34	9	100.0	37	AR07090	AR07090 Sequence 18
35	9	100.0	37	AR07160	AR07160 Sequence 20
36	9	100.0	38	AR07076	AR07076 Sequence 4
37	9	100.0	38	AR07120	AR07120 Sequence 30
38	9	100.0	38	AR07144	AR07144 Sequence 4
39	9	100.0	38	AR07171	AR07171 Sequence 6
40	9	100.0	38	AR159979	AR159979 Sequence
41	9	100.0	38	AR206374	AR206374 Sequence
42	9	100.0	38	AX028965	AX028965 Sequence
43	9	100.0	39	AR07099	AR07099 Sequence 9
44	9	100.0	39	AR183718	AR183718 Sequence
45	9	100.0	39	AR206353	AR206353 Sequence

ALIGNMENTS

RESULT 1	AX268753	9 bp	DNA	Linear	PAT 29-OCT-2001
LOCUS	AX268753				
DEFINITION	Sequence 1 from Patent WO0174342.				
ACCESSION	AX268753				
VERSION	AX268753.1				
KEYWORDS	GI:16541825				
SOURCE					
ORGANISM					
REFERENCE	1				
AUTHORS	Gilchrist,B.A., Yaar,M. and Eiler,M.				
TITLE	Use of locally applied dna fragments				
JOURNAL	Patent: WO 0174342-A 1 11-OCT-2001;				
	TRUSTEES OF BOSTON UNIVERSITY (US)				

FEATURES Location/Qualifiers
 source 1..9
 /organism="Synthetic construct"
 /db_xref="taxon:32630"
 /note="Synthetic DNA Fragment"

BASE COUNT 3 a 0 c 4 g 2 t

Query Match 100.0%; Score 9; DB 6; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.2e+09;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 |||||
 1 GAGTATGAG 9

RESULT 2
 ARI30719/c
 LOCUS ARI30719 15 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 6 from patent US 6190866.
 ACCESSION ARI30719
 VERSION ARI30719.1 GI:14119044
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Nielsen,P.E. and Good,L.
 TITLE Methods of bacterial gene function determination using peptide
 nucleic acids
 JOURNAL Patent: US 6190866-A 6 20-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..15
 /organism="unknown"

BASE COUNT 3 a 6 c 0 g 6 t

Query Match 100.0%; Score 9; DB 6; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 |||||
 11 GAGTATGAG 3

RESULT 3
 ARI30720/c
 LOCUS ARI30720 15 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 7 from patent US 6190866.
 ACCESSION ARI30720
 VERSION ARI30720.1 GI:14119045
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Nielsen,P.E. and Good,L.
 TITLE Methods of bacterial gene function determination using peptide
 nucleic acids
 JOURNAL Patent: US 6190866-A 7 20-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..15
 /organism="unknown"

BASE COUNT 5 a 4 c 1 g 5 t

Query Match 100.0%; Score 9; DB 6; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9

DB 14 GAGTATGAG 6
 |||||

RESULT 4
 AR039517/c
 LOCUS AR039517 17 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 365 from patent US 5807743.
 ACCESSION AR039517
 VERSION AR039517.1 GI:5958880
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
 TITLE Interleukin-2 receptor gamma-chain ribozymes
 JOURNAL Patent: US 5807743-A 365 15-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 3 a 7 c 2 g 5 t

Query Match 100.0%; Score 9; DB 6; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 |||||
 17 GAGTATGAG 9

RESULT 5
 AR039519/c
 LOCUS AR039519 17 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 367 from patent US 5807743.
 ACCESSION AR039519
 VERSION AR039519.1 GI:5958882
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
 TITLE Interleukin-2 receptor gamma-chain ribozymes
 JOURNAL Patent: US 5807743-A 367 15-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 3 a 7 c 2 g 5 t

Query Match 100.0%; Score 9; DB 6; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 |||||
 15 GAGTATGAG 7

RESULT 6
 AR039521/c
 LOCUS AR039521 17 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 369 from patent US 5807743.
 ACCESSION AR039521
 VERSION AR039521.1 GI:5958884
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)

AUTHORS Stinchcomb,D.T. and MCSwiggan,J.A.
 TITLE Interleukin-2 receptor gamma-chain ribozymes
 JOURNAL Patent: US 5807743-A 369 15-SEP-1998;
 FEATURES Location/Qualifiers
 SOURCE 1..17
 BASE COUNT 3 a 8 c 1 g 5 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 ||||||||
 DB 12 GAGTATGAG 4

RESULT 7
 AR039523/c AR039523 17 bp DNA linear PAT 29-SEP-1999
 LOCUS Sequence 371 from patent US 5807743.
 DEFINITION AR039523
 ACCESSION AR039523
 VERSION AR039523.1 GI:5958886
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T. and MCSwiggan,J.A.
 TITLE Interleukin-2 receptor gamma-chain ribozymes
 JOURNAL Patent: US 5807743-A 371 15-SEP-1998;
 FEATURES Location/Qualifiers
 SOURCE 1..17
 BASE COUNT 4 a 9 c 0 g 4 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 ||||||||
 DB 9 GAGTATGAG 1

RESULT 8
 AX306555/c AX306555 18 bp DNA linear PAT 11-DEC-2001
 LOCUS Sequence 1 from Patent WO0187285.
 DEFINITION AX306555
 ACCESSION AX306555
 VERSION AX306555.1 GI:17645773
 KEYWORDS
 SOURCE black rat.
 ORGANISM Rattus
 Rattus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
 Rattus.
 REFERENCE 1
 AUTHORS Johns,R.A. and Tao,Y.C.
 TITLE Inhibition of the interaction of psd93 and psd95 with the nmos and
 nmda receptors
 JOURNAL Patent: WO 0187285-A 1 22-NOV-2001;
 The Johns Hopkins University (US) ; Johns, Roger A. (US) ; Tao,
 Yianxiang (US)
 FEATURES Location/Qualifiers
 SOURCE 1..18
 BASE COUNT 3 a 6 c 2 g 7 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 18;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 ||||||||
 DB 18 GAGTATGAG 10

RESULT 9
 AR116520 AR116520 20 bp DNA linear PAT 16-MAY-2001
 LOCUS Sequence 101 from patent US 6133246.
 DEFINITION AR116520
 ACCESSION AR116520
 VERSION AR116520.1 GI:14096842
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS McKay,R., Dean,N., Monia,B.P., Nero,P.S. and Gaarde,W.A.
 TITLE Antisense oligonucleotide compositions and methods for the
 modulation of JNK proteins
 JOURNAL Patent: US 6133246-A 101 17-OCT-2000;
 FEATURES Location/Qualifiers
 SOURCE 1..20
 BASE COUNT 4 a 3 c 7 g 6 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.3e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 ||||||||
 DB 9 GAGTATGAG 17

RESULT 10
 AR116521 AR116521 20 bp DNA linear PAT 16-MAY-2001
 LOCUS Sequence 102 from patent US 6133246.
 DEFINITION AR116521
 ACCESSION AR116521
 VERSION AR116521.1 GI:14096843
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS McKay,R., Dean,N., Monia,B.P., Nero,P.S. and Gaarde,W.A.
 TITLE Antisense oligonucleotide compositions and methods for the
 modulation of JNK proteins
 JOURNAL Patent: US 6133246-A 102 17-OCT-2000;
 FEATURES Location/Qualifiers
 SOURCE 1..20
 BASE COUNT 5 a 3 c 7 g 5 t
 ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.3e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 ||||||||
 DB 9 GAGTATGAG 17

RESULT 11
 AX338664/c AX338664 22 bp DNA linear PAT 09-JAN-2002
 LOCUS Sequence 29 from Patent WO0164713.
 DEFINITION

ACCESSION AX338664
VERSION AX338664.1 GI:18129026
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Gasche, C., Zakeri, S.M. and Reinisch, W.
JOURNAL Mammalian Interleukin-10 (11-10) receptor variants
Patent: WO 0164713-A 29 07-SEP-2001;
Gasche, Christoph (AT) ; Zakeri, Schaker M. (AT)
Location/Qualifiers
FEATURES
source 1..22
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="primer"
BASE COUNT 6 a 6 c 5 g 5 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 5.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
|||||
Db 15 GAGTATGAG 7
RESULT 12
AX404121/c 23 bp DNA linear PAT 14-JUN-2002
LOCUS Sequence 17 from Patent WO0222819.
DEFINITION AX404121
ACCESSION AX404121
VERSION AX404121.1 GI:21437421
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Sonderogger, P., Hintsch, G., Kinter, J., Meskenalte, V., Schirmpf, S.,
Vogl, L. and Zurlinden, A.
TITLE Calcium binding proteins
JOURNAL Patent: WO 0222819-A 17 21-MAR-2002;
Universitaet Zuerich (CH)
Location/Qualifiers
FEATURES
source 1..23
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="primer"
BASE COUNT 6 a 8 c 3 g 5 t 1 others
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 5.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
|||||
Db 20 GAGTATGAG 12
RESULT 13
AX454970 25 bp DNA linear PAT 06-JUL-2002
LOCUS Sequence 37 from Patent WO0208453.
DEFINITION AX454970
ACCESSION AX454970
VERSION AX454970.1 GI:21714155
KEYWORDS
SOURCE dog.
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE 1

AUTHORS Farr, S.B., Pickett, G.C., Neft, R.E. and Dunn, R.T.
TITLE Canine toxicity genes
JOURNAL Patent: WO 0208453-A 37 31-JAN-2002;
Phase-1 Molecular Toxicology (US)
FEATURES
source 1..25
/organism="Canis familiaris"
/db_xref="taxon:9615"
BASE COUNT 8 a 2 c 10 g 5 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 25;
Best Local Similarity 100.0%; Pred. No. 5.2e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
|||||
Db 9 GAGTATGAG 17
RESULT 14
E13462 25 bp DNA linear PAT 27-APR-1998
LOCUS PCR primer for detecting mRNA which encode human cholecystokinin/
pancreozym.
DEFINITION E13462
ACCESSION E13462
VERSION E13462.1 GI:3252267
KEYWORDS JP 1997187299-A/24.
SOURCE unidentified.
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 25)
AUTHORS Kimoto, Y.
TITLE PRIMER FOR PCR
JOURNAL Patent: JP 1997187299-A 24 22-JUL-1997;
NIPPON BIO SERAPII KK
COMMENT
OS None
OC Artificial sequences.
PN JP 1997187299-A/24
PD 22-JUL-1997
PF 05-JAN-1996 JP 1996027222
PI KIMOTO YASUHIKO
PC C1201/68, C07H21/04, C12N15/09;
CC strandedness: Single;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: Yes;
FH Key
FH Location/Qualifiers
FT source 1..25
FT /organism="Artificial sequences" FT
FT misc-feature 1..25
FT /note="PCR primer, CCK-4".
FEATURES
source 1..25
/organism="unidentified"
/db_xref="taxon:32644"
BASE COUNT 5 a 8 c 6 g 6 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 25;
Best Local Similarity 100.0%; Pred. No. 5.2e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
|||||
Db 24 GAGTATGAG 16
RESULT 15
AX112180 26 bp DNA linear PAT 01-MAY-2001
LOCUS Sequence 32 from Patent WO0127287.
DEFINITION

ACCESSION AX112180
VERSION AX112180.1 GI:13939031
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 26)
AUTHORS Long,D.M., Metz,A.M. and Love,R.
TITLE Telomerase reverse transcriptase (tert) genes
JOURNAL Patent: WO 0127287-A 32 19-APR-2001;
Research & Development Institute Inc. (US)
FEATURES
source
1..26
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="RT-PCR primer used with P. falciparum sequences"
BASE COUNT 9 a 3 c 7 g 7 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 26;
Best Local Similarity 100.0%; Pred. No. 5.2e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GAGTATGAG 9
|||||
Db 16 GAGTATGAG 24
Search completed: June 2, 2003, 19:09:32
Job time : 320.073 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 17:32:40 ; Search time 150.366 Seconds
(Without alignments)
134.791 Million cell updates/sec

Title: US-09-540-843-1

Perfect score: 9
Sequence: 1 gagtalgag 9

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 2063506

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

N_Geneseq_101002: *
1: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT: *
2: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT: *
3: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT: *
4: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT: *
5: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT: *
6: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT: *
7: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT: *
8: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT: *
9: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT: *
10: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT: *
11: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT: *
12: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT: *
13: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT: *
14: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT: *
15: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT: *
16: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT: *
17: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT: *
18: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT: *
19: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT: *
20: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT: *
21: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT: *
22: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT: *
23: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT: *
24: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	9	100.0	9	AAZ10692	Oligonucleotide se
2	9	100.0	9	AAZ10692	Oligonucleotide se
3	9	100.0	9	AAZ10692	Oligonucleotide se
4	9	100.0	9	AAZ10692	Oligonucleotide se
5	9	100.0	9	AAZ10692	Oligonucleotide se
6	9	100.0	9	AAZ10692	Oligonucleotide se
7	9	100.0	9	AAZ10692	Oligonucleotide se
8	9	100.0	9	AAZ10692	Oligonucleotide se
9	9	100.0	9	AAZ10692	Oligonucleotide se

C	10	9	100.0	13	23	ABC29989	Oligonucleotide SE
C	11	9	100.0	13	23	ABC37140	Oligonucleotide SE
C	12	9	100.0	13	23	ABC37141	Oligonucleotide SE
C	13	9	100.0	13	23	ABC41298	Oligonucleotide SE
C	14	9	100.0	13	23	ABC41299	Oligonucleotide SE
C	15	9	100.0	13	23	ABC48092	Oligonucleotide SE
C	16	9	100.0	13	23	ABC48093	Oligonucleotide SE
C	17	9	100.0	13	23	ABC48093	Oligonucleotide SE
C	18	9	100.0	13	23	ABC51860	Oligonucleotide SE
C	19	9	100.0	13	23	ABC51861	Oligonucleotide SE
C	20	9	100.0	13	23	ABC51864	Oligonucleotide SE
C	21	9	100.0	13	23	ABC51865	Oligonucleotide SE
C	22	9	100.0	13	23	ABC78830	Oligonucleotide SE
C	23	9	100.0	13	23	ABC78831	Oligonucleotide SE
C	24	9	100.0	13	23	ABC99290	Oligonucleotide SE
C	25	9	100.0	13	23	ABC99291	Oligonucleotide SE
C	26	9	100.0	13	23	ABF09008	Oligonucleotide SE
C	27	9	100.0	13	23	ABF09009	Oligonucleotide SE
C	28	9	100.0	13	23	ABF15710	Oligonucleotide SE
C	29	9	100.0	13	23	ABF15711	Oligonucleotide SE
C	30	9	100.0	13	23	ABF17600	Oligonucleotide SE
C	31	9	100.0	13	23	ABF17601	Oligonucleotide SE
C	32	9	100.0	13	23	ABF20572	Oligonucleotide SE
C	33	9	100.0	13	23	ABF20573	Oligonucleotide SE
C	34	9	100.0	13	23	ABF20576	Oligonucleotide SE
C	35	9	100.0	13	23	ABF20577	Oligonucleotide SE
C	36	9	100.0	13	23	ABF48816	Oligonucleotide SE
C	37	9	100.0	13	23	ABF48817	Oligonucleotide SE
C	38	9	100.0	13	23	ABF56046	Oligonucleotide SE
C	39	9	100.0	13	23	ABF56047	Oligonucleotide SE
C	40	9	100.0	13	23	ABF64312	Oligonucleotide SE
C	41	9	100.0	13	23	ABF64313	Oligonucleotide SE
C	42	9	100.0	13	23	ABF64318	Oligonucleotide SE
C	43	9	100.0	13	23	ABF64319	Oligonucleotide SE
C	44	9	100.0	13	23	ABF95900	Oligonucleotide SE
C	45	9	100.0	13	23	ABF95901	Oligonucleotide SE
						ABH11442	Oligonucleotide SE

ALIGNMENTS

RESULT 1
AAZ10692
ID AAZ10692 standard; DNA; 9 BP.
XX
AC AAZ10692;
XX
DT 23-NOV-1999 (first entry)
XX
XX Oligonucleotide sequence that increases p53 activity in a cell.
XX
XX p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
KW UV-induced hyperproliferative disease; psoriasis; vitiligo;
KW atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;
KW skin cancer; ss.
XX
XX Synthetic.
OS
XX
XX GB2336157-A.
PN
XX
XX 13-OCT-1999.
PD
XX
XX 24-MAR-1999; 99GB-0006758.
PF
XX
XX 26-MAR-1998; 98US-0048927.
PR
XX
XX (UYBO-) UNITV BOSTON.
PA
XX
XX Gilchrist BA, Yaar M, Eller M;
PI WPI; 1999-543520/46.
XX
XX DNA fragments useful for increasing p53 activity in a cell and reducing

PT susceptibility to UV-induced hyperproliferative diseases -
 XX
 PS Claim 11; Page 29; 44pp; English.
 XX
 CC AA210692-97 represent DNA fragments that are used for increasing p53
 CC activity in a cell. The oligonucleotides are are UV mimetics and
 CC protect cells against subsequent exposure to UV-irradiation or
 CC chemicals. The oligonucleotides are useful for increasing p53 activity
 CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
 CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
 CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
 CC and reducing susceptibility to skin cancer.
 XX
 SQ Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
 Query Match 100.0%; Score 9; DB 20; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAGTATGAG 9
 Db 1 GAGTATGAG 9
 RESULT 2
 AAS14905
 ID AAS14905 standard; DNA; 9 BP.
 XX
 AC AAS14905;
 XX
 DT 14-FEB-2002 (first entry)
 XX
 DE Melanogenesis associated oligonucleotide #1.
 XX
 DE Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= g
 FT /note="Optionally phosphorylated"
 XX
 FT WO200174342-A2.
 XX
 PN 11-OCT-2001.
 PD
 XX
 PF 30-MAR-2001; 2001WO-US10162.
 XX
 PR 31-MAR-2000; 2000US-0540843.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PI Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI; 2001-626338/72.
 XX
 PT Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light -
 XX
 PS Claim 1; Page 36; 74pp; English.
 XX
 CC The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and

CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing more time
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis;
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage. In epithelial cell, this
 CC sequence is melanogenesis associated oligonucleotide #1, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.
 XX
 SQ Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
 Query Match 100.0%; Score 9; DB 23; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAGTATGAG 9
 Db 1 GAGTATGAG 9
 RESULT 3
 ABI05192
 ID ABI05192 standard; DNA; 12 BP.
 XX
 AC ABI05192;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 305165 for detecting SNP TSC0021329.
 XX
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FT WO200177384-A2.
 XX
 PN 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 305165; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 1 GAGTATGAG 9

RESULT 4
AB106838
ID AB106838 standard; DNA; 12 BP.
XX
AC AB106838;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306811 for detecting SNP TSC0022179.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single nucleotide polymorphisms and cytosine
XX methylation status -
XX
XX Claim 1; SEQ ID 306811; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation.
XX ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX AB100010-AB182073 represent the oligomers described in the invention.
XX NOTE: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 3 GAGTATGAG 11

RESULT 5
AB106839
ID AB106839 standard; DNA; 12 BP.
XX
AC AB106839;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306812 for detecting SNP TSC0022179.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single nucleotide polymorphisms and cytosine
XX methylation status -
XX
XX Claim 1; SEQ ID 306812; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation.
XX ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX AB100010-AB182073 represent the oligomers described in the invention.
XX NOTE: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 1 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 3 GAGTATGAG 11

RESULT 6
AB121133
ID AB121133 standard; DNA; 12 BP.
XX
AC AB121133;
XX
DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 321106 for detecting SNP TSC0030074.
 DE
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 321106; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989 and
 CC ABH00010-ABH82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 other;
 XX
 OY Query Match 100.0%; Score 9; DB 23; Length 12;
 XX Best Local Similarity 100.0%; Pred. No. 9e+03;
 XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 1 GAGTATGAG 9
 2 GAGTATGAG 10
 RESULT 7
 AB126099
 ID AB126099 standard; DNA; 12 BP.
 XX
 AC AB126099;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 326072 for detecting SNP TSC0032886.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 326072; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989 and
 CC ABH00010-ABH82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 other;
 XX
 OY Query Match 100.0%; Score 9; DB 23; Length 12;
 XX Best Local Similarity 100.0%; Pred. No. 9e+03;
 XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 1 GAGTATGAG 9
 4 GAGTATGAG 12
 RESULT 8
 AB148017/C
 ID AB148017 standard; DNA; 12 BP.
 XX
 AC AB148017;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 347990 for detecting SNP TSC0045390.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -

XX Claim 1; SEQ ID 347990; 29pp + Sequence Listing; German.
PS
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed CC specification, but was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
Db 10 GAGTATGAG 2
|||||
|
RESULT 9
ABC29988
ID ABC29988 standard; DNA; 13 BP.
XX
AC ABC29988;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 30005 for detecting SNP TSC0009039.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PE 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPig-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is PT designed to detect single nucleotide polymorphisms and cytosine PT methylation status
XX
XX
PS Claim 1; SEQ ID 30005; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed CC

CC specification, but was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
Db 4 GAGTATGAG 12
|||||
|
RESULT 10
ABC29989/C
ID ABC29989 standard; DNA; 13 BP.
XX
AC ABC29989;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 30006 for detecting SNP TSC0009039.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PE 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPig-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is PT designed to detect single nucleotide polymorphisms and cytosine PT methylation status
XX
XX
PS Claim 1; SEQ ID 30006; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed CC specification, but was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
Db 10 GAGTATGAG 2
|||||
|

```

RESULT 11
ABC37140
ID ABC37140 standard; DNA; 13 BP.
XX
AC ABC37140;
XX
DT 20-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 37157 for detecting SNP TSC0011603.
XX
KM SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 37157; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;
XX
Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9, 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
DB 3 GAGTATGAG 11
XX
RESULT 12
ABC37141/C
ID ABC37141 standard; DNA; 13 BP.
XX
AC ABC37141;
XX
DT 20-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 37158 for detecting SNP TSC0011603.
XX
KM SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX

```

```

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 37158; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;
XX
Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9, 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
DB 11 GAGTATGAG 3
XX
RESULT 13
ABC41298
ID ABC41298 standard; DNA; 13 BP.
XX
AC ABC41298;
XX
DT 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 41315 for detecting SNP TSC0012414.
XX
KM SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173;
XX
PA (EPIG-) EPIGENOMICS AG.
XX

```

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI, 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status
 PS
 XX Claim 1; SEQ ID 41315; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABR00010-ABF99989, ABR00010-ABH99989 and
 CC ABR00010-ABR82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 CC
 SO Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 other;
 Query Match 100.0%; Score 9; DB 23; Length 13;
 Best Local Similarity 100.0%; Pred. No. 9.1e+03;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GAGTATGAG 9
 Db 5 GAGTATGAG 13
 DB
 XX
 RESULT 14
 ID ABC41299/c
 XX ABC41299 standard; DNA; 13 BP.
 AC ABC41299;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 41316 for detecting SNP TSC0012414.
 XX
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PS (EPIG-) EPIGENOMICS AG.
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI, 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status
 PS
 XX Claim 1; SEQ ID 41316; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABR00010-ABF99989, ABR00010-ABH99989 and
 CC ABR00010-ABR82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 CC
 SO Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 other;
 Query Match 100.0%; Score 9; DB 23; Length 13;
 Best Local Similarity 100.0%; Pred. No. 9.1e+03;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GAGTATGAG 9
 Db 9 GAGTATGAG 1
 DB
 XX
 RESULT 15
 ID ABC48092
 XX ABC48092 standard; DNA; 13 BP.
 AC ABC48092;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 48109 for detecting SNP TSC0013750.
 XX
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PS (EPIG-) EPIGENOMICS AG.
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI, 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status
 PS
 XX Claim 1; SEQ ID 48109; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABR00010-ABF99989, ABR00010-ABH99989 and
 CC ABR00010-ABR82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 CC
 SO Sequence 13 BP; 6 A; 0 C; 5 G; 2 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
|||||||
Db 5 GAGTATGAG 13

Search completed: June 2, 2003, 18:45:09
Job time : 151.566 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:29:55 ; Search time 1129.39 Seconds
(without alignments)
129.060 Million cell updates/sec

Title: US-09-540-843-1

Perfect score: 9

Sequence: 1 gagatgag 9

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 60474

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*
1: em_estba:*
2: em_esthum:*
3: em_estlin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_estc:*
9: gb_estl:*
10: gb_est2:*
11: gb_est3:*
12: gb_est4:*
13: gb_est5:*
14: gb_est6:*
15: em_estfun:*
16: em_estom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vrt:*
22: em_gss_fun:*
23: em_gss_nam:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_rtd:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	100.0	22	17	A2658158	
2	100.0	29	17	BH856420	
3	100.0	36	17	AL771699	
4	100.0	40	9	AI613042	
5	88.9	24	10	AM059679	
6	88.9	24	17	A2478673	

c 7	8	88.9	25	17	A265844	A265844	1M0427322
c 8	8	88.9	27	14	DA5824	DA5824	HMG503044
c 9	8	88.9	30	17	AL766985	AL766985	Arabidops
c 10	8	88.9	33	17	A2778279	A2778279	2M0013N15
c 11	8	88.9	33	17	TA307A09Q	TA307A09Q	brucei
c 12	8	88.9	34	17	A2333219	A2333219	1M0062009
c 13	8	88.9	36	17	A276722	A276722	2M0010A12
c 14	8	88.9	36	17	BH789482	BH789482	SALK_0297
c 15	8	88.9	37	9	AA088913	AA088913	z169b11.s
c 16	8	88.9	37	17	A2429862	A2429862	1M0214I05
c 17	8	88.9	37	17	BH847696	BH847696	SALK_0558
c 18	8	88.9	38	17	BH130009	BH130009	G-6f16.f
c 19	8	88.9	38	17	TA131D03P	TA131D03P	brucei
c 20	8	88.9	39	17	A2659283	A2659283	1M0536M03
c 21	8	88.9	39	17	BH846916	BH846916	SALK_0110
c 22	8	88.9	40	17	A2311244	A2311244	1M0026M06
c 23	7.4	82.2	17	13	BG926068	BG926068	HNC23-1-E
c 24	7.4	82.2	19	9	AI747751	AI747751	u121h05.x
c 25	7.4	82.2	19	17	A2358656	A2358656	1M0101K12
c 26	7.4	82.2	19	17	A2457990	A2457990	1M0261R11
c 27	7.4	82.2	19	17	A2991531	A2991531	2M0275K15
c 28	7.4	82.2	20	17	A2646291	A2646291	1M0512D07
c 29	7.4	82.2	21	17	A2806440	A2806440	2M0068B05
c 30	7.4	82.2	22	9	AI052232	AI052232	oz21a12.x
c 31	7.4	82.2	22	9	AI630912	AI630912	tz31g03.x
c 32	7.4	82.2	22	17	A2591103	A2591103	1M0401K07
c 33	7.4	82.2	22	17	BH811671	BH811671	SALK_0595
c 34	7.4	82.2	22	17	TA119E04Q	TA119E04Q	brucei
c 35	7.4	82.2	23	17	A2484572	A2484572	1M0531D10
c 36	7.4	82.2	23	17	A2660131	A2660131	1M0538B03
c 37	7.4	82.2	23	17	A2830077	A2830077	2M0109S06
c 38	7.4	82.2	24	17	A2370614	A2370614	1M0121O10
c 39	7.4	82.2	24	17	A2772496	A2772496	1M0583123
c 40	7.4	82.2	24	17	A2847502	A2847502	2M0148C08
c 41	7.4	82.2	24	17	BH86517	BH86517	SALK_0987
c 42	7.4	82.2	25	9	AA871952	AA871952	vq43b09.r
c 43	7.4	82.2	25	17	A2810630	A2810630	2M0076I14
c 44	7.4	82.2	25	17	A2831709	A2831709	2M0110M06
c 45	7.4	82.2	25	17	BH856297	BH856297	SALK_0810

ALIGNMENTS

RESULT 1
LOCUS A2658158 22 bp DNA linear GSS 14-DEC-2000
DEFINITION 1M0534H17R Mouse 10kb plasmid UGCCIM library Mus musculus genomic
clone UGCCIM0534H17 R, DNA sequence.
ACCESSION A2658158
VERSION A2658158.1 GI:11795304
KEYWORDS GSS.

SOURCE
ORGANISM house mouse.
Mus musculus

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 22)

TITLE
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamli,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
'M', Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

JOURNAL
COMMENT Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: dduun@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0534 row: H column: 17
 Seq primer: CACACAGGAAACACCTATGACC
 Class: plasmid ends
 High quality sequence stop: 22.
 Location/Qualifiers

1..22
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UDGCM0534H17"
 /clone_1lb="Mouse 10Kb plasmid UDGCM library"
 /sex="Male"
 /lab_host="E. coli strain XL10-Gold, TI-resistant, F-"
 /note="Vector: PMD42nv, Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g1147321149b|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
 ORIGIN
 6 a 0 c 9 g 7 t

Query Match
 Best Local Similarity 100.0%; Score 9; DB 17; Length 22;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
 |||||
 Db 12 GAGTATGAG 20

RESULT 2
 BH856420/c 29 bp DNA linear GSS 08-JUL-2002
 LOCUS SALK_079762.18.10.x Arabidopsis thaliana T-DNA insertion lines
 DEFINITION Arabidopsis thaliana genomic clone SALK_079762.18.10.x, DNA sequence.

ACCESSION
 VERSION BH856420
 KEYWORDS GSS

SOURCE
 ORGANISM thale cress.
 Arabidopsis thaliana

REFERENCE
 AUTHORS Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrihab ,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P., Zimmerman,J. and Ecker,J.R.
 A Sequence-indexed library of Insertion Mutations in the Arabidopsis Genome
 Unpublished (2001)

TITLE
 JOURNAL
 COMMENT Contact: Joseph R. Ecker
 Salk Institute Genomic Analysis Laboratory (SIGAL)
 The Salk Institute for Biological Studies
 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
 Tel: 858 453 4100 x1752
 Fax: 858 558 6379
 Email: ecker@salk.edu

This is single pass sequence recovered from the left border of

TDNA. This sequence lies within an annotated exon of At5g63570.
 Class: TDNA tagged.
 Location/Qualifiers

1..29
 /organism="Arabidopsis thaliana"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="SALK_079762.18.10.x"
 /clone_1lb="Arabidopsis thaliana T-DNA insertion lines"
 /note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/tdna_protocols.html

BASE COUNT
 ORIGIN
 6 a 10 c 4 g 9 t

Query Match
 Best Local Similarity 100.0%; Score 9; DB 17; Length 29;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
 |||||
 Db 22 GAGTATGAG 14

RESULT 3
 AL771699 36 bp DNA linear GSS 19-JUN-2002
 LOCUS Arabidopsis thaliana T-DNA flanking sequence GK-182E01-013594,
 DEFINITION genomic survey sequence.

ACCESSION
 VERSION AL771699
 KEYWORDS GSS.

SOURCE
 ORGANISM thale cress.
 Arabidopsis thaliana

REFERENCE
 AUTHORS Strizhov,N., Li,Y., Rosso,M., Viehoveer,P., Dekker,K., Siedler,H. and Weishaar,B.

TITLE
 A pipeline for automated high-throughput generation of FSTs (flanking sequence tags) from Arabidopsis thaliana T-DNA transformed lines
 Unpublished

JOURNAL
 REFERENCE Rosso,M., Strizhov,N., Li,Y., Reiss,B., Dekker,K. and Weishaar,B.
 A new Arabidopsis thaliana T-DNA mutagenised population (GABI-Kat) for flanking sequence tag based reverse genetics

JOURNAL
 REFERENCE Rosso,M., Li,Y., Strizhov,N. and Weishaar,B.
 Direct Submission
 3 (bases 1 to 36)

TITLE
 JOURNAL
 COMMENT Submitted (17-JUN-2002) Weishaar B., Max-Planck-Institut fuer Zuechtungsforshung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
 This sequence is recovered from the left border of the T-DNA. It indicates an insertion within the locus defined by clone fls24.
 The sequences are generated at the MPI for Plant Breeding Research in the context of the GABI-Kat project. GABI-Kat is part of the German Plant Genomics program designated 'GABI'. Information on line availability can be found at:
<http://www.mpiz-koeln.mpg.de/GABI-Kat/>.

FEATURES
 SOURCE
 Location/Qualifiers

1..36
 /organism="Arabidopsis thaliana"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="GK-182E01-013594"
 /clone_1lb="Arabidopsis thaliana T-DNA insertion lines"
 /note="PCR was performed on DNA from Arabidopsis thaliana plants (T1) which were transformed with the T-DNA from

vector pAC161. The lines contain one or more T-DNA insertions. The DNA fragment(s) resulting from the PCR were directly sequenced to determine the genomic sequence flanking the insertion. Sequences displaying significant similarity to the A. thaliana nuclear genome sequence were processed for submission. T-DNA derived sequences were removed

BASE COUNT 9 a 8 c 6 g 13 t

Query Match 100.0%; Score 9; DB 17; Length 36;
Best Local Similarity 100.0%; Pred. No. 4.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
|||||||
DB 2 GAGTATGAG 10

RESULT 4 40 bp mRNA linear EST 16-DEC-1999
A1613042
LOCUS ty06h09.x1 NCI_CGAP_Ut3 Homo sapiens cDNA clone IMAGE:2278337 3'
DEFINITION similar to SW:RL11_FIG Q29205 60S RIBOSOMAL PROTEIN L11; mRNA sequence.

ACCESSION A1613042 GI:4622209
VERSION A1613042.1
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 40)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/ILIN at: www.bio.lnl.gov/dbip/image/image.html
Insert length: 705 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 1
POLYA-No.

FEATURES
source Location/Qualifiers
1..40

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2278337"
/clone_lib="NCI_CGAP_Ut3"
/tissue_type="poorly-differentiated endometrial adenocarcinoma 2 pooled tumors"
/lab_host="DH10B"
/note="Organ: uterus; Vector: pCMV-SPORT6; Site_1: Salt; Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.45 kb. Life Technologies catalog #: 11541-018"

BASE COUNT 9 a 15 c 3 g 13 t

Query Match 100.0%; Score 9; DB 9; Length 40;
Best Local Similarity 100.0%; Pred. No. 4.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
|||||||

DB 16 GAGTATGAG 8

RESULT 5 24 bp mRNA linear EST 23-AUG-2000
AM059679
LOCUS Ahutr.bsst.dnc15.aa.A050g08 DNC15 Homo sapiens cDNA, mRNA sequence.
DEFINITION AM059679
ACCESSION AM059679.1 GI:6652001
VERSION
KEYWORDS EST.
SOURCE human.

ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 24)
AUTHORS Brenner, S., Williams, S.R., Vernass, E.H., Storck, T., Moon, K., McCoilum, C., Mao, D.I., Kirchner, J.J., Ellett, S., Durrige, R.B., Burcham, T., and Albrecht, G.
In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs
Proc. Natl. Acad. Sci. U.S.A. 97 (4), 1665-1670 (2000)

JOURNAL 20144098
MEDLINE
COMMENT Contact: Burcham TS
LYNX Therapeutics, Inc.
25861 Industrial Blvd., Hayward, CA 94545, USA
Tel: 510 670 9338
Fax: 510 670 9302
Email: tlmbelynxgen.com

Sequence obtained from LYNX Therapeutics Megasort technology.
Collected from the down-regulated gate.
High quality sequence stop: 24.

FEATURES
source Location/Qualifiers
1..24

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="DNC15"
/cell_type="monocytic leukemia"
/note="Vector: pCR2.1; Cloning of PCR products from microbeads carrying 3' end of down-regulated cDNA. TBP-1 cells non-induced (treated with DMSO only)."

BASE COUNT 9 a 6 c 1 g 8 t

Query Match 88.9%; Score 8; DB 10; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGA 8
|||||||
DB 24 GAGTATGA 17

RESULT 6 24 bp DNA linear GSS 04-OCT-2000
A2478673
LOCUS 1K0298J20R Mouse 10kb plasmid U06C1M library Mus musculus genomic
DEFINITION clone U06C1M0298J20 R, DNA sequence.
ACCESSION A2478673
VERSION A2478673.1 GI:10637794
KEYWORDS GSS.

SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 24)
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamli, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A., and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0298 row: 7 column: 20
Seq primer: CACACGAGAAACAGCATATAC
Class: plasmid ends
High quality sequence stop: 24.

FEATURES

source

1. 24
Location/Qualifiers

/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG1M0298J20"
/clone_lib="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g14732114[gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT

6 a 8 c 3 g 7 t

ORIGIN

Query Match

Best Local Similarity 100.0%; Score 8; DB 17; Length 24;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGTATGAG 9
|||||||

DB 8 AGTATGAG 1

RESULT 7

A2605844/c

LOCUS 1M0427J22P Mouse 10kb plasmid UUCG1M library Mus musculus genomic
DEFINITION 25 bp DNA linear GSS 13-DEC-2000
ACCESSION A2605844
VERSION A2605844.1 GI:11728034
KEYWORDS GSS.

SOURCE

ORGANISM

house mouse.
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 25)

REFERENCE

1 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Rellily,
M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.
and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)

TITLE

Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)

JOURNAL

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0427 row: 7 column: 22
Seq primer: CGTGTAAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 25.

FEATURES

source

1. 25
Location/Qualifiers

/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG1M0427J22"
/clone_lib="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g14732114[gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT

7 a 6 c 5 g 7 t

ORIGIN

Query Match

Best Local Similarity 100.0%; Score 8; DB 17; Length 25;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGTATGAG 9
|||||||

DB 17 AGTATGAG 10

RESULT 8

D45824/c

LOCUS D45824 27 bp mRNA linear EST 21-FEB-1995
DEFINITION HUMG03044 Human adult lung 3' directed MboI cDNA Homo sapiens CDNA
ACCESSION D45824
VERSION D45824.1 GI:662778
KEYWORDS EST.

SOURCE

ORGANISM

human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
1 (bases 1 to 27)

REFERENCE

1 Itoh, K., Okubo, K., Yosi, J., Yokouchi, H. and Matsubara, K.
An expression profile of active genes in human lung
DNA Res. 1, 279-287 (1994)
95236275
MEDLINE

JOURNAL

Contact: Kohichi Itoh
Institute for Molecular and Cellular Biology
Osaka University

3-1, Yamadaoka, Suita, Osaka, 565, Japan
Tel: 06-877-5111 x3910
Fax: 06-877-1922.
Location/Qualifiers
1. .27
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="Human adult lung 3' directed MboI cDNA"
/note="Adult human lung, 3' directed MboI"

BASE COUNT
ORIGIN
12 a 6 c 1 g 8 t

Query Match
Best Local Similarity 88.9%; Score 8; DB 14; Length 27;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGA 8
|||||||
Db 24 GAGTATGA 17

RESULT 9
AL766985 30 bp DNA linear GSS 18-JUN-2002
LOCUS Arabidopsis thaliana T-DNA flanking sequence GK-215C11-014144,
DEFINITION genomic survey sequence.
ACCESSION AL766985
VERSION AL766985.1 GI:21520104
KEYWORDS GSS.
SOURCE thale cress.
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsids.
1
REFERENCE
AUTHORS Strizhov,N., Li,Y., Rosso,M., Viehoveer,P., Dekker,K., Saedler,H.
and Weissshaar,B.
TITLE A pipeline for automated high-throughput generation of PSTs
(flanking sequence tags) from Arabidopsis thaliana T-DNA
transformed lines
Unpublished
2
JOURNAL
REFERENCE Rosso,M., Strizhov,N., Li,Y., Reiss,B., Dekker,K. and Weissshaar,B.
AUTHORS A new Arabidopsis thaliana T-DNA mutagenised population (GABI-Kat)
TITLE for flanking sequence tag based reverse genetics
JOURNAL Unpublished
3 (bases 1 to 30)
Li,Y., Rosso,M., Strizhov,N. and Weissshaar,B.
DIRECT SUBMISSION Submitted (17-JUN-2002) Weissshaar B., Max-Planck-Institut fuer
Zuechtungsforschung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
This sequence is recovered from the left border of the T-DNA. It
indicates an insertion within the locus defined by clone F9L1. The
sequences are generated at the MPI for Plant Breeding Research in
Plant Genomics program designated 'GABI-Kat'. Information on line
availability can be found at:
http://www.mpiz-koeln.mpg.de/GABI-Kat/.
Location/Qualifiers
1. .30
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="GK-215C11-014144"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
/note="PCR was performed on DNA from Arabidopsis thaliana
plants (T1) which were transformed with the T-DNA from
vector PAC161. The lines contain one or more T-DNA
insertions. The DNA fragment(s) resulting from the PCR
were directly sequenced to determine the genomic sequence
flanking the insertion. Sequences displaying significant
similarity to the A. thaliana nuclear genome sequence were
processed for submission. T-DNA derived sequences were

BASE COUNT
ORIGIN
11 a 5 c 4 g 10 t removed"

Query Match
Best Local Similarity 88.9%; Score 8; DB 17; Length 30;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGA 8
|||||||
Db 19 GAGTATGA 26

RESULT 10
LOCUS A2778279/c 33 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0013N15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0013N15 F, DNA sequence.
ACCESSION A2778279
VERSION A2778279.1 GI:12907753
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 33)
REFERENCE
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Relilly
M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
JOURNAL
CONTACT: Robert B. Weiss
UNIVERSITY OF UTAH
Km. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0013 row: N column: 15
Seq primer: CGTTGTAAACGACGCCACT
Class: plasmid ends
High quality sequence stop: 33.
Location/Qualifiers
1. .33
/organism="Mus musculus"
/strain="C57Bl/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0013N15"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42ny; Purified genomic DNA from M.
musculus C57Bl/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g114732114|9b|AF19072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapored mouse DNA was annealed to
chemically-competent E. coli XL10-Gold (Stratagene) cells

BASE COUNT 14 a 9 c 3 g 7 t and selected for ampicillin resistance."

ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGTATGAG 9
| | | | | | | |
Db 23 AGTATGAG 16

RESULT 11
TA307A090 33 bp DNA linear GSS 13-DEC-2000
LOCUS
DEFINITION T. brucei sheared genomic DNA clone 307a09, reverse sequence,
genomic survey sequence.
ACCESSION AL488827
VERSION AL488827.1 GI:11864397
KEYWORDS
SOURCE
ORGANISM Trypanosoma brucei.
Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae;
Trypanosoma.
1 (bases 1 to 33)
Hall, N., Bowman, S., Lennard, N.J., Doggett, J., Atkin, R.,
Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L.,
Melville, S.E., Rajandream, M.A. and Barrell, B.G.
Direct Submission
Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
nh@sanger.ac.uk
Constructed at the Institute for Genomic Research (TIGR),
Rockville, MD. Genomic DNA isolated from a cloned population of
Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
to give a tight size distribution (4 kb). The v + 1 method used for the library construction is
described in detail in Smith, H. and Venter, J.C. (Making small
insert libraries for whole genome shotgun sequencing projects. In
Genome Sequencing: A Practical Approach, eds. M. Vaubin and B.
Barrell, Oxford University Press, 1999).
Email: nelsayed@tigr.org
Details of T. brucei sequencing at the Sanger Centre are available
at http://www.sanger.ac.uk/Projects/T_brucei/.
Location/Qualifiers
source
1. .33
/organism="Trypanosoma brucei"
/strain="TREU927"
/db_xref="taxon:5691"
/clone="307a09"

BASE COUNT 7 a 6 c 10 g 10 t

ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGA 8
| | | | | | | |
Db 8 GAGTATGA 15

RESULT 12
AZ333219/c 34 bp DNA linear GSS 29-SEP-2000
LOCUS
DEFINITION 1M0062009F Mouse 10kb plasmid UGCG1M library Mus musculus genomic
clone UGCG1M0062009 F, DNA sequence.
ACCESSION AZ333219
VERSION AZ333219.1 GI:10397621
KEYWORDS
SOURCE house mouse.

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murine; Mus.
1 (bases 1 to 34)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.,
and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0062 row: 0 column: 09
Seq primer: CCTGTAAACACGCGCCAGT
Class: plasmid ends
High quality sequence stop: 34.
Location/Qualifiers
source
1. .34
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UGCG1M0062009"
/clone_lib="Mouse 10kb plasmid UGCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42ny; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(<http://www.jax.org/resources/documents/dnares/>). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g147321419d/AF129072.1), a copy-number
inducible derivative of plasmid RL. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT 13 a 6 c 4 g 11 t

ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 34;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGTATGAG 9
| | | | | | | |
Db 22 AGTATGAG 15

RESULT 13
AZ776722 36 bp DNA linear GSS 16-FEB-2001
LOCUS
DEFINITION 2M0010A12R Mouse 10kb plasmid UGCG1M library Mus musculus genomic
clone UGCG2M0010A12 R, DNA sequence.
ACCESSION AZ776722
VERSION AZ776722.1 GI:12904580
KEYWORDS
SOURCE house mouse.

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 36)

REFERENCE 1 (bases 1 to 36)
Dunn, D., Aoyagi, A., Barber, M., Becorn, T., Duval, B., Hamill, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A., and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10Kb plasmid inserts
Unpublished (2000)

JOURNAL COMMENT
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 1000 Std Error: 0.00
Place: 0010 row: A column: 12
Seq primer: CACACGAGAAACGCTATGACC
Class: plasmid ends
High quality sequence stop: 36.

FEATURES
source
Location/Qualifiers
1..36
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U05C2M0010A12"
/clone_1lb="Mouse 10Kb plasmid U05C1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/note="Vector: PWD42mv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g114732114[9b]AR129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
13 a 4 c 8 g 11 t

ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGTATGAG 9
Db 10 AGTATGAG 17
|||||

RESULT 14
BH789482/c 36 bp DNA linear GSS 02-APR-2002
LOCUS SALK_029703.49.45.x Arabidopsis thaliana TDNA insertion lines
DEFINITION Arabidopsis thaliana genomic clone SALK_029703.49.45.x, DNA sequence.
ACCESSION BH789482
VERSION BH789482
KEYWORDS GSS.

SOURCE
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eustosids II; Brassicales; Brassicaceae; Arabidopsis. 1 (bases 1 to 36)

REFERENCE 1 (bases 1 to 36)
Alonso, J.M., Leisse, T.J., Barajas, P., Chen, H., Cheuk, R., Gadrihab, C., Jeske, A., Karnes, M., Kim, C.J., Parker, H., Predits, L., Shinn, P., Zimmerman, J., and Ecker, J.R.
A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome
Unpublished (2001)

JOURNAL COMMENT
Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of TDNA.
Class: TDNA tagged

FEATURES
source
Location/Qualifiers
1..36
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="SALK_029703.49.45.x"
/clone_1lb="Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/tdna_protocols.html"

BASE COUNT
10 a 6 c 7 g 13 t

ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGA 8
Db 28 GAGTATGA 21
|||||

RESULT 15
AA088913 37 bp mRNA linear EST 19-MAY-1997
LOCUS Z169D11.s1 Stratagene colon (#37204) Homo sapiens cDNA clone
DEFINITION IMAGE:509853 3' similar to TR:G189397 G189397 HYPOTHETICAL 33.4 KD
PROTEIN. ; mRNA sequence.
ACCESSION AA088913
VERSION AA088913
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 37)
Hillier, L., Lennon, G., Becker, M., Bonaldo, M.F., Chiapelli, B., Chissoe, S., Dietrich, N., Dubuque, T., Favell, A., Gish, W., Hawkins, M., Hultman, M., Kucaba, T., Lacey, M., Le, M., Le, N., Mardis, E., Moore, B., Morris, M., Parsons, J., Prange, C., Rifkin, L., Rohlfing, T., Schellenberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J., Trevisan, E., Underwood, K., Wollmann, P., Waterston, R., Wilson, R. and Marra, M.
Generation and analysis of 280,000 human expressed sequence tags
Genome Res. 6 (9), 807-828 (1996)

JOURNAL COMMENT
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800
 Fax: 314 286 1810
 Email: est@watson.wustl.edu
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lnl.gov) for further information.
 Insert Length: 1260 Std Error: 0.00
 Seq primer: -40M13 fwd. from Amersham
 High quality sequence stop: 1.
 Location/Qualifiers
 1. .37

/organism="Homo sapiens"
 /db_xref="GDB:3813185"
 /db_xref="taxon:9606"
 /clone="IMAGE:509853"
 /clone_id="Stratagene colon (#937204)"
 /tissue_type="tumor"
 /cell_line="T84 carcinoma cell line"
 /lab_host="SOBR cells (kanamycin resistant)"
 /note="Organ: colon; Vector: pBluescript SK-; Site_1:
 EcoRI; Site_2: XhoI; Cloned unidirectionally. Primer:
 Oligo dt. T-84 colonic epithelial cell line. Average
 insert size: 1.0 kb; Uni-ZAP XR Vector; ~5' adaptor
 sequence: 5' GAATTCGCGACGAG 3' ~3' adaptor sequence: 5'
 CTCGAGTTTTTTTTTTTTTTT 3'"

BASE COUNT 7 a 10 c 10 g 9 t 1 others
 ORIGIN

Query Match 88.9%; Score 8; DB 9; Length 37;
 Best Local Similarity 100.0%; Pred. No. 2e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAGTATGA 8
 |||||
 Db 22 GAGTATGA 15

Search completed: June 2, 2003, 20:35:33
 Job time : 1133.39 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:31:20 ; Search time 36.878 Seconds
(without alignments)
74.844 Million cell updates/sec

Title: US-09-540-843-1

Perfect score: 9

Sequence: 1 gagtatgag 9

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 441362 segs, 153338381 residues

Total number of hits satisfying chosen parameters: 558892

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents NA: *
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq: *
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq: *
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq: *
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq: *
5: /cgn2_6/ptodata/1/ina/PCRTUS.COMB.seq: *
6: /cgn2_6/ptodata/1/ina/backfile1.seq: *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	9	100.0	9	3	US-09-048-927-1
2	9	100.0	15	4	US-09-049-190-6
3	9	100.0	15	4	US-09-049-190-7
4	9	100.0	15	4	US-08-932-140C-6
5	9	100.0	15	4	US-08-932-140C-7
6	9	100.0	17	1	US-08-758-306-365
7	9	100.0	17	1	US-08-758-306-367
8	9	100.0	17	1	US-08-758-306-369
9	9	100.0	17	1	US-08-758-306-371
10	9	100.0	20	3	US-09-287-796-101
11	9	100.0	20	3	US-09-287-796-102
12	9	100.0	20	4	US-09-130-616-101
13	9	100.0	20	4	US-09-130-616-102
14	9	100.0	20	4	US-09-105-058C-15
15	9	100.0	20	4	US-09-851-062-29
16	9	100.0	20	4	US-09-517-467B-84
17	9	100.0	21	6	5455029-26
18	9	100.0	23	4	US-09-088-274-8
19	9	100.0	24	4	US-09-245-248B-23
20	9	100.0	27	4	US-08-932-140C-21
21	9	100.0	28	4	US-09-031-006-4
22	9	100.0	34	2	US-08-211-718-14
23	9	100.0	36	4	US-09-383-143-8
24	9	100.0	36	4	US-09-383-143-36
25	9	100.0	37	1	US-08-029-030-1
26	9	100.0	37	6	5455029-3
27	9	100.0	38	4	US-09-194-613-18

28	9	100.0	38	4	US-09-383-143-30	Sequence 30, Appl
29	9	100.0	39	3	US-08-980-032-4	Sequence 4, Appl
30	9	100.0	39	4	US-09-477-871-4	Sequence 4, Appl
31	9	100.0	39	4	US-09-383-143-9	Sequence 9, Appl
32	9	100.0	40	2	US-08-425-684-27	Sequence 27, Appl
33	9	100.0	40	2	US-08-425-684-34	Sequence 34, Appl
34	9	100.0	40	2	US-08-675-502-27	Sequence 27, Appl
35	9	100.0	40	2	US-08-675-502-34	Sequence 34, Appl
36	9	100.0	40	2	US-08-744-905A-4	Sequence 34, Appl
37	8	88.9	15	2	US-08-747-121-4	Sequence 24, Appl
38	8	88.9	15	2	US-08-585-684B-1315	Sequence 1315, Appl
39	8	88.9	15	2	US-09-038-073-1315	Sequence 1315, Appl
40	8	88.9	16	1	US-07-977-284A-59	Sequence 59, Appl
41	8	88.9	16	1	US-08-255-426B-59	Sequence 443, Appl
42	8	88.9	17	2	US-08-985-162-443	Sequence 444, Appl
43	8	88.9	17	3	US-08-985-162-444	Sequence 8, Appl
44	8	88.9	18	1	US-07-688-352C-8	
45						

ALIGNMENTS

```
RESULT 1
US-09-048-927-1
; Sequence 1, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Glitchrest, Barbara A.
; APPLICANT: Yaar, Mina
; APPLICANT: Eller, Mark
; TITLE OF INVENTION: Use of Locally Applied DNA Fragments
; FILE REFERENCE: B094-68A2
; CURRENT APPLICATION NUMBER: US/09/048,927
; CURRENT FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952,697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467,012
; EARLIER FILING DATE: 1995-06-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA Fragment
US-09-048-927-1

Query Match          100.0%; Score 9; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
Db 1 GAGTATGAG 9

RESULT 2
US-09-049-190-6/c
; Sequence 6, Application US/09049190
; Patent No. 6190866
; GENERAL INFORMATION:
; APPLICANT: Nielsen et al.
; TITLE OF INVENTION: Peptide Nucleic Acids Having
; TITLE OF INVENTION: Antibacterial Activity
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.

6 No. 6190866r1s LLP
```

ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/049,190
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site

LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-[acetyl(2-aminoethyl)]-C-lysine-glycine
OTHER INFORMATION: backbone
US-09-049-190-6
Query Match 100.0%; Score 9; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+03; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0;
QY 1 GAGTATGAG 9
DB 11 GAGTATGAG 3
RESULT 3
US-09-049-190-7/c
Sequence 7, Application US/09049190
Patent No. 6190866
GENERAL INFORMATION:
APPLICANT: Nielsen et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESS: Woodcock Washburn Kurtz Mackiewicz
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/049,190
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
6 No. 6190866R1s LLP

TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone

NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
US-09-049-190-7

Query Match 100.0%; Score 9; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
DB 14 GAGTATGAG 6

RESULT 4
US-08-932-140C-6/C
Sequence 6, Application US/08932140C
Patent No. 6300318
GENERAL INFORMATION:
APPLICANT: Nielsen et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having
TITLE OF INVENTION: Antibacterial Activity
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &
ADDRESSEE: No. 6300318ris LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Microsoft Word
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/932,140C
FILING DATE: September 16, 1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3

OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-[acetyl(2-aminoethyl)]-C-lysine-glycine backbone
US-08-932-140C-6
Query Match 100.0%; Score 9; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
Db 11 GAGTATGAG 3
RESULT 5
US-08-932-140C-7/C
Sequence 7, Application US/08932140C
Patent No. 6300318
GENERAL INFORMATION:
APPLICANT: Nielsen et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having
Antibacterial Activity
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &

ADDRESSEE: No. 630031818is LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Microsoft Word
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/932,140C
FILING DATE: September 16, 1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEO ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site

LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-[acetyl(2-aminoethyl)]-C-
OTHER INFORMATION: lysine-glycine backbone
US-08-932-140C-7

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 15;
Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
DB 14 GAGTATGAG 6

RESULT 6
US-08-758-306-365/C
Sequence 365, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Slinchcomb, Dan T.
APPLICANT: McSwiggen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306

FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 365:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-365

Query Match
Best Local Similarity 100.0%; Score 9; DB 1; Length 17;
Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
DB 17 GAGTATGAG 9

RESULT 7
US-08-758-306-367/C
Sequence 367, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Slinchcomb, Dan T.
APPLICANT: McSwiggen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 367:

SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-367

Query Match 100.0%; Score 9; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
DB 15 GAGTATGAG 7

RESULT 8
US-08-758-306-369/c
Sequence 369, Application US/08758306
Patent No. 5807743

GENERAL INFORMATION:
APPLICANT: Slinchcomb, Dan T.
APPLICANT: McSwiggen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Fastseq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO: 369:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-758-306-369

Query Match 100.0%; Score 9; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
DB 12 GAGTATGAG 4

RESULT 9
US-08-758-306-371/c
Sequence 371, Application US/08758306
Patent No. 5807743

GENERAL INFORMATION:
APPLICANT: Slinchcomb, Dan T.
APPLICANT: McSwiggen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Fastseq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ. ID NO: 371:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-371

Query Match 100.0%; Score 9; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
DB 9 GAGTATGAG 1

RESULT 10
US-09-287-796-101
Sequence 101, Application US/09287796A
Patent No. 6133246

GENERAL INFORMATION:
APPLICANT: McKay, Robert A.
APPLICANT: Dean, Nicholas M.
APPLICANT: Monia, Brett
APPLICANT: Nero, Pam
APPLICANT: Gaarde, William A.
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS

```

; FILE REFERENCE: ISPH-0350
; CURRENT APPLICATION NUMBER: US/09/287,796A
; CURRENT FILING DATE: 1999-04-07
; EARLIER APPLICATION NUMBER: 09/130,616
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 101
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-287-796-101

Query Match
Best Local Similarity 100.0%; Score 9; DB 3; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
DB 9 GAGTATGAG 17

RESULT 11
US-09-287-796-102
; Sequence 102, Application US/09287796A
; Patent No. 6133246
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; FILE REFERENCE: ISPH-0350
; CURRENT APPLICATION NUMBER: US/09/287,796A
; CURRENT FILING DATE: 1999-04-07
; EARLIER APPLICATION NUMBER: 09/130,616
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-287-796-102

Query Match
Best Local Similarity 100.0%; Score 9; DB 3; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
DB 9 GAGTATGAG 17

RESULT 12
US-09-130-616-101
; Sequence 101, Application US/09130616C
; Patent No. 6221850
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; FILE REFERENCE: 3053-4052

TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0318
; CURRENT APPLICATION NUMBER: US/09/130,616C
; CURRENT FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 178
; SEQ ID NO 101
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic sequence
US-09-130-616-101

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
DB 9 GAGTATGAG 17

RESULT 13
US-09-130-616-102
; Sequence 102, Application US/09130616C
; Patent No. 6221850
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; FILE REFERENCE: ISPH-0318
; CURRENT APPLICATION NUMBER: US/09/130,616C
; CURRENT FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 178
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic sequence
US-09-130-616-102

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
DB 9 GAGTATGAG 17

RESULT 14
US-09-105-058C-15
; Sequence 15, Application US/09105058C
; Patent No. 6403360
; GENERAL INFORMATION:
; APPLICANT: Blannar, Michael A.
; APPLICANT: Dworetzky, Steven
; APPLICANT: Gridkov, Valentin K.
; APPLICANT: Levesque, Paul C.
; APPLICANT: Little, Wayne A.
; APPLICANT: Neubauef, Michael G.
; APPLICANT: Yang, Wen-pin
; TITLE OF INVENTION: KONO POTASSIUM CHANNELS AND METHODS OF MODULATING SAME
; FILE REFERENCE: 3053-4052
```

```

; CURRENT APPLICATION NUMBER: US/09/105,058C
; CURRENT FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: US 60/055,599
; PRIOR FILING DATE: 1997-08-12
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Forward primer
; OTHER INFORMATION: from EST sequence similar to the KVLQT gene
US-09-105-058C-15

```

```

Query Match          100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 GAGTATGAG 9
        |||||
Db      1 GAGTATGAG 9

```

```

RESULT 15
US-09-851-062-29/C
; Sequence 29, Application US/09851062
; Patent No. 6448081
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF INTERLEUKIN 12 P40 SUBUNIT EXPRESSION
; FILE REFERENCE: RFS-0247
; CURRENT APPLICATION NUMBER: US/09/851,062
; CURRENT FILING DATE: 2001-05-07
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-851-062-29

```

```

Query Match          100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 GAGTATGAG 9
        |||||
Db      19 GAGTATGAG 11

```

```

Search completed: June 2, 2003, 20:38:31
Job time : 37.878 secs

```


GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using SW model

Run on: June 2, 2003, 19:09:45 ; Search time 63.878 Seconds
(without alignments)
189.976 Million cell updates/sec

Title: US-09-540-843-1

Perfect score: 9

Sequence: 1 gagatagag 9

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 845702 seqs, 674182571 residues

Total number of hits satisfying chosen parameters: 477662

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published_Applications_NA:*

1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/2/pubpna/PCT_NEW_PUB.seq:*
3: /cgn2_6/ptodata/2/pubpna/US06_NEW_PUB.seq:*
4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
5: /cgn2_6/ptodata/2/pubpna/US07_NEW_PUB.seq:*
6: /cgn2_6/ptodata/2/pubpna/PCTUS_PUBCOMB.seq:*
7: /cgn2_6/ptodata/2/pubpna/US08_NEW_PUB.seq:*
8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq:*
10: /cgn2_6/ptodata/2/pubpna/US09_PUBCOMB.seq:*
11: /cgn2_6/ptodata/2/pubpna/US10_NEW_PUB.seq:*
12: /cgn2_6/ptodata/2/pubpna/US10_PUBCOMB.seq:*
13: /cgn2_6/ptodata/2/pubpna/US60_NEW_PUB.seq:*
14: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	9	100.0	9	US-10-122-630-1	Sequence 1, Appl1
2	9	100.0	9	US-10-122-633-1	Sequence 1, Appl1
3	9	100.0	17	US-09-866-108-2750	Sequence 2750, Ap
4	9	100.0	17	US-09-866-108-2751	Sequence 2751, Ap
5	9	100.0	17	US-09-866-108-2752	Sequence 2752, Ap
6	9	100.0	17	US-09-866-108-2753	Sequence 2753, Ap
7	9	100.0	17	US-09-866-108-2754	Sequence 2754, Ap
8	9	100.0	17	US-09-866-108-2755	Sequence 2755, Ap
9	9	100.0	17	US-09-866-108-2756	Sequence 2756, Ap
10	9	100.0	17	US-09-866-108-2757	Sequence 2757, Ap
11	9	100.0	17	US-09-866-108-2758	Sequence 2758, Ap
12	9	100.0	18	US-09-853-895-1	Sequence 1, Appl1
13	9	100.0	20	US-10-128-870-15	Sequence 101, Appl
14	9	100.0	20	US-09-774-809-101	Sequence 101, Appl
15	9	100.0	20	US-09-774-809-102	Sequence 102, Appl
16	9	100.0	20	US-10-131-685-15	Sequence 15, Appl
17	9	100.0	20	US-10-067-514-32	Sequence 32, Appl
18	9	100.0	24	US-09-815-656-23	Sequence 23, Appl
19	9	100.0	25	US-10-215-112-4205	Sequence 4205, Ap

20	9	100.0	25	9	US-10-215-112-4329	Sequence 4329, Ap
21	9	100.0	25	9	US-10-215-112-10765	Sequence 10765, A
22	9	100.0	25	9	US-10-215-112-10891	Sequence 10891, A
23	9	100.0	25	9	US-09-911-904-37	Sequence 37, Appl
24	9	100.0	25	10	US-09-866-108-5679	Sequence 5679, Ap
25	9	100.0	25	10	US-09-866-108-5680	Sequence 5680, Ap
26	9	100.0	25	10	US-09-866-108-5681	Sequence 5681, Ap
27	9	100.0	25	10	US-09-866-108-5682	Sequence 5682, Ap
28	9	100.0	25	10	US-09-866-108-5683	Sequence 5683, Ap
29	9	100.0	25	10	US-09-866-108-5684	Sequence 5684, Ap
30	9	100.0	25	10	US-09-866-108-5685	Sequence 5685, Ap
31	9	100.0	25	10	US-09-866-108-5686	Sequence 5686, Ap
32	9	100.0	25	10	US-09-866-108-5687	Sequence 5687, Ap
33	9	100.0	25	10	US-09-866-108-5688	Sequence 5688, Ap
34	9	100.0	25	10	US-09-866-108-5689	Sequence 5689, Ap
35	9	100.0	25	10	US-09-866-108-5690	Sequence 5690, Ap
36	9	100.0	25	10	US-09-866-108-5691	Sequence 5691, Ap
37	9	100.0	25	10	US-09-866-108-5692	Sequence 5692, Ap
38	9	100.0	25	10	US-09-866-108-5693	Sequence 5693, Ap
39	9	100.0	25	10	US-09-866-108-5694	Sequence 5694, Ap
40	9	100.0	25	10	US-09-866-108-5695	Sequence 5695, Ap
41	9	100.0	31	9	US-09-776-474-2450	Sequence 2450, Ap
42	9	100.0	31	10	US-09-801-274-1613	Sequence 1613, Ap
43	9	100.0	32	9	US-10-014-101-24	Sequence 24, Appl
44	9	100.0	33	10	US-09-828-313-39	Sequence 39, Appl
45	9	100.0	33	10	US-09-828-313-94	Sequence 94, Appl

ALIGNMENTS

RESULT 1
US-10-122-630-1
; Sequence 1, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Glitchest, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaer, Mina
; TITLE OF INVENTION: Method to inhibit cell growth using
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-1

Query Match 100.0%; Score 9; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 9; Conservative 0; Mismatches 0; Indels 0;

QY 1 GAGTATGAG 9
|||||||
DB 1 GAGTATGAG 9

```
RESULT 2
US-10-122-633-1
; Sequence 1, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eiler, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth using
; FILE REFERENCE: 0054,1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-1

Query Match          100.0%; Score 9; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GAGTATGAG 9
Db      1 GAGTATGAG 9

RESULT 3
US-09-866-108-2750
; Sequence 2750, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2750
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2750

Query Match          100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GAGTATGAG 9
Db      9 GAGTATGAG 17

RESULT 4
US-09-866-108-2751
; Sequence 2751, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
```

SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 2751
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2751

Query Match 100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
DB 8 GAGTATGAG 16

RESULT 5
US-09-866-108-2752
Sequence 2752, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 2752
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2752

Query Match 100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
DB 7 GAGTATGAG 15

RESULT 6
US-09-866-108-2753
Sequence 2753, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 2753
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2753

Query Match 100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
DB 6 GAGTATGAG 14

RESULT 7
US-09-866-108-2754
Sequence 2754, Application US/09866108
Patent No. US20020048800A1

```
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 2754
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-2754

Query Match          100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7,1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GAGTATGAG 9
        |||||||
DB      5 GAGTATGAG 13

RESULT 8
US-09-866-108-2755
;; Sequence 2755, Application US/09866108
;; Patent No. US20020048800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
```

```
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 2755
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-2755

Query Match          100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7,1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GAGTATGAG 9
        |||||||
DB      4 GAGTATGAG 12

RESULT 9
US-09-866-108-2756
;; Sequence 2756, Application US/09866108
;; Patent No. US20020048800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
```

;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 2756
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-2756

Query Match 100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
Db 3 GAGTATGAG 11

RESULT 10
US-09-866-108-2757
;; Sequence 2757, Application US/09866108
;; Patent No. US20020048800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30

;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 2757
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-2757

Query Match 100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
Db 2 GAGTATGAG 10

RESULT 11
US-09-866-108-2758
;; Sequence 2758, Application US/09866108
;; Patent No. US20020048800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecmics Sequence Listing Engine
; SEQ ID NO 2758
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2758

Query Match 100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 1 GAGTATGAG 9

RESULT 12
US-09-853-895-1/c
; Sequence 1, Application US/09853895
; Patent No. US20020045590A1
; GENERAL INFORMATION:
; APPLICANT: Johns, Roger
; APPLICANT: Tao, Yuan-Xiang
; TITLE OF INVENTION: Inhibition of Interaction of PSD93 and
; TITLE OF INVENTION: PSD95 with nNOS and NMDA receptors
; FILE REFERENCE: 01107, 00130
; CURRENT APPLICATION NUMBER: US/09/853,895
; CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: 60/242590
; PRIOR FILING DATE: 2000-10-23
; PRIOR APPLICATION NUMBER: 60/203894
; PRIOR FILING DATE: 2000-05-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Rattus rattus
US-09-853-895-1

Query Match 100.0%; Score 9; DB 10; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 18 GAGTATGAG 10

RESULT 13
US-10-128-870-15
; Sequence 15, Application US/10128870
; Patent No. US20020168724A1
; GENERAL INFORMATION:
; APPLICANT: Bianar, Michael A.
; APPLICANT: Dworetzky, Steven
; APPLICANT: Grikoff, Valentin K.
; APPLICANT: Levesque, Paul C.
; APPLICANT: Little, Wayne A.
; APPLICANT: Neudauer, Michael G.
; APPLICANT: Yang, Wen-Pin
; TITLE OF INVENTION: KCNQ POTASSIUM CHANNELS AND METHODS OF MODULATING SAME
; FILE REFERENCE: DCS6adiV
; CURRENT APPLICATION NUMBER: US/10/128,870
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: 09/105,058
; PRIOR FILING DATE: June 26, 1998
; PRIOR APPLICATION NUMBER: 60/055,599
; PRIOR FILING DATE: August 12, 1997
; NUMBER OF SEQ ID NOS: 28

; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Forward
; OTHER INFORMATION: primer from EST sequence similar to the Kv1QT gene
US-10-128-870-15

Query Match 100.0%; Score 9; DB 9; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 1 GAGTATGAG 9

RESULT 14
US-09-774-809-101
; Sequence 101, Application US/09774809
; Publication No. US20030004120A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0412
; CURRENT APPLICATION NUMBER: US/09/774,809
; CURRENT FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: 09/396,902
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 08/130,616
; PRIOR FILING DATE: 1998-08-07
; PRIOR APPLICATION NUMBER: 08/910,629
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 101
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-774-809-101

Query Match 100.0%; Score 9; DB 9; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 9 GAGTATGAG 17

RESULT 15
US-09-774-809-102
; Sequence 102, Application US/09774809
; Publication No. US20030004120A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0412
; CURRENT APPLICATION NUMBER: US/09/774,809
; CURRENT FILING DATE: 2001-01-31

; PRIOR APPLICATION NUMBER: 09/396,902
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 09/130,616
; PRIOR FILING DATE: 1998-08-07
; PRIOR APPLICATION NUMBER: 08/910,629
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-774-809-102

Query Match 100.0%; Score 9; DB 9; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0;
QY 1 GAGTATGAG 9
| | | | | | | | | |
Db 9 GAGTATGAG 17

Search completed: June 2, 2003, 23:43:11
Job time : 64.8781 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Comugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 17:32:40 ; Search time 150.366 Seconds
(without alignments)
134.791 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 tagagagat 9

Scoring table:

Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 2063506

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N_Geneseq_101002:*

1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*

2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*

3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*

4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*

5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*

6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*

7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*

8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*

9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*

10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*

11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*

12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*

13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*

14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*

15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*

16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*

17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*

18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*

19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*

20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*

21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*

22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*

23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*

24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	9	100.0	9	20	AAZ10693
2	9	100.0	9	23	AAZ14906
3	9	100.0	9	23	ABH73149
4	9	100.0	9	23	ABH79033
5	9	100.0	9	23	ABH83668
6	9	100.0	9	23	ABH86802
7	9	100.0	9	23	ABH95571
8	9	100.0	9	23	ABH99034
9	9	100.0	9	23	ABH106447

10	9	100.0	12	23	ABH14652	Oligonucleotide pr
11	9	100.0	12	23	ABH16049	Oligonucleotide pr
12	9	100.0	12	23	ABH138611	Oligonucleotide pr
13	9	100.0	12	23	ABH139203	Oligonucleotide pr
14	9	100.0	12	23	ABH140401	Oligonucleotide pr
15	9	100.0	12	23	ABH175163	Oligonucleotide pr
16	9	100.0	12	23	ABH176166	Oligonucleotide pr
17	9	100.0	12	23	ABH178087	Oligonucleotide pr
18	9	100.0	12	23	ABH180232	Oligonucleotide pr
19	9	100.0	13	23	ABH06168	Oligonucleotide pr
20	9	100.0	13	23	ABH06169	Oligonucleotide pr
21	9	100.0	13	23	ABH20906	Oligonucleotide pr
22	9	100.0	13	23	ABH20907	Oligonucleotide pr
23	9	100.0	13	23	ABH40316	Oligonucleotide pr
24	9	100.0	13	23	ABH40317	Oligonucleotide pr
25	9	100.0	13	23	ABH54924	Oligonucleotide pr
26	9	100.0	13	23	ABH54925	Oligonucleotide pr
27	9	100.0	13	23	ABH72172	Oligonucleotide pr
28	9	100.0	13	23	ABH72173	Oligonucleotide pr
29	9	100.0	13	23	ABH84890	Oligonucleotide pr
30	9	100.0	13	23	ABH84891	Oligonucleotide pr
31	9	100.0	13	23	ABH18052	Oligonucleotide pr
32	9	100.0	13	23	ABH18053	Oligonucleotide pr
33	9	100.0	13	23	ABH28786	Oligonucleotide pr
34	9	100.0	13	23	ABH28787	Oligonucleotide pr
35	9	100.0	13	23	ABH66366	Oligonucleotide pr
36	9	100.0	13	23	ABH66367	Oligonucleotide pr
37	9	100.0	13	23	ABH92852	Oligonucleotide pr
38	9	100.0	13	23	ABH92853	Oligonucleotide pr
39	9	100.0	13	23	ABH01812	Oligonucleotide pr
40	9	100.0	13	23	ABH01813	Oligonucleotide pr
41	9	100.0	13	23	ABH16364	Oligonucleotide pr
42	9	100.0	13	23	ABH16365	Oligonucleotide pr
43	9	100.0	13	23	ABH32012	Oligonucleotide pr
44	9	100.0	13	23	ABH32013	Oligonucleotide pr
45	9	100.0	13	23	ABH40490	Oligonucleotide pr

ALIGNMENTS

RESULT 1

AAZ10693

ID AAZ10693 standard; DNA; 9 BP.

XX

AC AAZ10693;

DT 23-NOV-1999 (first entry)

XX

DE Oligonucleotide sequence that increases p53 activity in a cell.

XX

XX p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;

KW UV-induced hyperproliferative disease; psoriasis; vitiligo;

KW atopic dermatitis; allergic rhinitis; conjunctivitis; photogingiv;

KW skin cancer; ss.

XX

OS Synthetic.

XX

PN GB2336157-A.

PD 13-OCT-1999.

XX

PF 24-MAR-1999; 99GB-0006758.

XX

PR 26-MAR-1998; 98US-0048927.

XX

PA (UYBO-) UNTV BOSTON.

XX

PI Gilchrist BA, Yaar M, Eller M;

XX WPI; 1999-543520/46.

DR

XX

PT DNA fragments useful for increasing p53 activity in a cell and reducing

PT susceptibility to UV-induced hyperproliferative diseases -
XX
PS Claim 11, Page 29; 44pp; English.
CC
XX AA210692-97 represent DNA fragments that are used for increasing p53
CC activity in a cell. The oligonucleotides are UV mimetics and
CC protect cells against subsequent exposure to UV-irradiation or
CC chemicals. The oligonucleotides are useful for increasing p53 activity
CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
CC and reducing susceptibility to skin cancer.
XX
SQ Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
Query Match 100.0%; Score 9; DB 20; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.4e+08;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TAGGAGCAT 9
Db 1 TAGGAGCAT 9
RESULT 2
AAS14906 standard; DNA; 9 BP.
XX
AC AAS14906;
XX
DT 14-FEB-2002 (first entry)
XX
DE Melanogenesis associated oligonucleotide #2.
XX
KM Melanin; melanogenic; oligomer; cytosolic; anti-allergic; p53;
KM anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
KM immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
KM tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
KM carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
KM conjunctivitis; allergic rhinitis; vitiligo; ss.
XX
OS Synthetic.
XX
PN WO200174342-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US10162.
XX
PR 31-MAR-2000; 2000US-0540843.
XX
PA (UYBO-) UNIV BOSTON.
XX
PI GlaxoSmithKline, Yaar M, Eller M;
XX
DR WPI; 2001-626338/72.
XX
PT Inhibiting proliferation of epithelial cells, useful e.g. for treating
PT carcinoma, using specific oligonucleotides that mimic the effects of
PT ultra-violet light -
XX
PS Claim 1; Page 36; 74pp; English.
XX
CC The invention describes inhibition of mammalian epithelial cell
CC proliferation by treating cells with at least one oligonucleotide, or
CC its fragment. The compounds, which have cytostatic, anti-allergic,
CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
CC DNA repair processes (or a protective response to later exposure to
CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
CC or a tumour necrosis factor inhibitor. Probably they mimic products of
CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
CC pathway, resulting in transient arrest of cell growth, allowing more time

CC for DNA repair to occur before cell division takes place. The method is
CC especially used to treat carcinoma but may also be used to: treat other
CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
CC allergic rhinitis and conjunctivitis; prevent or reduce DNA damage in
CC cells caused by radiation or chemicals; increase melanin production
CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
CC promote apoptosis in epithelial cells that contain damaged DNA. Also
CC oligonucleotides that contain non-hydrolyzable backbones are used to
CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
CC sequence is melanogenesis associated oligonucleotide #2, a scrambled
CC version of the oligonucleotide shown in AAS14905, one of the
CC oligonucleotides used to inhibit mammalian epithelial cell proliferation,
CC described in the method of the invention.
XX
SQ Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.4e+08;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TAGGAGCAT 9
Db 1 TAGGAGCAT 9
RESULT 3
ABH73149 standard; DNA; 12 BP.
XX
AC ABH73149;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 273134 for detecting SNP TSC0003058.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIC-) EPIDERMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 273134; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABE00010-ABE99989, ABE00010-ABE99989, ABE00010-ABE99989 and
CC ABE00010-ABE99989 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pcl_sequences.

SQ Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
| | | | | | | |
DB 3 TAGGAGGAT 11

RESULT 4

ABH79033/c
ID ABH79033 standard; DNA; 12 BP.

AC ABH79033;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 279026 for detecting SNP TSC0006799.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB00713.

PR 07-APR-2000; 2000DE-1019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single nucleotide polymorphisms and cytosine
methylation status -

PS Claim 1; SEQ ID 279026; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation.

CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and

CC ABH00010-ABH82073 represent the oligomers described in the invention.

CC NOTE: The sequence data for this patent did not form part of the printed
specification, but was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pcl_sequences.

CC Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
| | | | | | | |
DB 12 TAGGAGGAT 4

RESULT 5

ABH83668
ID ABH83668 standard; DNA; 12 BP.

AC ABH83668;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 283661 for detecting SNP TSC0011446.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB00713.

PR 07-APR-2000; 2000DE-1019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single nucleotide polymorphisms and cytosine
methylation status -

PS Claim 1; SEQ ID 283661; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation.

CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and

CC ABH00010-ABH82073 represent the oligomers described in the invention.

CC NOTE: The sequence data for this patent did not form part of the printed
specification, but was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pcl_sequences.

CC Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
| | | | | | | |
DB 3 TAGGAGGAT 11

RESULT 6

ABH86802/c
ID ABH86802 standard; DNA; 12 BP.

AC ABH86802;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 286795 for detecting SNP TSC0012825.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 286795; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC AB100010-AB182073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 12 BP; 4 A; 5 G; 3 T; 0 other;
 XX
 Query Match 100.0%; Score 9; DB 23; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 TAGGAGGAT 9
 Db 9 TAGGAGGAT 1
 DE
 XX
 AC ABH95571;
 XX
 DF 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 295564 for detecting SNP TSC0016640.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 295564; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC AB100010-AB182073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 12 BP; 4 A; 0 G; 5 C; 3 T; 0 other;
 XX
 Query Match 100.0%; Score 9; DB 23; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 TAGGAGGAT 9
 Db 4 TAGGAGGAT 12
 DE
 XX
 AC ABH99034;
 XX
 DF 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 299027 for detecting SNP TSC0018404.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 299027; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX

SO Sequence 12 BP; 3 A; 5 C; 0 G; 4 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCAT 9
| | | | | | | |
Db 12 TAGGAGCAT 4

RESULT 9
AB106447
ID AB106447 standard; DNA; 12 BP.

XX AC AB106447;

XX DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 306420 for detecting SNP TSC0022000.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB00713.

XX PR 07-APR-2000; 2000DE-1019173.

XX PA (EP1G-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX

PS Claim 1; SEQ ID 306420; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX

SO Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCAT 9
| | | | | | | |
Db 1 TAGGAGCAT 9

RESULT 10

AB114652
ID AB114652 standard; DNA; 12 BP.

XX AC AB114652;

XX DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 314625 for detecting SNP TSC0026468.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB00713.

XX PR 07-APR-2000; 2000DE-1019173.

XX PA (EP1G-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX

PS Claim 1; SEQ ID 314625; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX

SO Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCAT 9
| | | | | | | |
Db 4 TAGGAGCAT 12

RESULT 11

AB116049
ID AB116049 standard; DNA; 12 BP.

XX

AC AB116049;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 316022 for detecting SNP TSC0027234.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single nucleotide polymorphisms and cytosine
XX methylation status -
XX
XX Claim 1; SEQ ID 316022; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation.
XX ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX AB100010-AB182073 represent the oligomers described in the invention.
XX NOTE: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 other;
XX
XX Query Match 100.0%; Score 9; DB 23; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.4e+04;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 TAGGAGGAT 9
XX |||||||||
DB 2 TAGGAGGAT 10
XX
RESULT 12
XX AB138611/C
XX ID AB138611 standard; DNA; 12 BP.
XX
XX AB138611;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 338584 for detecting SNP TSC0040564.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX

XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single nucleotide polymorphisms and cytosine
XX methylation status -
XX
XX Claim 1; SEQ ID 338584; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation.
XX ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX AB100010-AB182073 represent the oligomers described in the invention.
XX NOTE: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 12 BP; 2 A; 5 C; 0 G; 5 T; 0 other;
XX
XX Query Match 100.0%; Score 9; DB 23; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.4e+04;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 TAGGAGGAT 9
XX |||||||||
DB 12 TAGGAGGAT 4
XX
RESULT 13
XX AB139203/C
XX ID AB139203 standard; DNA; 12 BP.
XX
XX AB139203;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 339176 for detecting SNP TSC0040884.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
PS
XX Claim 1; SEQ ID 339176; 29pp + Sequence Listing; German.
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04; Mismatches 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TAGGAGGAT 9
DB 12 TAGGAGGAT 4
RESULT 14
ABI40401
ID ABI40401 standard; DNA; 12 BP.
XX
AC ABI40401;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 340374 for detecting SNP TSC0041493.
XX
KM SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPig-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
PS
XX Claim 1; SEQ ID 340374; 29pp + Sequence Listing; German.
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.

CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04; Mismatches 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TAGGAGGAT 9
DB 1 TAGGAGGAT 9
RESULT 15
ABI75163/C
ID ABI75163 standard; DNA; 12 BP.
XX
AC ABI75163;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 375136 for detecting SNP TSC0061083.
XX
KM SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPig-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
PS
XX Claim 1; SEQ ID 375136; 29pp + Sequence Listing; German.
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 5 C; 0 G; 4 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04; Mismatches 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TAGGAGGAT 9

Wed Jun 4 11:08:12 2003

us-09-540-843-2.szlm40.rng

Page 8

|||||||
Db 11 TAGGAGAT 3

Search completed: June 2, 2003, 18:45:10
Job time : 151.566 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:29:55 ; Search time 1129.39 Seconds

(without alignments)
129,060 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 tagaggatg 9

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 60474

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

EST:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estinu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_estl:*
10: gb_estl2:*
11: gb_hic:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vrt:*
22: em_gss_fun:*
23: em_gss_mam:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_rod:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	9	100.0	35	17	AZ454138 IM0256A01
2	9	100.0	40	9	AA912717 o1a1a03.s
3	8	88.9	19	17	AZ500675 IM0339J10
4	8	88.9	20	17	AZ393773 IM0157B04
5	8	88.9	21	17	AZ387199 IM0146P20
6	8	88.9	21	17	AZ645664 IM0511C13

7	8	88.9	22	9	AT631347
8	8	88.9	22	17	AZ411934
9	8	88.9	23	17	AZ822831
10	8	88.9	24	13	BG925475 HNC5-1-C6
11	8	88.9	24	17	AZ503909 IM0343E24
12	8	88.9	24	17	BH789331 SALK_0190
13	8	88.9	25	17	AZ491057
14	8	88.9	25	17	AZ496986
15	8	88.9	28	17	AZ480483
16	8	88.9	28	17	AZ799431
17	8	88.9	29	14	N22525
18	8	88.9	29	17	AZ759923
19	8	88.9	29	17	TA6H120
20	8	88.9	30	17	AZ312621
21	8	88.9	30	17	AZ658025
22	8	88.9	30	17	AZ817062
23	8	88.9	31	9	A1583630
24	8	88.9	31	9	AA209595
25	8	88.9	31	17	AZ500072
26	8	88.9	31	17	AZ663905
27	8	88.9	32	13	BJ059143
28	8	88.9	32	17	AZ325144
29	8	88.9	33	17	AZ435186
30	8	88.9	33	17	AZ486766
31	8	88.9	33	17	BH856998
32	8	88.9	34	17	BH814333
33	8	88.9	35	14	H38132
34	8	88.9	35	17	BH848385
35	8	88.9	36	13	BJ048452
36	8	88.9	36	14	T67214
37	8	88.9	37	9	A1629177
38	8	88.9	37	17	BH023763
39	8	88.9	37	17	BH850593
40	8	88.9	38	14	R37318
41	8	88.9	38	17	AZ802603
42	8	88.9	38	17	AZ818796
43	8	88.9	38	17	AL758045
44	8	88.9	40	9	AA743356
45	8	88.9	40	9	AT273000

ALIGNMENTS

RESULT 1
AZ454138 35 bp DNA linear GSS 04-OCT-2000
DEFINITION IM0256A01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
LOCUS AZ454138
ACCESSION AZ454138
VERSION
KEYWORDS
SOURCE
ORGANISM
house mouse.
Mus musculus
REFERENCE
AUTHORS
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
1 (Dases 1 to 35)
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Rellly
'M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
Plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunne@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0256 row: A column: 01
 Seq primer: CGTGTAAACGACGCCACT
 Class: plasmid ends
 High quality sequence stop: 35.
 Location/Qualifiers

FEATURES

source

1..35
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0256A01"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
 /note="Vector: PWD42nv, Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMDA2 (g14732114gb) (API29072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT

7 a 1 c 20 g 7 t

Query Match 100.0%; Score 9; DB 17; Length 35;
 Best Local Similarity 100.0%; Pred. No. 1.2e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCAT 9
 |||||
 Db 6 TAGGAGCAT 14

RESULT 2

LOCUS

DEFINITION

AA912717 40 bp mRNA linear EST 26-AUG-1998
 0141a03.s1 Soares_NFL_T_GBC-ST Homo sapiens cDNA clone
 IMAGE:1525996 3' similar to SW:BI3_MOUSE P28662 BRAIN PROTEIN I3 ;
 mRNA sequence.

ACCESSION

AA912717
 AA912717.1 GI:3052109

VERSION

EST.

KEYWORDS

human.

ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

1 (bases 1 to 40)

NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.

National Cancer Institute, Cancer Genome Anatomy Project (CGAP),

Tumor Gene Index

Unpublished (1997)

Contact: Robert Strausberg, Ph.D.

Email: cgapbs-r@mail.nih.gov

This clone is available royalty-free through LNL; contact the

IMaB Consortium (info@image.lnl.gov) for further information.

Insert Length: 449 Std Error: 0.00

Seq primer: -40m13 fwd. ET from Amersham

High quality sequence stop: 1.

Location/Qualifiers

1..40

/organism="Homo sapiens"

BASE COUNT

8 a 10 c 10 g 12 t

Query Match 100.0%; Score 9; DB 9; Length 40;
 Best Local Similarity 100.0%; Pred. No. 1.3e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCAT 9
 |||||
 Db 24 TAGGAGCAT 32

RESULT 3

LOCUS

DEFINITION

AZ500675 19 bp DNA linear GSS 05-OCT-2000
 1M0339J10F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC1M0339J10 F. DNA sequence.

ACCESSION

AZ500675
 AZ500675.1 GI:10680728

VERSION

GSS.

KEYWORDS

house mouse.

ORGANISM

Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 19)

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,

Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Rellly

,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausen,A.

and Wright,D., Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah

Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: dunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0339 row: J column: 10

Seq primer: CGTGTAAACGACGCCACT

Class: plasmid ends

High quality sequence stop: 19.

Location/Qualifiers

1..19

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC1M0339J10"

/clone_lib="Mouse 10kb plasmid UUGC1M library"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"

/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g11473211419b1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance.

BASE COUNT
ORIGIN
4 a 0 c 9 g 6 t

Query Match 88.9%; Score 8; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGCA 8
Db 11 TAGGAGCA 18

RESULT 4
A2393773/c 20 bp DNA linear GSS 03-OCT-2000
LOCUS 1M0157B04F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0157B04 F, DNA sequence.
ACCESSION A2393773
VERSION A2393773.1 GI:10508845
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 20)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
' and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0157 row: B column: 04
Seq primer: CGTTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 20.

FEATURES
source

1. 20
location/Qualifiers
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0157B04"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g11473211419b1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance.

BASE COUNT
ORIGIN
2 a 11 c 1 g 6 t

Query Match 88.9%; Score 8; DB 17; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGGAGGAT 9
Db 20 AGGAGGAT 13

RESULT 5
A2387199/c 21 bp DNA linear GSS 02-OCT-2000
LOCUS 1M0146P20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0146P20 R, DNA sequence.
ACCESSION A2387199
VERSION A2387199.1 GI:10500900
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 21)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
' and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0146 row: P column: 20
Seq primer: CACACAGAAACGCTATGACC
Class: plasmid ends
High quality sequence stop: 21.

FEATURES
source

1. 21
location/Qualifiers
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0146P20"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource

(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-treated with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g11473211419b1AR129072.1), a copy-number inducible derivative of plasmid p1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match	88.9%;	Score 8;	DB 17;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 4.2e+05;		
Matches	8;	Conservative	0;	Mismatches 0;
				Indels 0;
				Gaps 0;
QY	1	TAGGAGCA	8	
Db	15	TAGGAGCA	8	

LOCUS	DEFINITION	21 bp DNA	linear	GSS 14-DEC-2000
A2645664/c	1M051C13F Mouse 10kb plasmid U06C1M library Mus musculus genomic clone U06C1M051C13 F, DNA sequence.			

VERSION	A204C004.1
KEYWORDS	GSS.
SOURCE	house mouse.
ORGANISM	Mus musculus

REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT
1 (bases 1 to 21)	Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tinley, A., von Niederhausern, A. and Wright, D., Weiss, R.	Mouse whole genome scaffolding with paired end reads from 10kb	Unpublished (2000)	
		Plasmid inserts		
		Unpublished (2000)		
		Contact: Robert B. Weiss		

Rm 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112 USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0511 row: C column: 13
Seq primer: CATTCTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 21.
location/Qualifiers
1. 21

```

/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UG061M0511C13"
/clone_11b="Mouse 10kb plasmid UG061M library"
/sex="Male"
/lab_host="E. Coll strain XL10-Gold, Ti-resistant, F-"
/note="Vector: pMD24my: Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
laboratory Mouse DNA Resource

```

(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repeated with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The digested DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g11473211419b1AR129072.1), a copy-number inducible derivative of plasmid RI. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match	88.9%	Score 8:	DB 1/;	Length 21:
Best Local Similarity	100.0%	Pred. No. 4.2e+05:		
Matches	8;	Conservative	0;	Mismatches 0;
				Indels 0;
				Gaps 0;
0Y	1	TAGAGGA	8	
DB	8	TAGAGGA	1	

	RESULT 7			
A1631347				
LOCUS				
DEFINITION	A1631347	22 bp	mRNA	linear EST 16-DEC-1998
	tz33c04.x1 NCI CGAP_Pan1 Homo sapiens cDNA clone IMAGE:2295174 3'			
	similar to SW:PRR2_HUMAN P02812 SALIVARY PROLINE-RICH PROTEIN			
	PRECURSOR ; contains element MRR22 repetitive element ; , mRNA			

ACCESSION	AI631347	GI:4682677
VERSION	AI631347.1	
KEYWORDS	EST.	
SOURCE	human	

ORGANISM	REFERENCE AUTHORS TITLE	JOURNAL COMMENT
Homo sapiens		
Eumetazoa; Metazoa; Chordata; Cranialata; Vertebrata; Euteleostomi		
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
1 (bases 1 to 22)		
NCI-CCGAP http://www.ncbi.nlm.nih.gov/ncicgap .		
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),		
Tumor Gene Index		
Unpublished (1997)		
Contact: Robert Strausberg, Ph.D.		

Email: cgabps-r@mail.nih.gov
Life Technologies catalog #: 11548-013
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution Information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.dio.llnl.gov/dbip/image/image.html

Trace considered overall poor quality
Insert Length: 1010 Std Error: 0.000
Seq primer: -400p from Gibco
High quality sequence stop: 1.
Location/Qualifiers

```

FEATURES
  source      location/Qualifiers
              1..22
              /Organism="Homo sapiens"
              /db_xref="taxon:9606"
              /locus="TM6CF.329517A"

```

```

/tissue.type="adenocarcinoma"
/lab.host="DH10B"
/note="Organ: pancreas; Vector: pCMV-SPORT6; Site_1: Sali
Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.72 kb. Life Technologies catalog #:
11548-013"

```

Query Match 88.9%; Score 8; DB 9; Length 22;
 Best Local Similarity 100.0%; Pred. No. 4.2e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCA 8
 |||||
 12 TAGGAGCA 19

RESULT 8
 AZ411934/c 22 bp DNA linear GSS 03-OCT-2000
 LOCUS 1M0185409F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 DEFINITION
 AZ411934
 AZ411934
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM
 house mouse.
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 22)
 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
 Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
 M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A.
 and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts
 Unpublished (2000)
 JOURNAL
 COMMENT
 Contact: Robert B. Weiss
 University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0185 row: M column: 09
 Seq primer: CGTTGTAAACGACGCCACT
 Class: plasmid ends
 High quality sequence stop: 22.
 Location/Qualifiers
 1..22
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0185M09"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
 /note="Vector: PMD42ny; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of PMD42 (g1147321149b/AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

BASE COUNT
 ORIGIN
 2 a 8 c 5 g 7 t

Query Match 88.9%; Score 8; DB 17; Length 22;
 Best Local Similarity 100.0%; Pred. No. 4.2e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGGAGCAT 9
 |||||
 9 AGGAGCAT 2

RESULT 9
 A2822831/c 23 bp DNA linear GSS 20-FEB-2001
 LOCUS 2M0096J21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 DEFINITION
 A2822831
 A2822831
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM
 house mouse.
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 23)
 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
 Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
 M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A.
 and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts
 Unpublished (2000)
 JOURNAL
 COMMENT
 Contact: Robert B. Weiss
 University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0096 row: J column: 21
 Seq primer: CGTTGTAAACGACGCCACT
 Class: plasmid ends
 High quality sequence stop: 23.
 Location/Qualifiers
 1..23
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M0096J21"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
 /note="Vector: PMD42ny; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of PMD42 (g1147321149b/AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

BASE COUNT
 ORIGIN
 7 a 5 c 6 g 5 t

Query Match 88.9%; Score 8; DB 17; Length 23;
 Best Local Similarity 100.0%; Pred. No. 4.3e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGA 8
 14 TAGGAGGA 7

Db 14 TAGGAGGA 7

RESULT 10
 BG925475/c 24 bp mRNA linear EST 06-NOV-2001
 LOCUS HNC5-1-C6.R HNC (Human Normal Cartilage) Homo sapiens cDNA, mRNA
 DEFINITION Sequence.
 ACCESSION BG925475
 VERSION BG925475.1 GI:14319998
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 24)
 AUTHORS Kumar,S., Connor,J.R., Dodds,R.A., Halsey,W., Van Horn,M., Mao,J.,
 Sathe,G., Mul,P., Agarwal,P., Badger,A.M., Lee,J.C., Gowen,M. and
 Latk,M.W.
 TITLE Identification and initial characterization of 5000 expressed
 sequenced tags (ESTs) each from adult human normal and
 osteoarthritic cartilage cDNA libraries
 JOURNAL Osteoarthr. Cartil. 9 (7), 641-653 (2001)
 MEDLINE 21482651
 COMMENT Contact: Sanjay Kumar
 DM2109
 GlaxoSmithKline
 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406, USA
 Tel: 610-270-7245
 Fax: 610-270-5598
 Email: sanjay_kumar-1@sk.com
 Seq primer: 17.
 FEATURES
 Location/Qualifiers
 1..24
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_lib="HNC (Human Normal Cartilage)"
 /tissue_type="cartilage"
 /lab_host="E.coli DH10 B"
 /note="Vector: pSPORT 1; site_1: SalI; site_2: NotI;
 Directional"
 BASE COUNT 4 a 9 c 1 g 10 t
 ORIGIN

Query Match 88.9%; Score 8; DB 13; Length 24;
 Best Local Similarity 100.0%; Pred. No. 4.3e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGGAGGAT 9
 11 AGGAGGAT 4

Db 11 AGGAGGAT 4

RESULT 11
 AZ503909 24 bp DNA linear GSS 05-OCT-2000
 LOCUS 1M0343E24R Mouse 10kb plasmid UUGCIM library Mus musculus genomic
 DEFINITION clone UUGCIM0343E24 R, DNA sequence.
 ACCESSION AZ503909
 VERSION AZ503909.1 GI:10685225
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
 REFERENCE 1 (bases 1 to 24)

AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
 M., Rose,M., Rose,R., Stokes,R., Tinger,A., von Niederhausen,A.,
 and Wright,D., Weiss,R.
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb
 Plasmid inserts
 JOURNAL Unpublished (2000)
 COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunne@genetics.utah.edu
 Insert length: 10000 Std Error: 0.00
 Plate: 0343 row: E column: 24
 Seq primer: CACACAGGAACACGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 24.
 FEATURES
 Location/Qualifiers
 1..24
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone_lib="UUGCIM0343E24"
 /clone_lib="Mouse 10kb plasmid UUGCIM library"
 /sex="Male"
 /lab_host="E. coli strain XL10-gold, Ti-resistant, F-"
 /note="Vector: pMD42ny; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 ligated DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of pMD42 (g14732114/gb/AP129072.1), a copy-number
 inducible derivative of plasmid RL. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

BASE COUNT 4 a 3 c 9 g 8 t
 ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 24;
 Best Local Similarity 100.0%; Pred. No. 4.3e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGA 8
 7 TAGGAGGA 14

Db 7 TAGGAGGA 14

RESULT 12
 BH789331/c 24 bp DNA linear GSS 02-APR-2002
 LOCUS BH789331
 DEFINITION SALK_019058.23.05 x Arabidopsis thaliana TDM insertion lines
 Arabidopsis thaliana genomic clone SALK_019058.23.05.x, DNA
 sequence.
 ACCESSION BH789331
 VERSION BH789331.1 GI:19882429
 KEYWORDS GSS.
 SOURCE thale cress.
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

REFERENCE Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1 (bases 1 to 24)
AUTHORS Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab,
C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P.,
Zimmerman,J. and Ecker,J.R.
TITLE A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis Genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA.
Class: TDNA tagged.
FEATURES
source Location/Qualifiers
1..24
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="SALK_019058.23.05.x"
/clone_lib="Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/tdna_protocols.html"
BASE COUNT 2 a 14 c 0 g 8 t
ORIGIN
Query Match 88.9%; Score 8; DB 17; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.3e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 AGGAGGAT 9
|||||||
Db 8 AGGAGGAT 1
RESULT 13
AZ491057 25 bp DNA linear GSS 05-OCT-2000
LOCUS IM0324124F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0324124 F, DNA sequence.
ACCESSION AZ491057
VERSION AZ491057.1 GI:10662392
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 25)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0324 row: I column: 24

Seq primer: CGTGTAAACGAGCCACG
Class: plasmid ends
High quality sequence stop: 25.
FEATURES
source Location/Qualifiers
1..25
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0324124"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, RI-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(<http://www.jax.org/resources/documents/dnares/>). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (q114732114[gb|AF129072.1]), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT 7 a 4 c 12 g 2 t
ORIGIN
Query Match 88.9%; Score 8; DB 17; Length 25;
Best Local Similarity 100.0%; Pred. No. 4.4e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 AGGAGGAT 9
|||||||
Db 9 AGGAGGAT 16
RESULT 14
AZ496986 25 bp DNA linear GSS 05-OCT-2000
LOCUS IM03333H09R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M03333H09 R, DNA sequence.
ACCESSION AZ496986
VERSION AZ496986.1 GI:10673556
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 25)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0333 row: H column: 09

Seq primer: CACACAGGAAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 25.
 Location/Qualifiers
 1..25
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUCG1M033H09"
 /clone_1lb="Mouse 10kb plasmid UUCG1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g11473211419b1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 12 a 1 c 10 g 2 t
 ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 25;
 Best Local Similarity 100.0%; Pred. No. 4.4e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCA 8
 |||||||
 DB 17 TAGGAGCA 24

RESULT 15 AZ480483 28 bp DNA linear GSS 04-OCT-2000
 LOCUS 1M030204F Mouse 10kb plasmid UUCG1M library Mus musculus genomic
 DEFINITION clone UUCG1M030204 F, DNA sequence.
 ACCESSION AZ480483
 VERSION AZ480483.1 GI:10641548
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 28)
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A. and Wright,D., Weiss,R.
 Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0302 Row: J Column: 04

Seq primer: CATTGTAAACGACGCCAGT
 Class: plasmid ends
 High quality sequence stop: 28.
 Location/Qualifiers
 1..28
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUCG1M030204"
 /clone_1lb="Mouse 10kb plasmid UUCG1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g11473211419b1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 4 a 11 c 6 g 7 t
 ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 28;
 Best Local Similarity 100.0%; Pred. No. 4.5e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCA 8
 |||||||
 DB 13 TAGGAGCA 6

Search completed: June 2, 2003, 20:35:37
 Job time: 1133.39 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:31:20 ; Search time 36.878 Seconds
(Without alignments)
74.844 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 tagaggagat 9

Scoring table:

IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 558892

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued_Patents_MN:*
1: /cgn2_6/ptodata1/1na/5A.COMB.seq:*
2: /cgn2_6/ptodata1/1na/5B.COMB.seq:*
3: /cgn2_6/ptodata1/1na/6A.COMB.seq:*
4: /cgn2_6/ptodata1/1na/6B.COMB.seq:*
5: /cgn2_6/ptodata1/1na/PCTUS.COMB.seq:*
6: /cgn2_6/ptodata1/1na/Backfile1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	9	100.0	9	3	US-09-048-927-2	Sequence 2, Appl
2	9	100.0	20	4	US-09-096-172-6	Sequence 6, Appl
3	9	100.0	22	4	US-09-240-918-9	Sequence 9, Appl
4	9	100.0	24	4	US-09-416-050A-15	Sequence 15, Appl
5	9	100.0	24	4	US-09-664-800-15	Sequence 15, Appl
6	9	100.0	24	4	US-09-665-309-15	Sequence 15, Appl
7	9	100.0	24	4	US-09-661-569-15	Sequence 15, Appl
8	9	100.0	28	4	US-09-061-768A-33	Sequence 33, Appl
9	9	100.0	29	4	US-08-310-356-20	Sequence 20, Appl
10	9	100.0	30	4	US-09-019-793A-105	Sequence 105, Appl
11	9	100.0	33	2	US-08-189-256A-46	Sequence 46, Appl
12	9	100.0	33	4	US-09-193-853-46	Sequence 46, Appl
13	9	100.0	36	5	PCT-US95-00605-12	Sequence 12, Appl
14	9	100.0	36	5	PCT-US95-00605-13	Sequence 13, Appl
15	8	88.9	12	3	US-09-290-449-15	Sequence 15, Appl
16	8	88.9	15	1	US-08-182-968A-168	Sequence 168, App
17	8	88.9	15	1	US-08-182-968A-169	Sequence 169, App
18	8	88.9	15	2	US-08-774-306A-168	Sequence 168, App
19	8	88.9	15	2	US-08-774-306A-169	Sequence 169, App
20	8	88.9	15	3	US-09-105-515-4	Sequence 4, Appl
21	8	88.9	15	3	US-09-064-156A-168	Sequence 168, App
22	8	88.9	15	3	US-09-064-156A-169	Sequence 169, App
23	8	88.9	15	4	US-09-748-044-4	Sequence 4, Appl
24	8	88.9	16	1	US-07-664-989B-100	Sequence 100, App
25	8	88.9	16	1	US-07-664-989B-101	Sequence 101, App
26	8	88.9	16	2	US-08-282-197C-20	Sequence 20, Appl
27	8	88.9	17	1	US-08-184-422-4	Sequence 4, Appl

C 28	8	88.9	17	1	US-08-758-306-1307	Sequence 1307, Ap
C 29	8	88.9	17	1	US-08-758-306-1309	Sequence 1309, Ap
C 30	8	88.9	17	1	US-08-758-306-1311	Sequence 1311, Ap
C 31	8	88.9	17	3	US-08-589-771B-4	Sequence 4, Appl
C 32	8	88.9	17	3	US-08-606-505B-45	Sequence 45, Appl
C 33	8	88.9	17	4	US-09-616-990-45	Sequence 45, Appl
C 34	8	88.9	17	4	US-08-584-040-1958	Sequence 1958, Ap
C 35	8	88.9	18	1	US-08-135-511-12	Sequence 12, Appl
C 36	8	88.9	18	1	US-08-319-492B-735	Sequence 735, App
C 37	8	88.9	18	1	US-08-320-558-9	Sequence 9, Appl
C 38	8	88.9	18	1	US-08-327-392-9	Sequence 9, Appl
C 39	8	88.9	18	1	US-08-187-453-12	Sequence 12, Appl
C 40	8	88.9	18	1	US-08-758-306-1379	Sequence 1379, Ap
C 41	8	88.9	18	1	US-08-207-412B-7	Sequence 7, Appl
C 42	8	88.9	18	3	US-08-545-860D-9	Sequence 9, Appl
C 43	8	88.9	18	3	US-08-912-272-87	Sequence 87, Appl
C 44	8	88.9	18	4	US-09-050-158-26	Sequence 26, Appl
C 45	8	88.9	18	4	US-09-071-433-79	Sequence 79, Appl

ALIGNMENTS

```
RESULT 1
; Sequence 2, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Use of locally Applied DNA Fragments
; FILE REFERENCE: BU94-68A2
; CURRENT APPLICATION NUMBER: US/09/048, 927
; EARLIER FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952, 697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467, 012
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA Fragment
; US-09-048-927-2

Query Match          100.0%; Score 9; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
DB 1 TAGGAGGAT 9

RESULT 2
US-09-096-172-6
; Sequence 6, Application US/09096172
; Patent No. 6284252
; GENERAL INFORMATION:
; APPLICANT: MEHTALI, Majid
; APPLICANT: SORG, Tania
; TITLE OF INVENTION: NEW TRANSDOMINANT TAT VARIANTS OF THE
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Burns, Doane, Swecker & Mathis
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
```

```
COUNTRY: United States
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/096,172
FILING DATE:
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/08/177,145
FILING DATE: 04-JAN-1994
APPLICATION NUMBER: FR 93 00004
FILING DATE: 04-JAN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Crane-Feury, Sharon E
REGISTRATION NUMBER: 36,113
REFERENCE/DOCKET NUMBER: 017753-040
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: YES
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: mutagenesis oligonucleotide (TAT
US-09-096-172-6

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
DB 5 TAGGAGGAT 13

RESULT 3
US-09-240-918-9
Sequence 9, Application US/09240918
Patent No. 6265165
GENERAL INFORMATION:
APPLICANT: Gruenert, Dieter C.
APPLICANT: Xu, Zhidong
TITLE OF INVENTION: METHODS FOR EST-SPECIFIC FULL LENGTH cDNA CLONING
FILE REFERENCE: 480.85.1(HV)
CURRENT APPLICATION NUMBER: US/09/240,918
CURRENT FILING DATE: 1999-01-29
PRIOR APPLICATION NUMBER: 60/108,183
PRIOR FILING DATE: 1998-11-12
NUMBER OF SEQ ID NOS: 96
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 9
LENGTH: 22
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-240-918-9

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 22;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 TAGGAGGAT 9
DB 9 TAGGAGGAT 17

RESULT 4
US-09-416-050A-15/c
Sequence 15, Application US/09416050A
Patent No. 6194559
GENERAL INFORMATION:
APPLICANT: Kim, Soo Young
TITLE OF INVENTION: Abscisic Acid Responsive Element -Binding Transcription Fac
FILE REFERENCE: 1942/42
CURRENT APPLICATION NUMBER: US/09/416,050A
CURRENT FILING DATE: 1999-10-12
NUMBER OF SEQ ID NOS: 83
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 15
LENGTH: 24
TYPE: DNA
ORGANISM: Arabidopsis thaliana
US-09-416-050A-15

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 24;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
DB 17 TAGGAGGAT 9

RESULT 5
US-09-664-800-15/c
Sequence 15, Application US/09664800
Patent No. 6218527
GENERAL INFORMATION:
APPLICANT: Kim, Soo Young
TITLE OF INVENTION: Abscisic Acid Responsive Element -Binding Transcription Fac
FILE REFERENCE: 1942/42
CURRENT APPLICATION NUMBER: US/09/664,800
CURRENT FILING DATE: 2000-09-19
PRIOR APPLICATION NUMBER: 09/416,050
PRIOR FILING DATE: 1999-10-12
NUMBER OF SEQ ID NOS: 83
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 15
LENGTH: 24
TYPE: DNA
ORGANISM: Arabidopsis thaliana
US-09-664-800-15

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 24;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
DB 17 TAGGAGGAT 9

RESULT 6
US-09-665-309-15/c
Sequence 15, Application US/09665309
Patent No. 6232461
GENERAL INFORMATION:
APPLICANT: Kim, Soo Young
TITLE OF INVENTION: Abscisic Acid Responsive Element -Binding Transcription Fac
FILE REFERENCE: 1942/42
CURRENT APPLICATION NUMBER: US/09/665,309
CURRENT FILING DATE: 2000-09-19
PRIOR APPLICATION NUMBER: 09/416,050
PRIOR FILING DATE: 1999-10-12
```

NUMBER OF SEQ ID NOS: 83
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Arabidopsis thaliana
US-09-665-309-15

Query Match 100.0%; Score 9; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
Db 17 TAGGAGGAT 9

RESULT 7

US-09-661-569-15/c
; Sequence 15, Application US/09661569
; Patent No. 6245905
; GENERAL INFORMATION:
; APPLICANT: KIM, Soo Young
; TITLE OF INVENTION: Abscisic Acid Responsive Element -Binding Transcription Factor
; FILE REFERENCE: 1942/42
; CURRENT APPLICATION NUMBER: US/09/661,569
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: 09/416,050
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 83
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Arabidopsis thaliana
US-09-661-569-15

Query Match 100.0%; Score 9; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
Db 17 TAGGAGGAT 9

RESULT 8

US-09-061-768A-33
; Sequence 33, Application US/09061768A
; Patent No. 6204037
; GENERAL INFORMATION:
; APPLICANT: BRASH, ALAN R.
; APPLICANT: BOEGLIN, WILLIAM E.
; APPLICANT: JISAKA, MITSUO
; TITLE OF INVENTION: LIPOXYGENASE PROTEINS AND NUCLEIC ACIDS
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARLES A. TAYLOR, JR.
; STREET: SUITE 1400, UNIVERSITY TOWER, 3100 TOWER BOULEVARD
; CITY: DURHAM
; STATE: NORTH CAROLINA
; COUNTRY: USA
; ZIP: 27707

COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 Inch, 1.4 MB storage
; OPERATING SYSTEM: IBM PC/XT/AT compatible
; SOFTWARE: WORD PERFECT 6.1 and ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/061,768A
; FILING DATE: APRIL 16, 1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: NONE

APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: ARLES A. TAYLOR, JR.
; REGISTRATION NUMBER: 39,395
; REFERENCE/DOCKET NUMBER: 1242/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 493-8000
; TELEFAX: (919) 419-0383
; TELEX:
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-061-768A-33

Query Match 100.0%; Score 9; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
Db 7 TAGGAGGAT 15

RESULT 9

US-08-310-356-20/c
; Sequence 20, Application US/08310356
; Patent No. 5648243
; GENERAL INFORMATION:
; APPLICANT: Hurwitz, David R
; APPLICANT: Nathan, Margret
; APPLICANT: Shani, Moshe
; TITLE OF INVENTION: Transgenic Protein Production
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rhone-Poulenc Rorer Legal Department
; STREET: 500 Arcola Road
; CITY: Collegeville
; STATE: PA
; COUNTRY: USA
; ZIP: 19426
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: Macintosh System 7.0
; SOFTWARE: Microsoft Word Version 5.0 (PatentIn)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/310,356
; FILING DATE:
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/737,853
; FILING DATE: 31-JUL-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Goodman, Rosanne
; REGISTRATION NUMBER: 32,534
; REFERENCE/DOCKET NUMBER: A0856
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 454-3817
; TELEFAX: (215) 454-3808
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 29 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-310-356-20

Query Match 100.0%; Score 9; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 2e+03;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9
| | | | | | | |
Db 23 TAGGAGGAT 15

RESULT 10
US-09-019-793A-105/c
Sequence 105, Application US/09019793A
Patent No. 6380376
GENERAL INFORMATION:
APPLICANT: PAUL, Prem
APPLICANT: MENG, Xiang-jin
APPLICANT: MOROZOV, Igor
APPLICANT: HALBUR, Patrick
TITLE OF INVENTION: PROTEINS ENCODED BY POLYNUCLEIC ACIDS OF PORCINE
TITLE OF INVENTION: REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV)
FILE REFERENCE: 4625-0039-55X CIP
CURRENT APPLICATION NUMBER: US/09/019,793A
CURRENT FILING DATE: 1998-02-06
PRIOR APPLICATION NUMBER: 08/478,316
PRIOR FILING DATE: 1995-06-07
PRIOR APPLICATION NUMBER: 08/301,435
PRIOR FILING DATE: 1994-09-01
PRIOR APPLICATION NUMBER: 08/131,625
PRIOR FILING DATE: 1993-10-05
PRIOR APPLICATION NUMBER: 07/969,071
PRIOR FILING DATE: 1992-10-30
NUMBER OF SEQ ID NOS: 108
SOFTWARE: Patentln. Ver. 2.1
SEQ ID NO: 105
LENGTH: 30
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: synthetic DNA
US-09-019-793A-105

Query Match 100.0%; Score 9; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 2e+03; 0; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9
| | | | | | | |
Db 15 TAGGAGGAT 7

RESULT 11
US-08-189-256A-46/c
Sequence 46, Application US/08189256A
Patent No. 5877402
GENERAL INFORMATION:
APPLICANT: Maliga, Pal
APPLICANT: Svab, Zora
APPLICANT: Staub, Jeffrey
APPLICANT: Zoubenko, Oleg V.
APPLICANT: Allison, Lori A.
APPLICANT: Carier, Helaine
APPLICANT: Kanevski, Ivan
TITLE OF INVENTION: DNA Constructs and Methods for Stably
TITLE OF INVENTION: Transforming Plasmids of Multicellular Plants and
TITLE OF INVENTION: Expressing Recombinant Proteins Therein
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dann, Dorfman, Herrell and Skillman
STREET: 1601 Market Street Suite 720
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103-2307
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentln Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/189,256A
FILING DATE: 31-JAN-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/111,398
FILING DATE: 25-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/518,763
FILING DATE: 01-MAY-1990
ATTORNEY/AGENT INFORMATION:
NAME: Reed, Janet E.
REGISTRATION NUMBER: 36,252
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 563-4100
TELEFAX: (215) 563-4044
INFORMATION FOR SEQ ID NO: 46:
SEQUENCE CHARACTERISTICS:
LENGTH: 33 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-189-256A-46

Query Match 100.0%; Score 9; DB 2; Length 33;
Best Local Similarity 100.0%; Pred. No. 2e+03; 0; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9
| | | | | | | |
Db 27 TAGGAGGAT 19

RESULT 12
US-09-193-853-46/c
Sequence 46, Application US/09193853
Patent No. 6386168
GENERAL INFORMATION:
APPLICANT: Maliga, Pal
APPLICANT: Svab, Zora
APPLICANT: Staub, Jeffrey
APPLICANT: Zoubenko, Oleg V.
APPLICANT: Allison, Lori A.
APPLICANT: Carier, Helaine
APPLICANT: Kanevski, Ivan
TITLE OF INVENTION: DNA Constructs and Methods for Stably
TITLE OF INVENTION: Transforming Plasmids of Multicellular Plants and
TITLE OF INVENTION: Expressing Recombinant Proteins Therein
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dann, Dorfman, Herrell and Skillman
STREET: 1601 Market Street Suite 720
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103-2307
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentln Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/193,853
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/189,256

FILED DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/518,763
FILING DATE: 01-MAY-1990
ATTORNEY/AGENT INFORMATION:
NAME: Reed, Janet E.
REGISTRATION NUMBER: 36,252
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 563-4100
TELEFAX: (215) 563-4044
SEQUENCE CHARACTERISTICS:
LENGTH: 33 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-09-193-853-46

Query Match 100.0%; Score 9; DB 4; Length 33;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGAT 9
Db 27 TAGGAGAT 19

RESULT 13

PCT-US95-00605-12
Sequence 12, Application PC/TUS9500605
GENERAL INFORMATION:
APPLICANT: Lyle, Leon
APPLICANT: Thomas-Miller, Beth
TITLE OF INVENTION: THERAPEUTIC TREATMENT FOR INHIBITING
TITLE OF INVENTION: VASCULAR RESTENOSIS
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Mallinckrodt Medical, Inc.
STREET: 675 McDonnell Boulevard, P.O. Box 5840
CITY: St. Louis
STATE: Missouri
COUNTRY: USA
ZIP: 63134
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/00605
FILING DATE: 13-JAN-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/182,917
FILING DATE: 14-JAN-1994
APPLICATION NUMBER: US 07/965,678
FILING DATE: 22-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Vacca, Rita D.
REGISTRATION NUMBER: 33,624
REFERENCE/DOCKET NUMBER: 0783.2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 314-895-7215
TELEFAX: 314-895-2156
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: RNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: YES
ORIGINAL SOURCE:
ORGANISM: Macrophage Inflammatory Protein-1 Beta
STRAIN: human
PCT-US95-00605-12

Query Match 100.0%; Score 9; DB 5; Length 36;
Best Local Similarity 77.8%; Pred. No. 2e+03;
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGAT 9
Db 2 UAGGAGAU 10

RESULT 14

PCT-US95-00605-13
Sequence 13, Application PC/TUS9500605
GENERAL INFORMATION:
APPLICANT: Lyle, Leon
APPLICANT: Thomas-Miller, Beth
TITLE OF INVENTION: THERAPEUTIC TREATMENT FOR INHIBITING
TITLE OF INVENTION: VASCULAR RESTENOSIS
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Mallinckrodt Medical, Inc.
STREET: 675 McDonnell Boulevard, P.O. Box 5840
CITY: St. Louis
STATE: Missouri
COUNTRY: USA
ZIP: 63134
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/00605
FILING DATE: 13-JAN-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/182,917
FILING DATE: 14-JAN-1994
APPLICATION NUMBER: US 07/965,678
FILING DATE: 22-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Vacca, Rita D.
REGISTRATION NUMBER: 33,624
REFERENCE/DOCKET NUMBER: 0783.2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 314-895-7215
TELEFAX: 314-895-2156
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: YES
ORIGINAL SOURCE:
ORGANISM: Macrophage Inflammatory Protein-1 Beta
STRAIN: human
PCT-US95-00605-13

Query Match 100.0%; Score 9; DB 5; Length 36;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGAT 9

Db |||||||
 2 TAGGAGAT 10

RESULT 15
US-09-290-449-15

; Sequence 15, Application US/09290449A

; Patent No. 6096505

; GENERAL INFORMATION:

; APPLICANT: SELBY, Mark

; APPLICANT: THIDDIM, Kent

; APPLICANT: DINH, Dino

; TITLE OF INVENTION: NONCLONING TECHNIQUE FOR EXPRESSING A GENE OF INTEREST

; FILE REFERENCE: 1448.002

; CURRENT APPLICATION NUMBER: US/09/290,449A

; CURRENT FILING DATE: 1999-04-13

; EARLIER APPLICATION NUMBER: US 60/081,777

; EARLIER FILING DATE: 1998-04-14

; NUMBER OF SEQ ID NOS: 20

; SOFTWARE: Patent Ver. 2.0

; SEQ ID NO 15

; LENGTH: 12

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (1)..(12)

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Flexible Hinge

; OTHER INFORMATION: Sequence (Fig. 1)

; Patent No. 6096505

US-09-290-449-15

Query Match 88.9%; Score 8; DB 3; Length 12;

Best Local Similarity 100.0%; Pred. No. 8.5e+03;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGGAGAT 9
 |||||||

Db 3 AGGAGAT 10

Search completed: June 2, 2003, 20:38:32
Job time : 37.878 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 19:09:45 ; Search time 63.878 Seconds
(without alignments)
189.976 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 tagagagat 9

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 845702 seqs, 674182571 residues

Total number of hits satisfying chosen parameters: 477662

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Published Applications_NA:*

1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/2/pubpna/PCr_NEM_PUB.seq:*
3: /cgn2_6/ptodata/2/pubpna/US06_NEM_PUB.seq:*
4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
5: /cgn2_6/ptodata/2/pubpna/US07_NEM_PUB.seq:*
6: /cgn2_6/ptodata/2/pubpna/PCrUS_PUBCOMB.seq:*
7: /cgn2_6/ptodata/2/pubpna/US08_NEM_PUB.seq:*
8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/2/pubpna/US09_NEM_PUB.seq:*
10: /cgn2_6/ptodata/2/pubpna/US09_PUBCOMB.seq:*
11: /cgn2_6/ptodata/2/pubpna/US10_NEM_PUB.seq:*
12: /cgn2_6/ptodata/2/pubpna/US10_PUBCOMB.seq:*
13: /cgn2_6/ptodata/2/pubpna/US60_NEM_PUB.seq:*
14: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	ID	Description
1	9	100.0	9	US-10-122-630-2
2	9	100.0	9	US-10-122-633-2
3	9	100.0	9	US-09-828-344-162
4	9	100.0	20	US-09-828-344-163
5	9	100.0	20	US-09-828-344-164
6	9	100.0	20	US-09-766-154-19
7	9	100.0	21	US-09-816-814-13
8	9	100.0	26	US-09-949-427-202
9	9	100.0	28	US-09-764-246-33
10	9	100.0	30	US-10-104-019-105
11	9	100.0	31	US-09-912-263-64
12	9	100.0	36	US-10-011-672-5
13	9	100.0	36	US-10-012-013-5
14	9	100.0	36	US-10-012-070A-5
15	9	88.9	10	US-10-055-713-67
16	9	88.9	10	US-09-990-186-1611
17	9	88.9	10	US-09-989-789-1611
18	9	88.9	15	US-10-287-919-1170
19	9	88.9	15	US-10-287-919-1205

C	20	8	88.9	15	10	US-09-504-231A-190	Sequence 190, App
C	21	8	88.9	15	10	US-09-504-231A-191	Sequence 191, App
C	22	8	88.9	15	10	US-09-274-553D-190	Sequence 190, App
C	23	8	88.9	15	10	US-09-274-553D-191	Sequence 191, App
C	24	8	88.9	16	9	US-10-287-919-1008	Sequence 1008, App
C	25	8	88.9	16	9	US-10-287-919-1009	Sequence 1009, App
C	26	8	88.9	16	10	US-09-781-988-100	Sequence 100, App
C	27	8	88.9	16	10	US-09-781-988-101	Sequence 101, App
C	28	8	88.9	17	9	US-10-060-830-246	Sequence 246, App
C	29	8	88.9	17	9	US-10-060-830-247	Sequence 247, App
C	30	8	88.9	17	9	US-10-060-830-248	Sequence 248, App
C	31	8	88.9	17	9	US-10-060-830-249	Sequence 249, App
C	32	8	88.9	17	9	US-10-060-830-250	Sequence 250, App
C	33	8	88.9	17	9	US-10-060-830-251	Sequence 251, App
C	34	8	88.9	17	9	US-10-060-830-252	Sequence 252, App
C	35	8	88.9	17	9	US-10-060-830-253	Sequence 253, App
C	36	8	88.9	17	9	US-10-060-830-254	Sequence 254, App
C	37	8	88.9	17	9	US-10-060-830-255	Sequence 255, App
C	38	8	88.9	17	9	US-09-780-164-26	Sequence 26, App
C	39	8	88.9	17	9	US-09-780-164-394	Sequence 394, App
C	40	8	88.9	17	9	US-09-780-164-760	Sequence 760, App
C	41	8	88.9	17	9	US-09-780-164-859	Sequence 859, App
C	42	8	88.9	17	9	US-09-780-164-967	Sequence 967, App
C	43	8	88.9	17	9	US-09-780-164-968	Sequence 968, App
C	44	8	88.9	17	9	US-09-780-164-969	Sequence 969, App
C	45	8	88.9	17	9	US-09-780-164-970	Sequence 970, App

ALIGNMENTS

RESULT 1
US-10-122-630-2
Sequence 2, Application US/10122630
Publication No. US20030032610A1
GENERAL INFORMATION:
APPLICANT: Gilchrist, Barbara A.
APPLICANT: Eller, Mark S.
TITLE OF INVENTION: Method to Inhibit Cell Growth Using
FILE REFERENCE: Oligonucleotides
CURRENT APPLICATION NUMBER: US/10/122,630
CURRENT FILING DATE: 2002-04-12
PRIOR APPLICATION NUMBER: US 08/467,012
PRIOR FILING DATE: 1995-06-06
PRIOR APPLICATION NUMBER: PCT/US96/08386
PRIOR FILING DATE: 1996-06-03
PRIOR APPLICATION NUMBER: US 09/048,927
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: US 09/540,843
PRIOR FILING DATE: 2000-03-31
PRIOR APPLICATION NUMBER: PCT/US01/10162
PRIOR FILING DATE: 2001-03-30
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-2

Query Match 100.0%; Score 9; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGCAGAGAT 9
|||||
DB 1 TAGCAGAGAT 9

```
RESULT 2
US-10-122-633-2
; Sequence 2, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-2

Query Match
Best Local Similarity 100.0%; Score 9; DB 9; Length 9;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9

RESULT 3
US-09-828-344-162
; Sequence 162, Application US/09828344
; Publication No. US20030044979A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE I EXPRESSION
; FILE REFERENCE: RTS-0147
; CURRENT APPLICATION NUMBER: US/09/828,344
; CURRENT FILING DATE: 2001-04-06
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 162
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-828-344-162

Query Match
Best Local Similarity 100.0%; Score 9; DB 9; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9

RESULT 4
US-09-828-344-163
; Sequence 163, Application US/09828344
; Publication No. US20030044979A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE I EXPRESSION
```

```
; FILE REFERENCE: RTS-0147
; CURRENT APPLICATION NUMBER: US/09/828,344
; CURRENT FILING DATE: 2001-04-06
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 163
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-828-344-163

Query Match
Best Local Similarity 100.0%; Score 9; DB 9; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 3 TAGGAGGAT 11

RESULT 5
US-09-828-344-164
; Sequence 164, Application US/09828344
; Publication No. US20030044979A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE I EXPRESSION
; FILE REFERENCE: RTS-0147
; CURRENT APPLICATION NUMBER: US/09/828,344
; CURRENT FILING DATE: 2001-04-06
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 164
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-828-344-164

Query Match
Best Local Similarity 100.0%; Score 9; DB 9; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 4 TAGGAGGAT 12

RESULT 6
US-09-766-154-19
; Sequence 19, Application US/09766154
; Patent No. US20020010948A1
; GENERAL INFORMATION:
; APPLICANT: Patience, Clive
; TITLE OF INVENTION: Swine Defective for Transmission of Porcine Endogenous
; FILE REFERENCE: 61750-311
; CURRENT APPLICATION NUMBER: US/09/766,154
; CURRENT FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: U.S. 60/243695
; PRIOR FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: U.S. 60/182965
; PRIOR FILING DATE: 2000-02-16
; PRIOR APPLICATION NUMBER: U.S. 60/177003
; PRIOR FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```


FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
OTHER INFORMATION: sequence used in amplification of PERY-sequences.
US-09-766-154-19

Query Match 100.0%; Score 9; DB 10; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
|||||
DB 2 TAGGAGGAT 10

RESULT 7

US-09-816-814-13/C
Sequence 13, Application US/09816814
Publication No. US20030027136A1
GENERAL INFORMATION:
APPLICANT: Goronzy, Jorg J.
APPLICANT: Weyand, Cornelia M.
TITLE OF INVENTION: RHEUMATOID ARTHRITIS MARKERS
FILE REFERENCE: 07039-251001
CURRENT FILING DATE: 2001-03-23
NUMBER OF SEQ ID NOS: 23
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 13
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: primer for PCR
US-09-816-814-13

Query Match 100.0%; Score 9; DB 9; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.6e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
|||||
DB 15 TAGGAGGAT 7

RESULT 8

US-09-949-427-202
Sequence 202, Application US/09949427
Publication No. US20030054418A1
GENERAL INFORMATION:
APPLICANT: Bodnar, Jackie S.
APPLICANT: Castellani, Lawrence W.
APPLICANT: Chatterjee, Anubindo
APPLICANT: de Jong, Pieter
APPLICANT: Lusis, Aldons J.
APPLICANT: Ohmen, Jeff
APPLICANT: Ross, David
APPLICANT: Tafari, Sherlie
APPLICANT: Mu, Chenyan
TITLE OF INVENTION: Gene and Sequence Variation Associated with Cancer
FILE REFERENCE: 02810.0014.NPUS02
CURRENT APPLICATION NUMBER: US/09/949,427
CURRENT FILING DATE: 2001-09-07
PRIOR APPLICATION NUMBER: 60/231,322
PRIOR FILING DATE: 2000-09-08
NUMBER OF SEQ ID NOS: 405
SOFTWARE: PatentIn version 3.1
SEQ ID NO 202
LENGTH: 26
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Primer
US-09-949-427-202

Query Match 100.0%; Score 9; DB 9; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
|||||
DB 6 TAGGAGGAT 14

RESULT 9

US-09-764-246-33
Sequence 33, Application US/09764246
Patent No. US20010046672A1
GENERAL INFORMATION:
APPLICANT: BRASH, ALAN R.
BOESLIN, WILLIAM E.
JISAKA, MITSUO
TITLE OF INVENTION: LIPOXYGENASE PROTEINS AND NUCLEIC ACIDS
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: ARLES A. TAYLOR, JR.
STREET: SUITE 1400, UNIVERSITY TOWER, 3100 TOWER BOULEVARD
CITY: DURHAM
STATE: NORTH CAROLINA
COUNTRY: USA
ZIP: 27707
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 Inch, 1.4 MB storage
COMPUTER: IBM PC/XT/AT compatible
OPERATING SYSTEM: Windows 3.1
SOFTWARE: WORD PERFECT 6.1 and ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/764,246
FILING DATE: 17-Jan-2001
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: <Unknown>
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: ARLES A. TAYLOR, JR.
REGISTRATION NUMBER: 39,395
REFERENCE/DOCKET NUMBER: 1242/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (919) 493-8000
TELEFAX: (919) 419-0383
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 28 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-764-246-33

Query Match 100.0%; Score 9; DB 10; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
|||||
DB 7 TAGGAGGAT 15

RESULT 10

US-10-104-019-105/C
Sequence 105, Application US/10104019
Patent No. US20020168379A1
GENERAL INFORMATION:
APPLICANT: PAUL, Prem
APPLICANT: MENG, Xiang-jin
APPLICANT: MOROZOV, Igor

```
; APPLICANT: HALBOR, Patrick
; TITLE OF INVENTION: PROTEINS ENCODED BY POLYNUCLEIC ACIDS OF PORCINE
; FILE REFERENCE: 4625-0039-55X CIP
; CURRENT APPLICATION NUMBER: US/10/104,019
; CURRENT FILING DATE: 2002-03-25
; PRIOR APPLICATION NUMBER: 09/019,793
; PRIOR FILING DATE: 1998-02-06
; PRIOR APPLICATION NUMBER: 08/301,435
; PRIOR FILING DATE: 1994-09-01
; PRIOR APPLICATION NUMBER: 08/131,625
; PRIOR FILING DATE: 1993-10-05
; PRIOR APPLICATION NUMBER: 07/969,071
; PRIOR FILING DATE: 1992-10-30
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 105
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:synthetic DNA
US-10-104-019-105
```

```
Query Match          100.0%; Score 9; DB 9; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 TAGGAGGAT 9
        |||||||||
Db       15 TAGGAGGAT 7
```

```
RESULT 11
US-09-912-263-64/c
; Sequence 64, Application US/09912263
; Publication No. US20030039973A1
; GENERAL INFORMATION:
; APPLICANT: Gargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Lander, Eric S.
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: 2825.2017-001
; CURRENT APPLICATION NUMBER: US/09/912,263
; CURRENT FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: US 60/220,315
; PRIOR FILING DATE: 2000-07-24
; NUMBER OF SEQ ID NOS: 552
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 64
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-912-263-64
```

```
Query Match          100.0%; Score 9; DB 9; Length 31;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 TAGGAGGAT 9
        |||||||||
Db       31 TAGGAGGAT 23
```

```
RESULT 12
US-10-011-672-5/c
; Sequence 5, Application US/10011672
; Publication No. US20030049814A1
; GENERAL INFORMATION:
; APPLICANT: Hawkes, Timothy
; APPLICANT: Warner, Simon
; APPLICANT: Andrews, Christopher
; APPLICANT: Bachoo, Satvinder
```

```
; APPLICANT: Pickerill, Andrew
; TITLE OF INVENTION: HERBICIDE RESISTANT PLANTS
; FILE REFERENCE: 50489/UST
; CURRENT APPLICATION NUMBER: US/10/011,672
; CURRENT FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: PCT/GB00/01559
; PRIOR FILING DATE: 2000-04-20
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Primer
US-10-011-672-5
```

```
Query Match          100.0%; Score 9; DB 9; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 TAGGAGGAT 9
        |||||||||
Db       26 TAGGAGGAT 18
```

```
RESULT 13
US-10-012-013-5/c
; Sequence 5, Application US/10012013
; Publication No. US20030079246A1
; GENERAL INFORMATION:
; APPLICANT: Hawkes, Timothy
; APPLICANT: Warner, Simon
; APPLICANT: Andrews, Christopher
; APPLICANT: Bachoo, Satvinder
; APPLICANT: Pickerill, Andrew
; TITLE OF INVENTION: Herbicide Resistant Plants
; FILE REFERENCE: 50450/UST
; CURRENT APPLICATION NUMBER: US/10/012,013
; CURRENT FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: PCT/GB00/01572
; PRIOR FILING DATE: 2000-04-20
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer
US-10-012-013-5
```

```
Query Match          100.0%; Score 9; DB 9; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 TAGGAGGAT 9
        |||||||||
Db       26 TAGGAGGAT 18
```

```
RESULT 14
US-10-012-070A-5/c
; Sequence 5, Application US/10012070A
; Publication No. US20030077801A1
; GENERAL INFORMATION:
; APPLICANT: Hawkes, Timothy
; APPLICANT: Warner, Simon
; APPLICANT: Andrews, Christopher
; APPLICANT: Bachoo, Satvinder
; APPLICANT: Pickerill, Andrew
; TITLE OF INVENTION: Herbicide Resistant Plants
; FILE REFERENCE: 50490/UST
```

```

; CURRENT APPLICATION NUMBER: US/10/012,070A
; CURRENT FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: PCT/GB00/01573
; PRIOR FILING DATE: 2000-04-20
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer
US-10-012-070A-5

```

```

Query Match          100.0%; Score 9; DB 9; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 TAGGAGGAT 9
        |||||
Db      26 TAGGAGGAT 18

```

```

RESULT 15
US-10-055-713-67
; Sequence 67, Application US/10055713
; Publication No. US20030044957A1
; GENERAL INFORMATION:
; APPLICANT: JAMIESON, Andrew
; APPLICANT: LI, Guofu
; TITLE OF INVENTION: ZINC FINGER PROTEINS FOR DNA BINDING AND GENE
; TITLE OF INVENTION: REGULATION IN PLANTS
; FILE REFERENCE: 8325-0026 / S26-US1
; CURRENT APPLICATION NUMBER: US/10/055,713
; CURRENT FILING DATE: 2002-06-17
; PRIOR APPLICATION NUMBER: 60/263,445
; PRIOR FILING DATE: 2001-01-22
; PRIOR APPLICATION NUMBER: 60/290,716
; PRIOR FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 67
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: ZFP 9 target sequence
US-10-055-713-67

```

```

Query Match          88.9%; Score 8; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 7e+04;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      2 AGGAGGAT 9
        |||||
Db      2 AGGAGGAT 9

```

Search completed: June 2, 2003, 23:43:12
Job time : 64.8781 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:33:41 ; Search time 1862.56 Seconds

(without alignments)
121.490 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 tagagagat 9

Scoring table:

IDENTITY-NUC
Gapop 10.0 , Gapext 1.0

Searched: 24791104 seqs, 12571243825 residues

Total number of hits satisfying chosen parameters: 11746948

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

Pending-Patents_NA_Main:*

- 1: /cgn2_6/ptodata/1/pna/PCUS.COMB.seq:*
- 2: /cgn2_6/ptodata/1/pna/US06.COMB.seq:*
- 3: /cgn2_6/ptodata/1/pna/US07.COMB.seq:*
- 4: /cgn2_6/ptodata/1/pna/US08.COMB.seq:*
- 5: /cgn2_6/ptodata/1/pna/US081.COMB.seq:*
- 6: /cgn2_6/ptodata/1/pna/US082.COMB.seq:*
- 7: /cgn2_6/ptodata/1/pna/US083.COMB.seq:*
- 8: /cgn2_6/ptodata/1/pna/US084.COMB.seq:*
- 9: /cgn2_6/ptodata/1/pna/US085.COMB.seq:*
- 10: /cgn2_6/ptodata/1/pna/US086.COMB.seq:*
- 11: /cgn2_6/ptodata/1/pna/US087.COMB.seq:*
- 12: /cgn2_6/ptodata/1/pna/US088.COMB.seq:*
- 13: /cgn2_6/ptodata/1/pna/US089.COMB.seq:*
- 14: /cgn2_6/ptodata/1/pna/US090.COMB.seq:*
- 15: /cgn2_6/ptodata/1/pna/US091.COMB.seq:*
- 16: /cgn2_6/ptodata/1/pna/US092.COMB.seq:*
- 17: /cgn2_6/ptodata/1/pna/US093.COMB.seq:*
- 18: /cgn2_6/ptodata/1/pna/US094.COMB.seq:*
- 19: /cgn2_6/ptodata/1/pna/US095.COMB.seq:*
- 20: /cgn2_6/ptodata/1/pna/US096.COMB.seq:*
- 21: /cgn2_6/ptodata/1/pna/US097.COMB.seq:*
- 22: /cgn2_6/ptodata/1/pna/US098.COMB.seq:*
- 23: /cgn2_6/ptodata/1/pna/US099.COMB.seq:*
- 24: /cgn2_6/ptodata/1/pna/US100.COMB.seq:*
- 25: /cgn2_6/ptodata/1/pna/US101.COMB.seq:*
- 26: /cgn2_6/ptodata/1/pna/US102.COMB.seq:*
- 27: /cgn2_6/ptodata/1/pna/US103.COMB.seq:*
- 28: /cgn2_6/ptodata/1/pna/US104.COMB.seq:*
- 29: /cgn2_6/ptodata/1/pna/US105.COMB.seq:*
- 30: /cgn2_6/ptodata/1/pna/US106.COMB.seq:*
- 31: /cgn2_6/ptodata/1/pna/US107.COMB.seq:*
- 32: /cgn2_6/ptodata/1/pna/US108.COMB.seq:*
- 33: /cgn2_6/ptodata/1/pna/US109.COMB.seq:*
- 34: /cgn2_6/ptodata/1/pna/US110.COMB.seq:*
- 35: /cgn2_6/ptodata/1/pna/US111.COMB.seq:*
- 36: /cgn2_6/ptodata/1/pna/US112.COMB.seq:*
- 37: /cgn2_6/ptodata/1/pna/US113.COMB.seq:*
- 38: /cgn2_6/ptodata/1/pna/US114.COMB.seq:*
- 39: /cgn2_6/ptodata/1/pna/US115.COMB.seq:*
- 40: /cgn2_6/ptodata/1/pna/US116.COMB.seq:*
- 41: /cgn2_6/ptodata/1/pna/US117.COMB.seq:*
- 42: /cgn2_6/ptodata/1/pna/US118.COMB.seq:*
- 43: /cgn2_6/ptodata/1/pna/US119.COMB.seq:*

	44:	/cgn2_6/ptodata/1/pna/US6001_COMB.seq:*
	45:	/cgn2_6/ptodata/1/pna/US6001_COMB.seq:*
	46:	/cgn2_6/ptodata/1/pna/US6002_COMB.seq:*
	47:	/cgn2_6/ptodata/1/pna/US6003_COMB.seq:*
	48:	/cgn2_6/ptodata/1/pna/US6004_COMB.seq:*
	49:	/cgn2_6/ptodata/1/pna/US6005_COMB.seq:*
	50:	/cgn2_6/ptodata/1/pna/US6006_COMB.seq:*
	51:	/cgn2_6/ptodata/1/pna/US6007_COMB.seq:*
	52:	/cgn2_6/ptodata/1/pna/US6008_COMB.seq:*
	53:	/cgn2_6/ptodata/1/pna/US6009_COMB.seq:*
	54:	/cgn2_6/ptodata/1/pna/US6010_COMB.seq:*
	55:	/cgn2_6/ptodata/1/pna/US6011_COMB.seq:*
	56:	/cgn2_6/ptodata/1/pna/US6012_COMB.seq:*
	57:	/cgn2_6/ptodata/1/pna/US6013_COMB.seq:*
	58:	/cgn2_6/ptodata/1/pna/US6014_COMB.seq:*
	59:	/cgn2_6/ptodata/1/pna/US6015_COMB.seq:*
	60:	/cgn2_6/ptodata/1/pna/US6016_COMB.seq:*
	61:	/cgn2_6/ptodata/1/pna/US6017_COMB.seq:*
	62:	/cgn2_6/ptodata/1/pna/US6018_COMB.seq:*
	63:	/cgn2_6/ptodata/1/pna/US6019_COMB.seq:*
	64:	/cgn2_6/ptodata/1/pna/US6020_COMB.seq:*
	65:	/cgn2_6/ptodata/1/pna/US6021_COMB.seq:*
	66:	/cgn2_6/ptodata/1/pna/US6022_COMB.seq:*
	67:	/cgn2_6/ptodata/1/pna/US6023_COMB.seq:*
	68:	/cgn2_6/ptodata/1/pna/US6024_COMB.seq:*
	69:	/cgn2_6/ptodata/1/pna/US6025_COMB.seq:*
	70:	/cgn2_6/ptodata/1/pna/US6026_COMB.seq:*
	71:	/cgn2_6/ptodata/1/pna/US6027_COMB.seq:*
	72:	/cgn2_6/ptodata/1/pna/US6028_COMB.seq:*
	73:	/cgn2_6/ptodata/1/pna/US6029_COMB.seq:*
	74:	/cgn2_6/ptodata/1/pna/US6030_COMB.seq:*
	75:	/cgn2_6/ptodata/1/pna/US6031_COMB.seq:*
	76:	/cgn2_6/ptodata/1/pna/US6032_COMB.seq:*
	77:	/cgn2_6/ptodata/1/pna/US6033_COMB.seq:*
	78:	/cgn2_6/ptodata/1/pna/US6034_COMB.seq:*
	79:	/cgn2_6/ptodata/1/pna/US6035_COMB.seq:*
	80:	/cgn2_6/ptodata/1/pna/US6036_COMB.seq:*
	81:	/cgn2_6/ptodata/1/pna/US6037_COMB.seq:*
	82:	/cgn2_6/ptodata/1/pna/US6038_COMB.seq:*
	83:	/cgn2_6/ptodata/1/pna/US6039_COMB.seq:*
	84:	/cgn2_6/ptodata/1/pna/US6040_COMB.seq:*
	85:	/cgn2_6/ptodata/1/pna/US6041_COMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	9	100.0	9	21	US-09-540-843-2
2	9	100.0	9	40	US-10-122-630-2
3	9	100.0	9	40	US-10-122-633-2
4	9	100.0	10	42	US-10-223-765-202
5	9	100.0	16	33	US-09-882-945A-169
6	9	100.0	18	65	US-60-216-745-6947
7	9	100.0	18	65	US-60-216-745-11899
8	9	100.0	19	1	PCT-US00-25479-22
9	9	100.0	19	1	PCT-US00-25479-76
10	9	100.0	19	17	US-09-398-522-76
11	9	100.0	19	17	US-09-398-522-76
12	9	100.0	19	65	US-60-216-745-8613
13	9	100.0	20	1	PCT-US01-01857-19
14	9	100.0	20	1	PCT-US02-10529-162
15	9	100.0	20	1	PCT-US02-10529-163
16	9	100.0	20	1	PCT-US02-10529-164
17	9	100.0	20	5	PCT-US02-12063-200
18	9	100.0	20	5	US-08-177-145-6
19	9	100.0	20	16	US-09-201-228A-7181
20	9	100.0	20	16	US-09-201-228A-7376
21	9	100.0	20	18	US-09-422-978-6304

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

```
22 9 100.0 20 30 US-09-766-154-19 Sequence 19, Appl
23 9 100.0 20 31 US-09-828-344-162 Sequence 162, App
24 9 100.0 20 31 US-09-828-344-163 Sequence 163, App
25 9 100.0 20 31 US-09-828-344-164 Sequence 164, App
26 9 100.0 20 38 US-10-006-191-104 Sequence 104, App
27 9 100.0 20 40 US-10-126-022-200 Sequence 200, App
28 9 100.0 21 18 US-09-422-978-9775 Sequence 9775, App
29 9 100.0 21 31 US-09-816-814-113 Sequence 13, Appl
30 9 100.0 22 3 US-07-598-420-16 Sequence 16, Appl
31 9 100.0 23 1 PCT-US97-02396-33 Sequence 1428, Ap
32 9 100.0 23 8 US-08-472-801-1428 Sequence 1428, Ap
33 9 100.0 23 10 US-08-668-235-1428 Sequence 1428, Ap
34 9 100.0 23 24 US-09-634-306B-68219 Sequence 68219, A
35 9 100.0 23 38 US-10-027-632-68219 Sequence 68219, A
36 9 100.0 23 80 US-60-361-523-12 Sequence 12, Appl
37 9 100.0 23 80 US-60-361-523-13 Sequence 13, Appl
38 9 100.0 24 1 PCT-US00-20638-318 Sequence 318, Appl
39 9 100.0 25 17 US-09-396-196F-27650 Sequence 27650, A
40 9 100.0 25 17 US-09-396-196F-27651 Sequence 27651, A
41 9 100.0 25 17 US-09-396-196F-53922 Sequence 53922, A
42 9 100.0 25 17 US-09-396-196F-92449 Sequence 92449, A
43 9 100.0 25 17 US-09-396-196F-94038 Sequence 94038, A
44 9 100.0 25 17 US-09-396-196F-98060 Sequence 98060, A
45 9 100.0 25 17 US-09-396-196F-98061 Sequence 98061, A
```

ALIGNMENTS

```
RESULT 1
; Sequence 2, Application US/09540843
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Yaer, Mina
; TITLE OF INVENTION: USE OF LOCALLY APPLIED DNA FRAGMENTS
; FILE REFERENCE: 0054.1088-015
; CURRENT APPLICATION NUMBER: US/09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 08/952,697
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-09-540-843-2
```

```
Query Match 100.0%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+09;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9

RESULT 2
US-10-122-630-2
; Sequence 2, Application US/10122630
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaer, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
```

```
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-2
```

```
Query Match 100.0%; Score 9; DB 40; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+09;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9
```

```
RESULT 3
US-10-122-633-2
; Sequence 2, Application US/10122633
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaer, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-2
```

```
Query Match 100.0%; Score 9; DB 40; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+09;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9
```

```
RESULT 4
US-10-223-765-202
; Sequence 202, Application US/10223765
; GENERAL INFORMATION:
; APPLICANT: Kim, Jin-Soo
```

```

; APPLICANT: Bae, Kwang-Hee
; APPLICANT: Park, Kyung-Soon
; APPLICANT: Kwon, Young Do
; APPLICANT: Ryu, Eun-Hyun
; APPLICANT: Hwang, Moon-Sun
; TITLE OF INVENTION: ZINC FINGER DOMAIN LIBRARIES
; FILE REFERENCE: 12279-005001
; CURRENT APPLICATION NUMBER: US/10/223,765
; CURRENT FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: 60/374,355
; PRIOR FILING DATE: 2002-04-22
; PRIOR APPLICATION NUMBER: 60/313,402
; PRIOR FILING DATE: 2001-08-17
; NUMBER OF SEQ ID NOS: 305
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 202
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetically generated oligonucleotide
US-10-223-765-202

```

```

Query Match      100.0%; Score 9; DB 42; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 TAGGAGGAT 9
        |||||
Db      2 TAGGAGGAT 10

```

```

RESULT 5
US-09-882-945A-169/c
; Sequence 169, Application US/09882945A
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neel, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 169
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-882-945A-169

```

```

Query Match      100.0%; Score 9; DB 33; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 TAGGAGGAT 9
        |||||
Db      12 TAGGAGGAT 4

```

```

RESULT 6
US-60-216-745-6947
; Sequence 6947, Application US/60216745
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Abderrahim, Hadi
; APPLICANT: Dufaire-Gare, Isabelle

```

```

; TITLE OF INVENTION: BIALLELIC MARKER MAPS FOR USE IN CONSTRUCTING A HIGH DENSITY
; FILE REFERENCE: 84.US1.PRO
; CURRENT APPLICATION NUMBER: US/60/216,745
; CURRENT FILING DATE: 2000-06-30
; NUMBER OF SEQ ID NOS: 13665
; SOFTWARE: Patent.pm
; SEQ ID NO 6947
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-38923 for SEQ 2416,
US-60-216-745-6947

```

```

Query Match      100.0%; Score 9; DB 65; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 TAGGAGGAT 9
        |||||
Db      1 TAGGAGGAT 9

```

```

RESULT 7
US-60-216-745-11899
; Sequence 11899, Application US/60216745
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Abderrahim, Hadi
; APPLICANT: Dufaire-Gare, Isabelle
; TITLE OF INVENTION: BIALLELIC MARKER MAPS FOR USE IN CONSTRUCTING A HIGH DENSITY
; FILE REFERENCE: 84.US1.PRO
; CURRENT APPLICATION NUMBER: US/60/216,745
; CURRENT FILING DATE: 2000-06-30
; NUMBER OF SEQ ID NOS: 13665
; SOFTWARE: Patent.pm
; SEQ ID NO 11899
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-43555 for SEQ 2837, in comp
US-60-216-745-11899

```

```

Query Match      100.0%; Score 9; DB 65; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 TAGGAGGAT 9
        |||||
Db      4 TAGGAGGAT 12

```

```

RESULT 8
PCT-US00-25479-22/c
; Sequence 22, Application PC/TUS0025479
; GENERAL INFORMATION:
; APPLICANT: The Johns Hopkins University School of Medicine
; TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: JH01590WO
; CURRENT APPLICATION NUMBER: PCT/US00/25479
; CURRENT FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19

```

TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Bisulfite-PCR primer
NAME/KEY: misc_feature
LOCATION: (0)...(0)
OTHER INFORMATION: r = G or A
PCT-US00-25479-22

Query Match 100.0%; Score 9; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
DB 17 TAGGAGGAT 9

RESULT 9
PCT-US00-25479-76
Sequence 76, Application PC/TUS0025479
GENERAL INFORMATION:
APPLICANT: The Johns Hopkins University School of Medicine
TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
FILE REFERENCE: JHU1590M0
CURRENT APPLICATION NUMBER: PCT/US00/25479
CURRENT FILING DATE: 2000-09-14
NUMBER OF SEQ ID NOS: 120
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 76
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Target sequence for bisulfite-PCR primer
NAME/KEY: misc_feature
LOCATION: (0)...(0)
OTHER INFORMATION: y = C or T
PCT-US00-25479-76

Query Match 100.0%; Score 9; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
DB 3 TAGGAGGAT 11

RESULT 10
US-09-398-522-22/C
Sequence 22, Application US/09398522
GENERAL INFORMATION:
APPLICANT: Issa, Jean-Pierre
TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
FILE REFERENCE: JHU1590
CURRENT APPLICATION NUMBER: US/09/398,522
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 120
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Bisulfite-PCR primer
NAME/KEY: misc_feature
LOCATION: (0)...(0)
OTHER INFORMATION: r = G or A
US-09-398-522-22

Query Match 100.0%; Score 9; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
DB 17 TAGGAGGAT 9

RESULT 11
US-09-398-522-76
Sequence 76, Application US/09398522
GENERAL INFORMATION:
APPLICANT: Issa, Jean-Pierre
TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
FILE REFERENCE: JHU1590
CURRENT APPLICATION NUMBER: US/09/398,522
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 120
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 76
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Target sequence for bisulfite-PCR primer
NAME/KEY: misc_feature
LOCATION: (0)...(0)
OTHER INFORMATION: y = C or T
US-09-398-522-76

Query Match 100.0%; Score 9; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
DB 3 TAGGAGGAT 11

RESULT 12
US-60-216-745-8613
Sequence 8613, Application US/60216745
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
APPLICANT: Abderrahim, Hadi
APPLICANT: Dufaire-Gare, Isabelle
TITLE OF INVENTION: BIASELIC MARKER MAPS FOR USE IN CONSTRUCTING A HIGH DENSITY.
FILE REFERENCE: 84, US1, PRO
CURRENT APPLICATION NUMBER: US/60/216,745
CURRENT FILING DATE: 2000-06-30
NUMBER OF SEQ ID NOS: 13665
SOFTWARE: Patent.pm
SEQ ID NO 8613
LENGTH: 19
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: primer_bind
LOCATION: 1..19
OTHER INFORMATION: upstream amplification primer 99-27815 for SEQ 4082,
US-60-216-745-8613

Query Match 100.0%; Score 9; DB 65; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9

Db 7 TAGGAGGAT 15

RESULT 13

PCT-US01-01857-19
Sequence 19, Application PC/TUS0101857
GENERAL INFORMATION:
APPLICANT: Patience, Clive
TITLE OF INVENTION: Swine Defective for Transmission of Porcine Endogenous
FILE REFERENCE: 61750-311
CURRENT APPLICATION NUMBER: PCT/US01/01857
CURRENT FILING DATE: 2001-01-19
PRIOR APPLICATION NUMBER: U.S. 60/243695
PRIOR FILING DATE: 2000-10-27
PRIOR APPLICATION NUMBER: U.S. 60/182965
PRIOR FILING DATE: 2000-02-16
PRIOR APPLICATION NUMBER: U.S. 60/177003
PRIOR FILING DATE: 2000-01-19
NUMBER OF SEQ ID NOS: 33
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 19
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
PCT-US01-01857-19

Query Match

Best Local Similarity 100.0%; Score 9; DB 1; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 2 TAGGAGGAT 10

RESULT 14

PCT-US02-10529-162
Sequence 162, Application PC/TUS0210529
GENERAL INFORMATION:
APPLICANT: Isis Pharmaceuticals, Inc.
APPLICANT: C. Frank Bennett
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE I EXPRESSION
FILE REFERENCE: RTSP-0291
CURRENT APPLICATION NUMBER: PCT/US02/10529
CURRENT FILING DATE: 2002-04-02
PRIOR APPLICATION NUMBER: 09/828,344
PRIOR FILING DATE: 2001-04-05
NUMBER OF SEQ ID NOS: 176
SEQ ID NO 162
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-10529-162

Query Match

Best Local Similarity 100.0%; Score 9; DB 1; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9

RESULT 15

PCT-US02-10529-163

Sequence 163, Application PC/TUS0210529
GENERAL INFORMATION:
APPLICANT: Isis Pharmaceuticals, Inc.
APPLICANT: C. Frank Bennett
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE I EXPRESSION
FILE REFERENCE: RTSP-0291
CURRENT APPLICATION NUMBER: PCT/US02/10529
CURRENT FILING DATE: 2002-04-02
PRIOR APPLICATION NUMBER: 09/828,344
PRIOR FILING DATE: 2001-04-05
NUMBER OF SEQ ID NOS: 176
SEQ ID NO 163
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
PCT-US02-10529-163

Query Match

Best Local Similarity 100.0%; Score 9; DB 1; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 3 TAGGAGGAT 11

Search completed: June 2, 2003, 23:00:11
Job time : 1863.56 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:06:10 ; Search time 176.707 Seconds

(without alignments)
823.475 Million cell updates/sec

Title: US-09-540-843-4

Perfect score: 5

Sequence: 1 gtagt 5

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 774614

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl: *
1: gb_ba: *
2: gb_bt: *
3: gb_in: *
4: gb_om: *
5: gb_ov: *
6: gb_pat: *
7: gb_ph: *
8: gb_pl: *
9: gb_pr: *
10: gb_ro: *
11: gb_sts: *
12: gb_sy: *
13: gb_un: *
14: gb_vl: *
15: em_ba: *
16: em_fun: *
17: em_hum: *
18: em_in: *
19: em_mu: *
20: em_om: *
21: em_or: *
22: em_ov: *
23: em_pat: *
24: em_ph: *
25: em_pl: *
26: em_ro: *
27: em_sts: *
28: em_un: *
29: em_vl: *
30: em_htg_hum: *
31: em_htg_inv: *
32: em_htg_other: *
33: em_htg_mus: *
34: em_htg_pla: *
35: em_htg_rtd: *
36: em_htg_mam: *
37: em_htg_vrt: *
38: em_sy: *
39: em_htgo_hum: *
40: em_htgo_mus: *
41: em_htgo_other: *

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	5	100.0	5	6	AX268756 Sequence
2	5	100.0	5	6	AX268758 Sequence
3	5	100.0	7	6	AX268755 Sequence
4	5	100.0	7	6	AX268759 Sequence
5	5	100.0	8	6	AX047565 Sequence
6	5	100.0	8	6	AX104946 Sequence
7	5	100.0	8	6	AX119567 Sequence
8	5	100.0	9	6	AX268753 Sequence
9	5	100.0	9	9	S50583
10	5	100.0	9	9	S50585
11	5	100.0	10	6	A18263
12	5	100.0	10	6	AR065157 Sequence
13	5	100.0	10	6	AR079101 Sequence
14	5	100.0	10	6	AR079103 Sequence
15	5	100.0	10	6	AR098909 Sequence
16	5	100.0	10	6	AR107335 Sequence
17	5	100.0	10	6	AR107344 Sequence
18	5	100.0	10	6	AR123039 Sequence
19	5	100.0	10	6	AR136787 Sequence
20	5	100.0	10	6	AR160130 Sequence
21	5	100.0	10	6	AR202278 Sequence
22	5	100.0	10	6	AX080424 Sequence
23	5	100.0	10	6	AX104930 Sequence
24	5	100.0	10	6	AX112988 Sequence
25	5	100.0	10	6	AX112993 Sequence
26	5	100.0	10	6	AX113002 Sequence
27	5	100.0	10	6	AX152720 Sequence
28	5	100.0	10	6	AX152760 Sequence
29	5	100.0	10	6	AX152761 Sequence
30	5	100.0	10	6	AX153151 Sequence
31	5	100.0	10	6	AX153528 Sequence
32	5	100.0	10	6	AX153564 Sequence
33	5	100.0	10	6	AX153578 Sequence
34	5	100.0	10	6	AX153616 Sequence
35	5	100.0	10	6	AX252791 Sequence
36	5	100.0	10	6	AX252792 Sequence
37	5	100.0	10	6	AX252795 Sequence
38	5	100.0	10	6	AX252796 Sequence
39	5	100.0	10	6	AX252827 Sequence
40	5	100.0	10	6	AX252828 Sequence
41	5	100.0	10	6	AX252832 Sequence
42	5	100.0	10	6	AX252867 Sequence
43	5	100.0	10	6	AX252869 Sequence
44	5	100.0	10	6	AX252871 Sequence
45	5	100.0	10	6	AX252873 Sequence

ALIGNMENTS

RESULT 1
AX268756 LOCUS 5 bp
DEFINITION Sequence 4 from Patent WO0174342.
ACCESSION AX268756
VERSION AX268756.1 GI:16541828
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1
AUTHORS Gilchrist, B.A., Yaar, M. and Eller, M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 4 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)

Pred. No. is the number of results predicted by chance to have a

FEATURES
source
Location/Qualifiers
1. .5
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
1 a 0 c 2 g 2 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 5; DB 6; Length 5;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
|||||
Db 1 GRATG 5

RESULT 2
AX268758/c AX268758 5 bp DNA linear PAT 29-OCT-2001

LOCUS AX268758
DEFINITION Sequence 6 from Patent WO0174342.
ACCESSION AX268758
VERSION AX268758.1 GI:16541830

KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
artificial sequences.

REFERENCE
AUTHORS Gilchrist,B.A., Yaar,M. and Eller,M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 6 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)

FEATURES
source
1. .5
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
2 a 2 c 0 g 1 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 5; DB 6; Length 5;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
|||||
Db 5 GRATG 1

RESULT 3
AX268755 AX268755 7 bp DNA linear PAT 29-OCT-2001

LOCUS AX268755
DEFINITION Sequence 3 from Patent WO0174342.
ACCESSION AX268755
VERSION AX268755.1 GI:16541827

KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
artificial sequences.

REFERENCE
AUTHORS Gilchrist,B.A., Yaar,M. and Eller,M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 3 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)

FEATURES
source
1. .7
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
3 a 0 c 2 g 2 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 5; DB 6; Length 7;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match
Best Local Similarity 100.0%; Pred. No. 4.2e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
|||||
Db 2 GRATG 6

RESULT 4
AX268759 AX268759 7 bp DNA linear PAT 29-OCT-2001

LOCUS AX268759
DEFINITION Sequence 7 from Patent WO0174342.
ACCESSION AX268759
VERSION AX268759.1 GI:16541831

KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
artificial sequences.

REFERENCE
AUTHORS Gilchrist,B.A., Yaar,M. and Eller,M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 7 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)

FEATURES
source
1. .7
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
3 a 0 c 2 g 2 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 5; DB 6; Length 7;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
|||||
Db 2 GRATG 6

RESULT 5
AX047565/c AX047565 8 bp DNA linear PAT 15-DEC-2000

LOCUS AX047565
DEFINITION Sequence 6 from Patent WO0068399.
ACCESSION AX047565
VERSION AX047565.1 GI:11876656

KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
artificial sequences.

REFERENCE
AUTHORS McIvor,R.S., Hackett,P.B. and Aguilar-Cordova,E.
TITLE Vector-mediated delivery of integrating transposon sequences
JOURNAL Patent: WO 0068399-A 6 16-NOV-2000;
REGENTS OF THE UNIVERSITY OF MINNESOTA (US) ; BAYLOR COLLEGE OF
MEDICINE (US) ; McIVOR, R. Scott (US) ; HACKETT, Perry B. (US) ;
Aguilar-Cordova, Estuardo (US)

FEATURES
source
1. .8
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Direct Repeat Sequence"
BASE COUNT
4 a 3 c 0 g 1 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 5; DB 6; Length 8;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
|||||
Db 6 GRATG 2

RESULT 6
AX104946 8 bp DNA linear PAT 30-APR-2001
LOCUS Sequence 1138 from Patent WO0122972.
DEFINITION AX104946
ACCESSION AX104946
VERSION AX104946.1 GI:13921143
KEYWORDS
SOURCE
ORGANISM synthetic construct.
REFERENCE
AUTHORS I (bases 1 to 8)
TITLE Kriegl, A.M., Schetter, C. and Vollmer, J.C.
JOURNAL Immunostimulatory nucleic acids
Patent: WO 0122972-A 1138 05-APR-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical GmbH (DE)
FEATURES
source
1..8
/organism="synthetic construct"
/db_xref="taxon:32630"
BASE COUNT 2 a 1 c 2 g 3 t
ORIGIN

Query Match 100.0%; Score 5; DB 6; Length 8;
Best Local Similarity 100.0%; Pred. No. 3.6e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
DB 3 GTATG 7

RESULT 7
AX119567 8 bp DNA linear PAT 11-MAY-2001
LOCUS Sequence 224 from Patent WO0129251.
DEFINITION AX119567
ACCESSION AX119567
VERSION AX119567.1 GI:14036486
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS I (bases 1 to 8)
TITLE Messiaen, L. and Callens, T.
JOURNAL Improved mutation analysis of the nfi gene
Patent: WO 0129251-A 224 26-APR-2001;
UNIVERSITEIT GENT (BE)
FEATURES
source
1..8
/organism="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT 1 a 0 c 4 g 3 t
ORIGIN

Query Match 100.0%; Score 5; DB 6; Length 8;
Best Local Similarity 100.0%; Pred. No. 3.6e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
DB 3 GTATG 7

RESULT 8
AX268753 9 bp DNA linear PAT 29-OCT-2001
LOCUS Sequence 1 from Patent WO0174342.
DEFINITION AX268753
ACCESSION AX268753
VERSION AX268753.1 GI:16541825
KEYWORDS
SOURCE synthetic construct.

ORGANISM synthetic construct
artificial sequences.
REFERENCE
AUTHORS 1
TITLE Gilchrist, B.A., Yaar, M. and Eller, M.
JOURNAL Use of locally applied dna fragments
Patent: WO 0174342-A 1 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
FEATURES
source
1..9
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT 3 a 0 c 4 g 2 t
ORIGIN

Query Match 100.0%; Score 5; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
DB 3 GTATG 7

RESULT 9
S50583 9 bp mRNA linear PRI 07-MAY-1993
LOCUS type I procollagen [human, mRNA Mutant, 9 nt].
DEFINITION S50583
ACCESSION S50583
VERSION S50583.1 GI:233928
KEYWORDS
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS I (bases 1 to 9)
TITLE Tsuneyoshi, T., Westerhausen, A., Constantinou, C.D. and Prockop, D.J.
JOURNAL Substitutions for glycine alpha 1-637 and glycine alpha 2-694 of type I procollagen in lethal osteogenesis imperfecta. The conformational strain on the triple helix introduced by a glycine substitution can be transmitted along the helix
J. Biol. Chem. 266 (24), 15608-15613 (1991)
MEDLINE 91340689
PUBMED 1874719
REMARK Genbank staff at the National Library of Medicine created this entry [NCBI gi233928 50583] from the original journal article. This sequence comes from Fig 5A.

FEATURES
source
1..9
/organism="Homo sapiens"
/db_xref="taxon:9606"
gene
1..9
/gene="type I procollagen"
BASE COUNT 1 a 3 c 2 g 3 t
ORIGIN

Query Match 100.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
DB 5 GTATG 9

RESULT 10
S50585 9 bp DNA linear PRI 07-MAY-1993
LOCUS type I procollagen [human, Genomic Mutant, 9 nt].
DEFINITION S50585
ACCESSION S50585
VERSION S50585.1 GI:233929
KEYWORDS
SOURCE Homo sapiens.

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 9)
AUTHORS Tsuneyoshi,T., Westerhausen,A., Constantinou,C.D. and Prockop,D.J.
TITLE Substitutions for glycine alpha 1-637 and glycine alpha 2-694 of type I procollagen in lethal osteogenesis imperfecta. The conformational strain on the triple helix introduced by a glycine substitution can be transmitted along the helix
JOURNAL J. Biol. Chem. 266 (24), 15608-15613 (1991)
MEDLINE 91340689
PUBMED 1874719
REMARK GenBank staff at the National Library of Medicine created this entry [NCBI g1bdsq 50585] from the original journal article.
This sequence comes from Fig 5B.
Location/Qualifiers
source 1..9 /organism="Homo sapiens"
gene 1..9 /db_xref="taxon:9606"
BASE COUNT 2 a 1 c 3 g 3 t
ORIGIN
Query Match 100.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|||||
Db 5 GTATG 9

RESULT 11
A18263
LOCUS A18263 10 bp DNA linear PAT 12-APR-1994
DEFINITION oligonucleotide.
ACCESSION A18263
VERSION A18263.1 GI:512254
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 10)
AUTHORS Della Valle,F., Callegaro,L. and Negro,A.
TITLE Process for the preparation of genetic vectors for the nerve growth factor expression in eukaryotic cells
JOURNAL Patent: EP 0432510-A 12 19-JUN-1991;
FIDIA S.p.A
Location/Qualifiers
source 1..10 /organism="synthetic construct"
BASE COUNT 3 a 1 c 3 g 3 t
ORIGIN
Query Match 100.0%; Score 5; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.8e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|||||
Db 6 GTATG 10

RESULT 12
AR065157/c
LOCUS AR065157 10 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5849489.
ACCESSION AR065157
VERSION AR065157.1 GI:5959373
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 10)
AUTHORS Heiler,M.O.
TITLE Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system
JOURNAL Patent: US 5849489-A 1 15-DEC-1998;
FEATURES
source 1..10 Location/Qualifiers
BASE COUNT 3 a 2 c 2 g 3 t
ORIGIN
Query Match 100.0%; Score 5; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.8e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|||||
Db 8 GTATG 4

RESULT 13
AR079101
LOCUS AR079101 10 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 23 from patent US 5965409.
ACCESSION AR079101
VERSION AR079101.1 GI:10005847
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 10)
AUTHORS Pardee,A.B. and Liang,P.
TITLE System for comparing levels or amounts of mRNAs
JOURNAL Patent: US 5965409-A 23 12-OCT-1999;
FEATURES
source 1..10 Location/Qualifiers
BASE COUNT 1 a 1 c 3 g 4 t 1 others
ORIGIN
Query Match 100.0%; Score 5; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.8e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|||||
Db 1 GTATG 5

RESULT 14
AR079103
LOCUS AR079103 10 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 25 from patent US 5965409.
ACCESSION AR079103
VERSION AR079103.1 GI:10005849
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 10)
AUTHORS Pardee,A.B. and Liang,P.
TITLE System for comparing levels or amounts of mRNAs
JOURNAL Patent: US 5965409-A 25 12-OCT-1999;
FEATURES
source 1..10 Location/Qualifiers
BASE COUNT 1 a 2 c 3 g 3 t 1 others
ORIGIN
Query Match 100.0%; Score 5; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.8e+06;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
 |||||

Db 1 GTATG 5

RESULT 15

AR098909

LOCUS

AR098909 10 bp DNA linear PAT 14-FEB-2001

DEFINITION Sequence 45 from patent US 6077685.

ACCESSION

AR098909

VERSION

AR098909.1

KEYWORDS

GI:12808675

SOURCE

Unknown.

ORGANISM

Unknown.

REFERENCE

1 (bases 1 to 10)

AUTHORS

Trofatter,J.A., Maccollin,M.M. and Gusella,J.F.

TITLE

Tumor suppressor merlin and antibodies thereof

JOURNAL

Patent: US 6077685-A 45 20-JUN-2000;

FEATURES

Location/Qualifiers

1..10

source

/organism="unknown"

BASE COUNT

2 a 2 c 3 g 3 t

ORIGIN

Query Match

Best Local Similarity 100.0%; Score 5; DB 6; Length 10;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5

Db 1 GTATG 5

Search completed: June 2, 2003, 19:09:37
 Job time : 177.707 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 17:32:40 ; Search time 83.5366 Seconds
(without alignments)
134.791 Million cell updates/sec

Title: US-09-540-843-4

Perfect score: 5
Sequence: 1 gtag 5

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues
Total number of hits satisfying chosen parameters: 2063506

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N.Geneseq.101002.*

- 1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT.*
- 2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT.*
- 3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT.*
- 4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT.*
- 5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT.*
- 6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT.*
- 7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT.*
- 8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT.*
- 9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT.*
- 10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT.*
- 11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT.*
- 12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT.*
- 13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT.*
- 14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT.*
- 15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT.*
- 16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT.*
- 17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT.*
- 18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT.*
- 19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT.*
- 20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT.*
- 21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT.*
- 22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT.*
- 23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT.*
- 24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	5	100.0	5	20	AAZ10695
2	5	100.0	5	20	AAZ10696
3	5	100.0	5	23	AAZ14908
4	5	100.0	5	23	AAZ14910
5	5	100.0	7	20	AAZ10694
6	5	100.0	7	23	AAZ14907
7	5	100.0	7	23	AAZ14911
8	5	100.0	8	22	AAZ14911
9	5	100.0	9	19	AAZ23350

10	5	100.0	9	19	AAV22283	GAS complement gen
11	5	100.0	9	19	AAV15899	Cyclin D transcript
12	5	100.0	9	20	AAZ10692	Oligonucleotide se
13	5	100.0	9	23	AAZ14905	Melanogenesis asso
14	5	100.0	9	24	ABO71504	zinc finger protei
15	5	100.0	9	24	ABO71922	zinc finger protei
16	5	100.0	9	24	ABO71958	zinc finger protei
17	5	100.0	10	14	AAO43164	Donor oligomer vlt
18	5	100.0	10	15	AAO71104	Merlin exon 14 spl
19	5	100.0	10	16	AAO97224	Oligonucleotide Ec
20	5	100.0	10	16	AAZ32625	Anticancer duplex
21	5	100.0	10	17	AAZ35734	Primer E19 for V.d
22	5	100.0	10	18	AAZ66073	(dc-d)n (dc-d)n
23	5	100.0	10	19	AAV50271	Yeast tag for addi
24	5	100.0	10	19	AAV50250	Yeast tag for addi
25	5	100.0	10	19	AAV50184	Yeast tag for addi
26	5	100.0	10	19	AAV50127	Yeast tag for addi
27	5	100.0	10	19	AAV50127	Yeast tag for addi
28	5	100.0	10	19	AAV35934	Primer used in RAP
29	5	100.0	10	19	AAV35910	p53 serial analysi
30	5	100.0	10	20	AAZ18629	Chromophore contai
31	5	100.0	10	20	AAZ73806	Human dendritic ce
32	5	100.0	10	21	AAZ73931	Human dendritic ce
33	5	100.0	10	21	AAZ74120	Human dendritic ce
34	5	100.0	10	21	AAZ74154	Human dendritic ce
35	5	100.0	10	21	AAZ93858	Human dendritic ce
36	5	100.0	10	21	AAZ93865	Human dendritic ce
37	5	100.0	10	21	AAZ93865	Human dendritic ce
38	5	100.0	10	21	AAZ15244	Mouse DNA adapter
39	5	100.0	10	21	AAZ56166	Primer MR15 for mo
40	5	100.0	10	21	AAZ56218	Human monocyte gen
41	5	100.0	10	21	AAZ56224	Human monocyte gen
42	5	100.0	10	21	AAZ56294	Human monocyte gen
43	5	100.0	10	21	AAZ56321	Human monocyte gen
44	5	100.0	10	21	AAZ56331	Human monocyte gen
45	5	100.0	10	21	AAZ56407	Human monocyte gen
					AAZ56440	Human monocyte gen

ALIGNMENTS.

RESULT 1	AAZ10695	AAZ10695 standard; DNA; 5 BP.
XX	XX	XX
AC	AAZ10695;	
XX	XX	XX
DT	23-NOV-1999	(first entry)
XX	XX	XX
DE	Oligonucleotide sequence that increases p53 activity in a cell.	
XX	XX	XX
KW	p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;	
KW	UV-induced hyperproliferative disease; psoriasis; vitiligo;	
KW	atopic dermatitis; allergic rhinitis; conjunctivitis; photodag;	
KW	skin cancer; ss.	
XX	XX	XX
OS	Synthetic.	
XX	XX	XX
PN	GB2336157-A.	
XX	XX	XX
PD	13-OCT-1999.	
XX	XX	XX
PF	24-MAR-1999;	99GB-0006758.
XX	XX	XX
PR	26-MAR-1998;	98US-0048927.
XX	XX	XX
PA	(UYBO-) UNITV BOSTON.	
XX	XX	XX
PI	Gilchrest BA, Yaar M, Eller M;	
XX	XX	XX
DR	WPI, 1999-543520/46.	
XX	XX	XX
PT	DNA fragments useful for increasing p53 activity in a cell and reducing	

PT susceptibility to UV-induced hyperproliferative diseases -
 XX
 PS Claim 11; Page 30; 44pp; English.
 CC AA210692-97 represent DNA fragments that are used for increasing p53
 CC activity in a cell. The oligonucleotides are UV mimetics and
 CC protect cells against subsequent exposure to UV-irradiation or
 CC chemicals. The oligonucleotides are useful for increasing p53 activity
 CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
 CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
 CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
 CC and reducing susceptibility to skin cancer.
 XX
 SQ Sequence 5 BP; 1 A; 0 C; 2 G; 2 T; 0 other;

Query Match 100.0%; Score 5; DB 20; Length 5;
 Best Local Similarity 100.0%; Pred. No. 4.3e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 Db 1 GTATG 5

RESULT 2

AA210696/C
 ID AA210696 standard; DNA; 5 BP.

AA210696;
 AC

23-NOV-1999 (first entry)
 DT

Oligonucleotide sequence that increases p53 activity in a cell.
 XX

p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
 KW UV-induced hyperproliferative disease; psoriasis; vitiligo;
 KW atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;
 KW skin cancer; ss.

XX
 OS Synthetic.

XX
 GB2336157-A.

XX
 13-OCT-1999.

XX
 24-MAR-1999; 99GB-0006758.

XX
 26-MAR-1998; 98US-0048927.

XX
 (UYBO-) UNIV BOSTON.

XX
 Gilchrist BA, Yaar M, Eller M;

XX
 WPI; 1999-543520/46.

XX
 DNA fragments useful for increasing p53 activity in a cell and reducing
 PT susceptibility to UV-induced hyperproliferative diseases -
 XX
 XX

XX
 Claim 11; Page 30; 44pp; English.

XX
 AA210692-97 represent DNA fragments that are used for increasing p53
 CC activity in a cell. The oligonucleotides are UV mimetics and
 CC protect cells against subsequent exposure to UV-irradiation or
 CC chemicals. The oligonucleotides are useful for increasing p53 activity
 CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
 CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
 CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
 CC and reducing susceptibility to skin cancer.
 CC
 XX
 SQ Sequence 5 BP; 2 A; 2 C; 0 G; 1 T; 0 other;

Query Match 100.0%; Score 5; DB 20; Length 5;
 Best Local Similarity 100.0%; Pred. No. 4.3e+08;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 Db 5 GTATG 1

RESULT 3

AA214908
 ID AA214908 standard; DNA; 5 BP.

AA214908;
 AC

14-FEB-2002 (first entry)
 DT

Melanogenesis associated oligonucleotide #4.
 DE

Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.

XX
 OS Synthetic.

XX
 WO200174342-A2.

XX
 11-OCT-2001.

XX
 30-MAR-2001; 2001WO-US10162.

XX
 31-MAR-2000; 2000US-0540843.

XX
 (UYBO-) UNIV BOSTON.

XX
 Gilchrist BA, Yaar M, Eller M;

XX
 WPI; 2001-626338/72.

XX
 Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light -
 XX
 XX

XX
 Claim 1; Page 36; 74pp; English.

The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis);
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #4, a truncated
 CC version of the oligonucleotide shown in AA214908, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.

Sequence 5 BP; 1 A; 0 C; 2 G; 2 T; 0 other;

Query Match 100.0%; Score 5; DB 23; Length 5;
 Best Local Similarity 100.0%; Pred. No. 4,3e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 Db 1 GTATG 5

RESULT 4
 AAS14910/c
 ID AAS14910 standard; DNA; 5 BP.
 XX
 AC AAS14910;
 XX
 DT 14-FEB-2002 (first entry)
 XX
 DE Melanogenesis associated oligonucleotide #6.
 XX
 KW Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX
 OS Synthetic.
 XX
 PN WO200174342-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US10162.
 XX
 PR 31-MAR-2000; 2000US-0540843.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PI Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI: 2001-626338/72.
 XX
 PT Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light
 XX
 PS Claim 1; Page 36; 74pp; English.

The invention describes inhibition of mammalian epithelial cell proliferation by treating cells with at least one oligonucleotide, or its fragment. The compounds, which have cytostatic, anti-allergic, anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and immunosuppressive activities, function as 'ultra-violet mimics' to induce DNA repair processes (or a protective response to later exposure to radiation or chemicals), as a proliferative inhibitor, apoptosis inducer or a tumour necrosis factor inhibitor. Probably they mimic products of DNA damage, or processed DNA-damage intermediates, by inducing the p53 pathway, resulting in transient arrest of cell growth, allowing more time for DNA repair to occur before cell division takes place. The method is especially used to treat carcinoma but may also be used to: treat other hyperproliferative states (e.g. psoriasis or precancerous conditions); reduce photoaging, oxidative stress or damage; prevent skin cancer; treat allergic rhinitis and conjunctivitis; prevent or reduce dermatitis, cells caused by radiation or chemicals; increase melanin production (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to promote apoptosis in epithelial cells that contain damaged DNA. Also oligonucleotides that contain non-hydrolyzable backbones are used to inhibit apoptosis, in response to DNA damage, in epithelial cell. This sequence is melanogenesis associated oligonucleotide #6, one of the oligonucleotides used to inhibit mammalian epithelial cell proliferation, described in the method of the invention.

XX
 SQ Sequence 5 BP; 2 A; 2 C; 0 G; 1 T; 0 other;

Query Match 100.0%; Score 5; DB 23; Length 5;
 Best Local Similarity 100.0%; Pred. No. 4,3e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 Db 5 GTATG 1

RESULT 5
 AAZ10694
 ID AAZ10694 standard; DNA; 7 BP.
 XX
 AC AAZ10694;
 XX
 DT 23-NOV-1999 (first entry)
 XX
 DE Oligonucleotide sequence that increases p53 activity in a cell.
 XX
 KW p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
 KW UV-induced hyperproliferative disease; psoriasis; vitiligo;
 KW atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;
 KW skin cancer; ss.
 XX
 OS Synthetic.
 XX
 PN GB2336157-A.
 XX
 PD 13-OCT-1999.
 XX
 PF 24-MAR-1999; 99GB-0006758.
 XX
 PR 26-MAR-1998; 98US-0048927.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PI Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI: 1999-543520/46.
 XX
 PT DNA fragments useful for increasing p53 activity in a cell and reducing
 PT susceptibility to UV-induced hyperproliferative diseases -
 XX
 PS Claim 11; Page 30; 44pp; English.

AAZ10692-97 represent DNA fragments that are used for increasing p53 activity in a cell. The oligonucleotides are UV mimetics and protect cells against subsequent exposure to UV-irradiation or chemicals. The oligonucleotides are useful for increasing p53 activity in a cell, reducing the susceptibility to UV-induced hyperproliferative diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging and reducing susceptibility to skin cancer.

Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;

Query Match 100.0%; Score 5; DB 20; Length 7;
 Best Local Similarity 100.0%; Pred. No. 3,1e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 Db 2 GTATG 6

RESULT 6
 AAS14907
 ID AAS14907 standard; DNA; 7 BP.
 XX
 AC AAS14907;

XX 14-FEB-2002 (first entry)
 DT Melanogenesis associated oligonucleotide #3.
 XX
 DE Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX
 XX Synthetic.
 XX OS
 XX W0200174342-A2.
 XX PN
 XX 11-OCT-2001.
 XX PD
 XX 30-MAR-2001; 2001WO-US10162.
 XX PF
 XX 31-MAR-2000; 2000US-0540843.
 XX PR
 XX (UYBO-) UNIV BOSTON.
 XX PA
 XX Gilchrist BA, Yaar M, Eller M;
 XX PI
 XX WPI; 2001-626338/72.
 XX DR
 XX Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light -
 XX
 XX Claim 1; Page 36; 74pp; English.
 PS
 XX The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis;
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used. This
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #3, a truncated
 CC version of the oligonucleotide shown in AAS14906, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.
 CC
 XX Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;
 SO
 Query Match 100.0%; Score 5; DB 23; Length 7;
 Best local Similarity 100.0%; Pred. No. 3.1e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

ID AAS14911 standard; DNA; 7 BP.
 XX AAS14911;
 AC
 XX
 DE 14-FEB-2002 (first entry)
 DT Melanogenesis associated oligonucleotide #7.
 XX
 DE Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX
 XX Synthetic.
 XX OS
 XX W0200174342-A2.
 XX PN
 XX 11-OCT-2001.
 XX PD
 XX 30-MAR-2001; 2001WO-US10162.
 XX PF
 XX 31-MAR-2000; 2000US-0540843.
 XX PR
 XX (UYBO-) UNIV BOSTON.
 XX PA
 XX Gilchrist BA, Yaar M, Eller M;
 XX PI
 XX WPI; 2001-626338/72.
 XX DR
 XX Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light -
 XX
 XX Claim 1; Page 38; 74pp; English.
 PS
 XX The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis;
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #7, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.
 CC
 XX Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;
 SO
 Query Match 100.0%; Score 5; DB 23; Length 7;
 Best local Similarity 100.0%; Pred. No. 3.1e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 2 GTATG 6

RESULT 8
AAD02250/c
ID AAD02250 standard; DNA; 8 BP.
XX
AC AAD02250;
XX
DT 28-MAR-2001 (first entry)
XX

DE Direct repeat sequence that binds to SB protein.
XX
DE

KW Sleeping Beauty; SB; AdSB10; adenovirus; transposase;
KW non-integrating viral vector; cytosolic; anti-diabetic; cardiant;
KW neuroprotective; genetic disease; gene therapy; therapy; cancer;
KW cystic fibrosis; diabetes; cardiovascular disease; brain malfunction;
KW genome analysis; chemotherapy; transgenic host cell; direct repeat; ds.
XX
OS Unidentified.
XX
PN WO200068399-A2.
XX
PD 16-NOV-2000.
XX
PF 11-MAY-2000; 2000MO-US12827.
XX
PR 11-MAY-1999; 99US-0133569.
XX
XX (MING) UNIV MINNESOTA.
PA (BAYU) BAYLOR COLLEGE MEDICINE.
PA (MCIV) MCIVOR R S.
PA (HACK) HACKETT P B.
PA (AGUI) AGUILAR-CORDOVA E.
XX
PI McIvor RS, Hackett PB, Aguilar-Cordova E;
XX
DR WPI; 2001-024870/03.
XX

PT Non-integrating (adenovirus-based) viral vectors useful in gene
PT therapy, especially for treating patients suffering from a genetic
PT disease, e.g. cystic fibrosis, diabetes, cardiovascular disease, cancer
PT or brain malfunction -
XX
PS
XX

PS Disclosure; Page 14; 62pp; English.

CC The patent discloses non-integrating viral vectors comprising a
CC polynucleotide flanked by inverted repeats that bind a transposase, a
CC transposase-encoding polynucleotide operably linked to a regulatory
CC sequence comprising an operator, that alters expression of the
CC transposase-encoding polynucleotide. Transposon sequences can integrate
CC into genomic DNA whether or not the cell is dividing. AdSB10 is a SB
CC (Sleeping Beauty) transposase-transducing adenoviral non-integrating
CC vector. The non-integrating viral vectors are useful for treating
CC genetic disease characterized by subnormal production of a polypeptide or
CC RNA, e.g. for replacement of a defective gene, delivery of a polypeptide
CC drug or supplementation of a metabolic activity. These genetic diseases
CC include cystic fibrosis, diabetes, cardiovascular disease, cancer or
CC brain malfunction. The non-integrating viral vectors are useful as
CC nucleic acid delivery systems, e.g. for genome analysis or gene therapy
CC and can also be used for applications that involve long-term production
CC of a polypeptide. The non-integrating viral vectors are also useful for
CC creating transgenic host cells that provide normal cells with protection
CC against toxic side effects of chemotherapy.
CC The sequence of the present invention is a direct repeat sequence that
CC binds to SB protein.
XX
XX

SO Sequence 8 BP; 4 A; 3 C; 0 G; 1 T; 0 other;

Query Match 100.0%; Score 5; DB 22; Length 8;

Best Local Similarity 100.0%; Pred. No. 2.7e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 6 GTATG 2

RESULT 9
AAV22350
ID AAV22350 standard; RNA; 9 BP.
XX
AC AAV22350;
XX
DT 29-JUN-1998 (first entry)
XX

DE A promoter regulatory motif found in the utrons of the invention.
XX
XX 3' untranslated region; UTR; inhibition; gene expression; ICAM-7;
KW interferon-gamma; IFN-gamma; major histocompatibility complex; MHC;
KW antigen expression; gene promoter; utron; B7-1; B7-2; Fc gamma R;
KW HIV gene expression; transplant rejection; treatment;
KW autoimmune disease; inflammatory disease; ss.
XX
OS Unidentified.
XX
PN WO9744450-A1.
XX
PD 27-NOV-1997.
XX
PF 21-MAY-1997; 97MO-US09459.
XX
PR 21-MAY-1996; 96US-0646789.
XX
XX (UYA) UNIV YALE.
PA
PI Peyman JA;
XX
DR WPI; 1998-018505/02.
XX

PT Utrons, RNA molecules containing promoter regulatory motifs -
PT useful to suppress express expression from promoter of interest,
PT specifically TSD nucleic acid suppression of MHC Class I and II gene
PT expression
XX
PS
XX

PS Claim 20; Page 20; 200pp; English.

CC The present sequence represents a promoter regulatory element,
CC found in the utrons of the invention. Utrons are from, or are
CC homologous to, the 3' untranslated region (UTR), of an mRNA that
CC stimulates or inhibits a cellular response by sequence specific
CC interactions. The utron is able to suppress constitutive and
CC interferon-gamma (IFN-gamma) induced major histocompatibility complex
CC (MHC) class I and class II antigen expression and expression of other
CC antigens; the gene promoters of which contain related sequence motifs
CC that are stimulated by the same factors which stimulate MHC class I and
CC class II antigen expression. Such utrons can be used to regulate
CC gene expression in a subject, e.g. a human or a cell in vitro,
CC specifically inhibiting MHC Class I or II, ICAM-7, B7-1, B7-2,
CC Fe gamma R, IL-2 or HIV gene expression. They can be used to inhibit
CC transplant rejection, or treat an autoimmune or inflammatory disease or
CC disorder.
XX
XX

SO Sequence 9 BP; 3 A; 0 C; 3 G; 3 U; 0 other;

Query Match 100.0%; Score 5; DB 19; Length 9;
Best Local Similarity 60.0%; Pred. No. 2.4e+08;
Matches 3; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|:|:|
Db 1 GTATG 5

RESULT 10
 AAV22283
 ID AAV22283 standard; DNA: 9 BP.
 AC AAV22283;
 XX
 DT 29-JUN-1998 (first entry)
 XX
 DE GAS complement gene promoter motif found in a trophoblast STAR utron.
 XX
 KW Trophoblast STAR utron; TSU; 3' untranslated region; UTR; inhibition;
 KW interferon-gamma; IFN-gamma; major histocompatibility complex; MHC;
 KW antigen expression; gene promoter; class II; IFN signalling;
 KW GAS; ISRE; Interleukin-4 response element; gene expression; ICAM-7;
 KW B7-1; B7-2; Fc gamma R; HIV gene expression; transplant rejection;
 KW treatment; autoimmune disease; inflammatory disease; ss.
 XX
 OS Unidentified.
 XX
 PN MO9744450-A1.
 XX
 PD 27-NOV-1997.
 XX
 PF 21-MAY-1997; 97WO-US09459.
 XX
 PR 21-MAY-1996; 96US-0646789.
 XX
 PA (UYVA) UNITV YALE.
 XX
 PI Peyman JA;
 XX
 DR WPI: 1998-018505/02.
 XX
 PT Utrons, RNA molecules containing promoter regulatory motifs -
 XX useful to suppress express expression from promoter of interest.
 PT specifically TSU nucleic acid suppression of MHC Class I and II gene
 XX expression
 PS Claim 22; Page 90; 200pp; English.
 XX
 CC The present sequence represents a GAS complement gene promoter motif
 CC found in a trophoblast STAR utron (TSU). TSUs be isolated from a CDNA
 CC library prepared from mRNA isolated from trophoblast cells. Utrons are
 CC from, or are homologous to, the 3' untranslated region (UTR), of an mRNA
 CC that stimulates or inhibits a cellular response by sequence specific
 CC interactions. The TSU is able to suppress constitutive and
 CC interferon-gamma (IFN-gamma) induced major histocompatibility complex
 CC (MHC) Class I and class II antigen expression and expression of other
 CC antigens, the gene promoters of which contain related sequence motifs
 CC that are stimulated by the same factors which stimulate MHC class I and
 CC class II antigen expression. The TSU sequence contains motifs related to
 CC IFN signalling (GAS, ISRE and interleukin-4 response elements). The
 CC nucleic acid can be used to regulate gene expression in a subject, e.g. a
 CC human or a cell in vitro, specifically inhibiting MHC Class I or II,
 CC ICAM-7, B7-1, B7-2, Fc gamma R, II-2 or HIV gene expression. It can be
 CC used to inhibit transplant rejection, or treat an autoimmune or
 CC inflammatory disease or disorder. It can also be used to inhibit the
 CC action of STARI-6, or a cytokine.
 XX
 SQ Sequence 9 BP; 3 A; 0 C; 3 G; 3 T; 0 other;
 XX
 Query Match 100.0%; Score 5; DB 19; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTATG 5
 DB 1 GTATG 5
 DB 1 GTATG 5

RESULT 11
 AAV15899

ID AAV15899 standard; DNA: 9 BP.
 XX
 AC AAV15899;
 XX
 DT 26-MAY-1998 (first entry)
 XX
 DE Cyclin D transcription factor DMP1 nonamer consensus sequence.
 XX
 KW Cyclin D transcription factor; binding affinity; D-type cyclin; probe;
 KW cell cycle inhibitor; tumour; detection; cancer; DMP1; competitor;
 KW nonamer consensus sequence; ss.
 XX
 OS Mus musculus.
 XX
 OS Homo sapiens.
 XX
 PN MO9743415-A1.
 XX
 PD 20-NOV-1997.
 XX
 PF 16-MAY-1997; 97MO-US08480.
 XX
 PR 15-MAY-1997; 97US-0017815.
 PR 16-MAY-1996; 96US-0017815.
 PR 16-MAY-1996; 96US-0648837.
 XX
 PA (SUUD-) ST JUDE CHILDREN'S RES HOSPITAL.
 XX
 PI Hirai H, Inoue K, Sherr CJ;
 XX
 DR WPI: 1998-008884/01.
 XX
 PT Cyclin D transcription factor and related DNA - can be used to
 XX develop products for treatment of, e.g. cancer
 XX
 PS Claim 3; Page 99; 120pp; English.
 XX
 CC This is a nonamer consensus sequence of a cyclin D transcription factor
 CC DMP1. DMP1 is an amino acid polymer which has binding affinity for a
 CC D-type cyclin, in vitro, and for a specific DNA nucleotide sequence and
 CC is a transcription factor involved in the activation of genes that
 CC prevent cell proliferation. The DMP1 nucleic acid is operatively linked
 CC to an expression control sequence in an expression vector. The expression
 CC vector has a transcription control sequence comprising this nonamer
 CC sequence operably associated with a recombinant gene or a cassette
 CC insertion site for a recombinant animal. A probe or a
 CC recombinant in DMP1 transactivation assays is designed based on this
 CC nonamer sequence. The presence of activity of DMP1 can be determined by
 CC detecting binding of DMP1 and a probe by contacting a biological sample
 CC from a mammal with the probe under conditions that allow binding of the
 CC probe to DMP1, where the probe contains the core sequence GTR, and where
 CC the presence or activity of DMP1 is suspected in the sample. DMP1 can
 CC function as a cell cycle inhibitor when expressed in a tumour cell.
 CC Modulating the expression of DMP1 can be used to treat tumours and other
 CC cancers. DMP1 can also be used for controlling expression of heterologous
 CC proteins. Antisense sequences and ribozymes can be used to inhibit
 CC expression of the transcription factor. Detecting the level and activity
 CC of DMP1 in cells is useful for detection of cancer cells or
 CC dysproliferative cells.
 XX
 SQ Sequence 9 BP; 1 A; 3 C; 2 G; 3 T; 0 other;
 XX
 Query Match 100.0%; Score 5; DB 19; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTATG 5
 DB 4 GTATG 8
 DB 4 GTATG 8

RESULT 12
 AA210692

ID AA210692 standard; DNA; 9 BP.
 XX
 AC AA210692;
 XX
 DT 23-NOV-1999 (first entry)
 XX
 DE Oligonucleotide sequence that increases p53 activity in a cell.
 XX
 KM p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
 KM UV-induced hyperproliferative disease; psoriasis; vitiligo;
 KM atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;
 KM skin cancer; ss.
 XX
 OS Synthetic.
 XX
 PN GB2336157-A.
 XX
 PD 13-OCT-1999.
 XX
 PE 24-MAR-1999; 99GB-0006758.
 XX
 PR 26-MAR-1998; 98US-0048927.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PT Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI; 1999-543520/46.
 XX
 PT DNA fragments useful for increasing p53 activity in a cell and reducing
 PT susceptibility to UV-induced hyperproliferative diseases -
 XX
 PS Claim 11; Page 29; 44pp; English.
 XX
 CC AA210692-97 represent DNA fragments that are used for increasing p53
 CC activity in a cell. The oligonucleotides are are UV mimetics and
 CC protect cells against subsequent exposure to UV-irradiation or
 CC chemicals. The oligonucleotides are useful for increasing p53 activity
 CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
 CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
 CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
 CC and reducing susceptibility to skin cancer.
 CC
 SO Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
 Query Match 100.0%; Score 5; DB 20; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GTATG 5
 |||||
 DB 3 GTATG 7
 RESULT 13
 AAS14905
 ID AAS14905 standard; DNA; 9 BP.
 XX
 AC AAS14905;
 XX
 DT 14-FEB-2002 (first entry)
 XX
 DE Melanogenesis associated oligonucleotide #1.
 XX
 KM Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KM anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KM immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KM tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KM carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KM conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX
 OS Synthetic.
 XX

FH Key Location/Qualifiers
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= g
 FT /note= "Optionally phosphorylated"
 XX
 PN WO200174342-A2.
 XX
 PD 11-OCT-2001.
 XX
 PE 30-MAR-2001; 2001WO-US10162.
 XX
 PR 31-MAR-2000; 2000US-0540843.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PT Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI; 2001-626338/72.
 XX
 PT Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light -
 XX
 PS Claim 1; Page 36; 74pp; English.
 XX
 CC The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis,
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #1, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.
 CC
 SO Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
 Query Match 100.0%; Score 5; DB 23; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GTATG 5
 |||||
 DB 3 GTATG 7
 RESULT 14
 ABQ71504/c
 ID ABQ71504 standard; DNA; 9 BP.
 XX
 AC ABQ71504;
 XX
 DT 28-AUG-2002 (first entry)
 XX
 DE Zinc finger protein related oligonucleotide target SEQ ID NO:623.
 XX
 KM Zinc finger protein; ZFP; DNA binding protein; zinc finger; ss.
 XX

XX OS Homo sapiens.
 OS Synthetic.
 XX PN WO200242459-A2.
 XX PD 30-MAY-2002.
 XX PF 20-NOV-2001; 2001WO-US43438.
 XX PR 20-NOV-2000; 2000US-0716637.
 XX PA (SANG-) SANGAMO BIOSCIENCES INC.
 XX PI Liu Q;
 XX P1 WPI: 2002-500284/53.
 DR WPI: 2002-500284/53.
 XX PT New zinc finger protein that binds to target site, useful in studying
 PT gene function and for human therapeutics and plant engineering,
 PT comprises first, second and third zinc fingers, ordered from N- to
 PT C-terminus -
 XX PS Example 1; Page 45; 81pp; English.
 CC The present invention describes a zinc finger protein (I) that binds to
 CC a target site, comprising a first (F1), a second (F2), and a third (F3)
 CC zinc finger, ordered F1, F2, F3 from N-terminus to C-terminus, where the
 CC target site comprises, in 3'-5' direction, a first (S1), a second (S2),
 CC and a third (S3) target subsite. Also described are: (1) a polypeptide
 CC (II) comprising (I); (2) a polynucleotide (III) encoding (I) or (II); and
 CC (3) designing (M) (I) involves selecting the F1 zinc finger such that
 CC it binds to the S1 target subsite, selecting the F2 zinc finger such
 CC that it binds to the S2 target subsite, and selecting the F3 zinc
 CC finger such that it binds to the S3 target subsite, thus designing (I)
 CC that binds to a target site. (I) is useful for recognition of triplet
 CC target subsites having the nucleotide G in the 5'-most position of the
 CC subsite. (I) is useful in studying gene function, and for human
 CC therapeutics and plant engineering. (I), (II) or (III) is useful in
 CC therapeutic methods to modulate the expression of a target region within
 CC a subject, in diagnostic methods for sequence specific detection of
 CC target nucleic acid in a sample, and in assays to determine the
 CC phenotype and function of gene expression. (I) has improved affinity
 CC and specificity for their target sequences, as well as enhanced
 CC biological activity. ABQ71213 to ABQ72214 and ABP48191 to ABP51230
 CC represent DNA target sequences and zinc finger peptides which are given
 CC in the exemplification of the present invention.
 CC XX
 SQ Sequence 9 BP; 2 A; 2 C; 3 G; 2 T; 0 other;
 Query Match 100.0%; Score 5; DB 24; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GRATG 5
 DB 6 GRATG 2
 RESULT 15
 ID ABQ71922 standard; DNA: 9 BP.
 AC ABQ71922;
 XX 28-AUG-2002 (first entry)
 DT zinc finger protein related oligonucleotide target SEQ ID NO:2220.
 XX zinc finger protein; ZFP; DNA binding protein; zinc finger; ss.
 XX Homo sapiens.
 OS Synthetic.

XX PN WO200242459-A2.
 XX PD 30-MAY-2002.
 XX PF 20-NOV-2001; 2001WO-US43438.
 XX PR 20-NOV-2000; 2000US-0716637.
 XX PA (SANG-) SANGAMO BIOSCIENCES INC.
 XX PI Liu Q;
 XX P1 WPI: 2002-500284/53.
 DR WPI: 2002-500284/53.
 XX PT New zinc finger protein that binds to target site, useful in studying
 PT gene function and for human therapeutics and plant engineering,
 PT comprises first, second and third zinc fingers, ordered from N- to
 PT C-terminus -
 XX PS Example 1; Page 58; 81pp; English.
 CC The present invention describes a zinc finger protein (I) that binds to
 CC a target site, comprising a first (F1), a second (F2), and a third (F3)
 CC zinc finger, ordered F1, F2, F3 from N-terminus to C-terminus, where the
 CC target site comprises, in 3'-5' direction, a first (S1), a second (S2),
 CC and a third (S3) target subsite. Also described are: (1) a polypeptide
 CC (II) comprising (I); (2) a polynucleotide (III) encoding (I) or (II); and
 CC (3) designing (M) (I) involves selecting the F1 zinc finger such that
 CC it binds to the S1 target subsite, selecting the F2 zinc finger such
 CC that it binds to the S2 target subsite, and selecting the F3 zinc
 CC finger such that it binds to the S3 target subsite, thus designing (I)
 CC that binds to a target site. (I) is useful for recognition of triplet
 CC target subsites having the nucleotide G in the 5'-most position of the
 CC subsite. (I) is useful in studying gene function, and for human
 CC therapeutics and plant engineering. (I), (II) or (III) is useful in
 CC therapeutic methods to modulate the expression of a target region within
 CC a subject, in diagnostic methods for sequence specific detection of
 CC target nucleic acid in a sample, and in assays to determine the
 CC phenotype and function of gene expression. (I) has improved affinity
 CC and specificity for their target sequences, as well as enhanced
 CC biological activity. ABQ71213 to ABQ72214 and ABP48191 to ABP51230
 CC represent DNA target sequences and zinc finger peptides which are given
 CC in the exemplification of the present invention.
 CC XX
 SQ Sequence 9 BP; 2 A; 0 C; 4 G; 3 T; 0 other;
 Query Match 100.0%; Score 5; DB 24; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GRATG 5
 DB 4 GRATG 8
 Search completed: June 2, 2003, 18:45:12
 Job time : 84.7366 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:29:55 ; Search time 627.439 Seconds

(without alignments)
129.060 Million cell updates/sec

Title: US-09-540-843-4

Perfect score: 5

Sequence: 1 gtag 5

Scoring table: IDENTITY NUC

Gapop 10.0, Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 60474

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :
EST:
1: em_estba:*
2: em_estlum:*
3: em_estlin:*
4: em_estlmu:*
5: em_estlov:*
6: em_estlpl:*
7: em_estro:*
8: em_htc:*
9: gb_estcl:*
10: gb_estl2:*
11: gb_htc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estlum:*
16: em_estlom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vrt:*
22: em_gss_fun:*
23: em_gss_mam:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_rtd:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	5	100.0	14	13	BM398220
C 2	5	100.0	16	9	AI424037
C 3	5	100.0	16	9	AI685758
C 4	5	100.0	16	9	AI721735
C 5	5	100.0	16	13	BG928185
C 6	5	100.0	17	13	BG929060

RESULT 1	LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT	FEATURES	source
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA	EST 17-JAN-2002					
BM398220	5009-0-42-D11.t.1	Chilcoat/Turkewitz CDNA (large fraction)	BM398220	1	GI:18198273	EST.	Tetrahymena thermophila.	14 bp mRNA						

```

/db_xref="taxon:5911"
/clone.lib="Chicoat/Turkewitz cDNA (large fraction)"
/Note="Vector: Bluescript SK+; Details on library
preparation can be found in Chicoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."

BASE COUNT      4 a      5 c      0 g      5 t

ORIGIN
Query Match      100.0%; Score 5; DB 13; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.1e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTATG 5
        |||||
        5 GTATG 1

RESULT 2
A1424037/c      16 bp      mRNA      linear      EST 09-MAR-1999
LOCUS           tf51h06.x1 NCI_CGAP_Brn23 Homo sapiens cDNA clone IMAGE:2102843 3'
DEFINITION      similar to TR:069566 Q69566 ; mRNA sequence.
ACCESSION       A1424037
VERSION         A1424037.1 GI:4269968
KEYWORDS        EST.
SOURCE          human.
ORGANISM        Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE       1 (bases 1 to 16)
AUTHORS         NCI/NINDS-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE           National Cancer Institute / National Institute of Neurological
Disorders and Stroke, Brain Tumor Genome Anatomy Project
(CGAP/BTCAP), Tumor Gene Index
Unpublished (1998)
JOURNAL         Contact: Robert Strausberg, Ph.D.
COMMENT         Email: cgapbs-r@mail.nih.gov
Tissue Procurement: David N. Louis, M.D., Myrna R. Rosenfeld M.D.,
Ph.D.
cDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima
Bonaldo, Ph.D.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.bio.llnl.gov/dbp/image/image.html

FEATURES
source
Trace considered overall poor quality
Seq primer: -40UP from Glbco
High quality sequence stop: 1.
Location/Qualifiers
1..16
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone.lib="IMAGE:2102843"
/clone.lib="NCI_CGAP_Brn23"
/tissue_type="glioblastoma (pooled)"
/lab_host="DH10B"
/Note="Organ: brain; Vector: p7773D-Pac (Pharmacia) with a
modified polylinker; Site.1: Not I; Site.2: Eco RI; 1st
strand cDNA was primed with a Not I - oligo(dT) primer [5'
TGTTCACATCTGAGTGGAGCGCGCCATATCTTTTCTTTTCTTTT
T 3']; double-stranded cDNA was ligated to Eco RI
adaptors (Pharmacia), digested with Not I and cloned into
the Not I and Eco RI sites of the modified p7773 vector.
Library is normalized, and was constructed by Bento
Soares and M.Fatima Bonaldo."

BASE COUNT      8 a      6 c      1 g      1 t

ORIGIN
Query Match      100.0%; Score 5; DB 9; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 GTATG 5
        |||||
        6 GTATG 2

RESULT 3
A1685758/c      16 bp      mRNA      linear      EST 27-MAY-1999
LOCUS           tu37g09.x1 NCI_CGAP_Pr28 Homo sapiens cDNA clone IMAGE:2253280 3'
DEFINITION      similar to TR:002393 Q02393 HUMAN PAPILLOMAVIRUS 18 E5 CENTRAL
SEQUENCE MOTIF PROTEIN 1; contains element LTR4 repetitive element
; mRNA sequence.
ACCESSION       A1685758
VERSION         A1685758.1 GI:4897052
KEYWORDS        EST.
SOURCE          human.
ORGANISM        Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE       1 (bases 1 to 16)
AUTHORS         NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE           National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
JOURNAL         Contact: Robert Strausberg, Ph.D.
COMMENT         Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Michael J. Brownstein, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: M. Bento Soares, Ph.D.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.bio.llnl.gov/dbp/image/image.html

FEATURES
source
Trace considered overall poor quality
Seq primer: -40UP from Glbco
High quality sequence stop: 1.
Location/Qualifiers
1..16
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone.lib="IMAGE:2253280"
/clone.lib="NCI_CGAP_Pr28"
/sex="male"
/dev_stage="adult"
/lab_host="DH10B"
/Note="Organ: prostate; Vector: p7773D-Pac (Pharmacia)
with a modified polylinker; Plasmid DNA from the
normalized library NCI-CGAP_Pr22 was prepared, and ss
circles were used as tracer in a subtractive hybridization
reaction. The driver was PCR-amplified cDNAs from a pool
of 5,000 clones made from the same library (clonids
985608-986759, 1101192-1101959, and 1217928-1220615)."
Subtraction by Bento Soares and M. Fatima Bonaldo."

BASE COUNT      7 a      7 c      1 g      1 t

ORIGIN
Query Match      100.0%; Score 5; DB 9; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTATG 5
        |||||
        9 GTATG 5

RESULT 4
A1721735/c      16 bp      mRNA      linear      EST 07-JUN-2001
LOCUS           fc31g08.x1 zebrafish Washu MPING EST Danio rerio cDNA clone
DEFINITION

```

IMAGE:3723038 3' similar to SW:YM14_PAPER.P15615 HYPOTHETICAL 47.2
KD PROTEIN ; mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE

ORGANISM

zebrafish.

Danio rerio

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
Cyprinidae; Danio.

REFERENCE
AUTHORS

1 (bases 1 to 16)

Clark, M., Johnson, S.L., Lehnach, H., Lee, R., Li, F., Maria, M., Eddy,
S., Hillier, L., Kucaba, T., Martin, J., Beck, C., Wylie, T., Underwood,
K., Steptoe, M., Theising, B., Allen, M., Bowers, Y., Person, B.,
Swaller, T., Gibbons, M., Pape, D., Harvey, N., Schurk, R., Ritter, E.,
Kohn, S., Shin, T., Jackson, Y., Cardenas, M., McCann, R., Waterston, R.,
and Wilson, R.

WashU zebrafish EST Project 1998

Unpublished (1998)

Other ESTs: fc31g08.y1

Contact: Stephen L. Johnson

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA

Tel: 314 286 1800

Fax: 314 286 1810

Email: zbrafish@wustl.edu

CDNA Library Preparation: Matthew Clark, CDNA Library Arrayed by:

Matthew Clark, DNA Sequencing by: Washington University Genome

Sequencing Center Clone distribution: Genome Systems, St. Louis,

Missouri (web address: www.genomesystems.com) (email contact:

info@genomesystems.com) and Research Genetics, Huntsville, Alabama

(web address: www.resgen.com) (email contact: info@resgen.com) and

ResourceCenter@primardatenbank, Berlin, Germany (web address:

www.rzpd.de)

Trace considered overall poor quality

Possible reversed clone: similarity on wrong strand

Seq primer: 17 ET from Amersham

High quality sequence stop: 1.

FEATURES
SOURCE

Location/Qualifiers

1..16

/organism="Danio rerio"

/db_xref="taxon:7955"

/clone="IMAGE:3723038"

/clone_lib="zebrafish WashU MPIMG EST"

/sex="mixed"

/tissue_type="26 somite embryos, adult livers, shield

stage embryos"

/lab_host="XLI-blue MRF"

/note="Vector: pSPORT1; Site_1: NotI; Site_2: SalI; 1st

strand cDNA was primed with a Not I - oligo(dT)15 primer

[5'/GGACTAGTCTAGATCGCGAGCGCCGCTTTTCTTTTCTTTT3'];

double-stranded cDNA was ligated to Sal I adaptors (BRL),

digested with Not I and cloned into the Not I and Sal I

sites of the pSPORT1 vector (BRL). Library was constructed

by Matthew Clark (Lehrach lab; ICRF, London and Max Planck

Institut fuer Molekulare Genetik, Berlin). cDNAs for EST

analysis were selected following oligonucleotide

hybridization fingerprinting of arrayed clones from

zebrafish late somitogenesis (26 ss), adult liver or

embryonic shield stage (5,6 h) libraries. Fingerprint

data were used to computationally cluster cDNAs, and a

single cDNA from each cluster was chosen for sequencing.

In some cases multiple members of the same cluster were

sequenced to assess clustering parameters or single clones

were sequenced additional times to assess quality

control."

BASE COUNT
ORIGIN

6 a 8 c 1 g 1 t

Query Match

Best Local Similarity 100.0%; Score 5; DB 9; Length 16;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 13 GTATG 9

RESULT 5

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

human.

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

1 (bases 1 to 16)

Kumar, S., Connor, J.R., Dodds, R.A., Halsey, W., Van Horn, M., Mao, J.,

Sathe, G., Mul, P., Agarwal, P., Badger, A.M., Lee, J.C., Gowen, M. and

Lark, M.W.

Identification and initial characterization of 5000 expressed

sequenced tags (ESTs) each from adult human normal and

osteoarthritic cartilage cDNA libraries

osteocarthr. Cartil. 9 (7), 641-653 (2001)

21482651

Contact: Sanjay Kumar

UM2109

GlaxoSmithKline

709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406, USA

Tel: 610-270-7245

Fax: 610-270-5598

Email: sanjay.kumar-1@gsk.com

Seq primer: 17.

Location/Qualifiers

1..16

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone_lib="HNC (Human Normal Cartilage)"

/tissue_type="cartilage"

/lab_host="E.coli DH10 B"

/note="Vector: pSPORT 1; Site_1: SalI; Site_2: NotI;

Directional"

BASE COUNT

ORIGIN

4 a 6 c 2 g 3 t 1 others

Query Match

Best Local Similarity 100.0%; Score 5; DB 13; Length 16;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5

|||||

Db 12 GTATG 8

RESULT 6

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

human.

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

1 (bases 1 to 17)

Kumar, S., Connor, J.R., Dodds, R.A., Halsey, W., Van Horn, M., Mao, J.,

Sathe, G., Mul, P., Agarwal, P., Badger, A.M., Lee, J.C., Gowen, M. and

Lark, M.W.

Identification and initial characterization of 5000 expressed

sequenced tags (ESTs) each from adult human normal and

JOURNAL
MEDLINE
COMMENT

osteoarthritic cartilage cDNA libraries
Osteoarthritis. Cartil. 9 (7), 641-653 (2001)

21482651
Contact: Sanjay Kumar
TW2109

GlaxoSmithKline
709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406, USA
Tel: 610-270-7245
Fax: 610-270-5598
Email: sanjay.kumar-1@gsk.com
Seq primer: T7
Location/Qualifiers

FEATURES
source

1. 17
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="HNC (Human Normal Cartilage)"
/tissue_type="cartilage"
/lab_host="E.coli DH10 B"
/note="Vector: pSPORT I; Site_1: SalI; Site_2: NotI;
Directional"

BASE COUNT
ORIGIN

5 a 8 c 2 g 2 t

Query Match 100.0%; Score 5; DB 13; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 10 GTATG 6

RESULT 7
C21103 17 bp mRNA linear EST 23-OCT-1996
LOCUS HMGSO002626 Human adult (K.Okubo) Homo sapiens cDNA 3', mRNA
DEFINITION sequence.

ACCESSION C21103
VERSION C21103.1 GI:1622213
KEYWORDS EST.

SOURCE
ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 17)

Okubo, K.
BodyMap: human gene expression database
Unpublished (1995)
Contact: Okubo, K.
Institute for Molecular and Cellular Biol
Osaka University

COMMENT

1-3 Yamada-oka, Suita, Osaka Pref. 565, Japan
Tel: 06-877-5111 (ex. 3315)
Email: kousaku@imcb.osaka-u.ac.jp
Human gene signature, 3'-directed cDNA sequence. We are not
submitting the same cDNA sequence redundantly to DDBJ since 1993.
For the abundance information of clones with this sequence in this
library and as well as in other 3'-directed libraries, see
http://www.imcb.osaka-u.ac.jp/bodymap/. The sequences of the clones
represented by this GS sequence is also found there.

FEATURES
source

1. 17
Location/Qualifiers

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="Human adult (K.Okubo)"
/dev_stage="adult"

/note="Organ: blood; Vector: 1-gt-11; Site_1: Eco-RI;
Monocytes were prepared from blood by ficoll-hypaque,
percoll and T cell rosetting purification steps (purity:
96 %). mRNA was prepared from activated monocytes from a
patient with rheumatoid arthritis. mRNA was reverse
transcribed with MuLV. Using Eco-RI linkers cDNA was
cloned into 1-gt-11 vector arms. The cDNA library was

screened by differential hybridization using radioactively
marked ss-cDNA from activated and non-activated
monocytes.

BASE COUNT 5 a 5 c 2 g 5 t

Query Match 100.0%; Score 5; DB 14; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 13 GTATG 9

RESULT 8
BM397954 18 bp mRNA linear EST 17-JAN-2002
LOCUS 5009-0-39-G08.t.1 Chilcoat/Turkewitz cDNA (large fraction)
DEFINITION Tetrahymena thermophila cDNA, mRNA sequence.

ACCESSION BM397954
VERSION BM397954.1 GI:18198022
KEYWORDS EST.

SOURCE
ORGANISM

Tetrahymena thermophila.
Tetrahymena thermophila
Eukaryota; Alveolata; Ciliophora; Oligomonophorea;
Hymenostomatida; Tetrahymenina; Tetrahymena.

REFERENCE 1 (bases 1 to 18)
Turkewitz, A.P., Karrer, K.M., Jahn, C., Ortas, E., Kirk, K.E., Frankel
, J. and Klobutcher, L.

EST from Tetrahymena thermophila, strain CU428.1, growing cells
Unpublished (2002)
Contact: Turkewitz AP

Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu

Seq primer: T3.
Location/Qualifiers

1. 18
/organism="Tetrahymena thermophila"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/note="Vector: Bluescript SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."

FEATURES
source

1. 18
Location/Qualifiers
/organism="Tetrahymena thermophila"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/note="Vector: Bluescript SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."

BASE COUNT

3 a 7 c 5 g 3 t

Query Match 100.0%; Score 5; DB 13; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 5 GTATG 1

RESULT 9
AA977115 19 bp mRNA linear EST 26-MAY-1998

LOCUS oq24c08.s1 NC1_CGAP_GC4 Homo sapiens cDNA clone IMAGE:1587278 3'
DEFINITION similar to TR:Q69566 Q69566 ;, mRNA sequence.

ACCESSION AA977115
VERSION AA977115.1 GI:3154561
KEYWORDS EST.

SOURCE
ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 19)
 AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 TITLE National Cancer Institute, Cancer genome Anatomy Project (CGAP),
 JOURNAL Tumor Gene Index
 COMMENT Unpublished (1997)
 Contact: Robert Strausberg, Ph.D.
 Email: cgaps-ri@mail.nih.gov
 Tissue Procurement: Christopher A. Moskaluk, M.D., Ph.D., Michael
 Emmert-Buck, M.D., Ph.D.
 CDNA Library Preparation: M. Bento Soares, Ph.D.
 CDNA Library Arrayed by: Greg Lennon, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LNL at:
www.bio.linn.gov/bdrp/image/image.html

FEATURES
 SOURCE Trace considered overall poor quality
 Seq primer: -40ml3 fwd. ET from Amersham
 High quality sequence stop: 1.
 Location/Qualifiers
 1..19
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_image="1587278"
 /clone_lib="NCI_CGAP_GC4"
 /tissue_type="pooled germ cell tumors"
 /lab_host="DH10B"
 /note="Vector: pT773D-Pac (Pharmacia) with a modified
 polylinker; 1st strand cDNA was prepared from 3 pooled
 germ cell tumors, and was then primed with a Not I -
 oligo(dT) primer. Double-stranded cDNA was ligated to Eco
 RI adaptors (Pharmacia), digested with Not I and cloned
 into the Not I and Eco RI sites of the modified pT773
 vector. Library is normalized. Library was constructed by
 Bento Soares and M. Fatima Bonaldo."

BASE COUNT 2 a 0 c 7 g 10 t
 ORIGIN

Query Match 100.0%; Score 5; DB 9; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.2e+06;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 DB 3 GTATG 7

RESULT 10
 A1120725 19 bp mRNA linear EST 02-SEP-1998
 LOCUS ub72b11.r1 Soares.mammary.gland.NMLMG Mus musculus CDNA clone
 DEFINITION IMAGE:1383261 5' similar to TR:015009 015009 ORF, COMPLETE CDS. ;,
 mRNA sequence.
 ACCESSION A1120725 GI:3521049
 VERSION A1120725
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 19)
 Mairra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
 Giesel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
 Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
 Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
 Waterston,R.
 The Washu-HMI Mouse EST Project
 Unpublished (1996)
 CONTACT: Mairra M/Mouse EST Project
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800

TITLE
 JOURNAL
 COMMENT

Fax: 314 286 1810
 Email: mouseest@watson.wustl.edu
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lnl.gov) for further information.
 MGI:905729

Trace considered overall poor quality
 Possible reversed clone: similarity on wrong strand
 Seq primer: -28ml3 rev2 ET from Amersham
 High quality sequence stop: 1.
 Location/Qualifiers
 1..19
 /organism="Mus musculus"
 /db_xref="taxon:10090"
 /clone_image="1383261"
 /clone_lib="Soares.mammary.gland.NMLMG"
 /sex="Female (lactating)"
 /tissue_type="mammary gland"
 /lab_host="DH10B"
 /note="Vector: pT773D-Pac (Pharmacia) with a modified
 polylinker; 1st strand cDNA was prepared from mammary
 gland tissue from a lactating female, and was then primed
 with a Not I - oligo(dT) primer. Double-stranded cDNA was
 ligated to Eco RI adaptors (Pharmacia), digested with Not
 I and cloned into the Not I and Eco RI sites of the
 modified pT773 vector. Library is normalized. Library
 was constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 9 a 3 c 4 g 3 t
 ORIGIN

Query Match 100.0%; Score 5; DB 9; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.2e+06;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 DB 11 GTATG 7

RESULT 11
 A1747751 19 bp mRNA linear EST 22-JUN-1999
 LOCUS u121h05.x1 Sugano mouse embryo mewa Mus musculus CDNA clone
 DEFINITION IMAGE:2088249 3' similar to TR:P79101 P79101 CLEAVAGE AND
 POLYADENYLATION SPECIFICITY FACTOR PROTEIN. ;, mRNA sequence.
 ACCESSION A1747751 GI:5126015
 VERSION A1747751
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 19)
 Mairra,M., Hillier,L., Kucaba,T., Martin,J., Beck,C., Wylie,T.,
 Underwood,K., Steptoe,M., Theising,B., Allen,M., Bowers,Y., Person
 ,B., Swaller,T., Gibbons,M., Pape,D., Harvey,N., Schurk,R., Ritter
 ,E., Kohn,S., Shin,T., Jackson,Y., Cardenas,M., Mccann,R.,
 Waterston,R. and Wilson,R.
 The Washu-NCI Mouse EST Project 1999
 Unpublished (1999)
 CONTACT: Mairra M/Washu-NCI Mouse EST Project 1999
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: mouseest@watson.wustl.edu
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lnl.gov) for further information.
 MGI:995933

Trace considered overall poor quality
 Possible reversed clone: similarity on wrong strand
 Seq primer: custom primer used
 High quality sequence stop: 1.
 Location/Qualifiers

FEATURES

```

source
1. .19
/organism="Mus musculus"
/strain="C57BL"
/db_xref="taxon:10090"
/clone_lib="IMAGE:2088249"
/clone_lib="Sugano mouse embryo mewa"
/dev_stage="embryo, 14 dpc"
/label="DHI0B"
/note="Vector: PME18S-FL3; Site:1: DraIII (CACTGCTGTC);
Site:2: DraIII (CACCATGTC); 1st strand cDNA was primed
with an oligo(dT) primer [ATGTCCTCTTTTCTTTTCTTTT];
double-stranded cDNA was ligated to a DraIII adaptor
[TTTGGCTGCTGTC], digested and cloned into distinct DraIII
sites of the PME18S-FL3 vector (5' site CACTGCTGTC, 3' site
CACCATGTC). XhoI should be used to isolate the cDNA
insert. Size selection was performed to exclude fragments
<1.5kb. Library constructed by Dr. Sumio Sugano
(University of Tokyo Institute of Medical Science).
Custom primers for sequencing: 5' end primer
CTTTCCTCTTAAAGCTGCG and 3' end primer
CGACTGCTGCTGAGCACA."

BASE COUNT
6 a 2 c 8 g 3 t

Query Match
100.0%; Score 5; DB 9; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
13 GRATG 17

RESULT 12
LOCUS C00646 19 bp mRNA linear EST 23-JUL-1996
DEFINITION HMGSO008192 Human adult (K.Okubo) Homo sapiens cDNA, mRNA
sequence.
ACCESSION C00646
VERSION C00646.1 GI:1432876
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
1 (bases 1 to 19)
Okubo,K.
BodyMap: human gene expression database
Unpublished (1995)
Contact: Okubo,K.
Institute for Molecular and Cellular Biol
Osaka University
1-3, Yamada-oka, Suita, Osaka Pref. 565, Japan
Tel: 06-877-5111(ex 3315)
Email: kousaku@imcb.osaka-u.ac.jp
Human Gene Signature, 3'-directed cDNA sequence. We are not
submitting the same cDNA sequence redundantly to DDBJ since 1993.
For the abundance information of clones with this sequence in this
library and as well as in other 3'-directed libraries, see
http://www.imcb.osaka-u.ac.jp/bodymap/. The sequences of the clones
represented by this GS sequence is also found there.

FEATURES
source
1. .19
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="Human adult (K.Okubo)"
/dev_stage="adult"
/note="Organ: blood; Vector: 1-gt-11; Site:1: Eco-RI;
Monocytes were prepared from blood by ficoll-hypaque,
percoll and R cell rosetting purification steps (purity:
96 %). mRNA was prepared from activated monocytes from a
patient with rheumatoid arthritis. mRNA was reverse
transcribed with M-MLV. Using Eco-RI linkers cDNA was

```

```

BASE COUNT
4 a 1 c 8 g 6 t

Query Match
100.0%; Score 5; DB 14; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
14 GRATG 18

RESULT 13
LOCUS A2341880 19 bp DNA linear GSS 29-SEP-2000
DEFINITION IM0074004R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0074004 R, DNA sequence.
ACCESSION A2341880
VERSION A2341880
KEYWORDS A2341880.1 GI:10418570
SOURCE GSS.
ORGANISM house mouse.
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Rellily
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddu@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0074 row: 0 column: 04
Seq primer: CACACAGCAACACGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.

FEATURES
source
1. .19
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0074004"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42ny: Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (g114732114|g114732072.1), a copy-number
inducible derivative of plasmid RI. The vector was ligated
with adaptors complementary to the insert adaptors and

```

cloned into 1-gt-11 vector arms. The cDNA library was screened by differential hybridization using radioactively marked ss-cDNA from activated and non-activated monocytes.

purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN
4 a 4 c 6 g 5 t

Query Match
Best Local Similarity 100.0%; Score 5; DB 17; Length 19;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
11111
DB 8 GRATG 12

RESULT 14
AZ345849/c 19 bp DNA linear GSS 29-SEP-2000

LOCUS 1M0080D16R Mouse 10kb plasmid UUGCIM library Mus musculus genomic
DEFINITION clone UUGCIM0080D16 R, DNA sequence.

ACCESSION AZ345849
VERSION AZ345849.1 GI:10425086

KEYWORDS GSS.
SOURCE house mouse.

ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 19)

AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A. and Wright, D., Weis, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)

COMMENT Contact: Robert B. Weiss
University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA

Tel: 801 585 5606
Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0080 row: D column: 16

Seq primer: CACACAGCAACAGCTATGACC

Class: plasmid ends

High quality sequence stop: 19.

Location/Qualifiers

1. 19

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGCIM0080D16"

/clone_lib="Mouse 10kb plasmid UUGCIM library"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g114732114[9b]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and

purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN
9 a 4 c 0 g 6 t

Query Match
Best Local Similarity 100.0%; Score 5; DB 17; Length 19;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
11111
DB 13 GRATG 9

RESULT 15
AZ351195/c 19 bp DNA linear GSS 02-OCT-2000

LOCUS 1M0094G22R Mouse 10kb plasmid UUGCIM library Mus musculus genomic
DEFINITION clone UUGCIM0094G22 R, DNA sequence.

ACCESSION AZ351195
VERSION AZ351195.1 GI:10467355

KEYWORDS GSS.
SOURCE house mouse.

ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 19)

AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A. and Wright, D., Weis, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)

COMMENT Contact: Robert B. Weiss
University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA

Tel: 801 585 5606
Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0094 row: G column: 22

Seq primer: CACACAGCAACAGCTATGACC

Class: plasmid ends

High quality sequence stop: 19.

Location/Qualifiers

1. 19

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGCIM0094G22"

/clone_lib="Mouse 10kb plasmid UUGCIM library"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g114732114[9b]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and

purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT 7 a 7 c 3 g 2 t
ORIGIN

Query Match 100.0%; Score 5; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
Db 12 GTATG 8

Search completed: June 2, 2003, 20:35:43
Job time : 630.439 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:31:20 ; Search time 20.4878 Seconds

(without alignments)
74.844 Million cell updates/sec

Title: US-09-540-843-4

Perfect score: 5

Sequence: 1 gtag 5

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 558892

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents, NA.*
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq.*
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq.*
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq.*
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq.*
5: /cgn2_6/ptodata/1/ina/PCrus.COMB.seq.*
6: /cgn2_6/ptodata/1/ina/Backfile1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	5	100.0	5	US-08-855-372B-20	Sequence 20, Appl
2	5	100.0	5	US-09-048-927-4	Sequence 4, Appl
3	5	100.0	5	US-09-498-851-20	Sequence 20, Appl
4	5	100.0	7	US-08-615-170-10	Sequence 10, Appl
5	5	100.0	7	US-08-615-170-12	Sequence 12, Appl
6	5	100.0	7	US-09-048-927-3	Sequence 3, Appl
7	5	100.0	9	US-08-583-276-1	Sequence 8, Appl
8	5	100.0	9	US-08-646-789A-8	Sequence 8, Appl
9	5	100.0	9	US-08-646-789A-80	Sequence 8, Appl
10	5	100.0	9	US-09-048-927-1	Sequence 8, Appl
11	5	100.0	9	US-09-319-648-68	Sequence 1, Appl
12	5	100.0	10	US-08-335-565A-27	Sequence 68, Appl
13	5	100.0	10	US-08-250-951-1	Sequence 27, Appl
14	5	100.0	10	US-08-232-233-1	Sequence 1, Appl
15	5	100.0	10	US-08-232-233-1	Sequence 1, Appl
16	5	100.0	10	US-08-232-177A-422	Sequence 422, App
17	5	100.0	10	US-08-351-748-23	Sequence 23, Appl
18	5	100.0	10	US-08-202-927-25	Sequence 25, Appl
19	5	100.0	10	US-08-430-536A-23	Sequence 23, Appl
20	5	100.0	10	US-08-430-536A-25	Sequence 25, Appl
21	5	100.0	10	US-08-171-718-45	Sequence 45, Appl
22	5	100.0	10	US-08-703-601-1	Sequence 1, Appl
23	5	100.0	10	US-08-684-547-23	Sequence 1, Appl
24	5	100.0	10	US-08-684-547-25	Sequence 25, Appl
25	5	100.0	10	US-08-469-318-174	Sequence 23, Appl
26	5	100.0	10	US-08-468-609A-174	Sequence 174, App
27	5	100.0	10	US-08-478-087-45	Sequence 45, Appl

C 28	5	100.0	10	3	US-09-063-450-24	Sequence 24, Appl
C 29	5	100.0	10	3	US-09-063-450-33	Sequence 33, Appl
C 30	5	100.0	10	4	US-09-123-638-1	Sequence 1, Appl
C 31	5	100.0	10	4	US-08-646-695-30	Sequence 30, Appl
C 32	5	100.0	10	4	US-08-875-533-31	Sequence 31, Appl
C 33	5	100.0	10	4	US-08-446-872A-174	Sequence 174, App
C 34	5	100.0	10	4	US-09-724-753-1	Sequence 1, Appl
C 35	5	100.0	10	4	US-08-762-227A-174	Sequence 174, App
C 36	5	100.0	10	5	PCT-US92-09827-1	Sequence 1, Appl
C 37	5	100.0	10	5	PCT-US95-01185-174	Sequence 1, Appl
C 38	5	100.0	10	5	PCT-US95-02419-25	Sequence 25, Appl
C 39	5	100.0	10	5	PCT-US96-06053-30	Sequence 30, Appl
C 40	5	100.0	10	6	5198343-3	Sequence 19, Appl
C 41	5	100.0	11	1	US-08-401-512-19	Sequence 4, Appl
C 42	5	100.0	11	1	US-08-147-696E-4	Sequence 174, App
C 43	5	100.0	11	1	US-08-636-139-6	Sequence 6, Appl
C 44	5	100.0	11	1	US-08-484-334-4	Sequence 4, Appl
C 45	5	100.0	11	2	US-08-441-887A-82	Sequence 82, Appl

ALIGNMENTS

RESULT 1
US-08-855-372B-20
Sequence 20, Application US/08855372B

Patent No. 6090549

GENERAL INFORMATION:

APPLICANT: Mirzabekov, Andrei D

APPLICANT: Parinov, Sergei V

APPLICANT: Barsky, Victor E

APPLICANT: Kirillov, Eugene V

APPLICANT: Dubiley, Svetlana A

TITLE OF INVENTION: Use of Continuous/Contiguous Stacking Hybridization as a Di

NUMBER OF SEQUENCES: 88

CORRESPONDENCE ADDRESS:

ADDRESSEE: CHERSKOV & FLAYNIK

STREET: 20 N. Wacker Drive

CITY: Chicago

STATE: Illinois

COUNTRY: United States

ZIP: 60606

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.50 inch, 1.4 MB storage

COMPUTER: PC

OPERATING SYSTEM: Microsoft Windows 98

SOFTWARE: Wordperfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/855,372B

FILING DATE: 13-MAY-97

PRIOR APPLICATION DATA:

APPLICATION NUMBER: U.S. 08/587,332

FILING DATE: 16-JAN-96

ATTORNEY/AGENT INFORMATION:

NAME: Cherskov, Michael J.

REGISTRATION NUMBER: 33,664

REFERENCE/DOCKET NUMBER: ANL-IN-95-027

TELECOMMUNICATION INFORMATION:

TELEPHONE: (312) 621-1330

TELEFAX: (312) 621-0088

INFORMATION FOR SEQ ID NO: 20:

SEQUENCE CHARACTERISTICS:

LENGTH: 5 bases

TYPE: nucleic acid

STRANDEDNESS: No. 6090549 Applicable

MOLECULE TYPE: Genomic DNA

TOPOLOGY: linear

HYPOTHETICAL: yes

US-08-855-372B-20

Query Match

Best local Similarity 100.0%; Score 5; DB 3; Length 5;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 1 GTATG 5

RESULT 2
US-09-048-927-4
; Sequence 4, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Yaar, Mina
; APPLICANT: Eller, Mark
; TITLE OF INVENTION: Use of Locally Applied DNA Fragments
; FILE REFERENCE: BU94-68A2
; CURRENT APPLICATION NUMBER: US/09/048,927
; CURRENT FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952,697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467,012
; EARLIER FILING DATE: 1995-06-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 5
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA Fragment
US-09-048-927-4

Query Match 100.0%; Score 5; DB 3; Length 5;
Best Local Similarity 100.0%; Pred. No. 5.8e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 1 GTATG 5

RESULT 3
US-09-498-851-20
; Sequence 20, Application US/09498851
; Patent No. 6440671
; GENERAL INFORMATION:
; APPLICANT: Mirzabekov, Andrei D
; APPLICANT: Parinov, Sergei V
; APPLICANT: Barsky, Victor E
; APPLICANT: Kirillov, Eugene V
; APPLICANT: Dubiley, Svetlana A
; TITLE OF INVENTION: Use of Continuous/Contiguous
; TITLE OF INVENTION: Stacking Hybridization as a Diagnostic Tool.
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CHERSKOV & PLAYNIK
; STREET: 20 N. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.50 inch, 1.4 MB storage
; COMPUTER: PC
; OPERATING SYSTEM: Microsoft Windows 98
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/498,851
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/855,372
; FILING DATE: 13-MAY-97
; APPLICATION NUMBER: U.S. 08/587,332

FILING DATE: 16-JAN-96
; ATTORNEY/AGENT INFORMATION:
; NAME: Cherskov, Michael J.
; REGISTRATION NUMBER: 33,664
; REFERENCE/DOCKET NUMBER: ANL-IN-95-027
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 621-1330
; TELEFAX: (312) 621-0088
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 5 bases
; TYPE: nucleic acid
; STRANDEDNESS: No. 6440671 Applicable
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; HYPOTHETICAL: yes
US-09-498-851-20

Query Match 100.0%; Score 5; DB 4; Length 5;
Best Local Similarity 100.0%; Pred. No. 5.8e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 1 GTATG 5

RESULT 4
US-08-615-170-10/c
; Sequence 10, Application US/08615170
; Patent No. 576776
; GENERAL INFORMATION:
; APPLICANT: ORDAHL, Charles P.
; APPLICANT: AZAKIE, Anthony
; APPLICANT: MAR, Janet H.
; APPLICANT: FARRANCE, Iain K.G.
; APPLICANT: HALL, Deborah E.
; APPLICANT: STEWART, Alexandre F.R.
; TITLE OF INVENTION: DTEF-1 ISOFORMS AND USES THEREOF
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourile and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/615,170
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/01526
; FILING DATE: 06-FEB-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/191,493
; FILING DATE: 04-FEB-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Heslin, James M.
; REGISTRATION NUMBER: 29,541
; REFERENCE/DOCKET NUMBER: 2307U-053120
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 326-2400
; TELEFAX: (415) 326-2422
; INFORMATION FOR SEQ ID NO: 10:

```
SEQUENCE CHARACTERISTICS:
LENGTH: 7 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..7
OTHER INFORMATION: /standard_name="Sph-II binding"
US-08-615-170-10

Query Match
Best Local Similarity 100.0%; Score 5; DB 1; Length 7;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
DB 5 GTATG 1

RESULT 5
US-08-615-170-12/c
Sequence 12, Application US/08615170
Patent No. 5776776
GENERAL INFORMATION:
APPLICANT: ORDAHL, Charles P.
APPLICANT: AZAKIE, Anthony
APPLICANT: MAR, Janet H.
APPLICANT: FARRANCE, Iain K.G.
APPLICANT: HALL, Deborah E.
APPLICANT: STEWART, Alexandre F.R.
APPLICANT: LARKIN, Sarah B.
TITLE OF INVENTION: DTEF-1 ISOFORMS AND USES THEREOF
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Hourie and Crew
STREET: Stewart Street Tower, One Market Plaza
CITY: San Francisco
STATE: California
COUNTRY: US
ZIP: 94105-1493
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/615.170
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/01526
FILING DATE: 06-FEB-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/191,493
FILING DATE: 04-FEB-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Heslin, James M.
REGISTRATION NUMBER: 29,541
REFERENCE/DOCKET NUMBER: 2307U-053120
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 7 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
```

```
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..7
OTHER INFORMATION: /standard_name="Rat beta-Myosin"
US-08-615-170-12

Query Match
Best Local Similarity 100.0%; Score 5; DB 1; Length 7;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
DB 5 GTATG 1

RESULT 6
US-09-048-927-3
Sequence 3, Application US/09048927
Patent No. 6147056
GENERAL INFORMATION:
APPLICANT: Gilchrist, Barbara A.
APPLICANT: Yaar, Mina
APPLICANT: Eller, Mark
TITLE OF INVENTION: Use of Locally Applied DNA Fragments
FILE REFERENCE: BU94-68A2
CURRENT APPLICATION NUMBER: US/09/048,927
CURRENT FILING DATE: 1998-03-26
EARLIER APPLICATION NUMBER: 08/952,697
EARLIER FILING DATE: 1996-06-03
EARLIER APPLICATION NUMBER: 08/467,012
EARLIER FILING DATE: 1995-06-06
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 3
LENGTH: 7
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: DNA Fragment
US-09-048-927-3

Query Match
Best Local Similarity 100.0%; Score 5; DB 3; Length 7;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
DB 2 GTATG 6

RESULT 7
US-08-583-276-1
Sequence 1, Application US/08583276
Patent No. 5837536
GENERAL INFORMATION:
APPLICANT: McDonagh, Kevin T.
APPLICANT: Nienhuis, Arthur
APPLICANT: Tolstoshev, Paul
TITLE OF INVENTION: IMPROVED EXPRESSION OF HUMAN
TITLE OF INVENTION: MULTIDRUG RESISTANCE GENES AND IMPROVED
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carella, Byrne, Bain, Gillilan,
STREET: 6 Becker Farm Road
CITY: Roseland
STATE: New Jersey
COUNTRY: USA
ZIP: 07068
COMPUTER READABLE FORM:
```

MEDIUM TYPE: 3.5 Inch diskette
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: DM4.V2
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/583,276
FILING DATE: 05-JAN-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/332,444
FILING DATE: 31-OCT-1994
APPLICATION NUMBER: 07/887,712
FILING DATE: 22-MAY-1992
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 bases
TYPE: nucleic acid
STRANDEDNESS: singular
TOPOLOGY: linear
MOLECULE TYPE:
DESCRIPTION: Genomic DNA
US-08-583-276-1

Query Match 100.0%; Score 5; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 4 GTATG 8

RESULT 8
US-08-646-789A-8
Sequence 8, Application US/08646789A
Patent No. 6022863
GENERAL INFORMATION:
APPLICANT: Peyman, John A.
TITLE OF INVENTION: REGULATION OF GENE EXPRESSION
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: PENNIE & EDMONDS
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/646,789A
FILING DATE: May 21, 1996
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 6523-006
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-646-789A-8

Query Match 100.0%; Score 5; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 1 GTATG 5

RESULT 9
US-08-646-789A-80
Sequence 80, Application US/08646789A
Patent No. 6022863
GENERAL INFORMATION:
APPLICANT: Peyman, John A.
TITLE OF INVENTION: REGULATION OF GENE EXPRESSION
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: PENNIE & EDMONDS
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/646,789A
FILING DATE: May 21, 1996
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 6523-006
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 80:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-646-789A-80

Query Match 100.0%; Score 5; DB 3; Length 9;
Best Local Similarity 60.0%; Pred. No. 3.2e+07;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|:|:|
DB 1 GUADG 5

RESULT 10
US-09-048-927-1
Sequence 1, Application US/09048927
Patent No. 6147056
GENERAL INFORMATION:
APPLICANT: Glitchest, Barbara A.
APPLICANT: Yaer, Mina
TITLE OF INVENTION: Use of Locally Applied DNA Fragments
FILE REFERENCE: BU94-68A2
CURRENT APPLICATION NUMBER: US/09/048,927
CURRENT FILING DATE: 1998-03-26
EARLIER APPLICATION NUMBER: 08/952,697
EARLIER FILING DATE: 1996-06-03

EARLIER APPLICATION NUMBER: 08/467,012
EARLIER FILING DATE: 1995-06-06
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 1
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: DNA Fragment
US-09-048-927-1

Query Match 100.0%; Score 5; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
|||||
DB 3 GRATG 7

RESULT 11
US-09-319-648-68/c
Sequence 68, Application US/09319648
Patent No. 6451350
GENERAL INFORMATION:
APPLICANT: Hawkins, Mary
TITLE OF INVENTION: Fluorescent Nucleotide Analog Hairpin
FORMATION FOR DETECTION OF NUCLEIC ACID HYBRIDIZATION
NUMBER OF SEQUENCES: 68
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/319,648
FILING DATE: 30-Jul-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/032,844
FILING DATE: 13-DEC-1996
APPLICATION NUMBER: WO PCT/US97/22448
FILING DATE: 10-DEC-1997
ATTORNEY/AGENT INFORMATION:
NAME: Fang, Carol
REGISTRATION NUMBER: 48,631
REFERENCE/DOCKET NUMBER: 015280-288100US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 68:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 68:
US-09-319-648-68

Query Match 100.0%; Score 5; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GRATG 5

DB 7 GRATG 3
|||||

RESULT 12
US-08-335-565A-27
Sequence 27, Application US/08335565A
Patent No. 5527671
GENERAL INFORMATION:
APPLICANT: Li, Kenng
APPLICANT: Rouse, Douglas I.
APPLICANT: German, Thomas L.
TITLE OF INVENTION: ASSAY FOR VERTICILLIUM DAHLIAE
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Quarles and Brady
STREET: 1 South Pinckney St., PO BOX 2113
CITY: Madison
STATE: WI
COUNTRY: USA
ZIP: 53701-2113
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/335,565A
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Seay, Nicholas J.
REGISTRATION NUMBER: 27,386
REFERENCE/DOCKET NUMBER: 960296.93065
TELECOMMUNICATION INFORMATION:
TELEPHONE: 608-251-9166
TELEFAX: 608-251-5000
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-335-565A-27

Query Match 100.0%; Score 5; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.1e+04;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
|||||
DB 6 GRATG 10

RESULT 13
US-08-250-951-1/c
Sequence 1, Application US/08250951
Patent No. 5532128
GENERAL INFORMATION:
APPLICANT: Heller, Michael J.
TITLE OF INVENTION: SELF-ORGANIZING MOLECULAR PHOTONIC
STRUCTURES BASED ON CHROMOPHORE- AND FLUOROPHORE-CONTAINING
POLYNUCLEOTIDES AND METHODS OF THEIR USE
NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESS:
ADDRESSEE: Bingham & Fitting
STREET: 12526 High Bluff Drive, Suite 300
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92130
COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/250,951
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/790,262
FILING DATE: 07-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: Fitting, Thomas
REGISTRATION NUMBER: 34,163
REFERENCE/DOCKET NUMBER: HEL0002P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-792-3680
TELEFAX: 619-792-8477
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc_feature
LOCATION: 10
OTHER INFORMATION: /note="Donor chromophore at the 3'
US-08-250-951-1

Query Match 100.0%; Score 5; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.1e+04;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
DB 8 GTATG 4

RESULT 14
US-08-232-233-1/C
Sequence 1, Application US/08232233
Patent No. 5565332
GENERAL INFORMATION:
APPLICANT: Michael J. Heller
TITLE OF INVENTION: SELF-ORGANIZING MOLECULAR PHOTONIC
STRUCTURES BASED ON CHROMOPHORE- AND FLUOROPHORE-
CONTAINING POLYNUCLEOTIDES AND METHODS OF THEIR USE
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
SOFTWARE: Wordperfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/232,233
FILING DATE: May 4, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/790,262
FILING DATE: No. 5565322ember 7, 1992
ATTORNEY/AGENT INFORMATION:

NAME: Murphy, David B.
REGISTRATION NUMBER: 31,125
REFERENCE/DOCKET NUMBER: 207/170
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc_feature
LOCATION: 10
OTHER INFORMATION: /note="Donor chromophore at the 3' T nucleotide"
US-08-232-233-1

Query Match 100.0%; Score 5; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.1e+04;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
DB 8 GTATG 4

RESULT 15
US-08-222-177A-422/C
Sequence 422, Application US/08222177A
Patent No. 5582979
GENERAL INFORMATION:
APPLICANT: Weber, James L.
TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
(dc-da)n.(dg-dt)n SEQUENCES AND METHODS OF USING SAME
NUMBER OF SEQUENCES: 460
CORRESPONDENCE ADDRESS:
ADDRESSEE: Demilt Ross & Stevens, S.C.
STREET: 8000 Excelsior Drive, Suite 401
CITY: Madison
STATE: Wisconsin
COUNTRY: USA
ZIP: 53717-1914
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/222,177A
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/341,562
FILING DATE: 21-APR-1989
ATTORNEY/AGENT INFORMATION:
NAME: Sara, Charles S.
REGISTRATION NUMBER: 30,492
REFERENCE/DOCKET NUMBER: 09865,601
TELECOMMUNICATION INFORMATION:
TELEPHONE: (608) 831-2100
TELEFAX: (608) 831-2106
TELEX:
INFORMATION FOR SEQ ID NO: 422:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear

; MOLECULE TYPE: DNA (genomic)
US-08-222-177A-422

Query Match 100.0%; Score 5; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.1e+04;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
Db 8 GTATG 4

Search completed: June 2, 2003, 20:38:34
Job time : 21.4878 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 19:09:45 ; Search time 35.4878 Seconds
(without alignments)
189.976 Million cell updates/sec

Title: US-09-540-843-4
Perfect score: 5
Sequence: 1 gtag 5

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 845702 seqs, 674182571 residues

Total number of hits satisfying chosen parameters: 477662

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_NA:*

1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/2/pubpna/PCT_NEW_PUB.seq:*
3: /cgn2_6/ptodata/2/pubpna/US06_NEW_PUB.seq:*
4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
5: /cgn2_6/ptodata/2/pubpna/US07_NEW_PUB.seq:*
6: /cgn2_6/ptodata/2/pubpna/PCTUS_PUBCOMB.seq:*
7: /cgn2_6/ptodata/2/pubpna/US08_NEW_PUB.seq:*
8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq:*
10: /cgn2_6/ptodata/2/pubpna/US09_PUBCOMB.seq:*
11: /cgn2_6/ptodata/2/pubpna/US10_NEW_PUB.seq:*
12: /cgn2_6/ptodata/2/pubpna/US10_PUBCOMB.seq:*
13: /cgn2_6/ptodata/2/pubpna/US60_NEW_PUB.seq:*
14: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	5	100.0	5	9	US-10-122-630-4
2	5	100.0	5	9	US-10-122-630-6
3	5	100.0	5	9	US-10-122-633-4
4	5	100.0	5	9	US-10-122-633-6
5	5	100.0	7	9	US-10-122-630-3
6	5	100.0	7	9	US-10-122-630-7
7	5	100.0	7	9	US-10-122-633-3
8	5	100.0	7	9	US-10-122-633-7
9	5	100.0	8	10	US-09-142-593-11
10	5	100.0	8	10	US-09-127-886-17
11	5	100.0	8	10	US-09-861-014-6
12	5	100.0	9	9	US-10-122-630-1
13	5	100.0	9	9	US-10-122-633-1
14	5	100.0	9	9	US-10-096-596-32
15	5	100.0	9	9	US-09-990-186-623
16	5	100.0	9	9	US-09-990-186-623
17	5	100.0	9	9	US-09-990-186-2256
18	5	100.0	9	10	US-09-989-789-623
19	5	100.0	9	10	US-09-989-789-2220

20	5	100.0	9	10	US-09-989-789-2256	Sequence 2256, Ap
21	5	100.0	10	9	US-10-006-542B-5	Sequence 5, Appl1
22	5	100.0	10	9	US-09-962-602-7	Sequence 7, Appl1
23	5	100.0	10	9	US-09-962-602-8	Sequence 8, Appl1
24	5	100.0	10	9	US-09-990-186-622	Sequence 622, App
25	5	100.0	10	9	US-09-990-186-636	Sequence 636, App
26	5	100.0	10	9	US-09-990-186-1338	Sequence 1338, Ap
27	5	100.0	10	9	US-09-990-186-1341	Sequence 1341, Ap
28	5	100.0	10	9	US-09-990-186-1342	Sequence 1342, Ap
29	5	100.0	10	9	US-09-990-186-1343	Sequence 1343, Ap
30	5	100.0	10	10	US-09-822-250-16	Sequence 16, Appl
31	5	100.0	10	10	US-09-398-389-31	Sequence 31, Appl
32	5	100.0	10	10	US-09-989-789-622	Sequence 622, App
33	5	100.0	10	10	US-09-989-789-636	Sequence 636, App
34	5	100.0	10	10	US-09-989-789-1338	Sequence 1338, App
35	5	100.0	10	10	US-09-989-789-1341	Sequence 1341, Ap
36	5	100.0	10	10	US-09-989-789-1342	Sequence 1342, Ap
37	5	100.0	10	10	US-09-989-789-1343	Sequence 1343, Ap
38	5	100.0	10	10	US-09-899-381-31	Sequence 31, Appl
39	5	100.0	10	12	US-10-033-145-2	Sequence 2, Appl1
40	5	100.0	10	12	US-10-033-145-313	Sequence 313, App
41	5	100.0	10	12	US-10-033-145-549	Sequence 549, App
42	5	100.0	10	12	US-10-033-145-723	Sequence 723, App
43	5	100.0	10	12	US-10-033-145-766	Sequence 766, App
44	5	100.0	10	12	US-10-033-145-824	Sequence 824, App
45	5	100.0	10	12	US-10-033-145-979	Sequence 979, App

ALIGNMENTS

RESULT 1
US-10-122-630-4
Sequence 4, Application US/10122630
Publication No. US20030032610A1
GENERAL INFORMATION:
APPLICANT: Glitchest, Barbara A.
APPLICANT: Yaar, Mina
TITLE OF INVENTION: Method to inhibit Cell Growth using
FILE REFERENCE: 0054.1088-018
CURRENT APPLICATION NUMBER: US/10/122,630
PRIOR FILING DATE: 2002-04-12
PRIOR APPLICATION NUMBER: US 08/467,012
PRIOR FILING DATE: 1995-06-06
PRIOR APPLICATION NUMBER: PCT/US96/08386
PRIOR FILING DATE: 1996-06-03
PRIOR APPLICATION NUMBER: US 09/048,927
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: US 09/540,843
PRIOR FILING DATE: 2000-03-31
PRIOR APPLICATION NUMBER: PCT/US01/10162
PRIOR FILING DATE: 2001-03-30
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 4
LENGTH: 5
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-4

Query Match 100.0%; Score 5; DB 9; Length 5;
Best Local Similarity 100.0%; Pred. No. 2.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGG 5
DB 1 GTAGG 5

```
RESULT 2
US-10-122-630-6/c
; Sequence 6, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to inhibit cell growth using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 5
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-6
```

```
Query Match          100.0%; Score 5; DB 9; Length 5;
Best Local Similarity 100.0%; Pred. No. 2.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 GTATG 5
    |||||
Db 5 GTATG 1
```

```
RESULT 3
US-10-122-633-4
; Sequence 4, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to inhibit cell growth using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 5
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-4
```

```
Query Match          100.0%; Score 5; DB 9; Length 5;
Best Local Similarity 100.0%; Pred. No. 2.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 GTATG 5
    |||||
Db 1 GTATG 5
```

```
RESULT 4
US-10-122-633-6/c
; Sequence 6, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to inhibit cell growth using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 5
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-6
```

```
Query Match          100.0%; Score 5; DB 9; Length 5;
Best Local Similarity 100.0%; Pred. No. 2.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 GTATG 5
    |||||
Db 5 GTATG 1
```

```
RESULT 5
US-10-122-630-3
; Sequence 3, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to inhibit cell growth using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-3
```

Query Match 100.0%; Score 5; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 2 GTATG 6

RESULT 6

US-10-122-630-7
; Sequence 7, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-7

Query Match 100.0%; Score 5; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 2 GTATG 6

RESULT 7

US-10-122-633-3
; Sequence 3, Application US/10122633
; Publication No. US2003003611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 7

TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-3

Query Match 100.0%; Score 5; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 2 GTATG 6

RESULT 8

US-10-122-633-7
; Sequence 7, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-7

Query Match 100.0%; Score 5; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 2 GTATG 6

RESULT 9

US-09-142-593-11/C
; Sequence 11, Application US/09142593
; Patent No. US20020016975A1
; GENERAL INFORMATION:
; APPLICANT: HACKETT ET AL.
; TITLE OF INVENTION: DNA-BASED TRANSPOSON SYSTEM FOR THE
; NUMBER OF SEQUENCES: 63
; CORRESPONDENCE ADDRESS:
; ADDRESS: MUEITING, RAASCH & GEBHARDT, P.A.
; STREET: 119 NORTH FOURTH STREET, SUITE 203
; CITY: MINNEAPOLIS
; STATE: MINNESOTA
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/142,593
FILING DATE: 10-SEP-1998
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/040,664
FILING DATE: 11-MAR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/053,868
FILING DATE: 28-JUL-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/065,303
FILING DATE: 13-NOV-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US98/04687
FILING DATE: 11-MAR-1998
ATTORNEY/AGENT INFORMATION:
NAME: SANDBERG, VICTORIA A.
REGISTRATION NUMBER: 41,287
REFERENCE/DOCKET NUMBER: 110.00450101
TELEPHONE: 612-305-1226
TELEFAX: 612-305-1228
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-142-593-11

Query Match 100.0%; Score 5; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
|||||
Db 6 GRATG 2

RESULT 10
US-09-927-886-17/c
Sequence 17, Application US/09927886
Patent No. US20020103152A1
GENERAL INFORMATION:
APPLICANT: Kay, Mark A.
APPLICANT: Yant, Stephen
TITLE OF INVENTION: Methods of In Vivo Gene Transfer Using a
FILE REFERENCE: STAN-160CIP
CURRENT APPLICATION NUMBER: US/09/927,886
CURRENT FILING DATE: 2001-08-10
PRIOR FILING DATE: 1999-10-28
PRIOR APPLICATION NUMBER: 60/162,279
PRIOR FILING DATE: 1999-11-17
PRIOR APPLICATION NUMBER: 09/440,301
NUMBER OF SEQ ID NOS: 19
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 17
LENGTH: 8
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: transposon repeat sequence
US-09-927-886-17

Query Match 100.0%; Score 5; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
|||||
Db 6 GRATG 2

RESULT 11
US-09-861-014-6/c
Sequence 6, Application US/09861014
Patent No. US20020115216A1
GENERAL INFORMATION:
APPLICANT: Steer, Clifford
APPLICANT: Kren, Betsy
APPLICANT: Lindehan-Stleers, Cheryl
APPLICANT: McIvor, R.
APPLICANT: Hackett, Perry
TITLE OF INVENTION: Composition for Delivery of Compounds to Cells
FILE REFERENCE: 110.01330101
CURRENT APPLICATION NUMBER: US/09/861,014
CURRENT FILING DATE: 2001-05-19
PRIOR APPLICATION NUMBER: US 60/206,002
PRIOR FILING DATE: 2000-05-19
PRIOR APPLICATION NUMBER: US 60/285,121
PRIOR FILING DATE: 2001-04-20
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn version 3.0
SEQ ID NO 6
LENGTH: 8
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Direct repeat sequence
US-09-861-014-6

Query Match 100.0%; Score 5; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
|||||
Db 6 GRATG 2

RESULT 12
US-10-122-630-1
Sequence 1, Application US/10122630
Publication No. US20030032610A1
GENERAL INFORMATION:
APPLICANT: Ellert, Mark S.
APPLICANT: Yaar, Mina
TITLE OF INVENTION: Method to Inhibit Cell Growth Using
FILE REFERENCE: 0054.1088-018
CURRENT APPLICATION NUMBER: US/10/122,630
CURRENT FILING DATE: 2002-04-12
PRIOR APPLICATION NUMBER: US 08/467,012
PRIOR FILING DATE: 1995-06-06
PRIOR APPLICATION NUMBER: PCT/US96/08386
PRIOR FILING DATE: 1996-06-03
PRIOR APPLICATION NUMBER: US 09/048,927
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: US 09/540,843
PRIOR FILING DATE: 2000-03-31
PRIOR APPLICATION NUMBER: PCT/US01/10162
PRIOR FILING DATE: 2001-03-30
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 1
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-1

Query Match 100.0%; Score 5; DB 9; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
|||||
Db 3 GRATG 7

RESULT 13

US-10-122-633-1
; Sequence 1, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054,1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-1

Query Match 100.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
|||||
Db 3 GRATG 7

RESULT 14

US-10-096-596-32/c
; Sequence 32, Application US/10096596
; Publication No. US20030049653A1
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth W
; APPLICANT: Vogelstein, Bert
; APPLICANT: Velculescu, Victor
; APPLICANT: Zhang, Lin
; TITLE OF INVENTION: METHOD FOR SERIAL ANALYSIS OF GENE EXPRESSION
; FILE REFERENCE: 001107,00242
; CURRENT APPLICATION NUMBER: US/10/096,596
; PRIOR FILING DATE: 2002-03-14
; PRIOR APPLICATION NUMBER: US 08/527,154
; PRIOR FILING DATE: 1995-09-12
; PRIOR APPLICATION NUMBER: US 08/544,861
; PRIOR FILING DATE: 1995-10-18
; PRIOR APPLICATION NUMBER: US 09/107,228
; PRIOR FILING DATE: 1998-06-30
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 32
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-096-596-32

Query Match 100.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
|||||
Db 7 GRATG 3

RESULT 15

US-09-990-186-623/c
; Sequence 623, Application US/09990186
; Publication No. US20030068675A1
; GENERAL INFORMATION:
; APPLICANT: Liu, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; FILE REFERENCE: 8325-0011.21 / S11-US3
; CURRENT APPLICATION NUMBER: US/09/990,186
; PRIOR FILING DATE: 2001-11-20
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 623
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
US-09-990-186-623

Query Match 100.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
|||||
Db 6 GRATG 2

Search completed: June 2, 2003, 23:43:13
Job time : 35.4878 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:06:10 ; Search time 318.073 Seconds

(without alignments)
823.475 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 taggaagat 9

Scoring table: IDENTITY-NUC
Gapop 10.0 , Gapext 1.0

Searched: 2054640 segs, 14551402878 residues

Total number of hits satisfying chosen parameters: 774614

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

1: gb_da:*
2: gb_hcg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vt:*
15: em_da:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vt:*
30: em_hcg_hum:*
31: em_hcg_inv:*
32: em_hcg_other:*
33: em_hcg_mus:*
34: em_hcg_pin:*
35: em_hcg_rod:*
36: em_hcg_mam:*
37: em_hcg_vrt:*
38: em_sy:*
39: em_hcg_hum:*
40: em_hcg_mus:*
41: em_hcg_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	9	100.0	9	6 AX268754	AX268754 Sequence
2	9	100.0	16	6 AX419832	AX419832 Sequence
3	9	100.0	20	6 A39511	AX419832 Sequence
4	9	100.0	20	6 AR166936	A39511 Sequence
5	9	100.0	20	6 AX298850	AR166936 Sequence
6	9	100.0	20	6 AX327004	AX298850 Sequence
7	9	100.0	20	12 AB069488	AX327004 Sequence
8	9	100.0	22	6 E55148	AB069488 Synthetic
9	9	100.0	23	6 E36547	E55148 Method for
10	9	100.0	23	6 E40169	E36547 Method of
11	9	100.0	23	11 D0GC00506A	E40169 Genetic dia
12	9	100.0	24	6 AR135197	L77541 Canis fam11
13	9	100.0	24	6 AR146693	AR135197 Sequence
14	9	100.0	24	6 AR152264	AR146693 Sequence
15	9	100.0	24	6 AR157802	AR152264 Sequence
16	9	100.0	26	6 AX477111	AR157802 Sequence
17	9	100.0	27	6 A94623	AX477111 Sequence
18	9	100.0	27	6 AX017661	A94623 Sequence
19	9	100.0	28	6 AR143009	AX017661 Sequence
20	9	100.0	29	6 I55832	AR143009 Sequence
21	9	100.0	30	6 AX286793	I55832 Sequence
22	9	100.0	36	6 AX044051	AX286793 Sequence
23	9	100.0	36	6 AX044105	AX044051 Sequence
24	9	100.0	36	6 AX044153	AX044105 Sequence
25	9	100.0	37	6 A08117	AX044153 Sequence
26	9	100.0	39	6 E36735	A08117 pTG2416 DNA
27	9	100.0	40	6 AX147669	E36735 Novel DNA P
28	8	88.9	12	6 AR105116	AX147669 Sequence
29	8	88.9	15	6 AR033402	AR105116 Sequence
30	8	88.9	15	6 AR033403	AR033402 Sequence
31	8	88.9	15	6 AR108949	AR033403 Sequence
32	8	88.9	15	6 AR113224	AR108949 Sequence
33	8	88.9	15	6 BD005791	AR113224 Sequence
34	8	88.9	15	6 BD005791	BD005791 Novel pro
35	8	88.9	15	6 I57631	I57631 Sequence
36	8	88.9	15	6 A03756	I57631 Sequence
37	8	88.9	16	6 A15048	A03756 Nucleotide
38	8	88.9	16	6 A22501	A15048 Nucleotide
39	8	88.9	16	6 A30883	A22501 Oligonucleo
40	8	88.9	16	6 A89421	A30883 Synthetic h
41	8	88.9	16	6 AR035160	A89421 Sequence
42	8	88.9	16	6 AX419833	AR035160 Sequence
43	8	88.9	16	6 AX419834	AX419833 Sequence
44	8	88.9	16	6 AX419834	AX419834 Sequence
45	8	88.9	16	6 AX419835	AX419835 Sequence

ALIGNMENTS

RESULT 1
AX268754
LOCUS AX268754
DEFINITION Sequence 2 from Patent WO0174342.
ACCESSION AX268754
VERSION AX268754.1 GI:16541826
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Gilchrist, B.A., Yaar, M. and Eller, M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 2 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)

9 bp DNA linear PAT 29-OCT-2001

```

FEATURES
  source
    Location/Qualifiers
      1..9
      /organism="synthetic construct"
      /db_xref="taxon:32630"
      /note="Synthetic DNA Fragment"
BASE COUNT      3 a      0 c      4 g      2 t
ORIGIN

Query Match
  Best Local Similarity 100.0%; Score 9; DB 6; Length 9;
  Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TAGGAGGAT 9
        |||||
        1 TAGGAGGAT 9
Db

RESULT 2
AX419832/c      16 bp      DNA      linear      PAT 18-JUN-2002
LOCUS
DEFINITION      Sequence 169 from Patent WO0198537.
ACCESSION      AX419832
VERSION      AX419832.1 GI:21524199
KEYWORDS
SOURCE      synthetic construct.
ORGANISM      artificial sequences.
REFERENCE
  1 Lyamchev,V., Allawi,H., Dong,F., Nerl,B.P. and Vener,I.T.
  Nucleic acid accessible hybridization sites
  Patent: WO 0198537-A 169 27-DEC-2001;
  THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
  source
    1..16
    /organism="synthetic construct"
    /db_xref="taxon:32630"
BASE COUNT      5 a      7 c      0 g      4 t
ORIGIN

Query Match
  Best Local Similarity 100.0%; Score 9; DB 6; Length 16;
  Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TAGGAGGAT 9
        |||||
        12 TAGGAGGAT 4
Db

RESULT 3
A39511
LOCUS
DEFINITION      Sequence 6 from Patent EP0614980.
ACCESSION      A39511
VERSION      A39511.1 GI:2295829
KEYWORDS
SOURCE      unidentified.
ORGANISM      unidentified.
REFERENCE
  1 (bases 1 to 20)
  Mehrali,M. and Sorg,T.
  TAT transdominant variants from human Immunodeficiency virus
  Patent: EP 0614980-A 6 14-SEP-1994;
  TRANSGENE SA (FR)
  Other publication CA 2112652 940705
  Other publication JP 6234791 940823
  Other publication AU 5280393 940714
  Other publication AU 668441 960502
  Other publication FR 2700169 940708.
  Location/Qualifiers
    1..20
    /organism="unidentified"
    /db_xref="taxon:32644"
BASE COUNT      6 a      4 c      7 g      3 t

```

```

ORIGIN

Query Match
  Best Local Similarity 100.0%; Score 9; DB 6; Length 20;
  Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TAGGAGGAT 9
        |||||
        5 TAGGAGGAT 13
Db

RESULT 4
ARI66936
LOCUS
DEFINITION      Sequence 6 from patent US 6284252.
ACCESSION      ARI66936
VERSION      ARI66936.1 GI:16243331
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE
  1 (bases 1 to 20)
  Mehrali,M. and Sorg,T.
  Transdominant TAT variants of the human Immunodeficiency virus
  Patent: US 6284252-A 6 04-SEP-2001;
  Location/Qualifiers
    1..20
    /organism="unknown"
BASE COUNT      6 a      4 c      7 g      3 t
ORIGIN

Query Match
  Best Local Similarity 100.0%; Score 9; DB 6; Length 20;
  Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TAGGAGGAT 9
        |||||
        5 TAGGAGGAT 13
Db

RESULT 5
AX298850/c      20 bp      DNA      linear      PAT 26-NOV-2001
LOCUS
DEFINITION      Sequence 484 from Patent WO0183749.
ACCESSION      AX298850
VERSION      AX298850.1 GI:17128840
KEYWORDS
SOURCE      Mus sp.
ORGANISM      Mus sp.
REFERENCE
  1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
  Bachmanov,A.A., Beauchamp,G.K., Chatterjee,A., de Jong,P.J., Li,S.,
  Li,X., Ohmen,J.D., Reed,D.R., Ross,D. and Tordoff,M.G.
  Gene and sequence variation associated with sensing carbohydrate
  compounds and other sweeteners
  Patent: WO 0183749-A 484 08-NOV-2001;
  WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center
  (US)
FEATURES
  source
    Location/Qualifiers
      1..20
      /organism="Mus sp."
      /db_xref="taxon:10095"
BASE COUNT      3 a      7 c      4 g      6 t
ORIGIN

Query Match
  Best Local Similarity 100.0%; Score 9; DB 6; Length 20;
  Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TAGGAGGAT 9
        |||||
        17 TAGGAGGAT 9
Db

```



```

RESULT 6
LOCUS AX327004/c 20 bp DNA linear PAT 07-JAN-2002
DEFINITION Sequence 200 from Patent WO/18894.
ACCESSION AX327004
VERSION AX327004.1 GI:18097715
KEYWORDS
SOURCE synthetic construct.
ORGANISM artificial construct.
REFERENCE
1 Keith, T.
AUTHORS Novel human gene relating to respiratory diseases, obesity, and
TITLE inflammatory bowel disease
JOURNAL Patent: WO 0178894-A 200 25-OCT-2001;
Genome Therapeutics Corp. (US)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Primer"
BASE COUNT 2 a 8 c 4 g 6 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 19 TAGGAGGAT 11

RESULT 7
LOCUS AB069488/c 20 bp DNA linear SYN 08-AUG-2001
DEFINITION Synthetic construct DNA, forward primer for human STS-W47099 at
ACCESSION AB069488
VERSION AB069488
KEYWORDS
SOURCE synthetic construct DNA.
ORGANISM artificial construct.
REFERENCE
1 Chen, Y.-Z., Hayashi, Y., Wu, J.-G., Takeoka, E., Maekawa, K.,
AUTHORS Watanabe, N., Inazawa, J., Hosoda, F., Arai, Y., Mizushima, H.,
Morohashi, A., Ohira, M., Nakagawara, A., Liu, S., Hoshi, M., Horii, A.
and Soeda, E.
TITLE A BAC-based STS-content map spanning a 35-Mb region of human
JOURNAL chromosome 1p35-p36
MEDLINE Genomics 74 (1), 55-70 (2001)
REFERENCE 2 (bases 1 to 20)
AUTHORS Horii, A.
JOURNAL Direct Submission
TITLE Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
Miyagi 980-8575, Japan (E-mail: horii@mail.cc.tohoku.ac.jp,
Tel:81-22-717-8042, Fax:81-22-717-8047)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="forward primer for human STS-W47099 at 1p36
misc.feature sts-W47099 obtained from clones B61B17, B6A23, B26B112,
B316H11, B26P17, B179J2, B166I12, Human BAC library
RPCR-11"
BASE COUNT 3 a 9 c 2 g 6 t
ORIGIN

```

```

Query Match 100.0%; Score 9; DB 12; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 20 TAGGAGGAT 12

RESULT 8
LOCUS E55148/c 22 bp DNA linear PAT 31-JAN-2002
DEFINITION Method for determining the presence of apoptosis regulatory
function of drug Method for determining the presence of apoptosis
regulatory function of drug.
ACCESSION E55148
VERSION E55148.1 GI:18629759
KEYWORDS JP 2000217598-A/6.
SOURCE JP 2000217598-A/6.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 22)
AUTHORS Kamata, S., Tsujimoto, Y., Otsubo, T. and Murakami, Y.
TITLE Method for determining the presence of apoptosis regulatory
function of drug
JOURNAL Patent: JP 2000217598-A 6 08-AUG-2000;
SUMITOMO CHEM CO LTD
OS Artificial Sequence
PN JP 2000217598-A/6
PD 08-AUG-2000
PE 29-JAN-1999 JP 1999022356
PR
PI SHINGJI KAMATA, YOSHIHIDE TSUJIMOTO, TSUGUTERU OTSUBO, PI YUKO
MURAKAMI
LOCUS PC C1201/37.A61K31/00.A61K31/00.A61K31/00.A61K38/00, PC
A61K45/00,
PC A61K48/00.C12N15/09.G01N33/15.G01N33/50.G01N33/50, PC
G01N33/68/C07K14/47,
PC A61K37/02.C12N15/00
CC
FH Key
FT source Location/Qualifiers
1..22
/organism="Artificial Sequence".
location/Qualifiers
1..22
/organism="synthetic construct"
/db_xref="taxon:32630"
BASE COUNT 5 a 6 c 4 g 7 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 14 TAGGAGGAT 6

RESULT 9
LOCUS E36547 23 bp DNA linear PAT 31-JAN-2002
DEFINITION Method of gene diagnosis of bovine Chediak-Higashi syndrome.
ACCESSION E36547
VERSION E36547.1 GI:18626484
KEYWORDS JP 2000189165-A/34.
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 23)
AUTHORS Yamaguchi, H., Kashigunwa, A., Sugimoto, Y. and Tahara, N.
TITLE Method of gene diagnosis of bovine Chediak-Higashi syndrome

```

JOURNAL Patent: JP 2000189165-A 34 11-JUL-2000;
KAGOSHIMA PREF./LIVESTOCK TECHNOLOGY ASSOCIATION
OS Artificial Sequence
PN JP 2000189165-A/34
PD 11-JUL-2000
PF 25-DEC-1998 JP 1998368649

PI HIROSHI YAMAGUCHI, AGABA KASHIGUMA, YOSHINORI SUGIMOTO, PI
NORIO TAHARA
PC C12N15/09, C12Q1/68, C12N15/09, C12R1.91, C12N15/00, C12N15/00,
PC C12N1.91)
CC
FH
FT

FEATURES
source Location/Qualifiers
1..23
/organism="synthetic construct"
/db_xref="taxon:32630"

BASE COUNT 8 a 1 c 8 g 6 t

ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
|||||
Db 15 TAGGAGGAT 23

RESULT 10
E40169 23 bp DNA linear PAT 31-JAN-2002
LOCUS
DEFINITION Genetic diagnosis method of bovine Chediak-Higashi syndrome.
ACCESSION E40169
VERSION E40169.1 GI:18627243
KEYWORDS JP 2000189176-A/34.
SOURCE synthetic construct.
ORGANISM synthetic construct.
artificial sequences.
REFERENCE 1 (bases 1 to 23)
Yamaguchi, H., Kashiguma, A., Sugimoto, Y. and Tahara, N.
AUTHORS Genetic diagnosis method of bovine Chediak-Higashi syndrome
TITLE Patent: JP 2000189176-A 34 11-JUL-2000;
JOURNAL KAGOSHIMA PREF./LIVESTOCK TECHNOLOGY ASSOCIATION
COMMENT OS Artificial Sequence
PN JP 2000189176-A/34
PD 11-JUL-2000
PF 15-OCT-1999 JP 1999294619
PR
PI HIROSHI YAMAGUCHI, AGABA KASHIGUMA, YOSHINORI SUGIMOTO, PI
NORIO TAHARA
PC C12N15/09, C12Q1/68, C12N15/00
CC
FH
FT

FEATURES
source Location/Qualifiers
1..23
/organism="synthetic construct"
/db_xref="taxon:32630"

BASE COUNT 8 a 1 c 8 g 6 t

ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
|||||
Db 15 TAGGAGGAT 23

RESULT 11
DOGC00506A/c 23 bp DNA linear STS 11-APR-1996
LOCUS
DEFINITION Canis familiaris STS microsatellite marker (repeat motif in
reference clone (GI)2A(GT)9) DNA, sequence tagged site.
L77541
ACCESSION L77541.1 GI:1261665
KEYWORDS STS; PCR identification; microsatellite; sequence tagged site.
SOURCE Canis familiaris female adult peripheral blood DNA.
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
1 (bases 1 to 23)
Yuzbasizyan-Gurkan, V., Cao, Y., Gurkan, M., Yuxun, W., Venta, P.J.,
Brewer, G.J. and Blanton, S.H.
REFERENCES Microsatellite markers for the canine genome
Unpublished (1996)
Hotstart, touchdown PCR. Starting at 60 C, decreasing by one degree
for 10 cycles, 25 further cycles at 52. Motif and size of
product as found in the reference dog.
Location/Qualifiers
1..23
/organism="Canis familiaris"
/db_xref="taxon:9615"
/sex="female"
/cell_type="white blood cells"
/tissue_type="peripheral blood"
/dev_stage="adult"
1..23
/note="product size 173"

BASE COUNT 6 a 9 c 0 g 8 t

ORIGIN

Query Match 100.0%; Score 9; DB 11; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
|||||
Db 16 TAGGAGGAT 8

RESULT 12
AR135197/c 24 bp DNA linear PAT 16-MAY-2001
LOCUS
DEFINITION Sequence 15 from patent US 6194559.
ACCESSION AR135197
VERSION AR135197.1 GI:14124102
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
Kim, S. Young.
TITLE Abscisic acid responsive element-binding transcription factors
JOURNAL Patent: US 6194559-A 15 27-FEB-2001;
FEATURES Location/Qualifiers
1..24
/organism="unknown"

BASE COUNT 5 a 6 c 5 g 8 t

ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
|||||
Db 17 TAGGAGGAT 9

RESULT 13

```

ARI46693/c  ARI46693  24 bp  DNA  linear  PAT 08-AUG-2001
LOCUS       ARI46693
DEFINITION  Sequence 15 from patent US 6218527.
ACCESSION   ARI46693
VERSION     ARI46693.1  GI:15109882
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 24)
AUTHORS    Kim,S.Young
TITLE      Nucleic acid molecule encoding abscisic acid responsive
           element-binding factor 3
JOURNAL     Patent: US 6218527-A 15 17-APR-2001;
FEATURES
   source    1..24
             /organism="unknown"
BASE COUNT  5 a 6 c 5 g 8 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
   |||||||
Db 17 TAGGAGGAT 9

RESULT 14
ARI52264/c  ARI52264  24 bp  DNA  linear  PAT 08-AUG-2001
LOCUS       ARI52264
DEFINITION  Sequence 15 from patent US 6232461.
ACCESSION   ARI52264
VERSION     ARI52264.1  GI:15118314
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 24)
AUTHORS    Kim,S.Young.
TITLE      Nucleic acid molecule encoding abscisic acid responsive
           element-binding factor 4
JOURNAL     Patent: US 6232461-A 15 15-MAY-2001;
FEATURES
   source    1..24
             /organism="unknown"
BASE COUNT  5 a 6 c 5 g 8 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
   |||||||
Db 17 TAGGAGGAT 9

RESULT 15
ARI57802/c  ARI57802  24 bp  DNA  linear  PAT 17-OCT-2001
LOCUS       ARI57802
DEFINITION  Sequence 15 from patent US 6245905.
ACCESSION   ARI57802
VERSION     ARI57802.1  GI:16218814
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 24)
AUTHORS    Kim,S.Young.
TITLE      Nucleic acid molecule encoding abscisic acid responsive
           element-binding factor 2

```

```

JOURNAL     Patent: US 6245905-A 15 12-JUN-2001;
FEATURES
   source    1..24
             /organism="unknown"
BASE COUNT  5 a 6 c 5 g 8 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
   |||||||
Db 17 TAGGAGGAT 9

Search completed: June 2, 2003, 19:09:34
Job time : 320.073 secs

```


GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:06:10 ; Search time 388.756 Seconds

(without alignments)
823.475 Million cell updates/sec

Title: US-09-540-843-5

Perfect score: 11
Sequence: 1 gtagggtag 11

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 774614

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl:*
1: gb_da:*
2: gb_hcg:*
3: gb_in:*
4: gb_com:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vl:*
15: em_da:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vl:*
30: em_hcg_hum:*
31: em_hcg_inv:*
32: em_hcg_other:*
33: em_hcg_mus:*
34: em_hcg_pin:*
35: em_hcg_rtd:*
36: em_hcg_man:*
37: em_hcg_vtl:*
38: em_sy:*
39: em_higo_hum:*
40: em_higo_mus:*
41: em_higo_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	DB ID	Description
1	11	100.0	11	AR016034	AR016034 Sequence
2	11	100.0	11	AR026486	AR026486 Sequence
3	11	100.0	11	AR026487	AR026487 Sequence
4	11	100.0	11	AR059195	AR059195 Sequence
5	11	100.0	11	AR075506	AR075506 Sequence
6	11	100.0	11	AR161904	AR161904 Sequence
7	11	100.0	11	AR033373	AR033373 Sequence
8	11	100.0	11	AX268757	AX268757 Sequence
9	11	100.0	11	AX268761	AX268761 Sequence
10	11	100.0	11	AX283296	AX283296 Sequence
11	11	100.0	11	I31749	I31749 Sequence 2
12	11	100.0	15	AR026479	AR026479 Sequence
13	11	100.0	16	AR050942	AR050942 Sequence
14	11	100.0	16	AR204610	AR204610 Sequence
15	11	100.0	16	I51743	I51743 Sequence 11
16	11	100.0	17	A84605	A84605 Sequence 15
17	11	100.0	17	AR026488	AR026488 Sequence
18	11	100.0	17	AR145675	AR145675 Sequence
19	11	100.0	17	AR145676	AR145676 Sequence
20	11	100.0	18	A79654	A79654 Sequence 3
21	11	100.0	18	A79655	A79655 Sequence 14
22	11	100.0	18	A84598	A84598 Sequence 8
23	11	100.0	18	A84599	A84599 Sequence 9
24	11	100.0	18	AR016059	AR016059 Sequence
25	11	100.0	18	AR026482	AR026482 Sequence
26	11	100.0	18	AR026483	AR026483 Sequence
27	11	100.0	18	AR026484	AR026484 Sequence
28	11	100.0	18	AR037860	AR037860 Sequence
29	11	100.0	18	AR037861	AR037861 Sequence
30	11	100.0	18	AR037862	AR037862 Sequence
31	11	100.0	18	AR050936	AR050936 Sequence
32	11	100.0	18	AR050962	AR050962 Sequence
33	11	100.0	18	AR053263	AR053263 Sequence
34	11	100.0	18	AR054739	AR054739 Sequence
35	11	100.0	18	AR054740	AR054740 Sequence
36	11	100.0	18	AR054741	AR054741 Sequence
37	11	100.0	18	AR059509	AR059509 Sequence
38	11	100.0	18	AR059546	AR059546 Sequence
39	11	100.0	18	AR059547	AR059547 Sequence
40	11	100.0	18	AR069393	AR069393 Sequence
41	11	100.0	18	AR069394	AR069394 Sequence
42	11	100.0	18	AR069395	AR069395 Sequence
43	11	100.0	18	AR075504	AR075504 Sequence
44	11	100.0	18	AR079895	AR079895 Sequence
45	11	100.0	18	AR079896	AR079896 Sequence

ALIGNMENTS

RESULT 1
AR016034/c
LOCUS AR016034 11 bp DNA
DEFINITION Sequence 2 from patent US 5776679.
ACCESSION AR016034
VERSION AR016034.1 GI:3972311
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 11)
AUTHORS Villeponteau,B., Feng,J., Funk,W. and Andrews,W.H.
TITLE Assays for the DNA component of human telomerase
JOURNAL Patent: US 5776679-A 2 07-JUL-1998;
FEATURES Location/Qualifiers

```

source
1. .11
/organism="unknown"
BASE COUNT      4 a      5 c      0 g      2 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 11; DB 6; Length 11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTTAGGCTTAG 11
Db      11 GTTAGGCTTAG 1

RESULT 2
AR026486
LOCUS      AR026486
DEFINITION Sequence 11 from patent US 5856096.
ACCESSION  AR026486
VERSION     AR026486.1 GI:5937326
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Windle,B.E., Qiu,M., Chen,S.-F., Fletcher,T.M. and Maine,I.
TITLE       Rapid and sensitive assays for detecting and distinguishing between
            processive and non-processive telomerase activities
JOURNAL     Patent: US 5856096-A 11 05-JAN-1999;
            Location/Qualifiers
FEATURES
source      1. .11
            /organism="unknown"
BASE COUNT      2 a      0 c      5 g      4 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 11; DB 6; Length 11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTTAGGCTTAG 11
Db      1 GTTAGGCTTAG 11

RESULT 3
AR026487/c
LOCUS      AR026487
DEFINITION Sequence 12 from patent US 5856096.
ACCESSION  AR026487
VERSION     AR026487.1 GI:5937327
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Windle,B.E., Qiu,M., Chen,S.-F., Fletcher,T.M. and Maine,I.
TITLE       Rapid and sensitive assays for detecting and distinguishing between
            processive and non-processive telomerase activities
JOURNAL     Patent: US 5856096-A 12 05-JAN-1999;
            Location/Qualifiers
FEATURES
source      1. .11
            /organism="unknown"
BASE COUNT      4 a      5 c      0 g      2 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 11; DB 6; Length 11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTTAGGCTTAG 11
Db      11 GTTAGGCTTAG 11

```

```

RESULT 4
AR059195/c
LOCUS      AR059195
DEFINITION Sequence 2 from patent US 5837857.
ACCESSION  AR059195
VERSION     AR059195.1 GI:5984772
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Villeponteau,B., Feng,J., Funk,W. and Andrews,W.H.
TITLE       Mammalian telomerase
JOURNAL     Patent: US 5837857-A 2 17-NOV-1998;
            Location/Qualifiers
FEATURES
source      1. .11
            /organism="unknown"
BASE COUNT      4 a      5 c      0 g      2 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 11; DB 6; Length 11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTTAGGCTTAG 11
Db      11 GTTAGGCTTAG 11

RESULT 5
AR075506/c
LOCUS      AR075506
DEFINITION Sequence 3 from patent US 5958680.
ACCESSION  AR075506
VERSION     AR075506.1 GI:10002256
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Villeponteau,B., Feng,J., Funk,W. and Andrews,W.H.
TITLE       Mammalian telomerase
JOURNAL     Patent: US 5958680-A 3 28-SEP-1999;
            Location/Qualifiers
FEATURES
source      1. .11
            /organism="unknown"
BASE COUNT      4 a      5 c      0 g      2 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 11; DB 6; Length 11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTTAGGCTTAG 11
Db      11 GTTAGGCTTAG 11

RESULT 6
AR161904/c
LOCUS      AR161904
DEFINITION Sequence 2 from patent US 6258535.
ACCESSION  AR161904
VERSION     AR161904.1 GI:16228913
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Villeponteau,B., Feng,J., Funk,W. and Andrews,W.H.
TITLE       Mammalian telomerase
JOURNAL     Patent: US 6258535-A 2 10-JUL-2001;

```

FEATURES
source 1.11 Location/Qualifiers
BASE COUNT 4 a 5 c 0 g 2 t
ORIGIN

Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||

Db 11 GTTAGGGTTAG 1

RESULT 7
AX033373 11 bp mRNA linear PAT 21-SEP-2000
LOCUS
DEFINITION Sequence 5 from Patent WO0046601.
ACCESSION AX033373
VERSION AX033373.1 GI:10280147
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 11)
AUTHORS Larsen, F. and Skaanseng, M.
TITLE Detecting telomerase activity
JOURNAL Patent: WO 0046601-A 5 10-AUG-2000;
LARSEN FRANK (NO) ; SKAANSENG MARIANNE (NO)
LOCATION/Qualifiers
FEATURES
source 1.11
/organism="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT 4 a 5 c 0 g 2 t
ORIGIN

Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||

Db 11 GTTAGGGTTAG 1

RESULT 8
AX268757 11 bp DNA linear PAT 29-OCT-2001
LOCUS
DEFINITION Sequence 5 from Patent WO0174342.
ACCESSION AX268757
VERSION AX268757.1 GI:16541829
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Gilchrist, B.A., Yaar, M. and Eller, M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 5 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
LOCATION/Qualifiers
FEATURES
source 1.11
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT 2 a 0 c 5 g 4 t
ORIGIN

Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||

Db 1 GTTAGGGTTAG 11

RESULT 9
AX268761 11 bp DNA linear PAT 29-OCT-2001
LOCUS
DEFINITION Sequence 9 from Patent WO0174342.
ACCESSION AX268761
VERSION AX268761.1 GI:16541833
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Gilchrist, B.A., Yaar, M. and Eller, M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 9 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
LOCATION/Qualifiers
FEATURES
source 1.11
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT 4 a 5 c 0 g 2 t
ORIGIN

Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||

Db 1 GTTAGGGTTAG 11

RESULT 10
AX283296 11 bp DNA linear PAT 20-NOV-2001
LOCUS
DEFINITION Sequence 60 from Patent WO0179249.
ACCESSION AX283296
VERSION AX283296.1 GI:17044177
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Uhlmann, E., Breipohl, G. and Will, D.W.
TITLE Polyamide nucleic acid derivatives, agents and methods for
JOURNAL Patent: WO 0179249-A 60 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)
LOCATION/Qualifiers
FEATURES
source 1.11
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz:
Oligonukleotide"
BASE COUNT 2 a 0 c 5 g 4 t
ORIGIN

Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||

Db 1 GTTAGGGTTAG 11

RESULT 11

I31749/c
LOCUS I31749 11 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 2 from patent US 583016.
ACCESSION I31749
VERSION I31749.1 GI:1822540
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 11)
AUTHORS Villeponteau,B., Feng,J., Funk,W. and Andrews,W.H.
TITLE Mammalian telomerase
JOURNAL Patent: US 583016-A 2 10-DEC-1996.
FEATURES
source
1. .11
Location/Qualifiers
BASE COUNT 4 a 5 c 0 g 2 t
ORIGIN
Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTAGGCTTAG 11
Db 11 GTTAGGCTTAG 1

RESULT 12
LOCUS AR026479/c 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 4 from patent US 5856096.
ACCESSION AR026479
VERSION AR026479.1 GI:5937319
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Winkle,B.E., Qiu,M., Chen,S.-F., Fletcher,T.M. and Maine,I.
TITLE Rapid and sensitive assays for detecting and distinguishing between
processive and non-processive telomerase activities
JOURNAL Patent: US 5856096-A 4 05-JAN-1999;
FEATURES
source
1. .15
Location/Qualifiers
BASE COUNT 4 a 9 c 0 g 2 t
ORIGIN
Query Match 100.0%; Score 11; DB 6; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.3e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTAGGCTTAG 11
Db 13 GTTAGGCTTAG 3

RESULT 13
LOCUS AR050942/c 16 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 11 from patent US 5830644.
ACCESSION AR050942
VERSION AR050942.1 GI:5974306
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS West,M.D., Shay,J. and Wright,W.E.
TITLE Method for screening for agents which increase telomerase activity
in a cell
JOURNAL Patent: US 5830644-A 11 03-NOV-1998;

FEATURES
source
Location/Qualifiers
1. .16
/organism="unknown"
BASE COUNT 4 a 9 c 0 g 3 t
ORIGIN
Query Match 100.0%; Score 11; DB 6; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.3e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTAGGCTTAG 11
Db 13 GTTAGGCTTAG 3

RESULT 14
LOCUS AR204610/c 16 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 60 from patent US 6368789.
ACCESSION AR204610
VERSION AR204610.1 GI:21501980
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS West,M.D., Shay,J., Wright,W. and Blackburn,E.H.
TITLE Screening methods to identify inhibitors of telomerase activity
JOURNAL Patent: US 6368789-A 60 09-APR-2002;
FEATURES
source
1. .16
Location/Qualifiers
BASE COUNT 4 a 9 c 0 g 3 t
ORIGIN
Query Match 100.0%; Score 11; DB 6; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.3e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTAGGCTTAG 11
Db 13 GTTAGGCTTAG 3

RESULT 15
LOCUS I51743 16 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 11 from patent US 5645986.
ACCESSION I51743
VERSION I51743.1 GI:2472944
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS West,M.D., Harley,C.B., Strahl,C.M., McEachern,M.J., Shay,J.,
Wright,W.E., Blackburn,E.H. and Vaziri,H.
TITLE Therapy and diagnosis of conditions related to telomere length
and/or telomerase activity
JOURNAL Patent: US 5645986-A 11 08-JUL-1997;
FEATURES
source
1. .16
Location/Qualifiers
BASE COUNT 4 a 9 c 0 g 3 t
ORIGIN
Query Match 100.0%; Score 11; DB 6; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.3e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTAGGCTTAG 11
Db 13 GTTAGGCTTAG 3

Wed Jun 4 11:08:19 2003

Search completed: June 2, 2003, 19:09:39
job time : 390.756 secs

us-09-540-843-5.szlm40.rge

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 19:09:45 ; Search time 49.6829 Seconds
(without alignments)
189.976 Million cell updates/sec

Title: US-09-540-843-3

Perfect score: 7

Sequence: 1 agtatga 7

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 845702 seqs, 674182571 residues

Total number of hits satisfying chosen parameters: 477662

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_NA:*
1: /cgn2-6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
2: /cgn2-6/ptodata/2/pubpna/PCT_NEW_PUB.seq:*
3: /cgn2-6/ptodata/2/pubpna/US06_NEW_PUB.seq:*
4: /cgn2-6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
5: /cgn2-6/ptodata/2/pubpna/US07_NEW_PUB.seq:*
6: /cgn2-6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
7: /cgn2-6/ptodata/2/pubpna/US08_NEW_PUB.seq:*
8: /cgn2-6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
9: /cgn2-6/ptodata/2/pubpna/US09_NEW_PUB.seq:*
10: /cgn2-6/ptodata/2/pubpna/US09_PUBCOMB.seq:*
11: /cgn2-6/ptodata/2/pubpna/US10_NEW_PUB.seq:*
12: /cgn2-6/ptodata/2/pubpna/US10_PUBCOMB.seq:*
13: /cgn2-6/ptodata/2/pubpna/US60_NEW_PUB.seq:*
14: /cgn2-6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	7	100.0	7	9	US-10-122-630-3
2	7	100.0	7	9	US-10-122-630-7
3	7	100.0	7	9	US-10-122-633-3
4	7	100.0	7	9	US-10-122-633-7
5	7	100.0	9	9	US-10-122-630-1
6	7	100.0	9	9	US-10-122-633-1
7	7	100.0	10	10	US-09-398-399-31
8	7	100.0	10	10	US-09-899-381-31
9	7	100.0	10	12	US-10-033-145-143
10	7	100.0	14	9	US-09-875-440-22
11	7	100.0	15	10	US-09-504-231A-527
12	7	100.0	15	10	US-09-504-231A-528
13	7	100.0	15	10	US-09-504-231A-529
14	7	100.0	15	10	US-09-504-231A-1527
15	7	100.0	15	10	US-09-504-231A-1569
16	7	100.0	15	10	US-09-504-231A-1570
17	7	100.0	15	10	US-09-398-399-30
18	7	100.0	15	10	US-09-899-381-30
19	7	100.0	15	10	US-09-274-553D-527

20	7	100.0	15	10	US-09-274-553D-528	Sequence 528, App
21	7	100.0	15	10	US-09-274-553D-529	Sequence 529, App
22	7	100.0	15	10	US-09-274-553D-1527	Sequence 1527, Ap
23	7	100.0	15	10	US-09-274-553D-1569	Sequence 1569, Ap
24	7	100.0	15	10	US-09-274-553D-1570	Sequence 1570, Ap
25	7	100.0	15	10	US-09-272-343-1	Sequence 1, Appl
26	7	100.0	15	10	US-09-272-343-2	Sequence 2, Appl
27	7	100.0	17	9	US-10-060-830-716	Sequence 716, App
28	7	100.0	17	9	US-10-060-830-717	Sequence 717, App
29	7	100.0	17	9	US-10-060-830-718	Sequence 718, App
30	7	100.0	17	9	US-10-060-830-719	Sequence 719, App
31	7	100.0	17	9	US-10-060-830-720	Sequence 720, App
32	7	100.0	17	9	US-10-060-830-721	Sequence 721, App
33	7	100.0	17	9	US-10-060-830-722	Sequence 722, App
34	7	100.0	17	9	US-10-060-830-723	Sequence 723, App
35	7	100.0	17	9	US-10-060-830-724	Sequence 724, App
36	7	100.0	17	9	US-10-060-830-725	Sequence 725, App
37	7	100.0	17	9	US-10-060-830-726	Sequence 726, App
38	7	100.0	17	9	US-09-818-875-639	Sequence 639, App
39	7	100.0	17	9	US-09-818-875-640	Sequence 640, App
40	7	100.0	17	9	US-09-848-754A-443	Sequence 443, App
41	7	100.0	17	9	US-09-848-754A-444	Sequence 444, App
42	7	100.0	17	9	US-09-848-754A-2583	Sequence 2583, Ap
43	7	100.0	17	9	US-09-848-754A-2584	Sequence 2584, Ap
44	7	100.0	17	9	US-09-848-754A-2971	Sequence 2971, Ap
45	7	100.0	17	9	US-09-848-754A-3616	Sequence 3616, Ap

ALIGNMENTS

RESULT 1
US-10-122-630-3
Sequence 3, Application US/10122630
Publication No. US20030032610A1
GENERAL INFORMATION:
APPLICANT: Glitchest, Barbara A.
APPLICANT: Eiler, Mark S.
APPLICANT: Yaar, Mina
TITLE OF INVENTION: Method to Inhibit Cell Growth Using
Oligonucleotides
FILE REFERENCE: 0054, 1088-018
CURRENT APPLICATION NUMBER: US/10/122,630
CURRENT FILING DATE: 2002-04-12
PRIOR APPLICATION NUMBER: US 08/467,012
PRIOR FILING DATE: 1995-06-06
PRIOR APPLICATION NUMBER: PCT/US96/08386
PRIOR FILING DATE: 1996-06-03
PRIOR APPLICATION NUMBER: US 09/048,927
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: US 09/540,843
PRIOR FILING DATE: 2000-03-31
PRIOR APPLICATION NUMBER: PCT/US01/10162
PRIOR FILING DATE: 2001-03-30
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 3
LENGTH: 7
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-3

Query Match 100.0%, Score 7, DB 9, Length 7;
Best Local Similarity 100.0%, Pred. No. 1.9e+08;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||
Db 1 AGTATGA 7

```
RESULT 2
US-10-122-630-7
; Sequence 7, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; PRIORITY FILING DATE: 2002-04-12
; PRIORITY FILING DATE: 1995-06-06
; PRIORITY FILING DATE: PCT/US96/08386
; PRIORITY FILING DATE: 1996-06-03
; PRIORITY FILING DATE: 1998-03-26
; PRIORITY FILING DATE: 2000-03-31
; PRIORITY FILING DATE: 2000-03-31
; PRIORITY FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 7
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-7

Query Match          100.0%; Score 7; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
Db 1 AGTATGA 7

RESULT 3
US-10-122-633-3
; Sequence 3, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIORITY FILING DATE: 2002-04-12
; PRIORITY FILING DATE: 2000-03-31
; PRIORITY FILING DATE: PCT/US01/10162
; PRIORITY FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 3
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-3

Query Match          100.0%; Score 7; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
Db 1 AGTATGA 7
```

```
RESULT 4
US-10-122-633-7
; Sequence 7, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIORITY FILING DATE: 2002-04-12
; PRIORITY FILING DATE: 2000-03-31
; PRIORITY FILING DATE: 2000-03-31
; PRIORITY FILING DATE: PCT/US01/10162
; PRIORITY FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 7
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-7

Query Match          100.0%; Score 7; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
Db 1 AGTATGA 7

RESULT 5
US-10-122-630-1
; Sequence 1, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; PRIORITY FILING DATE: 2002-04-12
; PRIORITY FILING DATE: 2000-03-31
; PRIORITY FILING DATE: PCT/US96/08386
; PRIORITY FILING DATE: 1995-06-06
; PRIORITY FILING DATE: 1996-06-03
; PRIORITY FILING DATE: 2000-03-26
; PRIORITY FILING DATE: 2000-03-31
; PRIORITY FILING DATE: PCT/US01/10162
; PRIORITY FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-1
```

Query Match 100.0%; Score 7; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 2 AGTATGA 8

RESULT 6

US-10-122-633-1
; Sequence 1, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: 0034.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-1

Query Match 100.0%; Score 7; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 2 AGTATGA 8

RESULT 7

US-09-398-399-31
; Sequence 31, Application US/09398399
; Patent No. US20020051973A1
; GENERAL INFORMATION:
; APPLICANT: DELESTARR, GLENDA C.
; APPLICANT: LEFKOWITZ, STEVEN M.
; APPLICANT: LUEBEKE, KEVIN J.
; APPLICANT: OVERMAN, LESLIE B.
; APPLICANT: SAMPRAS, NICHOLAS M.
; APPLICANT: SAMPSON, JEFFREY R.
; APPLICANT: WOLBER, PAUL K.
; TITLE OF INVENTION: TECHNIQUES FOR ASSESSING NONSPECIFIC BINDING OF NUCLEIC
; TITLE OF INVENTION: ACIDS TO SURFACES
; FILE REFERENCE: 10981620-1
; CURRENT APPLICATION NUMBER: US/09/398,399
; CURRENT FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 31
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-398-399-31

Query Match 100.0%; Score 7; DB 10; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.9e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 1 AGTATGA 7

RESULT 8

US-09-899-381-31
; Sequence 31, Application US/09899381
; Patent No. US20020068293A1
; GENERAL INFORMATION:
; APPLICANT: Delestarr, Glend C.
; APPLICANT: Wolber, Paul K.
; APPLICANT: Sana, Theodore R.
; TITLE OF INVENTION: Arrays Having Background Features and
; TITLE OF INVENTION: Methods for Using the Same
; FILE REFERENCE: 10010760-1
; CURRENT APPLICATION NUMBER: US/09/899,381
; CURRENT FILING DATE: 2001-07-05
; PRIOR APPLICATION NUMBER: 09/398,399
; PRIOR FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic probe
US-09-899-381-31

Query Match 100.0%; Score 7; DB 10; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.9e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 1 AGTATGA 7

RESULT 9

US-10-033-145-1423/C
; Sequence 1423, Application US/10033145
; Patent No. US20020151515A1
; GENERAL INFORMATION:
; APPLICANT: GENZYME CORPORATION
; APPLICANT: ROBERTS, BRUCE
; APPLICANT: SHANKARA, SRINIVAS
; TITLE OF INVENTION: PREPARATION AND USE OF SUPERIOR VACCINES
; FILE REFERENCE: GAO201C
; CURRENT APPLICATION NUMBER: US/10/033,145
; CURRENT FILING DATE: 2001-11-05
; PRIOR APPLICATION NUMBER: PCT/US99/13800
; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 2137
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1423
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-033-145-1423

Query Match 100.0%; Score 7; DB 12; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.9e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 7 AGTATGA 1

RESULT 10
US-09-875-440-22/c

; Sequence 22, Application US/09875440
; Patent No. US2002015035A1
; GENERAL INFORMATION:
; APPLICANT: Reinhard, Christoph
; APPLICANT: Jefferson, Anne B.
; APPLICANT: Winter, Jill A.
; APPLICANT: Randazzo, Filippo
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: NEOPLASTIC DISEASE USING NET-4 MODULATORS
; FILE REFERENCE: PP-01701.002/200130.522
; CURRENT APPLICATION NUMBER: US/09/875,440
; CURRENT FILING DATE: 2001-06-05
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide NET-4 oligo 868 used for in-situ
; OTHER INFORMATION: hybridization
US-09-875-440-22

Query Match 100.0%; Score 7; DB 9; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.9e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||||
DB 13 AGTATGA 7

RESULT 11

US-09-504-231A-527

; Sequence 527, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
; FILE REFERENCE: IPI 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 527
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-527

Query Match 100.0%; Score 7; DB 10; Length 15;
Best Local Similarity 71.4%; Pred. No. 4.9e+04;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7

DB 9 AGUATGA 15
|||:|:|

RESULT 12

US-09-504-231A-528

; Sequence 528, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS REL
; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
; FILE REFERENCE: IPI 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 528
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-528

Query Match 100.0%; Score 7; DB 10; Length 15;
Best Local Similarity 71.4%; Pred. No. 4.9e+04;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||:|:|
DB 8 AGUATGA 14

RESULT 13

US-09-504-231A-529

; Sequence 529, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS REL
; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
; FILE REFERENCE: IPI 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 529
; LENGTH: 15

```

; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-1527
Query Match
Best Local Similarity 100.0%; Score 7; DB 10; Length 15;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 1 AGTATGA 7
Db 13 AGTATGA 7

RESULT 14
US-09-504-231A-1527/c
; Sequence 1527, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; FILE REFERENCE: IPI 247/282
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1998-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1527
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-1527
Query Match
Best Local Similarity 100.0%; Score 7; DB 10; Length 15;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AGTATGA 7
Db 13 AGTATGA 7

RESULT 15
US-09-504-231A-1569/c
; Sequence 1569, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; FILE REFERENCE: IPI 247/282
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1998-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1569
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-1569
Query Match
Best Local Similarity 100.0%; Score 7; DB 10; Length 15;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AGTATGA 7
Db 12 AGTATGA 6

Search completed: June 2, 2003, 23:43:13
Job time : 50.6829 secs
```

```

; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1569
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-1569
Query Match
Best Local Similarity 100.0%; Score 7; DB 10; Length 15;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 AGTATGA 7
Db 12 AGTATGA 6

Search completed: June 2, 2003, 23:43:13
Job time : 50.6829 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:31:20 ; Search time 28.6829 Seconds
(without alignments)
74.844 Million cell updates/sec

Title: US-09-540-843-3

Perfect score: 7

Sequence: 1 agataga 7

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 441362 segs, 15338381 residues

Total number of hits satisfying chosen parameters: 558892

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing:

Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	7	100.0	7	US-09-048-927-3	Sequence 3, Appl1
2	7	100.0	9	US-09-048-927-1	Sequence 1, Appl1
3	7	100.0	14	US-08-485-133-27	Sequence 27, Appl1
4	7	100.0	14	US-08-744-905A-4	Sequence 4, Appl1
5	7	100.0	15	US-08-334-847-24	Sequence 24, Appl1
6	7	100.0	15	US-08-334-847-327	Sequence 327, Appl1
7	7	100.0	15	US-08-671-071B-2	Sequence 2, Appl1
8	7	100.0	15	US-08-747-121-4	Sequence 4, Appl1
9	7	100.0	15	US-08-585-684B-130	Sequence 130, App
10	7	100.0	15	US-08-585-684B-1315	Sequence 1315, Ap
11	7	100.0	15	US-08-485-133-28	Sequence 28, Appl1
12	7	100.0	15	US-09-094-714A-33	Sequence 33, Appl1
13	7	100.0	15	US-09-094-714A-34	Sequence 34, Appl1
14	7	100.0	15	US-09-049-190-6	Sequence 6, Appl1
15	7	100.0	15	US-09-049-190-7	Sequence 7, Appl1
16	7	100.0	15	US-09-038-073-1315	Sequence 130, App
17	7	100.0	15	US-09-038-073-1315	Sequence 1315, Ap
18	7	100.0	15	US-08-932-140C-6	Sequence 6, Appl1
19	7	100.0	15	US-08-932-140C-7	Sequence 7, Appl1
20	7	100.0	15	US-09-253-977-2	Sequence 2, Appl1
21	7	100.0	16	US-07-977-284A-59	Sequence 59, Appl1
22	7	100.0	16	US-08-719-593-24	Sequence 24, Appl1
23	7	100.0	16	US-08-256-826B-59	Sequence 59, Appl1
24	7	100.0	16	US-08-458-814-1	Sequence 1, Appl1
25	7	100.0	17	US-08-390-850-461	Sequence 461, App
26	7	100.0	17	US-08-435-634-461	Sequence 461, App
27	7	100.0	17	US-08-758-306-365	Sequence 365, App

ALIGNMENTS

C 28	7	100.0	17	1	US-08-758-306-367	Sequence 367, App
C 29	7	100.0	17	1	US-08-758-306-369	Sequence 369, App
C 30	7	100.0	17	1	US-08-758-306-371	Sequence 371, App
C 31	7	100.0	17	1	US-08-758-306-813	Sequence 813, App
C 32	7	100.0	17	1	US-08-758-306-815	Sequence 815, App
C 33	7	100.0	17	2	US-08-671-320-6	Sequence 6, Appl1
C 34	7	100.0	17	2	US-08-868-577-6	Sequence 6, Appl1
C 35	7	100.0	17	2	US-08-485-133-2	Sequence 2, Appl1
C 36	7	100.0	17	3	US-08-985-162-443	Sequence 443, App
C 37	7	100.0	17	3	US-08-985-162-444	Sequence 444, App
C 38	7	100.0	18	1	US-07-688-352C-8	Sequence 8, Appl1
C 39	7	100.0	18	1	US-08-363-585-55	Sequence 55, Appl1
C 40	7	100.0	18	1	US-08-358-995-10	Sequence 10, Appl1
C 41	7	100.0	18	2	US-08-928-692-48	Sequence 48, Appl1
C 42	7	100.0	18	2	US-08-474-379C-8	Sequence 8, Appl1
C 43	7	100.0	18	2	US-09-200-141-19	Sequence 19, Appl1
C 44	7	100.0	18	2	US-09-213-768-24	Sequence 24, Appl1
C 45	7	100.0	18	2	US-09-213-768-25	Sequence 25, Appl1

```

RESULT 1
US-09-048-927-3
; Sequence 3, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Glitchest, Barbara A.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Use of Locally Applied DNA Fragments
; FILE REFERENCE: BU94-68A2
; CURRENT FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952,697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467,012
; EARLIER FILING DATE: 1995-06-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA Fragment
US-09-048-927-3
Query Match 100.0%; Score 7; DB 3; Length 7;
Best Local Similarity 100.0%; Pred. No. 4.1e+07;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGATAGA 7
Db 1 AGATAGA 7
RESULT 2
US-09-048-927-1
; Sequence 1, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Glitchest, Barbara A.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Use of Locally Applied DNA Fragments
; FILE REFERENCE: BU94-68A2
; CURRENT FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952,697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467,012

```

EARLIER FILING DATE: 1995-06-06
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FASTSEQ for Windows Version 3.0
SEQ ID NO 1
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: DNA Fragment
US-09-048-927-1

Query Match 100.0%; Score 7; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||
DB 2 AGTATGA 8

RESULT 3
US-08-485-133-27
Sequence 27, Application US/08485133
Patent No. 5976789

GENERAL INFORMATION:
APPLICANT: Allibert, Patrice A.
APPLICANT: Cros, Philippe
APPLICANT: Mach, Bernard F.
APPLICANT: Mandrand, Bernard F.
APPLICANT: Tiercy, Jean-Marie
TITLE OF INVENTION: SYSTEM OF PROBES ENABLING HLA-DR TYPING
TITLE OF INVENTION: TO BE PERFORMED, AND TYPING METHOD USING SAID PROBES
NUMBER OF SEQUENCES: 81
CORRESPONDENCE ADDRESS:
ADDRESSEE: OLIVE & BERRIDGE
STREET: P.O. Box 19928
CITY: Alexandria
STATE: Virginia
ZIP: 22320

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,133
FILING DATE: 7-JUN-1995
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/030,143

FILING DATE: 11-MAR-1993
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Berridge, William P.
REGISTRATION NUMBER: 30,024
REFERENCE/DOCKET NUMBER: WPB 28596A

TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-836-6400

TELEFAX: 703-836-2787

INFORMATION FOR SEQ ID NO: 27:

SEQUENCE CHARACTERISTICS:

LENGTH: 14 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-485-133-27

Query Match 100.0%; Score 7; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||

DB 8 AGTATGA 14

RESULT 4
US-08-744-905A-4/C
Sequence 4, Application US/08744905A
Patent No. 5990294

GENERAL INFORMATION:

APPLICANT: Murphy, Gerald

APPLICANT: Boynton, Alton

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

APPLICANT: Sengal, Anil

TITLE OF INVENTION: INHIBITING RESPIRATORY
TITLE OF INVENTION: SYNCTIAL VIRUS
NUMBER OF SEQUENCES: 909
CORRESPONDENCE ADDRESS:-
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/334,847
FILING DATE: No. 5693532ember 4, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/032
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-334-847-24

Query Match 100.0%; Score 7; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 6.1e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 1 AGTATGA 7
||:|:|
DB 5 AGUAGUA 11

RESULT 6
US-08-334-847-327
Sequence 327, Application US/08334847
Patent No. 5693532
GENERAL INFORMATION:
APPLICANT: McSwiggen, James
APPLICANT: Draper, Kenneth
APPLICANT: Pavco, Pam
APPLICANT: Woolf, Tod
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING RESPIRATORY
TITLE OF INVENTION: SYNCTIAL VIRUS
NUMBER OF SEQUENCES: 909
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/334,847
FILING DATE: No. 5693532ember 4, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/032
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 327:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-334-847-327

Query Match 100.0%; Score 7; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 6.1e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 1 AGTATGA 7
||:|:|
DB 5 AGUAGUA 11

RESULT 7
US-08-671-071B-2/C
Sequence 2, Application US/08671071B
Patent No. 5811270
GENERAL INFORMATION:
APPLICANT: Grandgenett, Duane
TITLE OF INVENTION: An in vitro method for concerted integration of
TITLE OF INVENTION: donor DNA molecules using retroviral integrase proteins.
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Grandgenett, Duane
STREET: 8610 Henrietta Ave
CITY: Brentwood
STATE: Missouri
COUNTRY: USA
ZIP: 63144
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch;
COMPUTER: Gateway 2000,4DX2-66E(Intel)
OPERATING SYSTEM: IBM clone
SOFTWARE: Microsoft Word
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/671,071B
CLASSIFICATION: 435
FILING DATE: 06/27/96
TELECOMMUNICATION INFORMATION:
TELEPHONE: (314) 962-0064
TELEFAX: (314) 577-8406
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE: Combination of avian or HIV-1 retrovirus
ORIGINAL SOURCE: DNA, plasmid and pGEM plasmid.
IMMEDIATE SOURCE: Same as in 2,vi.

FEATURE:
OTHER INFORMATION: The sequence is the bottom strand of
OTHER INFORMATION: M-2 U5 and the pGEM target of the top clone shown in
OTHER INFORMATION: Figure 14 of original application.
US-08-671-071B-2

Query Match 100.0%; Score 7; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
1111111
Db 9 AGTATGA 3

RESULT 8
US-08-747-121-4/c
Sequence 4, Application US/08747121
Patent No. 5874290
GENERAL INFORMATION:
APPLICANT: Murphy, Gerald
APPLICANT: Boynton, Alton
APPLICANT: Sehgal, Anil
TITLE OF INVENTION: NUCLEOTIDE AND AMINO ACID
TITLE OF INVENTION: SEQUENCES OF A D2-2 GENE ASSOCIATED WITH
TITLE OF INVENTION: BRAIN TUMORS AND METHODS BASED THEREON
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/747,121
FILING DATE: 08-NOV-1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Baldwin, Geraldine F
REGISTRATION NUMBER: 31,232
REFERENCE/DOCKET NUMBER: 8511-008
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)7909090
TELEFAX: (212)8698864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified Base
LOCATION: 1
OTHER INFORMATION: Where N is any nucleotide
US-08-747-121-4

Query Match 100.0%; Score 7; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
1111111
Db 15 AGTATGA 9

RESULT 9
US-08-585-684B-130
Sequence 130, Application US/08585684B
Patent No. 5877021

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 130:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-130

Query Match 100.0%; Score 7; DB 2; Length 15;
Best Local Similarity 71.4%; Pred. No. 6.1e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
1111111
Db 5 AGUATGA 11

RESULT 10
US-08-585-684B-1315
Sequence 1315, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1315:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1315

Query Match
Best Local Similarity 100.0%; Score 7; DB 2; Length 15;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
||:|:|
DB 5 AGUAGUA 11

RESULT 11
US-08-485-133-28
Sequence 28, Application US/08485133
Patent No. 5976789
GENERAL INFORMATION:
APPLICANT: Allibert, Patrice A.
APPLICANT: Cros, Philippe
APPLICANT: Mach, Bernard F.
APPLICANT: Mandrand, Bernard F.
APPLICANT: Tiercy, Jean-Marie
TITLE OF INVENTION: SYSTEM OF PROBES ENABLING HLA-DR TYPING
TITLE OF INVENTION: TO BE PERFORMED, AND TYPING METHOD USING SAID PROBES
NUMBER OF SEQUENCES: 81
CORRESPONDENCE ADDRESS:
ADDRESSEE: OLIFF & BERRIDGE
STREET: P. O. Box 19928
CITY: Alexandria
STATE: Virginia
ZIP: 22320
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,133
FILING DATE: 7-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/030,143

FILING DATE: 11-MAR-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Berridge, William P.
REGISTRATION NUMBER: 30,024
REFERENCE/DOCKET NUMBER: WPB 28596A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6400
TELEFAX: 703-836-2787
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-485-133-28

Query Match
Best Local Similarity 100.0%; Score 7; DB 2; Length 15;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
||:|:|
DB 9 AGTATGA 15

RESULT 12
US-09-094-714A-33/C
Sequence 33, Application US/09094714A
Patent No. 6117847
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Nicholas M. Dean
TITLE OF INVENTION: OLIGONUCLEOTIDES FOR ENHANCED MODULATION OF
NUMBER OF SEQUENCES: 69
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6117847rls, LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/094,714A
FILING DATE: June 15, 1998
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/601,269
FILING DATE: 14-FEB-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/478,178
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/089,996
FILING DATE: 09-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/852,852
FILING DATE: 16-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul K. Legard
REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-2943
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 15

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-094-714A-33

Query Match 100.0%; Score 7; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0;

Qy 1 AGTATGA 7
|||||
Db 12 AGTATGA 6

RESULT 13
US-09-094-714A-34/C
Sequence 34, Application US/09094714A
Patent No. 6117847

GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Nicholas M. Dean
TITLE OF INVENTION: OLIGONUCLEOTIDES FOR ENHANCED MODULATION OF
TITLE OF INVENTION: PROTEIN KINASE C EXPRESSION
NUMBER OF SEQUENCES: 69
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6117847r1s, LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/094,714A
FILING DATE: June 15, 1998

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/601,269
FILING DATE: 14-FEB-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/478,178
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/089,996
FILING DATE: 09-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/852,852
FILING DATE: 16-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul K. Legaard

REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-2943
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-094-714A-34

Query Match 100.0%; Score 7; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0;

Qy 1 AGTATGA 7
|||||
Db 14 AGTATGA 8

RESULT 14
US-09-049-190-6/C
Sequence 6, Application US/09049190
Patent No. 6190866

GENERAL INFORMATION:
APPLICANT: Nielsen et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having
TITLE OF INVENTION: Antibacterial Activity
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/049,190
FILING DATE:

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:

LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone

FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone

FEATURE:
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone

FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone

FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone

FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone

FEATURE:
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-[acetyl(2-aminoethyl)]-L-lysine-glycine
OTHER INFORMATION: backbone
US-09-049-190-6
Query Match 100.0%; Score 7; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGTATGA 7
1111111
DB 10 AGTATGA 4
RESULT 15
US-09-049-190-7/C
Sequence 7, Application US/09049190
Patent No. 6190866
GENERAL INFORMATION:
APPLICANT: Nielsen et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM: a No. 6190866r1s LLP

MEDIUM TYPE: 3.5 inch disk, 1.44 MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/049,190
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ. ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine

```
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-[acetyl(2-aminoethyl)]-C-lysine-glycine
OTHER INFORMATION: backbone
US-09-049-190-7

Query Match 100.0%; Score 7; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
DB 13 AGTATGA 7
```

Search completed: June 2, 2003, 20:38:33
Job time : 29.6829 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:29:55 ; Search time 878.415 Seconds
(without alignments)
129.060 Million cell updates/sec

Title: US-09-540-843-3

Perfect score: 7

Sequence: 1 agataga 7

Scoring table: Gapop 10.0, Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 60474

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : Listing first 45 summaries

EST:*
1: em_estha:*
2: em_esthum:*
3: em_estlin:*
4: em_estlinu:*
5: em_estov:*
6: em_estovl:*
7: em_estro:*
8: em_estro:*
9: gb_estcl:*
10: gb_estcl:*
11: gb_estcl:*
12: gb_estcl:*
13: gb_estcl:*
14: gb_estcl:*
15: em_estfun:*
16: em_estfun:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vrt:*
22: em_gss_fun:*
23: em_gss_man:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_fod:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	7	100.0	19	AZ817238	AZ817238 2M0086E01
2	7	100.0	19	AZ990856	AZ990856 2M0274E14
3	7	100.0	22	AZ623945	AZ623945 1M0462J10
4	7	100.0	22	AZ658158	AZ658158 1M0534H17
5	7	100.0	24	AW059679	AW059679 AHUTH.DBS
6	7	100.0	24	AZ423817	AZ423817 1M0203P19

C 7	7	100.0	24	AZ478673	AZ478673 1M0298J20
C 8	7	100.0	24	AZ816657	AZ816657 2M0085E05
C 9	7	100.0	25	H96935	H96935 yu01d01.r1
C 10	7	100.0	25	AZ605844	AZ605844 1M0427J22
C 11	7	100.0	25	AZ802490	AZ802490 2M0061I32
C 12	7	100.0	25	BH852860	BH852860 SALK_0756
C 13	7	100.0	25	BH852866	BH852866 SALK_0756
C 14	7	100.0	25	BH857761	BH857761 SALK_0156
C 15	7	100.0	26	AZ345685	AZ345685 1M0080C06
C 16	7	100.0	26	AZ473354	AZ473354 1M0289N08
C 17	7	100.0	27	D45824	D45824 HMG03044
C 18	7	100.0	27	TA187C01P	TA187519 T. brucei
C 19	7	100.0	28	A1790546	A1790546 u102e08.x
C 20	7	100.0	28	AZ861130	AZ861130 2M0167M21
C 21	7	100.0	29	BH856420	BH856420 SALK_0797
C 22	7	100.0	29	TA230F03P	TA230F03 T. brucei
C 23	7	100.0	30	C21099	C21099 HMG000262
C 24	7	100.0	30	AL766985	AL766985 Arabidops
C 25	7	100.0	31	A1159285	A1159285 v285b12.T
C 26	7	100.0	31	A1198585	A1198585 q150c03.x
C 27	7	100.0	31	BH853749	BH853749 SALK_0782
C 28	7	100.0	32	AZ587241	AZ587241 1M0394D14
C 29	7	100.0	32	BH862820	BH862820 SALK_0906
C 30	7	100.0	32	AL769600	AL769600 Arabidops
C 31	7	100.0	33	AZ463054	AZ463054 1M0271H10
C 32	7	100.0	33	AZ481169	AZ481169 1M0303D13
C 33	7	100.0	33	AZ778279	AZ778279 2M0013N15
C 34	7	100.0	33	AZ826520	AZ826520 2M0102B04
C 35	7	100.0	33	TA307A09Q	TA307A09 T. brucei
C 36	7	100.0	34	AU256929	AU256929 AU256929
C 37	7	100.0	34	AZ333219	AZ333219 1M0062C09
C 38	7	100.0	35	AZ476942	AZ476942 1M0296H11
C 39	7	100.0	35	AZ817309	AZ817309 2M0086N18
C 40	7	100.0	36	AU258145	AU258145 AU258145
C 41	7	100.0	36	AA624760	AA624760 v091a08..r
C 42	7	100.0	36	AZ405651	AZ405651 1M0174C03
C 43	7	100.0	36	AZ621129	AZ621129 1M0454I08
C 44	7	100.0	36	AZ776722	AZ776722 2M0010A12
C 45	7	100.0	36	BH789482	BH789482 SALK_0297

ALIGNMENTS

RESULT 1	AZ817238	19 bp	DNA	linear	GSS 20-FEB-2001
DEFINITION	2M0086E01R Mouse 10kb plasmid UGCCIM library Mus musculus genomic				
LOCUS	AZ817238				
ACCESSION	AZ817238.1	GI:12987146			
VERSION					
KEYWORDS	GSS.				
SOURCE	house mouse.				
ORGANISM	Mus musculus				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.				
AUTHORS	Dunn,D., Aoyagi,A., Barber,M., Beecorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A. and Wright,D., Weiss,R.				
TITLE	Mouse whole genome scaffolding with paired end reads from 10kb				
JOURNAL	Unpublished (2000)				
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert length: 10000 Std Error: 0.00				

Plate: 0086 row: E column: 01
Seq primer: CACACGAGAAACGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers

FEATURES
Source

```
1..19
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U062M0086E01"
/clone_lib="Mouse 10kb plasmid U062M library"
/sex="Male"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"/
/notes="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114[gb]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
```

BASE COUNT
ORIGIN

6 a 1 c 6 g 6 t

Query Match 100.0%; Score 7; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
1111111
Db 10 AGTATGA 16

RESULT 2

AZ990856/c 19 bp DNA linear GSS 27-APR-2001
LOCUS
DEFINITION
clone U062M0274F14 R, DNA sequence.

ACCESSION
AZ990856
VERSION
AZ990856.1 GI:13862083

KEYWORDS
SOURCE

GSS.
house mouse.

ORGANISM

Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

1 (bases 1 to 19)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
and Wright,D., Weis,R.

AUTHORS

Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

TITLE

JOURNAL
COMMENT

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0274 row: F column: 14
Seq primer: CACACGAGAAACGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers

FEATURES
Source

```
1..19
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U062M0274F14"
/clone_lib="Mouse 10kb plasmid U062M library"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"/
/notes="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114[gb]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
```

BASE COUNT
ORIGIN

8 a 5 c 0 g 6 t

Query Match 100.0%; Score 7; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
1111111
Db 18 AGTATGA 12

RESULT 3

AZ623945/c 22 bp DNA linear GSS 13-DEC-2000
LOCUS
DEFINITION
clone U062M0462J10 F, DNA sequence.

ACCESSION
AZ623945
VERSION
AZ623945.1 GI:11746135

KEYWORDS
SOURCE

GSS.
house mouse.

ORGANISM

Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

1 (bases 1 to 22)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
and Wright,D., Weis,R.

AUTHORS

Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

TITLE

JOURNAL
COMMENT

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0462 row: J column: 10
Seq primer: CCGTGAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 22.
Location/Qualifiers

FEATURES
SOURCE

1..22
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U061M0462J10"
/clone.lib="Mouse 10kb plasmid U061M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN

7 a 5 c 2 g 8 t

Query Match

Best Local Similarity 100.0%; Score 7; DB 17; Length 22;
Pred. No. 1.6e+05; Mismatches 0; Indels 0; Gaps 0;

Matches

QY 1 AGTATGA 7
|||||
DB 11 AGTATGA 5

RESULT 4
LOCUS

A2658158

DEFINITION 22 bp DNA linear GSS 14-DEC-2000
1M0534H17R Mouse 10kb plasmid U061M library Mus musculus genomic

ACCESSION A2658158
VERSION A2658158.1 GI:11795304

KEYWORDS GSS.
SOURCE house mouse.

ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 22)

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL COMMENT Unpublished (2000)

Contact: Robert B. Weiss
University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA

Tel: 801 585 5606
Fax: 801 585 7177

Email: ddunne@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0534 row: H column: 17
Seq primer: CACACAGCAACAGCATATGACC
Class: plasmid ends
High quality sequence stop: 22.
Location/Qualifiers

FEATURES
SOURCE

1..22
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U061M0534H17"
/clone.lib="Mouse 10kb plasmid U061M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN

6 a 0 c 9 g 7 t

Query Match

Best Local Similarity 100.0%; Score 7; DB 17; Length 22;
Pred. No. 1.6e+05; Mismatches 0; Indels 0; Gaps 0;

Matches

QY 1 AGTATGA 7
|||||
DB 4 AGTATGA 10

RESULT 5
LOCUS

AM059679/c

DEFINITION 24 bp mRNA linear EST 23-AUG-2000
AHUTH.bset.dnc15.aa.A050g08 DNC15 Homo sapiens cDNA, mRNA sequence.

ACCESSION AM059679
VERSION AM059679.1 GI:6652001

KEYWORDS EST.
SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 24)

Brenner, S., Williams, S.R., Vernass, E.H., Storck, T., Moon, K., McColium, C., Mao, J.I., Kirchner, J.J., Elster, S., Dubridge, R.B., Burman, T. and Albrecht, G.

In vitro cloning of complex mixtures of DNA on microbeads: Physical separation of differentially expressed cDNAs

Proc. Natl. Acad. Sci. U.S.A. 97 (4), 1665-1670 (2000)

20144098
Contact: Burcham TS
LYNX Therapeutics, Inc.
25861 Industrial Blvd., Hayward, CA 94545, USA

Tel: 510 670 9338
Fax: 510 670 9302

Email: timb@lynxgen.com
Sequence obtained from LYNX Therapeutics Megasort technology.
Collected from the down-regulated gate.

High quality sequence stop: 24.
Location/Qualifiers

FEATURES

```

source
1. 24
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="DNCL15"
/cell_type="monocytic leukemia"
/cell_line="THP-1 (TIB-202)"
/note="Vector: pCR2.1; Cloning of PCR products from
micro-beads carrying 3' end of down-regulated cDNA. THP-1
cells non-induced (treated with DMSO only)."
BASE COUNT      9 a      6 c      1 g      8 t
ORIGIN
Query Match      100.0%; Score 7; DB 10; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGTATGA 7
1111111
Db 23 AGTATGA 17

```

```

RESULT 6
AZ423817/c      24 bp      DNA      linear      GSS 03-OCT-2000
LOCUS
DEFINITION
IM0203P19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
AZ423817
ACCESSION
AZ423817
VERSION
AZ423817.1 GI:10547830
KEYWORDS
GSS.
SOURCE
house mouse.
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Mus.
REFERENCE
1 (bases 1 to 24)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL
Unpublished (2000)
COMMENT
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0203 row: P column: 19
Seq primer: CCGTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 24.
FEATURES
Location/Qualifiers
1. 24
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0203P19"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to

```

```

10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 (g14732114|db|AF129072.1), a copy-number
inducible derivative of plasmid RL. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT      7 a      3 c      2 g      12 t
ORIGIN
Query Match      100.0%; Score 7; DB 17; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGTATGA 7
1111111
Db 17 AGTATGA 11

```

```

RESULT 7
AZ478673/c      24 bp      DNA      linear      GSS 04-OCT-2000
LOCUS
DEFINITION
IM0298U20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
AZ478673
ACCESSION
AZ478673
VERSION
AZ478673.1 GI:10637794
KEYWORDS
GSS.
SOURCE
house mouse.
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Mus.
REFERENCE
1 (bases 1 to 24)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL
Unpublished (2000)
COMMENT
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0298 row: J column: 20
Seq primer: CACACAGAAACACCTVWGACC
Class: plasmid ends
High quality sequence stop: 24.
FEATURES
Location/Qualifiers
1. 24
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0298U20"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to

```


	M. Fatima Bonaldo. "			
	6 a	5 c	6 g	8 t
BASE COUNT				
ORIGIN				

Query Match	100.0%	Score 7;	DB 14;	length 25;
Best Local Similarity	100.0%	Pred. No. 1.7e+05;		
Matches	7;	Conservative	0;	Mismatches 0;
			Indels	0;
			Gaps	0.

QY	1	AGTATGA	7
Db	19	AGTATGA	13

RESULT	10
AZ605844/C	
LOCUS	
DEFINITION	25 bp DNA linear GSS 13-DEC-2000
ACCESSION	AZ605844
VERSION	IM0427J22F Mouse 10kb plasmid U06C1M library Mus musculus genomic clone U06C1M0427J22 F, DNA sequence.
KEYWORDS	AZ605844
SOURCE	AZ605844.1 GI:11728034
	GSS.
	house mouse.

REFERENCE

1 (bases 1 to 25)

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
Hartley, J., Johnson, G., Kishimoto, Y., Macdonald, F., Pedersen, W., Relliv,

M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausen, A. and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA

Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0427 row: J column: 22
Seq primer: CGTTGTAACGACGCCACGT

High quality sequence stop:
Location/Qualifiers

source

```

/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U06C1M042J22"
/clone_1lb="Mouse 10kb plasmid library"
/sex="Male"

```

BASE COUNT	and selected for ampicillin resistance.
7 a	6 c
5 g	7 t

Query Match	100.0%	Score 7;	DB 17;	length 25;
Similarity	100.0%	Pred. No. 1.7e+05;		
Best Local				
Matches	7;	Conservative	0;	Mismatches 0;
				Indels 0;
				Gaps 0;

QY	1	AGTATGA	7
Db	17	AGTATGA	11

RESULT	11
AZ802490/c	
LOCUS	AZ802490
DEFINITION	25 bp DNA linear GSS 16-FEB-2001
ACCESSION	200061122F Mouse 10kb plasmid tucG1M library Mus musculus genomic
VERSION	clone U06C2M0061122 F, DNA sequence.
KEYWORDS	AZ802490
SOURCE	AZ802490.1 GI:12954813
ORGANISM	GSS.
	house mouse.
	Mus musculus

REFERENCE
1 (bases 1 to 25)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
T. Nakamura, Y. Morono, & Nedorenko, P. (2011) v.

M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A., and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT
84112, USA

Fax: 801.505.1217
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0061 row: 1 column: 22
 Seq primer: CGTGTAAACGACGCGCCAGT

High quality sequence stop:
Location/Qualifiers

source

/organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="U06C2M0061122"
 /clone_11b="Mouse 10Kb plasmid U06C1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42nv: Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 Kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114[g14732114]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells

and selected for ampicillin resistance."

BASE COUNT 5 a 6 c 5 g 9 t

ORIGIN

Query Match 100.0%; Score 7; DB 17; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||

DB 22 AGTATGA 16

RESULT 12
BH852860
LOCUS

DEFINITION BH852860 25 bp DNA linear GSS 13-JUN-2002
Arabidopsis thaliana genomic clone SALK_075689.48.55.x, DNA sequence.

ACCESSION BH852860
VERSION BH852860
KEYWORDS GSS.
SOURCE GI:21423731
ORGANISM thale cress.
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1 (bases 1 to 25)
Alonso,J.M., Leisbe,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P., Zimmerman,J. and Ecker,J.R.
A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome
Unpublished (2001)
Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGNAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of TDNA. This sequence lies within an annotated exon of At3g41627.
Class: TDNA tagged.
Location/Qualifiers
1..25
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="SALK_075689.48.55.x"
/note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/tdna_protocols.html"

BASE COUNT 9 a 2 c 6 g 8 t

ORIGIN

Query Match 100.0%; Score 7; DB 17; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||

DB 12 AGTATGA 18

RESULT 13
BH852866
LOCUS

DEFINITION BH852866 25 bp DNA linear GSS 13-JUN-2002
Arabidopsis thaliana genomic clone SALK_075697.38.25.x, DNA sequence.

Arabidopsis thaliana genomic clone SALK_075697.38.25.x, DNA sequence.

ACCESSION BH852866
VERSION BH852866
KEYWORDS GSS.
SOURCE GI:21423737
ORGANISM thale cress.
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1 (bases 1 to 25)
Alonso,J.M., Leisbe,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P., Zimmerman,J. and Ecker,J.R.
A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome
Unpublished (2001)
Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGNAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of TDNA. This sequence lies within an annotated exon of At3g41627.
Class: TDNA tagged.
Location/Qualifiers
1..25
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="SALK_075697.38.25.x"
/note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/tdna_protocols.html"

BASE COUNT 9 a 2 c 6 g 8 t

ORIGIN

Query Match 100.0%; Score 7; DB 17; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||

DB 12 AGTATGA 18

RESULT 14
BH857761
LOCUS

DEFINITION BH857761 25 bp DNA linear GSS 08-JUL-2002
Arabidopsis thaliana genomic clone SALK_015664.41.95.x, DNA sequence.

ACCESSION BH857761
VERSION BH857761
KEYWORDS GSS.
SOURCE GI:21708582
ORGANISM thale cress.
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1 (bases 1 to 25)
Alonso,J.M., Leisbe,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P., Zimmerman,J. and Ecker,J.R.
A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome
Unpublished (2001)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 17:32:40 ; Search time 116.951 Seconds
(without alignments)
134.791 Million cell updates/sec

Title: US-09-540-843-3

Perfect score: 7

Sequence: 1 agtatga 7

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 2063506

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

N_Geneseq_101002.*
1: /SID52/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SID52/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SID52/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SID52/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SID52/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SID52/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SID52/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SID52/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SID52/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SID52/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SID52/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SID52/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SID52/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SID52/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SID52/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SID52/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SID52/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SID52/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SID52/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SID52/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SID52/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SID52/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SID52/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SID52/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	7	100.0	7	20	AAZ10694
2	7	100.0	7	23	AAZ14907
3	7	100.0	7	23	AAZ14911
4	7	100.0	9	20	AAZ10692
5	7	100.0	9	23	AAZ14905
6	7	100.0	10	21	AAZ78995
7	7	100.0	10	21	AAZ86425
8	7	100.0	10	22	AAZ32760
9	7	100.0	10	22	AAZ38936

10	7	100.0	10	22	AAF39793	Yeast NORF gene SA
11	7	100.0	10	22	AAF40876	Yeast NORF gene SA
12	7	100.0	10	24	ABK47394	Human PNA2G1B ASO
13	7	100.0	10	24	AAZ41859	Human GCNT1 allele
14	7	100.0	10	24	AAZ67680	Human IL-8 gene po
15	7	100.0	10	24	AAZ67681	Human IL-8 gene po
16	7	100.0	10	24	ABZ42801	Human maturation/a
17	7	100.0	11	24	ABQ86727	Human skin stress/
18	7	100.0	12	19	AAZ40922	Primer E2HMF-1726
19	7	100.0	12	20	AAZ19080	Oligonucleotide 1
20	7	100.0	12	23	ABH77740	Oligonucleotide pr
21	7	100.0	12	23	ABH68353	Oligonucleotide pr
22	7	100.0	12	23	ABH70774	Oligonucleotide pr
23	7	100.0	12	23	ABH71335	Oligonucleotide pr
24	7	100.0	12	23	ABH71445	Oligonucleotide pr
25	7	100.0	12	23	ABH71785	Oligonucleotide pr
26	7	100.0	12	23	ABH74658	Oligonucleotide pr
27	7	100.0	12	23	ABH74660	Oligonucleotide pr
28	7	100.0	12	23	ABH75445	Oligonucleotide pr
29	7	100.0	12	23	ABH78137	Oligonucleotide pr
30	7	100.0	12	23	ABH78185	Oligonucleotide pr
31	7	100.0	12	23	ABH79172	Oligonucleotide pr
32	7	100.0	12	23	ABH79256	Oligonucleotide pr
33	7	100.0	12	23	ABH79332	Oligonucleotide pr
34	7	100.0	12	23	ABH79629	Oligonucleotide pr
35	7	100.0	12	23	ABH80384	Oligonucleotide pr
36	7	100.0	12	23	ABH80608	Oligonucleotide pr
37	7	100.0	12	23	ABH80919	Oligonucleotide pr
38	7	100.0	12	23	ABH81994	Oligonucleotide pr
39	7	100.0	12	23	ABH82603	Oligonucleotide pr
40	7	100.0	12	23	ABH84469	Oligonucleotide pr
41	7	100.0	12	23	ABH84470	Oligonucleotide pr
42	7	100.0	12	23	ABH84926	Oligonucleotide pr
43	7	100.0	12	23	ABH86238	Oligonucleotide pr
44	7	100.0	12	23	ABH87108	Oligonucleotide pr
45	7	100.0	12	23	ABH87400	Oligonucleotide pr

ALIGNMENTS

RESULT 1
AAZ10694 standard; DNA; 7 BP.
ID AAZ10694
XX AAZ10694:
AC
XX
DT 23-NOV-1999 (first entry)
XX
DE Oligonucleotide sequence that increases p53 activity in a cell.
XX
KW p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
KW UV-induced hyperproliferative disease; psoriasis; vitiligo;
KW atopic dermatitis; allergic rhinitis; conjunctivitis; photodagging;
KW skin cancer; ss.
XX
OS Synthetic.
XX
PN GB2336157-A.
XX
PD 13-OCT-1999.
XX
PF 24-MAR-1999; 99GB-0006758.
XX
PR 26-MAR-1999; 98US-0048927.
XX
PA (UYBO-) UNTV BOSTON.
XX
PI Gilchrist BA, Yaar M, Eller M;
XX
DR WPI; 1999-543520/46.
XX
PT DNA fragments useful for increasing p53 activity in a cell and reducing

PT susceptibility to UV-induced hyperproliferative diseases -

XX Claim 11: Page 30; 44pp; English.

XX AA210692-97 represent DNA fragments that are used for increasing p53

XX activity in a cell. The oligonucleotides are are UV mimetics and

XX protect cells against subsequent exposure to UV-irradiation or

XX chemicals. The oligonucleotides are useful for increasing p53 activity

XX in a cell, reducing the susceptibility to UV-induced hyperproliferative

XX diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic

XX rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging

XX and reducing susceptibility to skin cancer.

SQ Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 20; Length 7;

Best Local Similarity 100.0%; Pred. No. 3.1e+08;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7

1111111

Db 1 AGTATGA 7

RESULT 2

AA514907

ID AA514907 standard; DNA; 7 BP.

AC AA514907;

XX 14-FEB-2002 (first entry)

DE Melanogenesis associated oligonucleotide #3.

XX Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;

KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;

KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;

KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;

KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;

XX conjunctivitis; allergic rhinitis; vitiligo; ss.

OS Synthetic.

PN WO200174342-A2.

XX 11-OCT-2001.

PD 30-MAR-2001; 2001WO-US10162.

PF 31-MAR-2000; 2000US-0540843.

XX (UYBO-) UNIV BOSTON.

PA Gilchrist BA, Yaar M, Eller M;

PI WPI; 2001-626338/72.

DR Inhibiting proliferation of epithelial cells, useful e.g. for treating

XX carcinoma, using specific oligonucleotides that mimic the effects of

PT ultra-violet light -

XX Claim 1; Page 36; 74pp; English.

XX The invention describes inhibition of mammalian epithelial cell

XX proliferation by treating cells with at least one oligonucleotide, or

XX its fragment. The compounds, which have cytostatic, anti-allergic,

XX anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and

XX immunosuppressive activities, function as 'ultra-violet mimics' to induce

XX DNA repair processes (or a protective response to later exposure to

XX radiation or chemicals), as a proliferation inhibitor, apoptosis inducer

XX or a tumour necrosis factor inhibitor. Probably they mimic products of

XX DNA damage, or processed DNA-damage intermediates, by inducing the p53

XX pathway, resulting in transient arrest of cell growth, allowing more time

CC for DNA repair to occur before cell division takes place. The method is

CC especially used to treat carcinoma but may also be used to: treat other

CC hyperproliferative states (e.g. psoriasis or precancerous conditions);

CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat

CC allergic rhinitis and inflammation (atopic or contact dermatitis);

CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in

CC cells caused by radiation or chemicals; increase melanin production

CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to

CC promote apoptosis in epithelial cells that contain damaged DNA. Also

CC oligonucleotides that contain non-hydrolyzable backbones are used to

CC inhibit apoptosis, in response to DNA damage, in epithelial cells. This

CC sequence is melanogenic associated oligonucleotide #3, a truncated

CC version of the oligonucleotide shown in AA514906, one of the

CC oligonucleotides used to inhibit mammalian epithelial cell

CC proliferation, described in the method of the invention.

SQ Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 23; Length 7;

Best Local Similarity 100.0%; Pred. No. 3.1e+08;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7

1111111

Db 1 AGTATGA 7

RESULT 3

AA514911

ID AA514911 standard; DNA; 7 BP.

AC AA514911;

XX 14-FEB-2002 (first entry)

DE Melanogenesis associated oligonucleotide #7.

XX Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;

KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;

KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;

KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;

KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;

XX conjunctivitis; allergic rhinitis; vitiligo; ss.

OS Synthetic.

PN WO200174342-A2.

XX 11-OCT-2001.

PD 30-MAR-2001; 2001WO-US10162.

PF 31-MAR-2000; 2000US-0540843.

XX (UYBO-) UNIV BOSTON.

PA Gilchrist BA, Yaar M, Eller M;

PI WPI; 2001-626338/72.

DR Inhibiting proliferation of epithelial cells, useful e.g. for treating

XX carcinoma, using specific oligonucleotides that mimic the effects of

PT ultra-violet light -

XX Claim 1; Page 38; 74pp; English.

XX The invention describes inhibition of mammalian epithelial cell

CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis;
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #7, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.

SO Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 23; Length 7;
 Best Local Similarity 100.0%; Pred. No. 3.1e+08;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 |||||
 1 AGTATGA 7

Db
 AA210692
 AA210692 standard; DNA; 9 BP.

AC AA210692;
 DT 23-NOV-1999 (first entry)

DE Oligonucleotide sequence that increases p53 activity in a cell.
 KW p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
 KW UV-induced hyperproliferative disease; psoriasis; vitiligo;
 KW atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;
 KW skin cancer; ss.

OS Synthetic.

PN GB2336157-A.

PD 13-OCT-1999.

PF 24-MAR-1999; 99GB-0006758.

PR 26-MAR-1998; 98US-0048927.

PA (UYBO-) UNIV BOSTON.

PI Gilchrist BA, Yaar M, Eller M;

DR WPI; 1999-543520/46.

PT DNA fragments useful for increasing p53 activity in a cell and reducing
 PT susceptibility to UV-induced hyperproliferative diseases -

PS Claim 11; Page 29; 44pp; English.

CC AA210692-97 represent DNA fragments that are used for increasing p53
 CC activity in a cell. The oligonucleotides are are UV mimetics and

CC protect cells against subsequent exposure to UV-irradiation or
 CC chemicals. The oligonucleotides are useful for increasing p53 activity
 CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
 CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
 CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
 CC and reducing susceptibility to skin cancer.

SO Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 20; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 |||||
 2 AGTATGA 8

Db
 AA514905
 AA514905 standard; DNA; 9 BP.

DT 14-FEB-2002 (first entry)

DE Melanogenesis associated oligonucleotide #1.

KW Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.

OS Synthetic.

Key Location/Qualifiers
 modified_base 1

FT /*tag= a
 FT /mod_base= g
 FT /note= "Optionally phosphorylated"

PN W0200174342-A2.

PD 11-OCT-2001.

PF 30-MAR-2001; 2001WO-US10162.

PR 31-MAR-2000; 2000US-0540843.

PA (UYBO-) UNIV BOSTON.

PI Gilchrist BA, Yaar M, Eller M;

DR WPI; 2001-626338/72.

PT Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light -

PS Claim 1; Page 36; 74pp; English.

CC The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time

CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photodaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergic rhinitis and conjunctivitis; prevent or reduce dermatitis;
 CC allergic rhinitis and conjunctivitis; prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #1, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.

CC Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 23; Length 9;

Best Local Similarity 100.0%; Pred. No. 2,4e+08; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 DB 2 AGTATGA 8

RESULT 6

AAZ78995/c
 ID AAZ78995 standard; DNA; 10 BP.

AAZ78995;

10-APR-2000 (first entry).

Human dendritic cell SAGE tag, SEQ ID NO:1423.

SAGE tag: serial analysis of gene expression; antigen-presenting cell;
 APC; monocyte-derived dendritic cell; differential gene expression;
 immunostimulatory cofactor; costimulatory factor; CTL;

cytotoxic T-lymphocyte; tumour antigen; immunotherapy; anticancer; ss.

Homo sapiens.

WO965924-A2.

23-DEC-1999.

18-JUN-1999; 99WO-US13800.

19-JUN-1998; 98US-0089833.

19-JUN-1998; 98US-0089844.

19-JUN-1998; 98US-0089853.

19-JUN-1998; 98US-0089878.

19-JUN-1998; 98US-0089991.

19-JUN-1998; 98US-0089992.

19-JUN-1998; 98US-0089993.

19-JUN-1998; 98US-0089994.

19-JUN-1998; 98US-0089997.

19-JUN-1998; 98US-0089999.

19-JUN-1998; 98US-0090000.

19-JUN-1998; 98US-0090003.

19-JUN-1998; 98US-0090036.

19-JUN-1998; 98US-0090039.

19-JUN-1998; 98US-0090040.

19-JUN-1998; 98US-0090041.

19-JUN-1998; 98US-0090042.

19-JUN-1998; 98US-0090043.

19-JUN-1998; 98US-0090044.

19-JUN-1998; 98US-0090045.

19-JUN-1998; 98US-0090047.

19-JUN-1998; 98US-0090048.

19-JUN-1998; 98US-0090072.

19-JUN-1998; 98US-0090076.

PR 19-JUN-1998; 98US-0090077.
 PR 19-JUN-1998; 98US-0090078.
 PR 19-JUN-1998; 98US-0090079.
 PR 19-JUN-1998; 98US-0090080.
 PR 08-DEC-1998; 98US-0111715.

(GENZ) GENZYME CORP.

(ROBE/) ROBERTS B L.

(SHAN/) SHANKARA S.

Roberts BL, Shankara S;

WPI; 2000-106077/09.

Isolated polynucleotides differentially expressed in antigen-presenting
 cells, useful in gene vaccines against cancer -

Claim 1; Page 105; 130pp; English.

Sequences AAZ7573-279709 represent SAGE (serial analysis of gene
 expression) tags used to identify mRNA transcripts encoding
 immunostimulatory cofactor proteins which are preferentially or
 differentially expressed in monocyte-derived dendritic cells compared
 with monocytes. Some of the transcripts correspond to known genes or
 ESTs (expressed sequence tags) which were previously unknown to be
 preferentially or differentially expressed in dendritic cells, while
 other transcripts correspond to novel genes. Antigen-presenting cell
 (APC)-associated costimulatory factors play an important role in the
 activation of the cytotoxic immune response, particularly against tumour
 cells. Tumour antigen presentation via the MHC (major histocompatibility
 complex) and subsequent recognition by T-cell receptors is alone
 insufficient to activate a robust cytotoxic immune response that can
 lyse the tumour cells. Immunostimulatory cofactors also being required
 for efficient activation of cytotoxic T-lymphocytes (CTLs). Nucleic acid
 sequences identified using the SAGE tags have several potential uses.
 They may be used in vaccines to induce an immune response, particularly
 against a tumour antigen; to modulate the genotype of an APC; to screen
 for agents that modulate expression of differentially expressed genes in
 an APC; and as hybridisation probes/amplification primers for the
 diagnosis, prognosis and monitoring of diseases related to abnormal
 expression of these genes. Detection of the dendritic cell
 differentially expressed genes, or of their encoded proteins, can be used
 to identify cells as belonging to the monocyte lineage. Cells containing
 these genes can be used in active immunotherapy (or to stimulate
 production of a population of antigen-specific effector cells) and
 vectors containing them are used in gene therapy. Co-administration of
 tumour antigens and APC-associated costimulatory factors ensures adequate
 antigen presentation to endogenous APCs and upregulates the APCs for the
 presentation of T cell growth factors and secretion of chemokines for
 recruitment of immune effector cells.

Sequence 10 BP; 4 A; 2 C; 1 G; 3 T; 0 other;

Query Match 100.0%; Score 7; DB 21; Length 10;

Best Local Similarity 100.0%; Pred. No. 4,7e+04; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 DB 7 AGTATGA 1

AAZ86425 standard; DNA; 10 BP.

AAZ86425;

07-APR-2000 (first entry)

Metastatic breast tumour cell downregulated transcript tag #5659.

Metastatic breast tumour cell downregulated transcript tag #5659.

KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.
 OS Homo sapiens.
 XX MO9965928-A2.
 PN 23-DEC-1999.
 PD 18-JUN-1999; 99MO-US13647.
 PF 19-JUN-1998; 98US-0089853.
 PR 19-JUN-1998; 98US-0089997.
 PR 19-JUN-1998; 98US-0090039.
 PR 19-JUN-1998; 98US-0090040.
 PR 19-JUN-1998; 98US-0090041.
 XX (GENZ) GENZYME CORP.
 PA (ROBE/) ROBERTS B L.
 PA (SHAN/) SHANKARA S.
 PI Roberts BL, Shankara S;
 DR WPI; 2000-106079/09.
 XX Isolated polynucleotides differentially expressed between metastatic
 PT and non-metastatic breast cancer cells, useful for diagnosis,
 PT prevention and treatment of cancer -
 PS Claim 1; Page 208; 219pp; English.
 XX AA280767 to AA283941 represent tags corresponding to distinct
 CC transcripts that are preferentially transcribed in the metastatic breast
 CC tumour tissue (i.e. are upregulated in metastatic breast tumour cells).
 CC AA283942 to AA286677 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the primary or non-metastatic
 CC breast tumour tissue (i.e. are downregulated in metastatic breast tumour
 CC cells). These transcripts can be used for diagnosis, prognosis,
 CC monitoring and treatment of breast cancer, particularly where metastatic.
 CC Diagnosis is by standard immunoassays or hybridisation/amplification
 CC reactions. Compounds that modulate expression of the transcripts are
 CC potentially useful for treatment of (metastatic) breast cancer, while
 CC promoters from the transcripts are used to direct expression, in selected
 CC cell types, of e.g. therapeutic genes (also ribozymes or antisense
 CC sequences), particularly an antigen-encoding sequence for use in gene or
 CC cell-based vaccines. Polypeptides encoded by the transcripts are also
 CC useful in vaccines; for diagnosing breast cancer and for raising
 CC specific antibodies (Ab). Ab are used to detect the polypeptides or as
 CC therapeutic agents. Host cells that produce the polypeptides can be used
 CC to expand and isolate populations of educated, antigen-specific immune
 CC effector cells, e.g. cytotoxic T lymphocytes, and these used for
 CC adoptive immunotherapy.
 XX SQ Sequence 10 BP; 5 A; 0 C; 3 G; 2 T; 0 other;
 QY Query Match 100.0%; Score 7; DB 21; Length 10;
 DE Best Local Similarity 100.0%; Pred. No. 4.7e+04;
 XX Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AGTATGA 7
 DE |||||
 XX 4 AGTATGA 10
 DB
 RESULT 8
 AAH32760 standard; CDNA; 10 BP.
 ID AAH32760;
 AC AAH32760;
 XX 13-AUG-2001 (first entry)
 DT
 XX

DE LPS activated human monocyte expression gene CDNA tag SEQ:133.
 XX Human; LPS; lipopolysaccharide; monocyte expression gene; tag; EST;
 KW expressed sequence tag; diagnosis; human disease; treatment; ss.
 XX Homo sapiens.
 OS JP2001069993-A.
 PN 21-MAR-2001.
 PD 28-APR-2000; 2000JP-0131079.
 PF 08-JUL-1999; 99JP-0195103.
 PR (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
 PA WPI; 2001-304369/32.
 DR LPS activated human monocyte expression gene group -
 XX Claim 10; Page 28; 52pp; Japanese.
 PS The present invention describes an lipopolysaccharide (LPS) activated
 CC human monocyte expression gene group consisting of the high-ranking 50
 CC genes of the highest expression among the genes expressed by human
 CC monocyte stimulated by LPS in which the CDNA of each gene has the base
 CC sequence of (AAH32628 to AAH32677) continuous to the base sequence
 CC 5'-CATG-3' nearest to the polyA region. The gene group is useful for the
 CC development of new means for the diagnosis and the treatment of various
 CC human diseases in which human monocyte plays an important role.
 CC AAH32628 to AAH32943 represent specifically claimed LPS activated human
 CC monocyte expression gene CDNA tags from the present invention. AAH32944
 CC represents an LPS activated human monocyte expression gene CDNA sequence
 CC encoding AAB96009, which are given in the exemplification of the present
 CC invention.
 XX SQ Sequence 10 BP; 4 A; 0 C; 4 G; 2 T; 0 other;
 QY Query Match 100.0%; Score 7; DB 22; Length 10;
 DE Best Local Similarity 100.0%; Pred. No. 4.7e+04;
 XX Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AGTATGA 7
 DE |||||
 XX 1 AGTATGA 7
 DB
 RESULT 9
 AAF38936 standard; DNA; 10 BP.
 ID AAF38936;
 AC AAF38936;
 XX 23-MAR-2001 (first entry)
 DT Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5675.
 XX Yeast: Saccharomyces cerevisiae; characterisation: cell cycle; NORF;
 KW not previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX Saccharomyces cerevisiae.
 OS MO200077214-A2.
 PN 21-DEC-2000.
 PD 14-JUN-2000; 2000MO-US16223.
 PF 16-JUN-1999; 99US-0335032.
 PR
 XX

```

XX (UVCJO ) UNIV JOHNS HOPKINS.
PI PI Velculescu V, Vogelstein B, Kinzler K;
XX DR WPI; 2001-061874/07.
XX PT Yeast gene coding sequences comprising NORF genes with serial analysis
XX of gene expression (SAGE) tags, useful for studying, monitoring and
XX affecting phases of the cell cycle -
XX Example: Page 202: 419pp; English.
PS
XX The present invention describes an isolated DNA molecule comprising a
XX coding sequence of a yeast gene selected from a group of 745 NORF (not
XX previously assigned open reading frame; or nonannotated ORF) genes
XX comprising a SAGE (serial analysis of gene expression) tag. Also
XX described are: (1) a method (M1) of using NORF genes to affect the cell
XX cycle comprising administering a NORF gene whose expression varies by at
XX least 10% between any two phases of the cell cycle selected from log
XX phase, S phase and G2/M; (2) a method (M2) for screening candidate
XX antifungal drugs comprising: (a) contacting a test substance with a
XX yeast cell; and (b) monitoring expression of a NORF gene whose
XX expression varies as in M1, where a test substance which modifies the
XX expression of the yeast gene is a candidate antifungal drug; (3) a method
XX (M3) for identifying human genes which are involved in cell cycle
XX progression comprising contacting human DNA with a probe which comprises
XX at least 10 contiguous nucleotides of a NORF gene whose expression varies
XX as in M1; and (4) a method (M4) for identifying a candidate drug as a
XX member of a class of drugs having a characteristic effect on gene
XX expression in a yeast cell comprising contacting a yeast cell with a
XX candidate drug and monitoring expression in the yeast cell of at least 1
XX NORF gene whose expression is affected by the class of drugs. The NORF
XX genes may be used to study, monitor and affect phases of the cell cycle,
XX the differentially expressed genes may be used as markers of phases of
XX the cell cycle. The methods may be used to identify candidate drugs which
XX affect the cell cycle and for identification of antifungal drugs.
XX AAF33268 to AAF40064 represent SAGE tags used in the exemplification of
XX the present invention. AAF33262 to AAF33267 represent linkers and PCR
XX primers used in the SAGE method, in the exemplification of the present
XX invention.
SQ Sequence 10 BP; 4 A; 1 C; 3 G; 2 T; 0 other;
OY 1 AGTATCA 7
   |||||
Db 2 AGTATCA 8
RESULT 10
AAF39793
ID AAF39793 standard; DNA; 10 BP.
AC AAF39793;
XX
DT 23-MAR-2001 (first entry)
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:6532.
XX
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
PD 21-DEC-2000.

```

```

FE 14-JUN-2000; 2000OWO-US162233.
XX
XX PR 16-JUN-1999; 990US-0335032.
XX
XX PA (UYJO ) UNIV JOHNS HOPKINS.
XX
XX PI Velculescu V, Vogelstein B, Kinzler K;
XX WPI; 2001-061874/07.
XX
XX PT Yeast gene coding sequences comprising NORF genes with serial analysis
XX of gene expression (SAGE) tags, useful for studying, monitoring and
XX affecting phases of the cell cycle.
XX
XX PS Example; Page 233; 419pp; English.
XX
XX CC The present invention describes an isolated DNA molecule comprising a
XX coding sequence of a yeast gene selected from a group of 745 NORF (not
XX previously assigned open reading frame; or nonannotated ORF) genes
XX comprising a SAGE (serial analysis of gene expression) tag. Also
XX described are: (1) a method (M1) of using NORF genes to affect the cell
XX cycle comprising administering a NORF gene whose expression varies by at
XX least 10% between any two phases of the cell cycle selected from 109
XX phase, S phase and G2/M; (2) a method (M2) for screening candidate
XX antifungal drugs comprising: (a) contacting a test substance with a
XX yeast cell; and (b) monitoring expression of a NORF gene whose
XX expression varies as in M1, where a test substance which modifies the
XX expression of the yeast gene is a candidate antifungal drug; (3) a method
XX (M3) for identifying human genes which are involved in cell cycle
XX progression comprising contacting human DNA with a probe which comprises
XX at least 10 contiguous nucleotides of a NORF gene whose expression varies
XX as in M1; and (4) a method (M4) for identifying a candidate drug as a
XX member of a class of drugs having a characteristic effect on gene
XX expression in a yeast cell comprising contacting a yeast cell with a
XX candidate drug and monitoring expression. In the yeast cell of at least 1
XX NORF gene whose expression is affected by the class of drugs. The NORF
XX genes may be used to study, monitor and affect phases of the cell cycle,
XX the differentially expressed genes may be used as markers of phases of
XX the cell cycle. The methods may be used to identify candidate drugs which
XX affect the cell cycle and for identification of antifungal drugs.
XX AAFF33268 to AAH44064 represent SAGE tags used in the exemplification of
XX the present invention. AAFF33262 to AAFF33267 represent linkers and PCR
XX primers used in the SAGE method, in the exemplification of the present
XX invention.
XX
XX SQ Sequence 10 BP; 4 A; 1 G; 2 G; 3 T; 0 other;
XX
XX QY Query Match 100.0%; Score 7; DB 22; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 4; Tc+04;
XX Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0
XX
XX 1 AGTATGA 7
XX |||||||
XX 1 AGTATGA 7
XX
XX DB
XX
XX RESULT 11
XX AAFF40876
XX ID AAFF40876 standard; DNA; 10 BP.
XX
XX AAFF40876;
XX
XX 23-MAR-2001 (first entry)
XX
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7615.
XX
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
XX not previously assigned open reading frame; nonannotated ORF; SAGE;
XX serial analysis of gene expression; antifungal; tag; identification;
XX linker; PCR primer; ds.
XX
XX OS Saccharomyces cerevisiae.
XX

```

PN WO200077214-A2.
XX 21-DEC-2000.
XX 14-JUN-2000; 2000WO-US16223.
XX 16-JUN-1999; 99US-0335032.
XX (UYO) UNIV JOHNS HOPKINS.
XX Velculescu V, Vogelstein B, Kinzler K;
XX WPI; 2001-061874/07.
DR
XX
XX Yeast gene coding sequences comprising NORF genes with serial analysis
PT of gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle -
XX
XX Example; Page 272; 419pp; English.
XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from 10g
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a
CC yeast cell; and (b) monitoring expression of a NORF gene whose
CC expression varies as in M1, where a test substance which modifies the
CC expression of the yeast gene is a candidate antifungal drug; (3) a method
CC (M3) for identifying human genes which are involved in cell cycle
CC progression comprising contacting human DNA with a probe which comprises
CC at least 10 contiguous nucleotides of a NORF gene whose expression varies
CC as in M1; and (4) a method (M4) for identifying a candidate drug as a
CC member of a class of drugs having a characteristic effect on gene
CC expression in a yeast cell comprising contacting a yeast cell with a
CC candidate drug and monitoring expression in the yeast cell of at least 1
CC NORF gene whose expression is affected by the class of drugs. The NORF
CC genes may be used to study, monitor and affect phases of the cell cycle,
CC the differentially expressed genes may be used as markers of phases of
CC the cell cycle. The methods may be used to identify candidate drugs which
CC affect the cell cycle and for identification of antifungal drugs.
CC AAF33268 to AAF44064 represent SAGE tags used in the exemplification of
CC the present invention. AAF33262 to AAF33267 represent linkers and PCR
CC primers used in the SAGE method, in the exemplification of the present
CC invention.
XX
XX Sequence 10 BP; 3 A; 3 C; 2 G; 2 T; 0 other;
SO
Query Match 100.0%; Score 7; DB 22; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.7e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGTATGA 7
DB 3 AGTATGA 9
RESULTS
ID ABR47394/C
XX ABR47394 standard; DNA; 10 BP.
XX ABR47394;
XX 18-JUN-2002 (first entry)
XX
XX Human PLA2G1B ASO primer extension primer 3' end #5.
XX
XX Human; ss; primer; SNP; single nucleotide polymorphism; pancreatitis;
KW pancreatic cancer; phospholipase A2 group IB; PLA2G1B; gene therapy;
KW haplotype; genotype; chromosome 12q23-q24.1; transgenic; drug screening;

KW ASO; allele specific oligonucleotide; primer extension.
XX Homo sapiens.
OS
XX WO200212562-A2.
XX
XX 14-FEB-2002.
XX
XX 06-AUG-2001; 2001WO-US24663.
XX
XX 04-AUG-2000; 2000US-223179P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX Kazem A, Klem SE, Koshy B;
XX WPI; 2002-303982/34.
XX
XX
XX Novel isolated human phospholipase A2, Group IB pancreas
PT polynucleotide, for therapeutic purposes, for studying expression and
PT function of the polynucleotide and for expressing the phospholipase
PT protein -
XX
XX Claim 19; Page 13; 51pp; English.
XX
XX The invention relates to an isolated human phospholipase A2, Group IB
CC (pancreas) (PLA2G1B) polynucleotide comprising a sequence which is a
CC polymorphic variant for a reference sequence for the PLA2G1B gene or
CC its fragment, or a polymorphic variant of a reference sequence for a
CC PLA2G1B cDNA or its fragment. Also included are haplotyping/genotyping
CC the PLA2G1B gene of an individual, predicting the haplotype pair for the
CC PLA2G1B gene of an individual, identifying an association between a trait
CC and at least one haplotype or haplotype pair of the PLA2G1B gene, an
CC isolated genotyping oligonucleotide for detecting a polymorphism in the
CC PLA2G1B gene, a recombinant non-human organism transformed or transfected
CC with the PLA2G1B sequence, where the organism expresses a PLA2G1B
CC protein encoded by the first nucleotide sequence or by the polymorphic
CC variant sequence, an isolated polypeptide comprising a sequence which is
CC a polymorphic variant of a reference sequence for the PLA2G1B protein or
CC its fragment, an anti-PLA2G1B monoclonal antibody, screening for drugs
CC targeting PLA2G1B, a computer system for storing and analysing
CC polymorphism data for the PLA2G1B gene and a genome anthology for PLA2G1B
CC gene. The PLA2G1B variant is useful in studying the expression and
CC function of PLA2G1B, and in expressing PLA2G1B protein for use in
CC screening for candidate drugs to treat diseases related to PLA2G1B
CC activity (e.g. pancreatitis and pancreatic cancer) and for
CC therapeutic purposes. The transgenic organism is useful for studying
CC expression of the PLA2G1B isogenes in vivo, for in vivo screening and
CC testing of drugs targeted against PLA2G1B protein, and for testing the
CC efficacy of therapeutic agents and compounds in a biological system.
CC The antibody is useful for studying the effect of the variation on the
CC biological activity of PLA2G1B as well as on the binding affinity of
CC candidate drugs targeting PLA2G1B. The PLA2G1B gene is located on
CC chromosome 12q23-q24.1. The present sequence is an allele specific
CC oligonucleotide (ASO) primer extension primer 3' end used to detect the
CC polymorphisms in PLA2G1B.
XX
XX Sequence 10 BP; 3 A; 3 C; 0 G; 4 T; 0 other;
SO
Query Match 100.0%; Score 7; DB 24; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.7e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGTATGA 7
DB 9 AGTATGA 3
RESULTS
ID AAL41859
XX AAL41859 standard; DNA; 10 BP.
XX AAL41859;
AC

XX 25-APR-2002 (first entry)
XX
XX Human GCNT1 allele specific primer extension oligo SEQ ID NO: 44.
DE
XX
XX Human: glucosaminyl (N-acetyl) transferase 1, core 2; GCNT1; cancer;
KW gene therapy; haploctypte; chromosome 9q13; SNP; primer; cytostatic;
XX single nucleotide polymorphism; ss.
XX
OS Homo sapiens.
XX
XX WO200204470-A2.
XX
XX 17-JAN-2002.
XX
XX 06-JUL-2001; 2001WO-US21451.
XX
XX 06-JUL-2000; 2000US-216281P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Duda A, Finkel K, Koshy B;
XX
XX WPI; 2002-171696/22.
XX
XX Genetic variants of glucosaminyl (N-acetyl) transferase 1, core 2 gene
PT useful in studying expression and function of the protein, and for
PT screening drugs to treat diseases e.g. cancer
XX
XX
XX Claim 18; Page 14; 72pp; English.
XX
XX The present invention provides the gene, protein and cDNA sequences of
CC the human glucosaminyl (N-acetyl) transferase 1, core 1 (GCNT1). Also
CC identified are single nucleotide polymorphisms (SNPs) located within the
CC sequences. The sequences can be used in the treatment of GCNT1 related
CC diseases, including cancer. The present sequence is an allele specific
CC primer extension oligonucleotide for the GCNT1 gene, which is located on
CC chromosome 9q13.
XX
XX
XX Sequence 10 BP; 3 A; 1 C; 2 G; 4 T; 0 other;
SO
Query Match 100.0%; Score 7; DB 24; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.7e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGTATGA 7
| | | | |
Db 1 AGTATGA 7
RESULT 14
AAI67680
ID AAI67680 standard; DNA; 10 BP.
XX
XX AAI67680;
XX
XX 27-FEB-2002 (first entry)
XX
XX Human IL-8 gene polymorphism detecting primer.
DE
XX IL-8; interleukin; single nucleotide polymorphism; haploctypte; primer;
KW genotyping; cancer; chronic obstructive pulmonary disease; human; ss.
XX
XX Homo sapiens.
XX
XX WO200183499-A2.
XX
XX
XX 08-NOV-2001.
XX
XX 30-APR-2001; 2001WO-US13957.
XX
XX 28-APR-2000; 2000US-200416P.
XX

PA (GENA-) GENAISSANCE PHARM INC.
XX
XX Bentivegna SC, Chew A, Choi JY, Denton RR, Nandabalan K;
PI
XX
XX WPI; 2002-049333/06.
DR
XX
XX Novel isolated human interleukin 8 polynucleotide, useful for
PT therapeutic purposes, comprises a sequence which is a polymorphic
PT variant of a reference sequence for interleukin 8 gene or its fragment
XX
XX
XX Claim 18; Page 13; 52pp; English.
XX
XX The invention relates to novel single nucleotide polymorphisms in the
CC human interleukin 8 (IL-8) gene. Methods for haploctypte and genotyping
CC the IL-8 gene are also provided. The methods are useful for improving the
CC efficacy and reliability of several steps in the discovery and
CC development of drugs for treating diseases associated with IL-8 activity,
CC e.g., cancer and chronic obstructive pulmonary disease, to validate IL-8
CC as a candidate agent; in the design of clinical trials of candidate
CC drugs; to screen for compounds targeting IL-8 to treat a specific
CC conditions or disease associated with IL8 activity. The IL-8 gene is
CC useful in studying the expression and function of IL8, and in expressing
CC IL-8 protein for use in screening for candidate drugs to treat diseases
CC related to IL-8 activity. Sequences AAI67679-90 represent primers for
CC detecting IL-8 gene polymorphisms by primer extension.
XX
XX
XX Sequence 10 BP; 3 A; 1 C; 4 G; 2 T; 0 other;
SO
Query Match 100.0%; Score 7; DB 24; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.7e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGTATGA 7
| | | | |
Db 4 AGTATGA 10
RESULT 15
AAI67681/c
ID AAI67681 standard; DNA; 10 BP.
XX
XX AAI67681;
XX
XX 27-FEB-2002 (first entry)
XX
XX Human IL-8 gene polymorphism detecting primer.
DE
XX IL-8; interleukin; single nucleotide polymorphism; haploctypte; primer;
KW genotyping; cancer; chronic obstructive pulmonary disease; human; ss.
XX
XX Homo sapiens.
XX
XX WO200183499-A2.
XX
XX
XX 08-NOV-2001.
XX
XX 30-APR-2001; 2001WO-US13957.
XX
XX 28-APR-2000; 2000US-200416P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Bentivegna SC, Chew A, Choi JY, Denton RR, Nandabalan K;
PI
XX
XX WPI; 2002-049333/06.
XX
XX Novel isolated human interleukin 8 polynucleotide, useful for
PT therapeutic purposes, comprises a sequence which is a polymorphic
PT variant of a reference sequence for interleukin 8 gene or its fragment
XX
XX
XX Claim 18; Page 13; 52pp; English.
XX

XX The invention relates to novel single nucleotide polymorphisms in the
CC human interleukin 8 (IL-8) gene. Methods for haplotyping and genotyping
CC the IL-8 gene are also provided. The methods are useful for improving the
CC efficacy and reliability of several steps in the discovery and
CC development of drugs for treating diseases associated with IL-8 activity,
CC e.g., cancer and chronic obstructive pulmonary disease, to validate IL-8
CC as a candidate agent; in the design of clinical trials of candidate
CC drugs; to screen for compounds targeting IL-8 to treat a specific
CC conditions or disease associated with IL8 activity. The IL-8 gene is
CC useful in studying the expression and function of IL8, and in expressing
CC IL-8 protein for use in screening for candidate drugs to treat diseases
CC related to IL-8 activity. Sequences A167679-90 represent primers for
CC detecting IL-8 gene polymorphisms by primer extension.
XX

SO Sequence 10 BP; 2 A; 3 C; 1 G; 4 T; 0 other;

Query Match 100.0%; Score 7; DB 24; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.7e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||||
Db 10 AGTATGA 4

Search completed: June 2, 2003, 18:45:11
Job time : 118.151 secs

